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Abstract 
Apoptin, a potential anticancer candidate, selectively kills tumour or transformed cells but 
remains harmless to normal and non-transformed cells. Besides, apoptin-induced apoptosis is 
independent of p53 apoptosis pathway, which is always mutated in cancer cells during 
tumorigenesis or after radiotherapy. This has made apoptin becoming more pharmacological 
valuable. In this study, the general aim was to develop a plant-derived apoptin which offers a 
safer and more cost-effective treatment for cancer patients. The scope of the study focused on 
the production of recombinant apoptin in a plant-based system and preliminary bioactivity 
evaluation of the purified plant-derived apoptin on human lung cancer adenocarcinoma A549 
cells. Recombinant apoptin was expressed in Nicotiana benthamiana as apoptin alone, in 
fusion to green fluorescent protein (GFP) as well as in fusion to lichenase (Lic) to increase 
the expression of recombinant protein in soluble fraction. Recombinant apoptin was also in 
fusion to H22 single chain antibody and epidermal growth factor (EGF) in order to target 
recombinant H22-apoptin and EGF-apoptin to cancer cells overexpressed with 
immunoglobulin G (IgG) receptor (CD64) and EGF receptors. Expression of recombinant 
apoptin was detected in N. benthamiana successfully, however, high amount of soluble 
protein was obtained in plants infiltrated with recombinant GFP-apoptin (gene casette: PR-
GFP-VP3-HK) and EGF-apoptin (gene casette: PR-EGF-CatAd-VP3-HK) that targeted the 
recombinant proteins to endoplasmic reticulum (ER). Protein purification using immobilised 
metal affinity chromatography (IMAC) recovered recombinant GFP-apoptin (GFP-VP3-HK) 
and EGF-apoptin (EGF-CatAd-VP3-HK) at a low purity when recombinant proteins were 
purified in a non-denaturing condition. Host cell protein contamination was not able to be 
removed when second chromatography and acid precipitation method were used. However, 
recombinant GFP-apoptin (GFP-VP3-H) and lichenase-apoptin (Lic-VP3-H) without targeted 
to specific cellular compartment were purified at a good purity using IMAC. Recombinant 
GFP-VP3-H extracted in a denaturing condition was successfully refolded without an 
addition of chemical additives while recombinant Lic-VP3-H required triton to refold the 
protein. In cell-based study, enzyme-linked immunosorbent assay (ELISA) showed that 
apoptin interacted with EGF receptors as well as A549 cells which finding is the first of its 
kind in report but with an unverified speculation. On the other hand, nuclear localisation 
activity and a few apoptosis-associated morphological features were observed in cells 
microinjected with recombinant GFP-VP3-H. Meanwhile, recombinant EGF-VP3-HK 
showed a dose-dependent growth inhibitory effect at higher concentration and caused the loss 
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of mitochondrial membrane potential (MMP) in treated A549 cells. However, internalisation 
of recombinant EGF-VP3-HK requires a further study for confirmation. Considering the 
findings on MMP and caspase 3/7 assays were not convincing enough, further evaluations are 
necessitated in order to verify the apoptosis events induced by the recombinant GFP-VP3-H 
and EGF-VP3-HK. Nonetheless, this study has heralded a new milestone for apoptin research 
by which its protein has been successfully produced in plants and some preliminary 
biological characteristics have been explored at a certain extent. 
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Chapter 1   
Introduction 
Chicken Anemia Virus (CAV), a member of Gyrovirus, was first isolated in Japan in year 1979. 
Severe anemia, atrophy of lymphoid as well as hemorrhages are the symptoms observed during 
viral infection (Notebornb and Koch, 1994). Viral Protein 3 (VP3) of CAV, a non-structural 14 
kDa small protein, is the main candidate responsible for the destruction of erythroblastoid cells 
and cortical thymocytes that leads to anemia and immunodeficiency symptoms. Depletion of 
both erythroblastoid cells and cortical thymocytes was found to be the result of apoptosis 
induced by VP3. Due to the induction of apoptosis by VP3 in CAV infected or transformed 
chicken cells, VP3 was named “apoptin” by Noteborn and his colleagues in 1995. Other than 
transformed or CAV susceptible chicken cells, tumourigenic and transformed mammalian cells 
are also susceptible to apoptin (Noteborn et al., 1998). However, most of the normal and non-
transformed mammalian cells are not susceptible to apoptin. Apoptin consists of 121 amino acids 
and three important functional regions are found on this small protein, including a leucine rich 
region (LRR), a bipartite nuclear localisation signal (NLS) and a nuclear export signal (NES).  
To date, more than 70 cancer cell lines are susceptible to apoptin, including breast tumour 
(MCF-7), osteosarcoma (Saos-2), small lung cell carcinoma (SLCC), hepatoma (HepG2), kidney 
rhabdoid tumour (G401), myeloid leukemia (K562), colon carcinoma (HT29) and etc (Noteborn 
et al., 1998). Some mechanistic studies of apoptin-induced apoptosis in cancer cells had been 
reported. Most of the studies showed that apoptosis induced by apoptin was independent of 
extrinsic apoptosis pathway; but instead it involved in intrinsic apoptosis pathway (Los et al., 
2009). Loss of mitochondrial membrane potential, release of cytochrome c and activation of 
caspase cascade, which are the underlying apoptosis events of intrinsic pathway, were observed 
in cancer cells undergoing an apoptin-induced apoptosis. Apoptin-induced apoptosis does not 
require the functional tumour gene suppressor p53 but it is regulated by anti-apoptotic proteins 
Bcl-2 family in most cell lines (Los et al., 2009). Tumour gene suppressor p53 is always mutated 
in tumourigenic cells, which leads to inefficiency of radiotherapy and chemotherapy on cells that 
require a functional p53. Hence, apoptin-induced apoptosis which is independent of p53 pathway 
has made apoptin a great anticancer candidate particularly for cells with malfunctioning p53. The 
Bcl-2 family proteins include pro-apoptotic (such as Bax, BAD, and Bak) and anti-apoptotic 
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groups (Bcl-2 and Bcl-xL) of proteins and the balance among these 2 groups of proteins 
determines the fate of cells (Elmore, 2007). Increasing availability of pro-apoptotic group of 
proteins leads induction of apoptosis via mitochondria-mediated apoptosis pathway; however, 
increasing availability of anti-apoptotic group of proteins inhibit apoptosis triggered by 
mitochondria- mediated apoptosis pathway, 
Plant molecular pharming is production of pharmaceutical recombinant proteins via genetic 
engineering approach by using plant as expression host. In relative to other expression hosts, 
several advantages such as ease in scaling up, high protein expression level, low production cost, 
low risk of contamination by pathogenic agents and capability of post translational modifications, 
have made plant an attractive expression system (Fischer et al., 1999). Up to date, various kinds 
of plant-derived therapeutic proteins are available and many of them are important for defeating 
the life-threatening pandemic diseases. For example, ZMapp, released by Mapp 
Biopharmaceutical Inc (San Diego, USA) in year 2014, was a chimeric monoclonal antibody 
raised against the surface glycoprotein of Ebola produced in Nicotiana benthamiana (Davidson 
et al., 2015). This product has successfully saved numerous lives from death, which caused by 
Ebola infection that was originated from the outbreak in West Africa. In comparison with the 
laborious and time consuming stable transformation, production of high protein expression level 
within a short period could be achieved via transient expression. By using the deconstructed or 
agroinfiltration approach, leaf tissues are infiltrated with agrobacterial transformants bearing the 
recombinant foreign gene sequences. Agrobacterium is delivered into intercellular space of 
mesophyll cells by using syringe or vacuum infiltration. Vacuum infiltration, serving as a 
feasible and effective delivery tool, is currently widely adopted by manufacturers such as 
Medicago Inc (USA), Fraunhofer Center for Molecular Biotechnology (FhCMB, USA), 
Kentucky Bioprocessing (USA) and Icon Genetics (Germany).  
Cancer is a disease caused by uncontrolled proliferation of transformed body’s cells. This disease 
leads to the death of estimated ~ 8.2 million of people in the world in 2012 (GLOBOCAN, 2012). 
The most common types of cancers in men and women include lung, breast, colorectal, stomach 
and prostate cancers. There are numerous factors that lead to the development of cancer 
including exposure to physical carcinogens (such as ultraviolet and ionizing radiation), chemical 
carcinogens (such as nicotine from cigarettes or presence of heavy metal in drinking water), 
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biological pathogenic agents (such as Human papillomavirus, HPV) and obesity. Non-small cell 
lung cancer (NSCLC) is one of the most common types of lung cancer and patients suffer from 
NSCLC accommodates 80-85% of lung cancer disease (American Cancer Society, 2016). The 
primary reason leads to the lung carcinogenesis is cigarette smoking. Various kind of 
carcinogens, such as polycyclic aromatic hydrocarbons (PAH) and 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK), are present in the cigarette smoke and can induce DNA mutation in 
cigarette smoker as well as second-hand smokers (Hecht, 2012). To date, available treatments for 
lung cancer disease include surgery, radiofrequency ablation, radiotherapy, chemotherapy and 
immunotherapy. Numbers of cancer markers for NSCLS have also been determined, including 
epidermal growth factors (EGF), anaplastic lymphoma kinase (ALK), Kirsten rat sarcoma viral 
oncogene (KRAS), and etc. Identification for the cancer markers could accelerate the 
development of diagnosis for NSCLS and verify the disease in the earlier stage.    
NSCLS is the most common type of lung cancer and only ~ 30% of patients survive for 1 year 
after diagnosed with lung cancer disease (CancerReasrch UK, 2016).  Side effects such as nausea, 
hair loss, breathing difficulty, loss of appetite, vomiting, fatigue and etc have caused patients to 
suffer after treatments, such as surgery, radiotherapy and chemotherapy. Especially, some of the 
patients could not get rid off the side effects, including breathing difficulty and long term chest 
pain, for the rest of the life after they received the surgery to remove lung tissues, where the 
tumour was located. Suicide cases are always observed especially when patients could not stand 
for the pain after treatments. Study of Cipriano et al., (2011) showed that the liability cost for 
lung cancer patients was ~ $1,617 to $2,004 per month if the patient received chemo-
radiotherapy in year of 2000. The cost for treatments is a huge burden for patients especially for 
patients who are not allowed to work due to their health problem.  
Apoptin, a potential anticancer candidate, showing a great selective killing activity in cancer 
cells have attracted great interest from researchers. Apoptin is always delivered into mammalian 
cells in DNA form or in recombinant protein form. Apoptin delivered into mammalian cells in 
DNA form requires the employment of human viral vectors or non-viral vectors (such as bacteria 
or transfection reagents) (Rollano Peñaloza et al., 2014; Zhuang et al., 1995); however, 
disadvantages of viral vector delivery approach include potential for development of replication 
competent virus as well insertional mutagenesis. Meanwhile, recombinant apoptin protein, which 
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is a relatively safer delivery approach, is delivered into mammalian cells via microinjection or 
animal models via cell penetrating peptides (CPPs) (Guelen et al., 2004; Zhang et al., 2003). 
Most of the recombinant apoptin was currently produced in Escherichia coli (Leliveld et al., 
2003; Guelen et al., 2004; Sun et al., 2009). Besides, recombinant apoptin was also produced in 
human umbilical vein endothelial cells (HUVEC) (Ma et al., 2012). However, high production 
cost as well as potential contamination of animal pathogens and toxin compounds are huge 
drawback for the production of recombinant protein in both bacterial and human cell line system. 
However, there are very scarce reports detailing the production of recombinant apoptin in plants. 
Plants are currently developed as one of the important biofactories for therapeutic protein 
production. Trastuzumab, a plant-derived anticancer antibody drug, has shown effectives in 
reducing size and growth of breast cancer tumours. Besides, PlantForm, manufacturer of 
Trastuzumab, also claimed that the production cost for plant-based system was 90% lower than 
that of conventional production approach (Generic and Biosimilars Initiative, 2013). Hence, the 
main goal of current study is to evaluate the feasibility of production for recombinant apoptin in 
a cost-effective plant-based expression system. Development of the cost-effective plant-derived 
apoptin is expected to reduce the overall cost for a cancer treatment making it affordable to 
needy and hence could save more lives (Fischer et al., 1999; Gleba et al., 2005). Low risk of 
contamination by animal pathogens as well as free of co-infection by mammalian viral vectors 
during drug delivery are also the main drivers to opt for production of recombinant apoptin in 
plant-based system (Fischer et al., 1999). Hence, optimisations for recombinant apoptin 
expression and protein purification process were the main focuses at current stage of study in 
order to obtain a high amount of recombinant protein. Besides, additional study for the 
preliminary assessment on bioactivity of recombinant apoptin was also performed using human 
lung cancer cells. The result might provide some understanding of bioactivities of plant-made 
apoptin on human cells and suggestion for improvement on the production of plant-made apoptin 
in future study.  
In order to optimise the expression level of recombinant apoptin in Nicotiana benthamiana, 
several groups of gene cassettes were designed by which details are described in Chapter 3. Gene 
cassettes, including apoptin alone, apoptin in fusion to C-terminal of GFP (GFP-apoptin) and 
apoptin in fusion to lichenase (lichenase-apoptin), were designed in order to optimise the 
expression of recombinant proteins. Signal peptide (PR1a), which directs the recombinant 
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protein into endoplasmic reticulum (ER) space, and ER retention signal (KDEL) were also added 
to apoptin, GFP-apoptin and lichenase-apoptin gene cassettes in order to accumulate the 
recombinant proteins in specific cellular compartments. For targeting therapy purpose, 
recombinant apoptin was in fusion to C-terminal of H22 single chain antibody and epidermal 
growth factor (EGF). A molecular adaptor CatAd, a kind of CPPs developed from immunotoxin, 
was inserted between apoptin and H22 single chain antibody as well as apoptin and EGF. All 
gene cassettes were cloned into high expression tobacco mosaic viral (TMV) vector and binary 
vector (pGR-DN).  
Chapter 4 describes the delivery of agrobacterium transformed with the respective recombinant 
vectors into 4-5-week-old N. benthamiana using vacuum infiltration approach. Expression 
profiles of recombinant apoptin were assessed using Western blotting analysis. Leaf tissues 
infiltrated with high expression recombinant vectors harbouring apoptin gene sequences were 
harvested and used for subsequent downstream processing, including immobilised metal affinity 
chromatography (IMAC), ion-exchanged chromatography (IEX), hydrophobic interaction 
chromatography (HIC) as well as size exclusion chromatography (SEC) which are deduced in 
Chapter 5.  
Subsequently, Chapter 6 describes the preliminary bioactivity of purified recombinant apoptin 
(GFP-apoptin and EGF-apoptin) which was investigated on human lung cancer A549 cells. 
Interaction between recombinant apoptin and A549 cells as well as EGF receptors was evaluated 
using enzyme-linked immunosorbent assay (ELISA). Then, recombinant GFP-apoptin was 
delivered into A549 cells using microinjection approach. Cell viability, localisation of apoptin, 
mitochondrial membrane potential (MMP) and activation of caspase 3/7 activities were 
examined after recombinant GFP-apoptin was microinjected into A549 cells. On the other hand, 
recombinant EGF-VP3-HK was directly applied to A549 cultures. Cell viability, localisation of 
apoptin, MMP and activation of caspase 3/7 activities were also assessed in the recombinant 
EGF-VP3-HK treated A549 cells.  
Hence, the ultimate goal for the study is to produce a safe and cost-effective recombinant apoptin 
as an anticancer drug candidate by using plant-based expression platform via the agroinfiltration 
strategy. The specific objectives of this study were: (i) to design and construct gene cassettes for 
the development of recombinant apoptin vector variants; (ii) to evaluate protein expression 
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profiles of N. benthamiana receiving recombinant apoptin vector variants via agroinfiltration; (iii) 
to purify recombinant apoptin extracted from N. benthamiana; and (iv) to provide a preliminary 
evaluation of in vitro bioactivity of recombinant apoptin on human lung cancer cells.  
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2.1 Viral Protein 3 (VP3) of Chicken Anemia Virus (CAV) 
2.1.1 Overview of CAV and apoptin 
The Chicken Anemia Virus (CAV), first isolated in Japan, causes anemia, lymphoid atrophy, 
hemorrhages and increased mortality in young chickens during infection (Yuasa et al., 1979). 
Destruction of hemocytoblasts in bone marrow as well as depletion of lymphocytes and 
thymocytes in thymic cortex are the major characteristics of a CAV viral infection (Adair, 2000; 
Jeurissen et al., 1992) which directly led to development of severe anemia and 
immunodeficiency in young chickens. This also causes vaccination failure and concurrent 
infection by other infectious diseases such as Marek’s disease virus, Infectious Bursal Disease 
Virus (IBDV) and lentogenic Newcastle disease virus (Notebornb and Koch, 1994).    
As a member of Gyrovirus in the family of Circoviridae, CAV is a non-enveloped and 
icosahedral virus with only 23-25 nm in diameter (Notebornb and Koch, 1994). Circular viral 
genome comprises 2.3 kilobases (kb) single strand DNA and the virus replicates via circular 
double-stranded replicative intermediate (Notebornb and Koch, 1994; Prasetyo et al., 2009). 
Unlike other Circoviridae members, all three partially and completely overlapping open reading 
frames (ORFs) (Figure 2.1 -a) encoding for three viral proteins of CAV are coded on the 
antigenomic (minus) strand of DNA. An unspliced polycistronic mRNA is generated during 
transcription (Prasetyo et al., 2009). Viral Protein 1 (VP1) of CAV, 50 kDa, encodes for capsid 
protein of the virus. The sixty capsid protein subunits are clustered into 12 pentagonal trumpet-
shaped units to form the three-dimension shape of virus (Figure 2.1 -b) (Crowther et al., 2003). 
On the other hand, the 24 kDa Viral Protein 2 (VP2) is a dual specificity protein phosphatase and 
it plays an important role in viral replication as well as cellular regulation in infected 
lymphocytes (Peter et al., 2002). The main candidate responsible for the destruction and cell 
death of lymphocytes via induction of apoptosis in infected chicken is the smallest 14 kDa non-
structural Viral Protein 3 (VP3) of CAV. With this apoptosis-inducing ability, VP3 is thus 
renamed as ‘Apoptin’ by Notebornb and Koch (1994).     
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Figure 2.1: Schematic diagram of genome and 3-D morphological structure of CAV. (a) Circular 
CAV genome encoding three partially or almost completely overlapping ORFs, which are VP1, 
VP2 and VP3. (b) Three-dimensional structure of CAV with petagonal trumpet shaped subunits. 
Sources are partly adopted from Artimo et al. (2012); Prasetyo et al. (2009) and Crowther et al., 
(2003). 
2.1.2 Structure and functional regions of apoptin 
Apoptin, a basic protein, consists of 121 amino acids with no similarity in sequence to any other 
known proteins (Notebornb and Koch, 1994). It is rich in proline, serine and threonine, 
harbouring two proline rich stretches, two positively charged regions and a leucine rich region.  
Bipartite nuclear localisation signals NLS1 and NLS2, located on amino acids 82-88 and 111-
121, from apoptin have been reported that these two regions play a crucial role in the 
accumulation of apoptin in nucleus and in the cell killing effectiveness of apoptin on transformed 
cells (Figure 2.2) (Danen-van Oorschot et al., 2003; Poon et al., 2005). Translocation of apoptin 
from cytoplasm into nucleus is believed to be modulated by importins (IMPs), a karyopherin 
which recognises specific short nuclear localisation sequence (Kuusisto et al., 2008). In addition, 
the nuclear export signal (NES) located on amino acid at the 97-105 position, which is 
recognised by the chromosomal maintenance 1 (CRM1) exportin, is responsible for the reduced 
nuclear accumulation of apoptin in normal cell lines (Kuusisto et al., 2008; Poon et al., 2005). A 
hydrophobic leucine rich region (LRR) on amino acids position 33-46, is a weak apoptosis 
inducing region on apoptin. This region may enhance nucleus retention and is also the main site 
(a) (b) 
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for the binding of a number of interacting proteins (Poon et al., 2005; Los et al., 2009). In 
addition, LRR region is also responsible for the multimerisation activity of apoptin. In the study 
of Leliveldb et al. (2013), biologically active recombinant MBP-apoptin was in multimerised 
state and comprised of ~ 30-40 monomers.  
 
Figure 2.2: Schematic diagram of functional regions and amino acids of apoptin.  Apoptin 
contains a leucine rich region (located on amino acids 33-46), a bipartite nuclear localisation 
signal (NLS) (located on amino acids 82-88 and 111-121) and a CRM1 recognised nuclear 
export signal (NES). The representative apoptin nucleotide sequence of is based on the sequence 
of a Malaysia isolate (GenBank accession number: AAB86420.1) reported by Mohd-Azmi et al. 
(1997).  
2.1.3 Bioactivity of apoptin in mammalian cells 
Apoptin-induced apoptosis was initially reported in transformed chicken lymphoblastoid T cells 
(MDCC-MSBI) and myeloid cells (LSCC-HD11) but not in normal chicken embryo fibroblasts 
(Noteborna et al., 1994). In year 1995, apoptin was first reported to induce apoptosis in human 
osteosarcoma cells (Zhuang et al., 1995). To date, apoptin has been widely exploited as 
antitumour agents due to its selective killing effect on tumour cells and transformed cells but not 
on normal or primary cells. More than 70 human cancer cell lines have shown apoptotic effect in 
response to apoptin drug. This includes breast tumour (MCF-7), osteosarcoma (Saos-2), small 
lung cell carcinoma (SLCC), hepatoma (HepG2), kidney rhabdoid tumour (G401), myeloid 
leukemia (K562), colon carcinoma (HT29) and other cells (Los et al., 2009; Noteborn et al., 
1998; Sun et al., 2003; Zhuang et al., 1995). Apoptin also induced apoptosis in some non-
tumorigenic transformed cell lines, such as monkey SV40-transformed kidney cells (Cos-7), 
avian myeloblastosis virus (AMV) transformed cells and Adenovirus-5-transformed baby rat 
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kidney cell. However, no apoptosis effect is observed in T cells, smooth muscle cells (HSMC), 
epidermal keratinocytes (FSK-1), fibroblasts cell (VH25) and human umbilical-cord vascular 
endothelial cells (HUVEC) (Noteborn et al., 1998). Detailed mechanism of apoptin-induced 
apoptosis is still not clear; whereas, protein structure and sequence of apoptin have been studied 
exclusively in order to understand each regions of this protein that contributes to apoptosis effect. 
2.1.4 Apoptosis and mechanisms of apoptin-induced apoptosis 
2.1.4.1 Apoptosis 
Apoptosis (or programmed cell death) refers to “falling off of petals from a flower” or “of leaves 
from a tree in autumn” in ancient Greek. It was first used by John Kerr in 1972 to illustrate 
distinct morphological features of apoptotic bodies formation and phagocytosis as well as 
lysosomal degradation of apoptotic bodies by phagosomes (Kerr et al., 1972). Various kinds of 
diseases and physiological development involve apoptosis process, for example, Alzheimer’s 
(Cotman and Anderson, 1995; De-la Monte et al., 1997), Parkinson’s (Mochizuki et al., 1996) 
and diabetes (Russell et al., 1999). Besides, apoptosis also plays roles in cell number control 
(Hall et al., 1994), elimination of self-reactive lymphocytes (Parijs et al., 1998), and removal of 
cellular stresses (induced by irradiation or drugs) and DNA damage cells (Enoch and Norbury, 
1995). In addition, arisen of several types of cancers could be also traced to malfunction of 
apoptosis signalling molecules, especially p53 deficient cells, which cause most of the cancerous 
cells resistant to chemotherapeutic drugs (Wattel et al., 1994).  
Characteristics of apoptotic cells include round in cell shape, shrinkage in cell size and the loss 
in contact with neighbouring cells (Lawen, 2003). Within the dense cytoplasm, organelles are 
more tightly packed while endoplasmic reticulum (ER) stretches and vesicles are budded off 
from cisternae. In nucleus, condensation of chromatin and degradation of genomic DNA by 
endonucleases to form “laddering DNA” features in agarose gel analysis can be observed 
(Walker et al., 1994; Walker et al., 1999). At later stage of apoptosis, plasma membrane blebs 
and cell content is separated into several membrane spheres shielded apoptotic bodies that are 
various in size. These apoptotic bodies, with recognition site for phagocytic cells, are 
subsequently degraded and digested by macrophages, parenchymal cells or neoplastic cells 
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(Elmore, 2007). Apoptosis process does not release cell content into intercellular compartment, 
hence, this cell death mechanism does not result in inflammation.  
There are two important pathways, the intrinsic and extrinsic pathways, that regulate apoptosis 
process, and both pathways work non-independently by sharing some signaling molecules. 
Extrinsic pathway, also named as receptor-mediated pathway, involves triggering of receptors 
that reside on plasma membrane to induce apoptosis. Numerous kinds of receptors, including Fas, 
tumor necrosis factor receptor (TNF-R) family and granzyme B/perforin system, are available to 
bind to ligands, such as FasL, apoptosis ligand 2 (Apo 2) and tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL), in order to initiate formation of death-inducing signaling 
complex (DISC) and downstream caspase cascades (Ashkenazi, 2008). For instance, binding of 
FasL (Fas ligand) to Fas receptor leads to the binding of adaptor Fas-associated death domain 
protein (FADD) to Fas receptor via death domain (DD), which is available on both Fas and 
FADD.  Death effector domain (DED) of FADD allows the binding of pro-caspase 8, which 
contains the same domain. Subsequently, pro-caspase 8 is activated to active caspase 8 that 
responsible to activate other apoptosis elements. Hence, DISC is the complex of Fas, FasL, 
FADD and pro-caspase 8 (Lawen, 2003). Active caspase 8 is responsible to activate caspase 3, 
cleave Bid protein, produce truncated Bid protein that travels into mitochondria and leads to the 
release of cytochrome c, which initiates intrinsic apoptosis events. 
Instead of depending on receptors, intrinsic pathway is induced by intracellular signals (such as 
Bax and Bak proteins) that subsequently leads to mitochondrial-mediated apoptosis process. 
Opening of mitochondrial permeability transition pore and loss of the mitochondrial 
transmembrane potential occur in order to release two main groups of pro-apoptotic proteins 
(Elmore, 2007). Cytochrome C, Smac/DIABLO and serine protease HtrA2/Omi are the first 
main group of pro-apoptotic proteins that are important to initiate apoptosis cascades. 
‘Apoptosome’, a signaling molecule to activate caspase-9, forms when cytochrome C, a key 
element binding to WD40 repeat of Apaf-1, is released from mitochondria and subsequently 
results in the activation and oligomerisation of Apaf-1 into a wheel-shaped oligomeric 
complexes in the presence of dATP (Riedl and Salvesen, 2007). Second group of pro-apoptotic 
proteins are Apoptosis-inducing factor (AIF), endonuclease G and Caspase-Activated DNase 
(CAD) (Elmore, 2007). This group of proteins translocate into nucleus and eventually lead to 
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DNA fragmentation (Daugas et al., 2000; Li et al., 2001; Van Loo et al., 2001; Widlak, 2000). A 
simple overview diagram of intrinsic and extrinsic pathway is shown in Figure 2.3. 
  
Figure 2.3: Schematic diagram for intrinsic and extrinsic pathway of apoptosis. Extrinsic 
apoptosis pathway involves receptors on plasma membrane. For example, binding of FasL to Fas 
causes the formation of DISC complexes, which is important for the activation of caspase 8 
(Lawen, 2003). Active caspase 8 is responsible to activate caspase 3 and produce truncated Bid 
protein, a messenger that translocates into mitochondria and initiates intrinsic apoptosis events. 
For intrinsic apoptosis pathway, increasing permeability of mitochondrial membrane results the 
release of cytochrome c and formation of apoptosome. Apoptosome is important for the 
activation of caspase 9, which subsequently activate caspase 3, 6 and 7. Schematic diagram is 
adopted from Lamkanfi and Dixit (2010). 
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Both intrinsic and extrinsic pathways are equivalently important for induction of apoptosis, 
whereas, both pathways are also regulated by several kinds of regulator proteins. For example, 
tumor suppressor protein p53, a nuclear DNA-binding phosphoprotein, is a transcriptional factor 
that regulates cell cycle, DNA repair and apoptosis (Bellamy, 1997). Apoptosis induced by p53 
may be caused by DNA damage, inappropriate oncogene activation, cytokines or heat shock. 
Another group of apoptosis regulator is Bcl-2 family proteins, which contain pro-apoptotic and 
anti-apoptotic two independent categories, and ratio between these two categories of proteins is 
key to determine the fate of cells (Gross et al., 1999; Oltval et al., 1993). With the understanding 
of apoptosis pathway, various kind of drugs are designed in order to target desired signaling 
molecules or pathway to regulate apoptosis process of diseased cells. 
2.1.4.2 Mechanisms of apoptin-induced apoptosis 
To date, complete mechanism of apoptin-induced apoptosis is not fully explained but several 
proteins interacting with apoptin has been reported. Although there is no concrete data proving 
that apoptin-triggered cell death is induced by extrinsic pathway, Guelen and his colleagues 
(2004) has found that apoptin partial colocalised with FADD and resulted in formation of death 
effector filaments (DEFs), which was formed when proteins containing death domains are 
overexpressed. Besides, apoptin also interacts with DED associated factor (DEDAF) and partial 
colocalised with this protein in osteosarcoma cells (Danen-van Oorschot et al., 2004). However, 
apoptin has also been observed working independently of extrinsic pathway, which induced 
significant apoptotic effect on Caspase-8 deficient and truncated FADD overexpressing cells 
(Maddika et al., 2005). Hence, relation between apoptin-induced apoptosis and extrinsic 
apoptosis pathway still remained controversial and more studies need to be carried out to clarify 
the association between apoptin and extrinsic pathway.    
In contrast, apoptin was believed triggering apoptosis via intrinsic pathway. Apoptin successfully 
causes loss of mitochondrial membrane potential (MMP) (Maddika et al., 2005). Cytochrome c, 
AIF and caspase-3 are detected within cytosol of apoptin-treated cells; in addition, Nur77 is 
suggested as the nucleo-cytoplasmic signal transmitting candidate between nucleus and 
mitochondria since apoptin is reported triggering apoptosis independently of p53 (Maddika et al., 
2005; Zhuang et al., 1995).     
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Instead of intrinsic and extrinsic pathways, PI3-K/Akt signaling pathway is triggered by apoptin. 
PI3 (phosphatidylinositol 3 kinase), a lipid kinase, is responsible to catalyse phosphorylation of 
inositol ring of phosphoinositides; while, Akt is a serine/threonine kinase that is activated by PI3 
(Maddika et al., 2007). PI3 was reported involving in proliferation differentiation and cells. 
Maddika and his colleagues (2010) proved that apoptin binds to SH3 domain of p85, a subunit of 
PI3-K, via proline-rich region (amino acid 80-90). They suggested that PI3-K is responsible for 
apoptin localisation and cytotoxic activity of apoptin. Increasing expression level and 
translocation of Akt into nucleus upon treatment of apoptin have also been reported by Maddika 
and his co-workers (2007). Akt is suggested involving in phosphorylation activities of apoptin 
within nucleus, in which phosphorylation of apoptin on Threonine (108 amino acid) of apoptin is 
crucial to trigger cell death in tumour cells (Poon et al., 2005; Rohn et al., 2002).     
Besides, peptidyl-prolyl isomerase–like 3 (Ppil3) also interacts with apoptin and localisation of 
apoptin is associated with amount of Ppil3 (Huo et al., 2008). In tumour cells, Ppils is expressed 
in low level and apoptin is localized into nucleus; whereas, high protein amount of Ppil3 in 
normal cells cause distribution of apoptin in cytoplasm.  Furthermore, Hippi, a protein 
interacting with Huntingtin-interacting protein 1 (Hip-1), is suggested responsible for 
suppression of apoptosis within normal cells by retention of apoptin in cytoplasm (Cheng et al., 
2003). Interaction between APC1, a subunit of the anaphase-promoting complex/cyclosome 
(APC/C), and apoptin is also reported. Binding of apoptin with APC/C causes APC/C complex 
disruption and degradation, which eventually results G2/M cell cycle arrest and induction of 
apoptosis (Teodoro et al., 2004). In addition, apoptin was reported to initiate apoptosis 
independent of p53, a tumour suppressor protein (Zhuang et al., 1995). p53 is always mutated 
during tumour development and causes poor response to anticancer therapies that require 
functional p53. Therefore, apoptin is a potential anticancer drug that do not require functional 
p53 for its action. Bcl-2, an anti-apoptotic protein, does not inhibit activity of apoptin, on the 
contrary, apoptosis is stimulated by overexpression of this protein in the study of Noteborn et al., 
1998. In the study of Burek et al. (2006), a contrary result was observed. They reported that 
apoptin-induced apoptosis was inhibited in MCF-7 cells overexpressed with Bcl-2 and Bcl-xL. 
Therefore, effect of Bcl-2 protein to apoptin-induced apoptosis is yet to confirmed.  
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In addition, researchers also studied apoptin-induced apoptosis in relation to the translocation of 
apoptin into nucleus of tumour cells and interaction of apoptin with nuclear compartments. 
Nucleo-cytoplasmic shuttling of apoptin is responsible by importins (IMPs) and exportins CRM-
1, which are nuclear envelope-embedded multi protein channels (Kuusisto et al., 2008; Poon et 
al., 2005). Both transport receptors recognise NLS or NES signal embedded in apoptin sequence 
and translocate apoptin into nucleus of tumour cell but apoptin remains in cytoplasm of normal 
cells. Within the nucleus, apoptin is able to form DNA-apoptin superstructure, which consists 20 
multimeric apoptin complexes and 3 kb of DNA. Formation of DNA-apoptin superstructure 
interrupts chromosomal organization and it is suggested that apoptin may plays role in regulating 
transcription of genes involving in apoptosis activities (Lelivedc et al., 2003). Besides, it is also 
interesting to note that apoptin is also colocalised with promyelocytic leukemia protein (PML) 
bodies, which plays roles in viral replication, tumour progression, apoptosis and cell cycle 
regulation. It was found that apoptin was sumoylated before being targeted to PML. Nevertheless, 
interaction between apoptin and PML is suggested not responsible for apoptosis but for CAV 
viral replication (Los, 2009).  A summary of cellular proteins interacting with apoptin is listed 
Table 2.1. 
Table 2.1: List of cellular proteins interacting with apoptin.  
Molecules Biological effects 
Extrinsic Pathway 
Fas-associated death 
domain protein 
(FADD) and 
DEDAF 
Apoptin is colocalised with FADD as well as DEDAF and induces 
formation of death effector filaments (DEFs); However, apoptin-
mediated apoptosis is also suggested independent of extrinsic pathway. 
Hence, interaction between apoptin and extrinsic pathway molecules 
requires for further investigation. 
Intrinsic Pathway 
Nur77 Maddika and his colleagues showed that apoptin induced apoptosis via 
intrinsic pathway by releasing cytochrome c, AIF, caspase 3 and 
Nur77 as the nucleo-cytoplasms transmitting signal.   
Phosphorylation Pathway 
Akt and PI3K Apoptin interacts with the SH3-domain of the p85 regulatory subunit 
of PI3K and activates PI3K. This event leads to sustained Akt 
activation and nuclear translocation of Akt. 
Others 
Peptidyl-prolyl 
isomerase-- like 3 
(Ppil3) 
Interaction between apoptin and Ppil3 may favor its cytoplasmic 
localisation. 
 
Hip-interacting In normal cells, apoptin colocalises with Hippi in the cytoplasm; 
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protein (Hippi) whereas apoptin migrates to the nucleus in tumour cells while Hippi 
remains in the cytoplasm. 
APC1 (subunit of 
anaphase-promoting 
complex/cyclosome) 
Interaction between apoptin and APC1 may lead to mitotic cell cycle 
arrest and apoptosis. 
Nucleus 
Promyelocytic 
leukemia protein 
(PML) 
SUMOylated apoptin interacts with PML in PML nuclear bodies. 
However, the disruption of interaction between PML and apoptin does 
not affect apoptin's cytotoxicity. 
Importin-β1 Importin-β1 plays a role in nuclear localisation of apoptin by 
translocating apoptin through the nuclear pore complex. 
CRM1 CRM1 is involved in nuclear exportation of apoptin 
DNA Formation of DNA-apoptin superstructure molecules was observed in 
the study of Leliveld et al. (2003). Apoptin interacts with genomic 
DNA of cancerous cells and the interaction is suggested involving in 
regulation of the transcription of genes involving in apoptosis activity.   
 
2.1.5 Cancer 
2.1.5.1 Overview of cancer 
Cancer is a disease characterised by the formation of tumours due to uncontrolled proliferation of 
transformed body’s cells that are induced by genetic mutation (Cancer Research UK, 2010; 
Golan et al., 2005; Rang et al., 2007). According to GLOBOCAN (2012), death of 8.2 million 
people in the world is due to cancer and 14.1 million of new cases are being detected. The most 
common cancers among men and women include lung, breast, colorectum, stomach and prostate. 
In South-East Asia, death from cancer accumulated more than 1 million people and more than 1 
million new cases has been diagnosed (GLOBOCAN, 2012). In Malaysia, nearly 7000 new 
cancer cases have been reported in Peninsular Malaysia between year 2003-2005 (MAKNA, 
2013).  Among these cases reported in Malaysia, the most common cancers are breast cancer 
(18%), large bowel cancer (11.9%) and lung cancer (7.4%). 
A numbers of risk factors have been identified that lead to the formation of this malignancy. In 
particularly, physical and chemical carcinogens that inevitably present around human beings or 
existing in the environment are the major causes for cancer. Physical carcinogens, such as 
ultraviolet and ionizing radiation, can induce irreversible DNA damage and mutation that lead to 
development of skin cancer (Gruijl, 1999; Gruijl et al., 2001; Kvam and Tyrrell, 1997). In 
addition, polycyclic aromatic hydrocarbons (PAH), an active component of cigarettes, is also 
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recognised as the carcinogen that promotes lung cancer in smokers (American Cancer Society, 
2016). According to WHO (2013), 22% of global cancer deaths and 71% of global lung cancer 
deaths are due to the usage of tobacco. Besides, several types of cancers, including liver, lung, 
bladder and kidney, are initiated by inorganic arsenic that is available in drinking water (Chen et 
al., 1992).  Biological agents, including virus, bacteria and parasites, are also another risk factor 
for stimulation of cancer. Human papillomavirus (HPV) has become a nightmare for women as 
this virus has successfully caused invasive cervical cancer and led to presence of estimated 
528,000 new cases globally (GLOBOCAN, 2012; Walboomers et al., 1999). Recently, obesity 
and lack of physical exercise are also suggested to correlate with cancer incidences (Calle and 
Thun, 2004; Michaud et al., 2001; Wolk et al., 2001). Mechanisms of obesity induced 
tumorigenesis are related to insulin resistance and resultant chronic hyperinsulinaemia, increased 
bioavailability of steroid hormones and localised inflammation (Calle and Kaaks, 2004). 
Moreover, aging is also another major risk factor that is responsible for cancer incidences. 
Continuous and prolonged exposure to carcinogens as well as less effective cellular repair 
mechanisms make people more susceptible to malignancy as they are growing older (Dix and 
Cohen, 1980).       
2.1.5.2 Pathogenesis of Cancer  
Development of cancer is a complex and multistep process (Weinberg, 2007). Instead of cell 
proliferation, maturation and differentiation occurred in normal cells, cancerous cells are 
uncontrollably dividing, resisting for maturation and differentiation, invading the underlying 
tissues as well as spreading to other part of body via circulatory system. 
 
Uncontrolled proliferation of cancerous cells 
Uncontrolled proliferation is the main characteristic of cancerous cells. This may be due to the 
over-expression of growth factors and abnormal activity of mutated receptors in the absence of 
ligands (Rajkumar, 2001). For example, Guo and his colleagues (2003) have showed that 
overexpression of vascular endothelial growth factor (VEGF) can promote the cell proliferation 
of breast cancer in vivo. Besides, over-proliferation of cancerous cells could be also due to the 
cells are resistant to apoptosis. Mutation occurs on several genes involved in apoptosis pathway, 
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such as proto-oncogenes (bcl-2) (Coultas and Strasser, 2003) and tumour suppressor genes (p53) 
(Greenblatt et al., 1994), directly inhibit apoptosis activity of cancerous cells. To prevent the end 
of DNA replication and cell senescence, telomerase activity is re-activated in 85-95% of most 
common cancers (Shay, 1997). Telomerase is a ribonucleoprotein enzyme. This enzyme involves 
in synthesising hexameric repeats (TTAGGG) on telemetric end, which is only detected in 
human during blastocyst stage embryogenesis.  A portion of telomere is eroded in each round of 
cell division because DNA polymerase cannot easily replicate the last few nucleotides on DNA 
(Rang et al, 2007). This causes the DNA to become non-functional and thus lead to cell 
senescence. Thus, re-activation of telomerase is important to compensate telomeric loss in each 
round of cell division.  In order to gain enough nutrients for tumours enlargement, tumours also 
induce angiogenesis. Angiogenesis is a process for development of new blood vessels in 
response to induction of growth factors (Rang et al, 2007). For example, VEGF and angiopoietin 
(Ang) play a vital role as the survival factor to maintain survival of endothelial cells to form new 
vessels and this kind of cells is normally killed by angiogenesis inhibitors by the induction of 
apoptosis (Carmeliet and Jain, 2000).  
 
Less of differentiation 
Another important characteristic of cancerous cells is differentiation of cells into varying degrees 
of different tumours. Normal cells are differentiated into specialised cell types after cell division 
and maturation. However, cancerous cells are less mature over time because they lost most of the 
genetic materials during each round of replication. Undeniably, this makes the cells more 
primitive and malfunctioned, but the cells tend to reproduce more rapidly. Based on this 
characteristic, severity of cancer can be classified into low, medium and high grade (Cancer 
Research UK, 2010). Cancer cells look normal and replicate slowly for low severity of cancer; 
whereas, cancer cells are less differentiated and more abnormal as well as proliferating in higher 
speed for high severity of cancer. This is a useful indicator for doctor to judge the severity of the 
disease and decide for the treatments for patients.  
Invasiveness and Metastasis  
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Tumours require more space and nutrients for enlargement as the benign tumours grow and 
expand. Hence, angiogenesis becomes a part of tumour growth in order to provide essential 
nutrients. As new blood vessels are formed, they become a new entryway for tumour cells to 
pass into circulation system and metastases to other parts of the body (Folkman and Shing, 1992). 
According to Liotta (1986), tumour cells require three important steps to invade the underlying 
cell layers, including binding to the matrix collagen of basement membrane, secreting of 
hydrolytic enzymes   
  to degrade the matrix and tumour locomotion into region of matrix modified by proteolysis.  
According to Weinberg (2007), tumours are basically classified into two categories based on 
their degree of aggressive growth, including benign and malignant tumours. Benign tumours are 
local and slow growing tumours that are harmless. They may cause certain degree of damage if 
located on vital body organs, such as brain. On the other hand, malignant tumours are capable to 
spread and invade nearby tissues as well as other parts of body organs to form secondary 
tumours (metastases). 
2.1.5.3 Case study: Lung cancer 
In study by GLOBOCAN (2012), lung cancer is the most common cancer in the world and 
approximately 1.8 million of new cases was estimated in 2012. In general, incidence rate of lung 
cancer is high in men (about 1.2 million) and lower in women (about 0.6 million). More than 50% 
of lung cancer patients were diagnosed with lung cancer at stage IV. Generally, there are several 
factors that induce lung carcinogenesis. Tobacco smoking is the main risk for lung 
carcinogenesis and it causes 80% death for lung cancer (American Cancer Society, 2016). 
Cigarette smoke contains lung carcinogens, including polycyclic aromatic hydrocarbons (PAH) 
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), that are responsible for induction 
of DNA mutation especially in TP53 and Kirsten rat sarcoma viral oncogene (KRAS) (Hecht, 
2012). Hence, there is also high risk for secondhand smokers to develop lung cancer. Besides, 
lung carcinogenesis could also be developed due to exposure to polluted air condition, asbestos 
and radon (American Cancer Society, 2016).  
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Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are two common types 
of lung cancer and NSCLC accommodates 80-85% of lung cancer (American Cancer Society, 
2016). Majority of lung cancer are adenocarcinoma (40% of lung cancer) following by squamous 
carcinoma (25-30% of lung cancer) and large cell carcinoma (10-15% of lung cancer). Several 
cancer markers or molecular alterations have been identified in NSCLS and these assist the 
identification of the correct treatment. Epidermal growth factor receptor (EGFR) mutations are 
one of the molecular alterations observed in lung carcinogenesis. Overexpression of EGFR and 
improper activation of EGFR tyrosine kinase domain induce hyperactivation of downstream pro-
survival signaling pathways (Gazdar, 2009). Besides, rearrangement of anaplastic lymphoma 
kinase (ALK), mutation on KRAS and overexpression of mesenchymal epithelial transition 
factor (MET) are also molecular alterations occurred in NSCLC (Dara et al., 2012).  
To date, there are several treatments available for NSCLC including surgery, radiofrequency 
ablation, radiotherapy, chemotherapy, targeted therapy and immunotherapy (American Cancer 
Society, 2016). Surgery and radiofrequency ablation are direct method to remove tumours. 
Surgery for NSCLC is categorised into pneumonectomy (removal of entire lung), lobectomy 
(removal lobe of lung), segmentectomy or wedge resection (removal part of lobe of lung) and 
sleeve resection (removal of tumourigenic region in large broncus and rejoining with remaining 
lobes) (American Cancer Society, 2016). Radiofrequency ablation is treatment for tumours 
located on the outer edges of lung. This therapy requires penetration of probe through the 
patient’s skin and tumours are destroyed by the high-energy radio waves. Radiofrequency 
ablation is also applied if patients cannot tolerate surgery (American Cancer Society, 2016). 
Radiotherapy is used if the tumours are not completely cleared by surgery or patients cannot 
tolerate surgery. Radiotherapy uses high energy rays, such as x-rays, gamma rays, or protons, to 
kill tumour cells. There are two types of radiotherapy including external radiotherapy and non-
commonly used internal radiation therapy.  External radiotherapy is applied from outside of body; 
while non-commonly used internal radiation therapy requires a piece of small source radioactive 
material to be implanted or taken by patients via oral delivery as well as injection to allocate 
radioactive elements near to tumour cells for effective killing activity. Internal radiation therapy 
is commonly used for treating bronchus tumours (American Cancer Society, 2016). Patients may 
feel tired, weak, skin soreness and hair fall after radiotherapy (Cancer Research UK, 2013). 
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Chemotherapy is the use of cytotoxic drugs to destroy cancerous cells either via mouth or 
injection. Chemotherapy drugs are commonly used for treating NSCLC including Paclitaxel, 
Cisplatin, Carboplatin and others. Instead of killing actively dividing cells randomly and causing 
various side effects, targeted therapy treats NSCLC by targeting drugs towards specific pathway 
or cancer markers found on NSCLC. For example, Erlotinib, Afatinib and Gefitinib are EGFR 
inhibitors that disturb activity of EGFR, which are overexpressed on NSCLC (Paez et al., 2004). 
Targeting drugs including ALKk inhibitors (Crizotinib, Ceritinib and Alectinib) (Ivana and 
David, 2016) and anti-angiogenesis monoclonal antibodies (such as Bevacizumab and 
Ramucirumab) (Das and Wakelee, 2014) are also used to treat NSCLC.       
2.1.6 Current study of apoptin with efficient delivery approaches 
Induction of apoptin-induced apoptosis in human cancer cells was first reported in 1995 (Zhuang 
et al., 1995) and diverse researches on apoptin-induced apoptosis was carried out after the report 
in human mammalian cell lines as well as in mice model. Based on previous studies, apoptin is a 
selective tumour killer since the protein selectively induces apoptosis in human transformed and 
tumorigenic cells but remains harmless to primary as well as non-transformed cells (Rollano 
Peñaloza et al., 2014). A huge variety of cancer cells have non-functional p53. p53 tumour 
suppressor pathway-based chemotherapeutic compounds as well as ionizing radiation are not 
effective in this condition. However, apoptin-induced apoptosis is independent of p53 tumour 
suppressor pathway. Therefore, apoptin is an attractive and potential anticancer candidate for 
cancer therapy.   
Delivery of apoptin into intracellular space of cells is a challenge for apoptin-based therapy since 
apoptin does not harbour cell penetrating peptide (CPP). Various kinds of delivery approaches 
have been established including employment of viral vectors, bacteria and direct apply of 
recombinant apoptin in fusion to CPPs. The most common delivery method of apoptin is by 
using viral vectors. Human viral vectors, including non-replicative viruses, replication-deﬁcient 
viruses, non-oncolytic lentiviral vectors as well as oncolytic viruses, have been used to deliver 
apoptin gene into intracellular space of mammalian cells (Rollano Peñaloza et al., 2014). The 
most commonly used viral vectors for delivery of apoptin is adenoviral vector. Adenoviral vector 
is a high potential viral vector for gene delivery since the vector is able to transduce non-mitotic 
cells, easily grown in high titers and non-integrated into host genome. Apoptin delivered by 
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adenoviral vector was tested in various cancer cells, including a xenogeneic tumor (HepG2) in 
Balb/Cnu/nu mice (Pietersen et al., 1999), in-vitro prostate cancer cells (LNCaP) (Vida et al., 
2016) and in-vitro cholangiocarcinoma cell lines (Pietersen et al., 2004). Other potential viral 
vector candidates, including replication deﬁcient fowlpox viral vector (tested in human hepatoma 
cell line (HepG2) and xenogeneic mouse hepatoma (H22) in C57BL/6 mice) (Li et al., 2006), 
lentiviral vector regulated by surviving promoter (tested in SW480, Hela and MCF-7 cell lines 
and xenogeneic tumor (SW480) (athymic NCR-nu/nu) nude mice) (Feng et al., 2013) and 
newcastle disease viral vector (tested in SMMC7721, A549 cell lines and xenogeneic tumor 
(Hep-2) in mice) (Wu et al., 2012), were also reported for delivery of apoptin.  
Besides, non-viral vector approach was also applied to transfer apoptin into tumour cells, 
including transfection reagents, nanoparticles and Salmonella typhimurium. The most common 
delivery tools for apoptin in vitro are transfection reagents, such as DEAE-dextran, calcium 
phosphate precipitation and lipofection (Zhuang et al., 1995). Besides, nanoparticles were also 
used to deliver apoptin, such as chitosan (Liu et al., 2008) and polyamidoamine dendrimer (Bae 
et al., 2016).  S. typhimurium, a biological delivery tool as well as a potential cancer therapeutic 
agent, selectively accumulates in tumour tissue and it is also actively against p53-deficient 
tumours (Guan et al., 2013). Recently, apoptin-induced apoptosis was reported when apoptin 
was delivered into human laryngeal cancer cell line (Hep-2). Significant reduction in tumour 
growth as well as tumour microvessel density was also observed when apoptin was delivered 
into xenogeneic tumor (Hep-2) in BALB/c nude mice.  
Instead of delivering apoptin in DNA form using vectors, protein form of apoptin could also be 
used. Currently, most of recombinant apoptin was produced in Escherichia coli expression 
system (Leliveld et al., 2003; Guelen et al., 2004; Sun et al., 2009). Preparation of recombinant 
apoptin in mammalian system was also reported by Ma et al. (2012) using human umbilical vein 
endothelial cells (HUVEC). Expression of recombinant apoptin in plants, Nicotiana benthamiana, 
was reported by Lacorte et al. (2007); however, no subsequent study was reported for bioactivity 
of plant-made apoptin in mammalian cells. Purified recombinant apoptin from E. coli expression 
system, recombinant MBP-apoptin, successfully induced apoptosis in human bone osteosarcoma 
(Saos-2) cells. However, MBP-apoptin was delivered into mammalian cells using microinjection 
since the protein could not directly pass through plasma membrane. In order to design a feasible 
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delivery way for long term study of recombinant apoptin, cell-penetrating peptides (CPPs) have 
been employed to assist protein penetrating plasma membrane. Trans-acting activator of 
transcription (Tat) protein from HIV, harbouring a protein transduction domain, was in fusion to 
apoptin (Guelen et al., 2004). Significant cell killing effect was observed when recombinant Tat-
apoptin was applied in Saos-2, HSC-3 cancer cells and human premyelocytic leukemia HL-60 
cells (Guelen et al., 2004; Lee et al., 2012). Besides, protein transduction domain 4 (PTD4) in 
fusion to apoptin, harvested from E. coli expression system, also harboured cell killing activity in 
human hepatocarcinoma HepG2 cells and restrained xenogeneic tumour growth in BALB/c nude 
mice (Sun et al., 2009). To date, no clinical study has been reported for apoptin; hence, effort for 
understanding apoptin-induced apoptosis as well as a good apoptin-based therapy approach is 
important to promote apoptin towards a great anticancer drug.    
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2.2 Plant as Expression Host 
2.2.1 Molecular Pharming 
2.2.1.1 Overview of plant as expression host for production of 
recombinant therapeutic proteins 
Molecular pharming is production of pharmaceutical recombinant proteins, such as vaccines and 
antibodies, in specific host using genetic engineering approach (Marsian and Lomonossoff, 
2016). Various kinds of expression hosts have been developed for the efficient production of 
recombinant proteins, such as prokaryotic system (E. coli and Bacillus subtilis), yeast 
(Saccharomyces cerevisiae), insect (Spodoptera frugiperda), mammalian cell lines (COS cells 
and CHO cells) and plants (N. benthamiana). Presence of pros and cons are always available for 
each of this expression systems; therefore, study should be performed and compared between the 
expression system in order to choose for the best expression host that gives the satisfied yield. 
For cell-based culture, recombinant protein can be produced within hours or days. Therefore, this 
production system, especially E. coli, becomes the most fascinated choice to produce large 
volume of targeted product within short period of time. However, expensive instruments and 
high maintenance cost for culture, fermentor and reactor have made production difficult to be 
scaled up. Besides, several critical problems are also arisen from this system, such as 
contamination of endotoxin in purified product, formation of inclusion body and lack of post-
translational modification system, and this has led to the development for alternative expression 
hosts (Yina et al., 2007). Mammalian cell expression system, as one of the alternative cell-based 
system, possess complete post-translational modification system; whereas, potential of 
mammalian viral contamination in purified product has also induced severe safety issue (Van der 
Pol and Tramper, 1998). As a result, plant-based expression system is highly gaining attention 
from researchers recently since all problems discussed above can be avoided using plants as 
expression host.   
Numbers of persuasive reasons using plant as alternative expression platform have driven 
researchers to focus on the establishment of this system. First, plant-based expression can be 
easily scaled up since plants can be grown in huge quantity in field. Plants require only simple 
and inexpensive sources for growing such as sunlight, mineral salt, water and soil (Fischer et al., 
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1999). There was estimated less than $50 required for 1 gram production of purified recombinant 
protein by Gleba et al., (2005). Besides, high expression level of recombinant protein could be 
obtained in plants. It was reported that milligrams or grams of recombinant proteins could be 
harvested within a month and 100 kg of products are possible collected less than a year (Gleba et 
al., 2005). In addition, potential infectious or pathogenic microbes are relatively lower in plant-
based system. Besides, presence of oncogenic sequences and viral contaminants, which are 
always the drawbacks of using mammalian viral vectors, could be also avoided by using plants 
(Fischer et al., 1999). Available of post translational modification system in plants is also 
another important reason for choosing plants as expression host, especially for the production of 
functional recombinant proteins that require proper folding. Production of improper folding 
protein in microbes (such as E. coli) has led to the formation of insoluble protein. In order to 
refold misfolded recombinant proteins, sophisticated and expensive downstream procedures are 
required to attain functional structure of proteins (Verma et al., 1998). On the way, expression of 
recombinant proteins in edible plant organs, such as seeds, could also eliminate the use of 
needles for delivery of the desired drug to human body. Instead of using leafy plants (such as 
tobacco), cereal seeds (such as maize, rice, wheat and barley) and some edible fruits as well as 
vegetables (potato, carrot and banana) have already been exploited to produce numbers of 
therapeutic drugs such as human serum albumin, tumour necrosis factor α (TNF-α) and 
antibodies (Fischer et al., 2004).  
2.2.1.2 Current status of plant-derived therapeutic proteins  
In 1986, human growth insulin, first plant-based recombinant therapeutics, was produced in 
sunflower and tobacco. By year 2011, there were more than 20 plant-derived therapeutic proteins 
undergoing preclinical and clinical trials (Yao et al., 2015). To date, several plant-derived 
therapeutic proteins have been commercialised in the market for research use as well as for 
human application. In year 2004, Sigma Aldrich announced that they would distribute tobacco-
derived aprotinin, which was a protease inhibitor produced by Large Scale Biology Corporation 
using GENEWARE technology (Outsourcing-Phama.com). Conventionally, aprotinin was 
extracted from lung of bovine; however, high cost as well as contamination of animal pathogens, 
such as bovine spongiform encephalopathy (BSE), were a concern of using this natural aprotinin. 
By using GENEWARE technology, which employing a full virus tobacco mosaic virus (TMV)-
 2-21 
 
based expression system, high amount of aprotinin was harvested (at ~ 150 to 300 mg/kg) and 
the risk for animal pathogen contamination is also low (Pogue et al., 2010).  
In year 2012, ELELYSO™, recombinant taliglucerase alfa produced from carrot cells, was the 
first FDA approved plant-derived therapeutic proteins for the treatment of Gaucher disease for 
adult (Yao et al., 2015). In addition, ZMapp, a chimeric monoclonal antibody against surface 
glycoprotein of Ebola produced in tobacco, was released by Mapp Biopharmaceutical Inc (San 
Diego, USA) in year 2014 (Davidson et al., 2015). ZMapp successfully saved several patients 
from death caused by Ebola disease although the drug has not been approved by FDA. In year 
2015, an outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) has killed 35% 
of infected patient. Plant Biotechnology Inc. (California, USA) reported that they have produced 
a tobacco-derived immunoadhesin (DPP4-Fc), by fusion of cell surface protein dipeptidyl 
peptidase 4 (DPP4) of MERS-CoV to constant region of human immunoglobulin (SBIRSource, 
2014). The recombinant protein prevents the infection of MERS-CoV by binding to MERS-CoV 
spike (S) glycoprotein. However, they claimed that high amount of recombinant protein is 
required to achieve 50% of inhibitory effect.  
2.2.2 Plant transformation strategies 
 Stable transformation and transient expression 
Stable transformation is a term for description regarding integration of foreign genes into 
recipient host genome and stably of integrated genes inherited by the progeny (Lico et al., 2008). 
There are numerous techniques available for plant stable transformation, including 
agrobacterium mediated transformation, biolistic, protoplast fusion, microinjection, employment 
of silicon carbide and tissue electroporation. The most commonly used stable transformation 
technique is agrobacterium-based transformation. In agrobacterium-based transformation 
approach, foreign genes are cloned on disarmed Ti plasmid, which is later delivered into host 
plants by agrobacterium (such as Agrobacterium tumefaciens and Agrobacterium rhizogene) 
(Gelvin, 2003). Agrobacterium-mediated transformation has been used widely in crops, such as 
soy bean, corn, rice and wheat (Nishimura et al., 2007; Sparks et al., 2014).  However, 
agrobacterium transformation is naturally available for dicotyledonous plants and favourable for 
transformation of monocotyledonous plants. Thus, direct gene transfer approach, using biolistic, 
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protoplast fusion, microinjection, employment of silicon carbide and tissue electroporation, is an 
alternative way to produce stable nuclear transformation for both monocotyledonous and 
dicotyledonous plants (Slater et al., 2003). 
Stable transformation is time consuming and requires tedious steps in order to generate 
transgenic plants. However, transient expression system is able to produce high protein 
expression level in short period of time after transformation (Slater et al., 2003). Foreign genes 
do not integrate into plant genome in transient expression system and non-integrated DNA is 
eventually lost over time. In plant, full viral vector as well as agroinfiltration are two major 
delivery approaches employed for transient expression. By using full viral vectors, DNA form of 
viral vectors or RNA transcripts of viral vector, harbouring genes of interest, is mechanically 
inonculated on plant leaves with carborandum (Escobar et al., 2003). Wounding sites on leaf 
surface generated by carbodandum allows the entry of plant viruses. For agroinfiltration 
approach, agrobacterium, harbouring disarmed Ti plasmid with gene of interest, is infiltrated into 
intercellular space of leaf mesophyll and agrobacterium is subsequently transfer Ti plasmid into 
plant genome (Chen et al., 2013). Since no selection activity for transformed cells with 
antibiotics is performed in both approaches, the expression of recombinant proteins is only 
expected from the infected or infiltrated plants and no seeds with stable transgenes are collected. 
Hence, protein expression using this method does not generate progeny with stable transgene.   
 
 Agroinfiltration strategy 
Agroinfiltration was initially used to study plant-virus interactions; however, this technique has 
been adopted recently for the production of recombinant proteins (Chen et al., 2013). By using 
agroinfiltration strategy, 2 common types of DNA vectors are available. General binary vector 
could be used for agroinfiltration by inserting an expression cassettes in T-DNA region of Ti 
plasmid. The second type of DNA vector involves the incorporation of partial or whole viral 
genome into T-DNA region of binary vector. Gene of interest is incorporated into the viral 
genome by inserting gene between viral elements, fusion to coat protein (CP) or replacing a non-
essential viral element.  
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Agroinfiltration can be performed using syringe or vacuum infiltration approaches. Syringe 
infiltration requires simple syringe rather than sophiscated machine. Besides, small amount of 
bacterial cultures is required and expression of multiple gene constructs could be assessed by 
infiltrating multiple construct on the same leaf. By using syringe infiltration, small amount of 
bacterial culture is pressed on the abaxial of leaves to deliver bacteria into intercellular space of 
leaf mesophyll. On the other hand, vacuum infiltration delivers bacteria into intercellular space 
of leaf mesophyll by changing the pressure in the infiltration chamber. Since infiltration work is 
performed by submerging plant leaves into bacterial suspension. larger amount of bacterial 
suspension is required for vacuum infiltration. However, this approach can infiltrate large 
batches of plants in short period of time. In addition, infiltration work performed using vacuum 
infiltration is consistent and severe mechanical injury could also be reduced. Currently, this 
platform is applied in several biopharmaceutical companies that produced recombinant proteins 
in plants, including Medicago Inc (USA), Fraunhofer Center for Molecular Biotechnology 
(FhCMB, USA), Kentucky Bioprocessing (USA) and Icon Genetics (Germany).    
 Emerging agro-based transformation approaches 
Although vacuum infiltration can efficiently infiltrate huge batches of plants, this approach is 
laborious and requires sophiscated machine. Hence, new delivery approaches are suggested to 
improve the current research challenge. In year 2008, Yang and his colleagues suggested 
delivery of agrobacterium into N. benthamiana using “root absorption” approach. They have 
successfully expressed recombinant GFP protein via this approach. From their study, expression 
of recombinant GFP in quadrifiliate phase and quinquefoliate phase is ~ 70% higher than in 
hexaphyllous phase. Seedling with root also showed higher expression of recombinant proteins. 
It is interesting to find that expression of recombinant GFP was ~60% higher when plants were 
not watered 7-10 days before inoculation.  
Besides, air-brush approach to deliver agrobacterium into tobacco plants was also reported in 
2015. Jin et al., (2015) successfully expressed recombinant GFP and human acidic fibroblast 
growth factor (ha FGF) in N. benthamiana using “air brush” method by employing carborandum 
and air-brush tube (pressure 75–80 psi). Similarly, recombinant protein has higher expression 
level in quadrifiliate phase and quinquefoliate phase. Highest expression of recombinant protein 
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was harvested from plants infiltrated for 7-9 dpi. Development for new delivery strategy is 
encouraged since this can directly reduce the cost as well as difficulty of the work for infiltration.
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3.1 Introduction 
Viral Protein 3 (VP3) is a small protein derived from Chicken Anemia Virus (CAV). This 
protein is renamed as ‘apoptin’ since it causes the depletion of myeloid cells and thymocytes 
by triggering apoptosis during viral infection in young chicken (Noteborn and Koch, 1995). It 
is believed that apoptin is a potential anticancer agent because apoptin exhibits selective 
killing feature towards cancer or transformed cells but not primary or non-transformed cells 
(Noteborn et al., 1995). DNA transfection with transfection reagents or mammalian viral 
vectors is a common tool used in most of the studies to deliver apoptin gene into cancer cells 
in vitro and in vivo (Backendorf et al., 2008). Moreover, production of recombinant apoptin 
had rapidly been discovered with predominant recovery from Escherichia coli expression 
system (Lelivelda et al., 2003; Nogueira-Dantas et al., 2007). 
Employment of plants as bioreactor to produce therapeutic drugs develops rapidly in both 
academia and industries. In comparison to other expression systems, plant-based system 
provides relatively more attractive benefits. These include low production cost, easy and 
scalable in production, short lead period and low risk of contamination with life-threatening 
biological agents (Fischer et al., 2004). With the advanced recombinant technology, high 
amount of recombinant proteins can be produced from plants with the creation of stable 
transformed lines or transient expression approach. Due to short incubation time and 
significantly high expression yield, transient expression is always a favourable method for 
large scale production of pharmaceutical products especially in an emergency situation 
(Gleba et al., 2005). Binary vectors and plant viral vectors are the two types of common 
vectors used in transient expression strategy to harbour gene of interest to be delivered into 
host plants. Due to several disadvantages of Ti plasmids originated from Agrobacterium 
tumefaciens, likewise the large molecular size leading to difficult manipulation in cloning 
activities, binary vectors have been developed to separate T-DNA region and vir genes that 
are important for transformation activities of Agrobacterium into two recombinant plasmids 
(Lee and Gelvin, 2008). Size reduction of recombinant plasmids enhances the transformation 
efficiency of foreign gene inserts with large molecular szie. The most commonly used binary 
vectors include pGreen, pBin19 and pPVP (Lee and Gelvin, 2008). More new binary vectors 
have been developed and modified based on these above mentioned binary vectors as vector 
backbones. On the other hand, plant viruses are also exploited and engineered to become 
compatible vectors for delivery of foreign DNA into plants. Expression of recombinant 
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protein with ‘full virus’ strategy requires several weeks for systemic movement of virus to 
whole plants; however, efficient delivery of foreign DNA into whole plants can be obtained 
by using deconstructed viral vectors (Gleba et al., 2007). Some viral elements that are 
responsible for systemic infection of virus, for example coat proteins or movement proteins, 
are removed and functions of these viral elements could be complemented by Agrobacterium 
via agroinfection or agroinfiltration technique.  
Yield and solubility are the two main challenges for recombinant protein expression 
following the successful delivery of transgene into host plants. In order to increase both yield 
and solubility of recombinant proteins, several approaches as mentioned below are always 
applied. First, codon sequences of foreign DNA could be optimised based on codon 
preferences of expression hosts. Codon optimisation removes rare codons and replaces 
synonymous codon sequences which are favourable by expression hosts; therefore, protein 
translation efficiency could be increased and yield of recombinant proteins could also be 
enhanced (Angov, 2011). Second, subcellular targeting is a way to accumulate recombinant 
proteins in a specific cell compartment in order to avoid high proteolytic activities occurring 
in cytoplasm. In plants, several subcellular compartments are always the preferred choices of 
researchers to store recombinant proteins, including endoplasmic reticulum (ER), vacuoles, 
apoplasts and chloroplasts (Streatfield, 2007). Third, fusion of recombinant proteins with 
large soluble protein molecules is an alternative way to enhance protein solubility. Large 
protein molecules, such as maltose binding protein (MBP) and glutathione S-transferase 
(GST), have always been used to increase solubility and correct folding of recombinant 
proteins (Terpe, 2003). Other than approaches mentioned above, protein expression may also 
be enhanced by inhibiting plant defense mechanisms by co-expression of recombinant protein 
with gene silencing suppressors, enhancing protein folding by co-expression with chaperones 
molecules as well as reducing proteolytic activity by co-expression of protease inhibitors 
(Feller et al., 2013; Kim et al., 2008). Nevertheless, these strategies do not necessary work 
well for all kinds of recombinant proteins and a good combination of these strategies should 
be investigated in order to achieve a better protein expression result.      
Development of a functional recombinant apoptin from plant-based system was the ultimate 
aim of the study. Previous studies showed several challenges that were needed to be solved in 
order to develop apoptin as a therapeutical drug. Up to date, expression of recombinant 
apoptin in plants was only once reported by Larcote et al. (2007) and only scarce information 
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was available for the production of apoptin in plant-based system. Recombinant apoptin 
produced in E. coli is always appeared in insoluble state, sophisticated purification and 
refolding processes are always required to recover the protein activities (Lelivelda et al., 
2003). Uneven delivery of apoptin gene into cancer cells is one of the major issues when 
apoptin is delivered via DNA transfection method (Backendorf et al., 2008). Besides, risk of 
potential infection by the mammalian virus, which it is used as a delivery tool, and cytotoxic 
effect of transfection reagents are also two major concerns with DNA transfection approaches 
(Anson, 2004). Hence, potential of production for recombinant apoptin in plants was 
explored in this study and several improvements had been made for recombinant apoptin 
expression in order to move a step forward for the production of apoptin as anticancer agent.  
In this chapter, design of apoptin gene cassettes and cloning of recombinant vectors are 
presented. In order to obtain high amount of soluble recombinant protein in Nicotiana 
benthamiana, optimisation was performed on codon sequences of apoptin to remove rare 
codons that might hamper expression of recombinant apoptin. Signal peptide (PR1a) and also 
ER retention signal were fused to apoptin sequence to redirect the accumulation of 
recombinant protein in apoplast and ER. Furthermore, green fluorescent protein (GFP) and a 
modified version of lichenase, a β-1,3-1,4-glucanase from Clostridium thermocellum, were 
fused to apoptin and it was believed that the fusion of large proteins was able to enhance the 
fraction of soluble protein. Sequences of single chain antibody H22 specifically binding to Fc 
gamma receptor I CD64+ and epidermal growth factor (EGF) that binds to EGF receptors 
were fused to apoptin sequence in order to target the action of apoptin towards cancer cells 
that overexpressed these receptors. A molecular adaptor was added between apoptin and 
tumor specific ligands to assist the internalisation of apoptin into cell cytosol. Besides, 
apoptin gene variants were co-expressed with ER stress proteins bZIP17, bZIP28 and bZIP60 
to enhance expression of recombinant apoptin.  
Hence, the specific objectives of this chapter were: (1) to optimise apoptin gene sequences 
based on the codon usage of N. benthamiana; (2) to design and construct apoptin gene 
cassettes harbouring apoptin gene with subcellular targeting signals, including signal peptide 
(PR1a) and ER retention signal (KDEL); (3) to construct apoptin gene cassettes in fusion 
with individual GFP and lichenase; (4) to construct apoptin gene cassettes in fusion with 
individual tumour specific ligands, namely H22 single chain antibody, EGF and the 
molecular adaptor CatAd; (5) to incorporate apoptin gene cassettes into vectors, pGR-D4, 
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pGR-D and pGR-DN, and lastly, (6) to integrate apoptin gene cassettes into vector, pGR-DN 
that harboured bZIP17, bZIP28 and bZIP60.       
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3.2 Materials and Methods 
 General materials 
3.2.1.1 Vectors 
Two types of vectors, including binary vectors (pGR-D and pGR-DN) and plant viral vector 
(pGR-D4), were used in this study to harbour apoptin gene cassettes and deliver into 
Nicotiana benthamiana via Agrobacterium. Tobacco mosaic virus (TMV) based expression 
vector (pGR-D4) as well as binary vectors, pGR-D and pGR-DN were kindly provided by 
Fraunhofer Center for Molecular Biotechnology (FhCMB), United States of America (USA). 
3.2.1.2 Synthetic gene cassettes 
All apoptin/VP3 gene cassettes based on sequence of Mohd-Azmi et al. (1997) (Malaysia 
isolate) (GenBank accession number: AAB86420.1) was synthesised by GeneArtTM Gene 
Synthesis, Thermo Scientific (USA). Synthetic gene cassette, PR-VP3-HK was designed as 
apoptin gene in fusion to C-terminal of signal peptide PR1a and N-terminal of hexahistidine 
as well as endoplasmic reticulum (ER) retention signal (Appendix 3.1). Individual green 
fluorescent protein (GFP) and lichenase were also synthesised in fusion to N-terminal of 
apoptin gene with signal peptide PR1a, hexahistidine and ER retention signal resulting the 
synthetic gene cassettes, PR-GFP-VP3-HK (Appendix 3.2) and PR-Lic-VP3-HK (Appendix 
3.3 Besides, synthetic gene sequences of red fluorescent protein, mCherryNuc (Appendix 
3.4), H22 single chain antibody (Appendix 3.5) and epidermal growth factor (EGF) 
(Appendix 3.6), bZIP17 (Appendix 3.7), bZIP28 (Appendix 3.8), bZIP60 (Appendix 3.9) 
were also synthesised by Gene Synthesis, Thermo Scientific (USA). All synthetic genes were 
provided in pMAT which served as a holding vector.  
Codon sequences of all synthetic genes were optimised based on the codon usage N. 
benthamiana. These synthetic genes are summarised in Table 3.1. 
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 Table 3.1: List of synthetic genes. 
No Synthetic gene cassettes Holding vector Source of sequences Appendix 
2 PR-VP3-HK pMAT:: PR-VP3-HK 
GeneArtTM Gene 
Synthesis, Thermo 
Scientific (USA) 
3.1 
3 PR-GFP-VP3-HK 
pMAT:: PR-GFP-VP3-
HK 
GeneArtTM Gene 
Synthesis, Thermo 
Scientific (USA) 
3.2 
4 PR-Lic-VP3-HK 
pMAT:: PR-Lic-VP3-
HK 
GeneArtTM Gene 
Synthesis, Thermo 
Scientific (USA) 
3.3 
5 mCherryNuc pMAT:: mCherryNuc 
GeneArtTM Gene 
Synthesis, Thermo 
Scientific (USA) 
3.4 
6 H22 
pMAT:: PR-HF-
H22catADGM 
GeneArtTM Gene 
Synthesis, Thermo 
Scientific (USA) 
3.5 
7 EGF 
pMAT:: PR-HF-EGF-
CatAD-Tau 
GeneArtTM Gene 
Synthesis, Thermo 
Scientific (USA) 
3.6 
8 bZIP17  - 
GeneArtTM Gene 
Synthesis, Thermo 
Scientific (USA) 
3.7 
9 bZIP28 - 
GeneArtTM Gene 
Synthesis, Thermo 
Scientific (USA) 
3.8 
10 bZIP60  - 
GeneArtTM Gene 
Synthesis, Thermo 
Scientific (USA) 
3.9 
 
3.2.1.3 Enzymes, kits and chemical reagents 
Polymerase enzymes used in polymerase chain reaction (PCR) assays included Phusion® 
High Fidelity PCR Master Mix with HF Buffer (New England Biolabs (NEB)® Inc, USA), 
Platinum® PCR SuperMix High Fidelity (Thermo Scientific, USA) and Platinum® PCR 
SuperMix (ThermoFisher Scientific, USA). DNA ladder, namely 1 kb Plus DNA ladder 
(ThermoFisher Scientific, USA) was used in gel electrophoresis. Restriction enzyme (RE) 
digestion was performed using enzymes inculduing PacI, XhoI, BsrGI and NheI (NEB® Inc, 
USA). Ligation was performed using T4 ligase (NEB® Inc, USA) and ligation buffer 
(ThermoFisher Scientific, USA). Gel purification was performed using ZymocleanTM Gel 
DNA Recovery Kit (Zymo Research, USA). Purification of DNA was also carried out using 
DNA Clean and ConcentratorTM-5 (Zymo Research, USA). Plasmid purification was 
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performed using ZyppyTM Plasmid Midiprep Kit (Zymo Research, USA). DNA gels were 
stained with ethidium bromide (ThermoFisher Scientific, USA).  
3.2.1.4 Consumable labware supplies and specialised equipment 
PCR was performed using Biometra T-Gradient (Biometra GmbH, Germany). DNA gel 
electrophoresis was carried out using DNA Plus gel electrophoresis system (USA Scientific, 
USA). Images of electrophoresed gels were captured using Kodak Capturing system with 
FOTO/Prep Transilluminator (Fotodyne Incorporated, USA). Concentration of DNA was 
measured using Nano Drop 1000 spectrophotometer (Thermo Scientific, USA). 
3.2.1.5 DNA sequencing, primer synthesis and data analysis  
Optimised DNA sequences were synthesised by GeneArtTM Gene Synthesis (Thermo 
Scientific, USA). Primers were synthesised by Integrated DNA Technologies (IDT, USA). 
DNA sequencing service was provided by Delaware Biotechnology Institute (DBI, USA). 
Codon adaptation indices (CAIs) of sequences were compared using CAIcal server. DNA 
sequences and maps were analysed using SeqBuilder (DNASTAR, Inc, USA) and GENtle 
(University of Cologne, 2003). Sequencing data were analysed and aligned using SeqMan 
Pro (DNASTAR, Inc, USA), BioEdit and ClustalW2 Multiple sequence alignment.  
 Overview of design and construction of recombinant of apoptin vector 
variants 
Synthetic apoptin gene in fusion to signal peptide from tobacco pathogenesis related protein 
1a (PR1a), hexa-histidine tag and endoplasmic reticulum (ER) retention signal (gene cassettes: 
PR-VP3-HK, PR-GFP-VP3-HK and PR-Lic-VP3-HK) (Table 3.2) were released from 
holding vector, pMAT using restriction enzymes, PacI and XhoI before incorporated into 
pGR-D4 vector. Recombinant apoptin expressed from these three gene cassettes were 
expected accumulating in ER of plant cells. Besides, ER retention signal was removed and 
the resultant gene cassettes, PR-VP3-H, PR-GFP-VP3-H and PR-Lic-VP3-H (Table 3.2) 
were generated. Removal of ER retention signal would be expected resulting recombinant 
proteins entering in secretory pathway and subsequently secreted into apoplast. Further 
removal of signal peptide generated gene cassettes, VP3-H, GFP-VP3-H and Lic-VP3-H 
(Table 3.2). Recombinant apoptin expressed from these gene cassettes were expected 
accumulating in cell cytoplasm. To 
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remove the fusion protein from apoptin after protein purification, an enterokinase site was 
incorporated between GFP and apoptin gene as well as lichenase and apoptin gene. Gene 
cassettes, PR-VP3-H, VP3-H, PR-GFP-VP3-H, GFP-VP3-H, PR-Lic-VP3-H and Lic-VP3-H 
were amplified from pMAT:: PR-VP3-HK, pMAT:: PR-GFP-VP3-HK and pMAT:: PR-Lic-
VP3-HK accordingly by the relevant primers (Table 3.3 and Appendix 3.10) via single step 
PCR using Phusion® High Fidelity PCR Master Mix with HF Buffer as described in section 
3.2.3. All PCR gene fragments were digested using PacI and XhoI before ligated to pGR-D4 
vector. 
Single chain antibody H22 and epidermal growth factor (EGF), for targeting to specific cell 
types, were also fused to N-terminal of apoptin gene with addition of signal peptide PR1a and 
ER retention signal. Instead of using full length apoptin gene sequence, truncated apoptin 
gene were also study while in fusion with H22 single chain antibody and EGF protein. A 
molecular adaptor was also incorporated between H22 single chain antibody and apoptin 
gene as well as EGF and apoptin gene. Therefore, gene cassettes, namely PR-H22-CatAd-
VP3-HK, PR-H22-CatAd-VP3-40-121-HK, PR-H22-CatAd-VP3-60-121-HK, PR-H22-
CatAd-VP3-80-121-HK, PR-EGF-CatAd-VP3-HK, PR-EGF-CatAd-VP3-40-121-HK, PR-
EGF-CatAd-VP3-60-121-HK, PR-EGF-CatAd-VP3-80-121-HK were amplified from 
recombinant vectors, pMAT:: PR-HF-H22catADGM, pMAT:: PR-HF-EGF-CatAD-Tau and 
pMAT:: PR-GFP-VP3-HK with corresponding primers (Table 3.3 and Appendix 3.10) via 
fusion PCR using Platinum® PCR SuperMix High Fidelity (section 3.2.3). All PCR gene 
fragments were digested using PacI and XhoI before ligated to pGR-D4 vector. 
Gene cassettes, PR-VP3-HK, PR-GFP-VP3-HK and PR-EGF-CatAd-VP3-HK (Table 
3.2Table 3.) were released from pGR-D4 vector using restriction enzymes, PacI and XhoI 
before ligated to pGR-DN vector that harboured the sequences of ER stress proteins, i.e. 
bZIP17, bZIP28 and bZIP60 located downstream of apoptin expression cassettes driven by 
individual promoters. 
Besides, gene cassettes, PR-GFP-VP3-HK, PR-GFP-VP3-H and GFP-VP3-H (Table 3.2) 
were also released from vectors, pMAT and pGR-D4 using restriction enzymes, PacI and 
XhoI before subcloned into binary vector, pGR-D. Recombinant GFP-apoptin was co-
expressed with a red fluorescent protein (mCherry) in order to evaluate the localisation of 
recombinant apoptin in N. benthamiana. mCherry was fused to N-terminal of nuclear 
localisation signal (Nuc) and the expression of mCherryNuc was directed by a separate 
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promoter located downstream of apoptin expression cassettes. Gene cassette, mCherryNuc 
was released from vector, pMAT:: mCherryNuc using BsrGI and NheI before ligated to pGR-
D. 
A schematic diagram is presented to illustrate the construction procedure of recombinant 
vectors in Figure 3.1. 
Table 3.2: List of apoptin gene cassettes. 
No 
Name of 
backbone  
Schematic diagrams of apoptin gene cassettes for the recombinant vector 
variants 
1 
p
G
R
-D
4
    PR-VP3-HK  
    
2 
p
G
R
-D
4
    PR-VP3-H 
    
3 
p
G
R
-D
4
    VP3-H 
    
4 
p
G
R
-D
4
    PR-GFP-VP3-HK  
    
5 
p
G
R
-D
4
    PR-GFP-VP3-H  
    
6 
p
G
R
-D
4
    GFP-VP3-H  
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7 
p
G
R
-D
4
    PR-Lic-VP3-HK  
    
8 
p
G
R
-D
4
    PR-Lic-VP3-H  
    
9 
p
G
R
-D
4
    Lic-VP3-H  
    
10 
p
G
R
-D
4
    PR-H22-CatAd-VP3-HK 
    
11 
p
G
R
-D
4
    PR-H22-CatAd-VP3-40-121-HK 
    
12 
p
G
R
-D
4
    PR-H22-CatAd-VP3-60-121-HK 
    
13 
p
G
R
-D
4
    PR-H22-CatAd-VP3-80-121-HK 
    
14 
p
G
R
-D
4
    PR-EGF-CatAd-VP3-HK 
    
15 
p
G
R
-D
4
    PR-EGF-CatAd-VP3-40-121-HK 
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16 
p
G
R
-D
4
    PR-EGF-CatAd-VP3-60-121-HK 
    
17 
p
G
R
-D
4
    PR-EGF-CatAd-VP3-80-121-HK 
    
18 
p
G
R
-D
N
    PR-VP3-HK__bZIP17 
    
19 
p
G
R
-D
N
    PR-VP3-HK__bZIP28 
    
20 
p
G
R
-D
N
    PR-VP3-HK__bZIP60 
    
21 
p
G
R
-D
N
    PR-GFP-VP3-HK__bZIP17 
    
22 
p
G
R
-D
N
    PR-GFP-VP3-HK__bZIP28 
    
23 
p
G
R
-D
N
    PR-GFP-VP3-HK__bZIP60 
    
24 
p
G
R
-D
N
    PR-EGF-CatAd-VP3-HK__bZIP17 
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25 
p
G
R
-D
N
    PR-EGF-CatAd-VP3-HK__bZIP28 
    
26 
p
G
R
-D
N
    PR-EGF-CatAd-VP3-HK__bZIP60 
    
27 
p
G
R
-D
 
   PR-GFP-VP3-HK__mCherryNuc 
    
 
28 
p
G
R
-D
 
   PR-GFP-VP3-H__mCherryNuc 
    
 
29 
p
G
R
-D
 
   GFP-VP3-H__mCherryNuc 
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Figure 3.1: Schematic representation of construction process of all recombinant vectors under 
the study.   
3.2.3 Polymerase chain reaction (PCR) 
All PCR preparations were done as recommended by manufacturer. General PCR mixtures 
were prepared as described: 1X reaction buffer, 1 unit of polymerase, forward and reverse 
primers (0.6 µM each), 15 ng DNA template and topped up with distilled water to 50 µl. PCR 
programme was initiated at 94-98°C from 30 seconds to 5 minutes, followed by 35 cycles of 
denaturation at 94-98°C for 10-45 seconds, annealing at 40-70°C for 40 seconds and 
extension at 68-72°C with 1-2kb/minute. The mixtures were incubated at 68-72°C for an 
additional 5-10 minutes and stored at 4-10°C after the amplification processes had finished. 
Amplified fragments were analysed in 1% agarose gel electrophoresis, subsequently, gel 
images were captured and recorded. Specific conditions of PCR for each gene cassette are 
listed clearly in Table 3.3 and primer sequences in Appendix 3.10. 
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Table 3.3: PCR conditions for apoptin gene cassettes. 
No 
Gene 
cassettes 
Templates 
Parameters of PCR 
Primers Annealing 
temperature 
Extension 
time Forward Reverse 
1 PR-VP3-H 
pMAT:: PR-VP3-
HK 
pVP3-F VP3H-R 56°C 
40 
seconds 
2 VP3-H 
pMAT:: PR-VP3-
HK 
VP3-F VP3H-R 56°C 
40 
seconds 
3 
PR-GFP-
VP3-H 
pMAT:: PR-GFP-
VP3-HK 
pVP3-F gVP3H-R 56°C 
40 
seconds 
4 
GFP-VP3-
H 
pMAT:: PR-GFP-
VP3-HK 
gVP3-F gVP3H-R 56°C 
40 
seconds 
5 
PR-Lic-
VP3-H 
pMAT:: PR-Lic-
VP3-HK 
pVP3-F VP3H-R 56°C 
40 
seconds 
6 Lic-VP3-H 
pMAT:: PR-Lic-
VP3-HK 
LicVP3-F VP3H-R 56°C 
40 
seconds 
7 
PR-H22-
CatAd-
VP3-HK 
pMAT:: PR-HF-
H22catADGM 
and  pMAT:: PR-
GFP-VP3-HK 
PRH22-F; 
HCatVP3-F;    
YFE1-T-F 
HCatVP3-R;       
VP3-HK_R 
56-63°C 
45-90 
seconds 
8 
PR-H22-
CatAd-
VP3-40-
121-HK 
pMAT:: PR-HF-
H22catADGM 
and  pMAT:: PR-
GFP-VP3-HK 
PRH22-F; 
HCatVP3-40-121-F; 
YFE1-T-F 
HCatVP3-40-121-R; 
VP3-HK_R 
56-63°C 
45-90 
seconds 
9 
PR-H22-
CatAd-
VP3-60-
121-HK 
pMAT:: PR-HF-
H22catADGM 
and  pMAT:: PR-
GFP-VP3-HK 
PRH22-F; 
HCatVP3-60-121-F; 
YFE1-T-F 
HCatVP3-60-121-R; 
VP3-HK_R 
56-63°C 
45-90 
seconds 
10 
PR-H22-
CatAd-
VP3-80-
121-HK 
pMAT:: PR-HF-
H22catADGM 
and  pMAT:: PR-
GFP-VP3-HK 
PRH22-F; 
HCatVP3-80-121-F; 
YFE1-T-F 
HCatVP3-80-121-R; 
VP3-HK_R 
56-63°C 
45-90 
seconds 
11 
PR-EGF-
CatAd-
VP3-HK 
pMAT:: PR-HF-
EGF-CatAD-Tau 
and  pMAT:: PR-
GFP-VP3-HK 
PREGF-F; 
ECatVP3-F;   
YFE1-T-F  
ECatVP3-R;       
VP3-HK_R 
56-63°C 
45-90 
seconds 
12 
PR-EGF-
CatAd-
VP3-40-
121-HK 
pGR-D4:: PR-
EGF-CatAd-VP3-
HK 
YFE-1-T-F; 
ECatVP3-40-121-F;  
ECatVP3-40-121-R; 
VP3-HK_R 
56-63°C 
45-90 
seconds 
13 
PR-EGF-
CatAd-
VP3-60-
121-HK 
pGR-D4:: PR-
EGF-CatAd-VP3-
HK 
YFE-1-T-F; 
ECatVP3-60-121-F;  
ECatVP3-60-121-R; 
VP3-HK_R 
56-63°C 
45-90 
seconds 
14 
PR-EGF-
CatAd-
VP3-80-
121-HK 
pGR-D4:: PR-
EGF-CatAd-VP3-
HK 
YFE-1-T-F; 
ECatVP3-80-121-F;  
ECatVP3-80-121-R; 
VP3-HK_R 
56-63°C 
45-90 
seconds 
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3.2.4 DNA purification 
ZymocleanTM Gel DNA Recovery Kit was used to recover the DNA pieces from agarose gel. 
Three volumes of ADB buffer were added to each volume of agarose excised from the gel 
and the mixture was incubated at 55°C for 10 minutes until the gel slice was completely 
dissolved. Melted agarose solution was transferred to a Zymo-Spin™ column with collection 
tube following by 30-second centrifugation at 13, 000 rpm. The pass-through was discarded 
and 200 µl of DNA wash buffer was added to the column followed by 30-second 
centrifugation at 13, 000 rpm. The washing step was repeated before DNA bound to the 
column matrix was eluted with 15-20 µl of distilled water. Columns were further incubated 
for 5 minutes at room temperature before centrifuging at 13, 000 rpm for 1 minute. Elution 
step was repeated to acquire higher amount of DNA from column matrix.  
RE-digested DNA was also purified by using DNA Clean and ConcentratorTM-5. 
Approximately 5 volumes of DNA Binding Buffer was added to 1 volume of DNA sample 
and mixed by vortexing. All mixtures were then transferred to Zymo-SpinTM columns with 
collection tubes followed by centrifugation for 30 seconds. The pass-through was discarded 
and 200 µl of DNA Wash Buffer was added to the column followed by another centrifugation 
for 30 seconds. Washing step was repeated before addition of 8-10 µl of distilled water to the 
column matrix. Columns were incubated at room temperature for 5 minutes before 
centrifuging for 30 seconds to elute DNA from the column matrix.  
Concentration and purity of all purified DNA products were then measured by Nano Drop 
1000 spectrophotometer. 
3.2.5 Restriction enzyme (RE) digestion 
A general double RE digestion was prepared as below: 0.5-2 µg of vectors, 500 ng of gene 
cassettes from PCR, 1-10 units of enzymes, 1X reaction buffer, 1X BSA and topped up to 50 
µl with distilled water. RE digestion for specific apoptin gene cassettes and vectors are listed 
clearly in Table 3.4. 
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Table 3.4: RE digestion details of apoptin gene cassettes and vectors. 
No Gene cassettes 
RE Incubation 
temperature 
Incubation period 
1 2 
1 PR-VP3-H PacI XhoI 37°C 2 hours 
2 VP3-H PacI XhoI 37°C 2 hours 
3 PR-GFP-VP3-H PacI XhoI 37°C 2 hours 
4 GFP-VP3-H PacI XhoI 37°C 2 hours 
5 PR-Lic-VP3-H PacI XhoI 37°C 2 hours 
6 Lic-VP3-H PacI XhoI 37°C 2 hours 
7 PR-H22-CatAd-VP3-HK PacI XhoI 37°C 2 hours 
8 PR-H22-CatAd-VP3-40-121-HK PacI XhoI 37°C 2 hours 
9 PR-H22-CatAd-VP3-60-121-HK PacI XhoI 37°C 2 hours 
10 PR-H22-CatAd-VP3-80-121-HK PacI XhoI 37°C 2 hours 
11 PR-EGF-CatAd-VP3-HK PacI XhoI 37°C 2 hours 
12 PR-EGF-CatAd-VP3-40-121-HK PacI XhoI 37°C 2 hours 
13 PR-EGF-CatAd-VP3-60-121-HK PacI XhoI 37°C 2 hours 
14 PR-EGF-CatAd-VP3-80-121-HK PacI XhoI 37°C 2 hours 
15 mCherryNuc BsrGI NheI 37°C 2 hours 
16 bZIP17 BsrGI NheI 37°C 2 hours 
17 bZIP28 BsrGI NheI 37°C 2 hours 
18 bZIP60 BsrGI NheI 37°C 2 hours 
19 pGR-D4 PacI XhoI 37°C 2 hours 
20 pGR-D PacI XhoI 37°C 2 hours 
21 pGR-D BsrGI NheI 37°C 2 hours 
22 pGR-DN PacI XhoI 37°C 2 hours 
23 pGR-DN BsrGI NheI 37°C 2 hours 
3.2.6 Ligation  
All RE-digested inserts were ligated to the respective vectors, pGR-D4, pGR-DN or pGR-D 
at 3:1 molar ratio. Ligation mixtures were prepared with inserts (3X molar of vector), 20 ng 
of vectors, 0.5 µl of T4 ligase, 1X Ligation Buffer and topped up with distilled water to 10 µl. 
Mixtures were incubated at room temperature for at least 2 hours. 
3.2.7 Transformation and selection of positive clones 
Ten µl of ligation mixture was added into 100 µl of Escherichia coli competent cells (XLI-B 
strain) and incubated on ice for at least 20 minutes. E. coli competent cells were heat-shocked 
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at 42°C for 45 seconds, subsequently, incubated on ice again for 2 minutes. Then, 400 µl of 
Luria Broth (LB) was added to the competent cells before bacterial suspensions were 
incubated at 37°C for at least an hour. After the incubation, bacterial suspensions were spread 
on LB agar plates containing 50 µg/ml kanamycin. All plates were incubated at 37°C 
overnight and PCR screening was performed to confirm the positive recombinant clones.   
3.2.8 Plasmid extraction 
Overnight bacterial cultures were purified using ZyppyTM Plasmid Midiprep Kit. Forty ml of 
overnight cultures were pelleted at 6, 000 rpm for 10 minutes and 6 ml of distilled water was 
used to resuspend bacterial pellets. Pellets were vortexed and 1 ml of 7X Lysis Buffer (Blue) 
was added and followed by inverting the tubes for 2-4 times. Mixtures were incubated at 
room temperature for 2 minutes and 3.5 ml of cold Neutralisation Buffer (Yellow) was added 
subsequently. Then, mixtures were inverted for 4-6 times to mix thoroughly while samples 
turned yellow with precipitates observed as neutralisation was complete. All mixtures were 
transferred to Zymo-Midi FilterTM columns, which were fixed onto a vacuum manifold, and 
vacuum was turned on to remove all the liquid lysate. All blue Zymo-Midi FilterTM columns 
from the top of Zymo-SpinTM V-E were discarded, nevertheless, Zymo-SpinTM V-E columns 
were transferred to a collection tube and centrifuged at 13, 000 rpm for 30 seconds to remove 
any retained liquid. Then, 200 µl of Endo-Wash Buffer was added to Zymo-SpinTM V-E 
columns and centrifuged at 13, 000 rpm for 30 seconds. Besides, 400 µl of ZyppyTM Wash 
Buffer was also added to the columns and centrifuged at 13, 000 rpm for another 30 seconds. 
Washing step of the columns with ZyppyTM Wash Buffer was repeated and the columns were 
centrifuged at 13, 000 rpm for additional 1 minute to remove any trace of buffer. Zymo-
SpinTM V-E columns were then transferred to new 1.5 ml microcentrifuge tubes and 150 µl of 
distilled water was added to the centre of the column. The column was incubated at room 
temperature for 5 minutes before centrifuging at 13, 000 rpm for 1 minute. Purity and 
concentration of DNA were measured using Nano Drop 1000 spectrophotometer. 
3.2.9 Verification of recombinant vectors 
Extracted recombinant vectors were verified by RE-digestion as illustrated in sections 3.2.3 
and 3.2.5. Verified recombinant vectors were then sent for sequencing. Sequencing results 
were assembled using SeqMan Pro and sequences were aligned using Bioedit and ClustalW2 
Multiple sequence alignment. 
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3.3 Results 
3.3.1 Codon optimisation of apoptin gene  
Codon sequences of apoptin gene cassettes were optimised based on codon usage of 
Nicotiana benthamiana in order to enhance the translation efficiency of recombinant protein. 
Codon adaptation index (CAI), a scoring or measure for codon adaptiveness in a gene 
sequence in reference to a given set of codon usage frequency analysed from highly 
expressed gene in a species and effective number of codons (ENC), a scoring for equal usage 
of synonymous codons in a gene, for native and optimised apoptin gene sequences are listed 
in Table 3.5. 
Table 3.5: Codon adaptation index (CAI) and effective number of codons (ENC) for apoptin 
gene cassettes. 
No 
Source of gene 
sequences 
Apoptin gene cassettes CAI  ENC GC content 
1 Genebank: AAB86420.1 VP3-A 0.681 61.0 53.0 
2 GeneArt, USA PR-VP3-HK 0.832 29.3 50.6 
3 GeneArt, USA PR-GFP-VP3-HK 0.815 28.0 49.7 
4 GeneArt, USA PR-Lic-VP3-HK 0.818 27.4 49.8 
Non-optimised apoptin sequences showed CAI approximately 0.68 and ENC at 61. However, 
optimised apoptin sequences showed a higher CAI, which is more than 0.8, and low ENC at 
approximately 27-29.     
3.3.2 Polymerase chain reaction (PCR) amplification and restriction enzyme 
(RE) digestion profiles of apoptin gene cassettes 
Apoptin gene cassettes were generated by using PCR and RE digestion in order to ligate to 
vectors, pGR-D4, pGR-DN and pGR-D. Apoptin gene cassettes, namely PR-VP3-H, VP3-H, 
PR-GFP-VP3-H, GFP-VP3-H, PR-Lic-VP3-H and Lic-VP3-H, were amplified by PCR and 
the amplified PCR products were analysed in 1% gel electrophoresis as shown in Figure 3.2.  
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 Lane Gene cassettes Estimated size  
 L 1 kb Plus DNA ladder   
 1 PR-VP3-H ~ 474 bp  
 2 VP3-H  ~ 384 bp  
 3 PR-GFP-VP3-H  ~ 1203 bp  
 4 GFP-VP3-H  ~ 1116 bp  
 5 PR-Lic-VP3-H  ~1158 bp  
 6 Lic-VP3-H  ~ 1068 bp  
     
Figure 3.2: PCR amplification profiles of apoptin gene cassettes, namely PR-VP3-H, VP3-H, 
PR-GFP-VP3-H, GFP-VP3-H, PR-Lic-VP3-H and Lic-VP3-H.  
Gene cassettes, namely PR-H22-CatAd-VP3-HK, PR-H22-CatAd-VP3-40-121-HK, PR-H22-
CatAd-VP3-60-121-HK, PR-H22-CatAd-VP3-80-121-HK, PR-EGF-CatAd-VP3-HK, PR-
EGF-CatAd-VP3-40-121-HK, PR-EGF-CatAd-VP3-60-121-HK and PR-EGF-CatAd-VP3-
80-121-HK were generated by fusion PCR and PCR amplification profiles of these gene 
cassettes are shown in Figure 3.3.  
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 Lane Gene cassettes Estimated size  
 L 1 kb Plus DNA ladder   
 1 PR-H22-CatAd-VP3-HK ~ 1338 bp  
 2 PR-H22-CatAd-VP3-40-121-HK ~ 1299 bp  
 3 PR-H22-CatAd-VP3-60-121-HK ~ 1279 bp  
 4 PR-H22-CatAd-VP3-80-121-HK ~ 1259 bp  
 5 PR-EGF-CatAd-VP3-HK ~ 756 bp  
 6 PR-EGF-CatAd-VP3-40-121-HK ~ 717 bp  
 7 PR-EGF-CatAd-VP3-60-121-HK ~ 697 bp  
 8 PR-EGF-CatAd-VP3-80-121-HK ~ 677 bp  
     
Figure 3.3: PCR amplification profiles of apoptin gene cassettes, namely PR-H22-CatAd-
VP3-HK, PR-H22-CatAd-VP3-40-121-HK, PR-H22-CatAd-VP3-60-121-HK, PR-H22-
CatAd-VP3-80-121-HK, PR-EGF-CatAd-VP3-HK, PR-EGF-CatAd-VP3-40-121-HK, PR-
EGF-CatAd-VP3-60-121-HK and PR-EGF-CatAd-VP3-80-121-HK. 
RE digestion profiles of recombinant vectors, pGR-D4:: PR-VP3-HK, pGR-D4:: PR-GFP-
VP3-HK and pGR-D4:: PR-EGF-CatAd-VP3-HK are also shown in Figure 3.4. Digested 
gene cassettes were purified from gel and cloned into pGR-DN vector. 
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Lane Vector backbone Gene cassettes Estimated size  
L  1 kb Plus DNA ladder   
1 pGR-D4 PR-EGF-CatAd-VP3-HK ~ 756 bp  
2 pGR-D4 PR-GFP-VP3-HK ~ 1215 bp  
3 pGR-D4 PR-VP3-HK ~ 486 bp  
      
Figure 3.4: RE digestion profiles of apoptin gene cassettes, namely PR-VP3-HK, PR-GFP-
VP3-HK and PR-EGF-CatAd-VP3-HK. 
RE digestion profiles of recombinant vectors, pMAT:: PR-VP3-HK, pMAT:: PR-GFP-VP3-
HK, pMAT:: PR-Lic-VP3-HK, pGR-D4:: PR-GFP-VP3-H, pGR-D4:: GFP-VP3-H and 
pMAT:: mCherryNuc are also shown in Figure 3.5. Digested gene cassettes were purified 
from gel and cloned into individual vectors, pGR-D4 and pGR-D. 
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Lane Vector backbone Gene cassettes Estimated size  
L  1 kb Plus DNA ladder   
1 pMA-T PR-VP3-HK ~ 486 bp  
2 pMA-T PR-GFP-VP3-HK ~ 1215 bp  
3 pMA-T PR-Lic-VP3-HK ~ 1184 bp  
4 pMA-T mCherryNuc ~ 780 bp  
5 pMA-T PR-GFP-VP3-HK ~ 1215 bp  
6 pGR-D4 PR-GFP-VP3-H ~ 1203 bp  
7 pGR-D4 GFP-VP3-H ~ 1116 bp  
      
Figure 3.5: RE digestion profiles of apoptin gene cassettes, namely PR-VP3-HK, PR-GFP-
VP3-HK, PR-Lic-VP3-HK, PR-GFP-VP3-H, GFP-VP3-H and mCherryNuc. 
3.3.3 Verification of recombinant vectors 
All recombinant vectors were analysed via RE digestion before the sequences of samples 
were further verified via sequencing. The results are shown following the RE digestion by 
PacI and XhoI for the verification of the recombinant vectors, namely pGR-D4:: PR-VP3-HK, 
pGR-D4:: PR-VP3-H, pGR-D4:: VP3-H, pGR-D4:: PR-GFP-VP3-HK, pGR-D4:: PR-GFP-
VP3-H, pGR-D4:: GFP-VP3-H (Figure 3.6), pGR-D4::PR-Lic-VP3-HK, pGR-D4:: PR-Lic-
VP3-H, pGR-D4:: Lic-VP3-H (Figure 3.7), pGR-D4:: PR-H22-CatAd-VP3-HK, pGR-D4:: 
PR-H22-CatAd-VP3-40-121-HK, pGR-D4:: PR-H22-CatAd-VP3-60-121-HK, pGR-D4:: 
PR-H22-CatAd-VP3-80-121-HK (Figure 3.8), pGR-D4:: PR-EGF-CatAd-VP3-HK, pGR-D4:: 
PR-EGF-CatAd-VP3-40-121-HK, pGR-D4:: PR-EGF-CatAd-VP3-60-121-HK, pGR-D4:: 
PR-EGF-CatAd-VP3-80-121-HK (Figure 3.9). 
 
 3-24 
 
 
 
 
 
  
(a) 
 
 
 
 
 
Lane Recombinant vectors 
Gene cassettes released 
from RE digestion 
Estimated size 
 
 L 1 kb Plus DNA ladder    
 1-2 pGR-D4:: PR-VP3-HK PR-VP3-HK ~ 486 bp  
 3-4 pGR-D4:: PR-GFP-VP3-HK PR-GFP-VP3-HK ~1215 bp  
 5-6 pGR-D4:: PR-VP3-H PR-VP3-H ~ 474 bp  
 7-8 pGR-D4:: VP3-H VP3-H ~ 384 bp  
 9-10 pGR-D4:: PR-GFP-VP3-H PR-GFP-VP3-H ~ 1203 bp  
 11-12 pGR-D4:: GFP-VP3-H GFP-VP3-H ~ 1116 bp  
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(b) 
 
Features 
 VP3 
GFP 
PR1a 
Ent 
H6 
K 
PacI and XhoI 
LB 
RB 
CaMV 35S  
126/183k replicase 
MP 
Nos terminator  
NPTI 
pSa-Ori 
ColEI 
 
: Apoptin gene 
: Green fluorescent protein 
: Signal peptide 
: Enterokinase site 
: Hexahistidine 
: Endoplasmic reticulum (ER) retention signal 
: Restriction enzymes 
: Left border 
: Right border 
: Cauliflower mosaic virus 35S promoter 
: Tobacco mosaic virus (TMV) replicase 
: Movement protein 
: Nopaline synthase terminator 
: Neomycin phosphotransferase 
: Origin of replication  
: Origin of replication for high copy number of plasmids in     
   Escherichia coli 
 
Figure 3.6: RE verification profiles for recombinant vectors, namely pGR-D4:: PR-VP3-HK, 
pGR-D4:: PR-VP3-H, pGR-D4:: VP3-H, pGR-D4:: PR-GFP-VP3-HK, pGR-D4:: PR-GFP-
VP3-H, pGR-D4:: GFP-VP3-H. (a) RE verification using PacI and XhoI for recombinant 
vectors; (b) Schematic diagram of the recombinant vector, pGR-D4 with apoptin gene 
cassettes as inserts. 
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(a) 
 
 
 
 
 
Lane Recombinant vectors 
Gene cassettes released 
from RE digestion 
Estimated size 
 
 L 1 kb Plus DNA ladder    
 1-2 pGR-D4:: PR-Lic-VP3-HK PR-Lic-VP3-HK ~ 1170 bp  
 3-4 pGR-D4:: PR-Lic-VP3-H PR-Lic-VP3-H ~1158 bp  
 5-6 pGR-D4:: Lic-VP3-H Lic-VP3-H ~ 1068 bp  
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(b) 
 
 
 
 
 
 
Features 
 VP3 
Lic 
PR1a 
Ent 
H6 
K 
PacI and XhoI 
LB 
RB 
CaMV 35S  
126/183k replicase 
MP 
Nos terminator  
NPTI 
pSa-Ori 
ColEI 
 
: Apoptin gene 
: Lichenase 
: Signal peptide 
: Enterokinase site 
: Hexahistidine 
: Endoplasmic reticulum (ER) retention signal 
: Restriction enzymes 
: Left border 
: Right border 
: Cauliflower mosaic virus 35S promoter 
: Tobacco mosaic virus (TMV) replicase 
: Movement protein 
: Nopaline synthase terminator 
: Neomycin phosphotransferase 
: Origin of replication  
: Origin of replication for high copy number of plasmids in     
   Escherichia coli 
 
Figure 3.7: RE verification profiles for recombinant vectors, namely pGR-D4:: PR-Lic-VP3-
HK, pGR-D4:: PR-Lic-VP3-H and pGR-D4:: Lic-VP3-H. (a) RE verification using PacI and 
XhoI for recombinant vectors; (b) Schematic diagram of the recombinant vector, pGR-D4 
with apoptin gene cassettes as inserts. 
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 (a) 
 
 
 
 
 
Lane Recombinant vectors 
Gene cassettes released from RE 
digestion 
Estimated 
size 
 
 L 1 kb Plus DNA ladder    
 1-2 pGR-D4:: PR-H22-CatAd-VP3-HK PR-H22-CatAd-VP3-HK ~ 1338 bp  
 3-4 pGR-D4:: PR-H22-CatAd-VP3-40-121-HK PR-H22-CatAd-VP3-40-121-HK ~ 1299 bp  
 5-6 pGR-D4:: PR-H22-CatAd-VP3-60-121-HK PR-H22-CatAd-VP3-60-121-HK ~ 1279 bp  
 7-8 pGR-D4:: PR-H22-CatAd-VP3-80-121-HK PR-H22-CatAd-VP3-80-121-HK ~ 1259 bp  
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(b) 
  
Features 
 VP3 
H22 
PR1a 
Cat-Ad 
H6 
K 
PacI and XhoI 
LB 
RB 
CaMV 35S  
126/183k replicase 
MP 
Nos terminator  
NPTI 
pSa-Ori 
ColEI 
 
: Apoptin gene 
: H22 single chain antibody 
: Signal peptide 
: Molecular adaptor 
: Hexahistidine 
: Endoplasmic reticulum (ER) retention signal 
: Restriction enzymes 
: Left border 
: Right border 
: Cauliflower mosaic virus 35S promoter 
: Tobacco mosaic virus (TMV) replicase 
: Movement protein 
: Nopaline synthase terminator 
: Neomycin phosphotransferase 
: Origin of replication  
: Origin of replication for high copy number of plasmids in     
   Escherichia coli 
 
Figure 3.8: RE verification profiles for recombinant vectors, namely pGR-D4:: PR-H22-
CatAd-VP3-HK, pGR-D4:: PR-H22-CatAd-VP3-40-121-HK, pGR-D4:: PR-H22-CatAd-
VP3-60-121-HK and pGR-D4:: PR-H22-CatAd-VP3-80-121-HK. (a) RE verification using 
PacI and XhoI for recombinant vectors; (b) Schematic diagram of the recombinant vector, 
pGR-D4 with apoptin gene cassettes as inserts. 
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(a) 
 
 
 
 
 
Lane Recombinant vectors 
Gene cassettes released from RE 
digestion 
Estimated 
size 
 
 L 1 kb Plus DNA ladder    
 1-2 pGR-D4:: PR-EGF-CatAd-VP3-HK PR-EGF-CatAd-VP3-HK ~ 756 bp  
 3-4 pGR-D4:: PR-EGF-CatAd-VP3-40-121-HK PR-EGF-CatAd-VP3-40-121-HK ~ 717 bp  
 5-6 pGR-D4:: PR-EGF-CatAd-VP3-60-121-HK PR-EGF-CatAd-VP3-60-121-HK ~ 697 bp  
 7-8 pGR-D4:: PR-EGF-CatAd-VP3-80-121-HK PR-EGF-CatAd-VP3-80-121-HK ~ 677 bp  
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(b)  
 
 
 
 
 
 
Features 
 VP3 
EGF 
PR1a 
Cat-Ad 
H6 
K 
PacI and XhoI 
LB 
RB 
CaMV 35S  
126/183k replicase 
MP 
Nos terminator  
NPTI 
pSa-Ori 
ColEI 
 
: Apoptin gene 
: Epidermal growth factor 
: Signal peptide 
: Molecular adaptor 
: Hexahistidine 
: Endoplasmic reticulum (ER) retention signal 
: Restriction enzymes 
: Left border 
: Right border 
: Cauliflower mosaic virus 35S promoter 
: Tobacco mosaic virus (TMV) replicase 
: Movement protein 
: Nopaline synthase terminator 
: Neomycin phosphotransferase 
: Origin of replication  
: Origin of replication for high copy number of plasmids in     
   Escherichia coli 
 
Figure 3.9: RE verification profiles for recombinant vectors, namely pGR-D4:: PR-EGF-
CatAd-VP3-HK, pGR-D4:: PR-EGF-CatAd-VP3-40-121-HK, pGR-D4:: PR-EGF-CatAd-
VP3-60-121-HK and pGR-D4:: PR-EGF-CatAd-VP3-80-121-HK. (a) RE verification using 
PacI and XhoI for recombinant vectors; (b) Schematic diagram of the recombinant vector, 
pGR-D4 with apoptin gene cassettes as inserts. 
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Recombinant vectors, pGR-DN:: PR-VP3-HK__bZIP17, pGR-DN:: PR-VP3-HK__bZIP28, 
pGR-DN:: PR-VP3-HK__bZIP60, pGR-DN:: PR-GFP-VP3-HK__bZIP17, pGR-DN:: PR-
GFP-VP3-HK__bZIP28, pGR-DN:: PR-GFP-VP3-HK__bZIP60, pGR-DN:: PR-EGF-
CatAd-VP3-HK__bZIP17, pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP28 and pGR-DN:: 
PR-EGF-CatAd-VP3-HK__bZIP60 were verified by released gene cassettes, PR-VP3-HK 
(Figure 3.10), PR-GFP-VP3-HK (Figure 3.11) and PR-EGF-CatAd-VP3-HK (Figure 3.12) 
using PacI and XhoI. Besides, recombinant vectors were also digested using BsrGI and NheI 
to release gene cassettes, bZIP17, bZIP28 and bZIP60. NheI RE site is present on bZIP60 
gene sequence (nucleotide 231); hence, bZIP gene released from pGR-DN vector is shorter 
than expected, which is approximately 670 bp. 
 
(a) 
 
 
 
 
 
Lane Recombinant vectors 
Gene cassettes released from RE 
digestion 
Estimated 
size 
 
 L 1 kb Plus DNA ladder    
 1-2 pGR-DN:: PR-VP3-HK__bZIP17 PR-VP3-HK ~ 520 bp  
 3-4 pGR-DN:: PR-VP3-HK__bZIP28 PR-VP3-HK ~ 520 bp  
 5-6 pGR-DN:: PR-VP3-HK__bZIP60 PR-VP3-HK ~ 520 bp  
 7-8 pGR-DN:: PR-VP3-HK__bZIP17 bZIP17 ~ 1092 bp  
 9-10 pGR-DN:: PR-VP3-HK__bZIP28 bZIP28 ~ 960 bp  
 11-12 pGR-DN:: PR-VP3-HK__bZIP60 bZIP60 ~ 900 bp  
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(b) 
  
Features 
 VP3 
PR1a 
H6 
K 
bZIP17 
bZIP28 
bZIP60 
PacI, XhoI, BsrGI and NheI 
LB 
RB 
CaMV 35S  
TEV enhancer 
PolyA signal 
Nos promoter  
Nos terminator  
NPTI 
Overdrive 
pSa-Ori 
ColEI 
 
: Apoptin gene 
: Signal peptide 
: Hexahistidine 
: Endoplasmic reticulum (ER) retention signal 
: bZIP17 transcriptional factor 
: bZIP28 transcriptional factor 
: bZIP60 transcriptional factor 
: Restriction enzymes 
: Left border 
: Right border 
: Cauliflower mosaic virus 35S promoter 
: Tobacco etch virus enhancer 
: PolyA terminator 
: Nopaline synthase promoter 
: Nopaline synthase terminator 
: Neomycin phosphotransferase 
: Overdrive 
: Origin of replication  
: Origin of replication for high copy number of plasmids in     
   Escherichia coli 
 
Figure 3.101: RE verification profiles for recombinant vectors, namely pGR-DN:: PR-VP3-
HK__bZIP17, pGR-DN:: PR-VP3-HK__bZIP28 and pGR-DN:: PR-VP3-HK__bZIP60. (a) 
RE verification using PacI and XhoI for recombinant vectors; (b) Schematic diagram of the 
recombinant vector, pGR-DN with apoptin gene cassettes and bZIP17, bZIP28 and bZIP60 as 
inserts. 
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(a) 
 
 
 
      
 
Lane Recombinant vectors 
Gene cassettes released from RE 
digestion 
Estimated 
size 
 
 L 1 kb Plus DNA ladder    
 1-2 pGR-DN:: PR-GFP-VP3-HK__bZIP17 PR-GFP-VP3-HK ~ 1249 bp  
 3-4 pGR-DN:: PR-GFP-VP3-HK __bZIP28 PR-GFP-VP3-HK ~ 1249 bp  
 5 pGR-DN:: PR-GFP-VP3-HK __bZIP60 PR-GFP-VP3-HK ~ 1249 bp  
 6-7 pGR-DN:: PR-GFP-VP3-HK__bZIP17 bZIP17 ~ 1092 bp  
 8-9 pGR-DN:: PR-GFP-VP3-HK __bZIP28 bZIP28 ~ 960 bp  
 
10 pGR-DN:: PR-GFP-VP3-HK __bZIP60 bZIP60 ~ 900 bp 
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(b) 
 
 
 
Features 
 VP3 
GFP 
Ent 
PR1a 
H6 
K 
bZIP17 
bZIP28 
bZIP60 
PacI, XhoI, BsrGI and NheI 
LB 
RB 
CaMV 35S  
TEV enhancer 
PolyA signal 
Nos promoter  
Nos terminator  
NPTI 
Overdrive 
pSa-Ori 
ColEI 
 
: Apoptin gene 
: Green fluorescent protein 
: Enterokinase site 
: Signal peptide 
: Hexahistidine 
: Endoplasmic reticulum (ER) retention signal 
: bZIP17 transcriptional factor 
: bZIP28 transcriptional factor 
: bZIP60 transcriptional factor 
: Restriction enzymes 
: Left border 
: Right border 
: Cauliflower mosaic virus 35S promoter 
: Tobacco etch virus enhancer 
: PolyA terminator 
: Nopaline synthase promoter 
: Nopaline synthase terminator 
: Neomycin phosphotransferase 
: Overdrive 
: Origin of replication  
: Origin of replication for high copy number of plasmids in     
   Escherichia coli 
 
Figure 3.21: RE verification profiles for recombinant vectors, namely pGR-DN:: PR-GFP-
VP3-HK__bZIP17, pGR-DN:: PR-GFP-VP3-HK__bZIP28 and pGR-DN:: PR-GFP-VP3-
HK__bZIP60. (a) RE verification using PacI and XhoI for recombinant vectors; (b) 
Schematic diagram of the recombinant vector, pGR-DN with apoptin gene cassettes and 
bZIP17, bZIP28 and bZIP60 as inserts. 
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(a) 
 
 
 
      
 
Lane Recombinant vectors 
Gene cassettes released from 
RE digestion 
Estimated 
size 
 
 L 1 kb Plus DNA ladder    
 1-2 pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP17 PR-EGF-CatAd-VP3-HK ~ 790 bp  
 3-4 pGR-DN:: PR-EGF-CatAd-VP3-HK __bZIP28 PR-EGF-CatAd-VP3-HK ~ 790 bp  
 5 pGR-DN:: PR-EGF-CatAd-VP3-HK __bZIP60 PR-EGF-CatAd-VP3-HK ~ 790 bp  
 6-7 pGR-DN:: PR-EGF-CatAd-VP3-HK __bZIP17 bZIP17 ~ 1092 bp  
 8-9 pGR-DN:: PR-EGF-CatAd-VP3-HK __bZIP28 bZIP28 ~ 960 bp  
 10 pGR-DN:: PR-EGF-CatAd-VP3-HK __bZIP60 bZIP60 ~ 900 bp  
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(b) 
 
Features 
 VP3 
EGF 
CatAd 
PR1a 
H6 
K 
bZIP17 
bZIP28 
bZIP60 
PacI, XhoI, BsrGI and NheI 
LB 
RB 
CaMV 35S  
TEV enhancer 
PolyA signal 
Nos promoter  
Nos terminator  
NPTI 
Overdrive 
pSa-Ori 
ColEI 
 
: Apoptin gene 
: Epidermal growth factor  
: Molecular adaptor 
: Signal peptide 
: Hexahistidine 
: Endoplasmic reticulum (ER) retention signal 
: bZIP17 transcriptional factor 
: bZIP28 transcriptional factor 
: bZIP60 transcriptional factor 
: Restriction enzymes 
: Left border 
: Right border 
: Cauliflower mosaic virus 35S promoter 
: Tobacco etch virus enhancer 
: PolyA terminator 
: Nopaline synthase promoter 
: Nopaline synthase terminator 
: Neomycin phosphotransferase 
: Overdrive 
: Origin of replication  
: Origin of replication for high copy number of plasmids in     
   Escherichia coli 
 
Figure 3.123: RE verification profiles for recombinant vectors, namely pGR-DN:: PR-EGF-
CatAd-VP3-HK__bZIP17, pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP28 and pGR-DN:: 
PR-EGF-CatAd-VP3-HK__bZIP60. (a) RE verification using PacI and XhoI for recombinant 
vectors; (b) Schematic diagram of the recombinant vector, pGR-DN with apoptin gene 
cassettes and bZIP17, bZIP28 and bZIP60 as inserts. 
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Verification of recombinant vectors, including pGR-D:: PR-GFP-VP3-HK__mCherryNuc, 
pGR-D:: PR-GFP-VP3-H__mCherryNuc and pGR-D:: GFP-VP3-H__mCherryNuc was 
performed by PacI and XhoI digestion to release apoptin gene cassettes, namely PR-GFP-
VP3-HK, PR-GFP-VP3-H and GFP-VP3-H (Figure 3.13). Besides, recombinant vectors were 
also RE-digested using BsrGI and NheI to release the gene cassette, mCherryNuc.  
 
(a) 
 
 
 
 
 
Lane Recombinant vectors 
Gene cassettes released from RE 
digestion 
Estimated 
size 
 
 L 1 kb Plus DNA ladder    
 1-2 pGR-D:: PR-GFP-VP3-HK__mCherryNuc PR-GFP-VP3-HK ~ 1215 bp  
 3-4 pGR-D:: PR-GFP-VP3-H__mCherryNuc PR-GFP-VP3-H ~ 1203 bp  
 5-6 pGR-D:: GFP-VP3-H__mCherryNuc GFP-VP3-H ~ 1116 bp  
 7 pGR-D:: PR-GFP-VP3-HK__mCherryNuc mCherryNuc ~ 783 bp  
 8 pGR-D:: PR-GFP-VP3-H__mCherryNuc mCherryNuc ~ 783 bp  
 9 pGR-D:: GFP-VP3-H__mCherryNuc mCherryNuc ~ 783 bp  
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(b) 
 
Features 
 VP3 
GFP 
mCherryNuc 
 
PR1a 
Ent 
H6 
K 
PacI, XhoI, BsrGI and NheI 
LB 
RB 
CaMV 35S  
TEV enhancer 
Nos terminator  
NPTI 
pSa-Ori 
ColEI 
 
: Apoptin gene  
: Green fluorescent protein 
: mCherry fluorescent protein in fusion to N-terminal of nuclear      
  localisation signal 
: Signal peptide 
: Enterokinase site 
: Hexahistidine 
: Endoplasmic reticulum (ER) retention signal 
: Restriction enzymes 
: Left border 
: Right border 
: Cauliflower mosaic virus 35S promoter 
: Tobacco etch virus enhancer 
: Nopaline synthase terminator 
: Neomycin phosphotransferase 
: Origin of replication  
: Origin of replication for high copy number of plasmids in     
   Escherichia coli 
 
Figure 3.13: RE verification profiles for recombinant vectors, namely pGR-D:: PR-GFP-
VP3-HK__mCherryNuc, pGR-D:: PR-GFP-VP3-H__mCherryNuc and pGR-D:: GFP-VP3-
H__mCherryNuc. (a) RE verification using PacI and XhoI for recombinant vectors; (b) 
Schematic diagram of the recombinant vector, pGR-D with apoptin gene cassettes and 
mCherryNuc as inserts. 
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3.3.4 Sequencing confirmation 
Following sequencing analysis, all recombinant vectors used for gene expression were 
confirmed harbouring the correct nucleotide sequences with no mutation or frameshift 
occurrence for all gene cassettes.  
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3.4 Discussion 
This chapter describes the upstream procedures for the production of recombinant apoptin in 
Nicotiana benthamiana, focusing on the design of apoptin gene cassettes and construction of 
recombinant vectors. In this study, apoptin gene cassettes were inserted after movement 
protein of tobacco mosaic virus (TMV) in pGR-D4 vector and expression of inserted genes 
were directed by a subgenomic promoter of TMV. Coat protein of this viral vector, 
responsible for systemic infection, had been removed and delivery of foreign genes to whole 
plant system was accomplished by agroinfiltration strategy (Roy et al., 2010). Besides, pGR-
DN vector was used in this study for co-expression of bZIP proteins with apoptin. For pGR-
DN vector, double 35S cauliflower mosaic virus promoter was used to direct the transcription 
of apoptin gene cassettes; however, a weaker promoter was chosen to control the 
transcription of bZIP genes (Streatfield, 2007). This design was aimed to have a higher 
expression of apoptin rather than bZIP proteins.  
Codon sequences of apoptin as well as fusion proteins, including green fluorescent protein 
(GFP), lichenase, H22 single chain antibody and epidermal growth factor (EGF), were 
optimised and synthesised based on codon usage preference of N. benthamiana. Codon bias, 
which is the preference of using specific type of synonymous codons during process of 
decoding genetic information into functional polypeptides, is found in diverse organisms as 
well as different genes within one genome. A favor for specific synonymous codon can cause 
significant impact on translation efficiency and protein folding (Quax et al., 2015) and 
studies showed that codon bias possesses high correlations with abundance of intracellular 
tRNA with specific anticodons (Angov, 2011). As high protein expression is directly affected 
by translation initiation as well as elongation, the presence of preferable codons with 
abundance of cognate tRNA are the keys for efficient translation. Hence, codon optimisation 
performed for foreign gene sequences based on preference codon of expression hosts is an 
important approach applied by researchers to boost up the expression of heterologous protein. 
Codon adaptation index (CAI), ranging from 0 to 1, is a measurement for codon adaptiveness 
of a gene sequence towards the favorable codon usage of highly expressed gene in a host 
species. This measurement was proposed as a way to predict the expression level of a gene 
(Sharp and Li, 1987). Therefore, higher the CAI value may indicate higher expression level 
of a protein. In this study, CAI values of synthetic and optimised apoptin gene cassettes 
showed more than 0.8 and are higher than non-optimised apoptin gene sequences (~ 0.6-0.7). 
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Thus, a relatively high protein expression level was expected to be obtained with codon 
optimised apoptin sequence. Instead of CAI value, effective number of codons (ENC), 
ranging from 20 to 61, was also used to justify the codon bias of a sequences. ENC value of 
20 means each amino acid coded by only one kind of codon sequence, hence, the codon 
sequence for that gene is extremely bias; however, ENC value of 61 means an equally use of 
all codons for all amino acids and no bias of codon usage is available (Behura and Severson, 
2012). In comparison to non-optimised apoptin sequences, codon optimised apoptin gene 
cassette sequences showed a huge bias of codon usage. Bias of codon usage in optimised 
sequences could be explained since a preference of usage for one or two codons for each 
amino acid was observed from codon usage frequency table of N. benthamiana (Appendix 
3.11). 
In this study, recombinant apoptin was aimed to be stored in s specific plant cellular 
compartment; hence, signal peptide sequences from tobacco pathogenesis related protein 1a 
(PR1a) was fused to N-terminal of apoptin gene cassettes in order to direct the protein 
entering into endoplasmic reticulum (ER) lumen (gene cassettes: PR-VP3-H, PR-GFP-VP3-H 
and PR-Lic-VP3-H). Presence of this signal peptide PR1a on N-terminal of polypeptide is 
highly important for the entry of recombinant protein into secretory pathway and 
subsequently passages to extracellular space (Lodish et al., 2004). Besides, an investigation 
was also performed for accumulation of recombinant apoptin in ER by adding signal peptide, 
PR1a on N-terminal of apoptin gene cassettes with ER retention signal on C-terminal 
concurrently (gene cassettes: PR-VP3-HK, PR-GFP-VP3-HK, PR-Lic-VP3-HK, PR-H22-
CatAd-VP3-HK, PR-H22-CatAd-VP3-40-121-HK, PR-H22-CatAd-VP3-60-121-HK, PR-
H22-CatAd-VP3-80-121-HK, PR-EGF-CatAd-VP3-HK, PR-EGF-CatAd-VP3-40-121-HK, 
PR-EGF-CatAd-VP3-60-121-HK and PR-EGF-CatAd-VP3-80-121-HK). Proteins targeting 
to ER and apoplast are favorable for subcellular storage compartment chosen by researchers 
since accumulation of proteins in these cellular compartments always lead to higher yield of 
recombinant proteins (Komarnytsky et al., 2000; Xu et al., 2002; Yang et al., 2005). 
Recombinant proteins targeted into secretory pathway obtain proper protein folding and post 
translational modifications, such as glycosylation, alkylation and carboxylation, which are 
highly important for the functional activity of proteins. 
High amount of recombinant apoptin was expressed as insoluble protein when fused only to 
hexahistidine tag in E. coli expression system (Lelivelda et al., 2003). Strong denaturants 
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were always used to harvest the protein and followed by a refolding step. This problem had 
been solved when apoptin was fused to large protein, maltose binding protein (MBP). 
Besides, a detectable soluble recombinant apoptin was also reported by Lacorte et al. (2007) 
when recombinant apoptin in fusion to GFP was expressed in N. benthamiana. In this study, 
GFP as well as lichenase were fused to N-terminal of apoptin gene (gene cassettes: PR-GFP-
VP3-HK, PR-GFP-VP3-H, GFP-VP3-H, PR-Lic-VP3-HK, PR-Lic-VP3-H and Lic-VP3-H) 
in order to enhance solubility and stability of protein. Signal peptides, PR1a and ER retention 
signal were also added to the gene cassettes in order to study the best location for subcellular 
storage of recombinant apoptin. An enterokinase cleavage site was purposely incorporated 
between GFP and apoptin gene or lichenase and apoptin gene for the removal of fusion 
proteins after the purification steps since these GFP and lichenase proteins might result 
unwanted side effects on subsequent cell-based assays. GFP is a common reporter protein and 
the employment of GFP protein in fusion to apoptin here is to ease detection of recombinant 
protein during purification process and functionality test of recombinant apoptin in 
mammalian cells. Lichenase, a thermostable enzyme, b-1,3-1,4-glucanase from Clostridium 
thermocellum, was successfully produced with more than 30 targeted recombinant proteins 
(Musiychuk et al., 2007). Enhancement of recombinant protein expression, stability and 
incorporation of multiple targets were able to be achieved with the fusion of protein of 
interest to lichenase (Musiychuk et al., 2007). 
Cancer treatments always aim to kill cancer cells selectively while confer negligible harm to 
healthy normal cells; however, common treatments, such as radiation, cytotoxic 
chemotherapeutic drugs and surgery, cause non-specific harmful effects to healthy 
neighboring cells or non-effective towards metastasized cancer cells. In order to enhance the 
effectiveness and specificity of drug towards cancer cells, targeting drug towards cancer cells 
is achieved via pathophysiological features of cancer cells as well as facilitation of surface 
receptors or antigens overexpressed on cancer cells (Mohanty et al., 2011). In current study, 
EGF and immunoglobulin G (IgG) receptor (CD64) were chosen as targets for drug delivery 
to cancer cells overexpressed with both receptors. CD64 is constitutively expressed in 
myelogenous cells, such as macrophages, monocytes and dendritic cells, and this receptor is 
upregulated during infection and on cancer cells such as acute myeloid leukemia (AML). 
CD64 has been chosen as a targeted receptor for the binding of immunotoxins using anti-
CD64 single chain antibody H22 for treatment of AML (Hetzel et al., 2008; Stahnke et al., 
2008). Epidermal growth factor receptor (EGFR), also known as ErbB1 receptor in EGF 
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receptor family, is overexpressed especially in breast tissue cancer (Hooper, 2016; Normanno 
et al., 2006). Several kinds of drugs, including non-hormonal cytotoxic drug, suramin and 
monoclonal antibody, cetuximab, have been developed for cancer treatment via inhibition of 
signal transduction activities of EGFR (Hooper, 2016). On the other hand, EGF, one of the 
ligands bound to EGFR, was chosen as ligands in fusion with immunotoxins for targeted 
therapy (Fuchs et al., 2007). EGF and H22 single chain antibody gene sequences were fused 
to N-terminal of apoptin gene with the addition of N-terminal signal peptide PR1a and C-
terminal ER retention signal (PR-H22-CatAd-VP3-HK and PR-EGF-CatAd-VP3-HK). 
Besides, a peptide transmembrane domain (PTD), CatAd was incorporated between EGF and 
apoptin gene as well as H22 single chain antibody and apoptin gene in order to enhance the 
internalization of apoptin into cancer cells. CatAd is a cleavable adaptor developed for the 
linking between ligands or antibodies and toxin moieties of immunotoxins used for cancer 
treatment (Keller et al., 2001). Incorporation of CadAd between ligands and toxin was 
reported causing an irreversible detainment of the toxin in the cell cytosol and making a short 
half-life of toxin, which significantly reduces non-specific toxicity that is always associated 
with undesirable side effects (Heisler et al., 2003).   
Instead of full length apoptin, expression of truncated apoptin was also investigated in this 
research. A bipartite nuclear localisation signals (NLS) are reported on C-terminal of apoptin 
and this region is believed playing a critical role for apoptosis induction. Hence, several 
truncated H22-apoptin gene cassettes (PR-H22-CatAd-VP3-40-121-HK, PR-H22-CatAd-
VP3-60-121-HK and PR-H22-CatAd-VP3-80-121-HK) and EGF-apoptin gene cassettes (PR- 
EGF-CatAd-P3-40-121-HK, PR- EGF-CatAd-VP3-60-121-HK and PR- EGF-CatAd-VP3-
80-121-HK) were designed by removing N-terminal region as well as reserving the full 
length and functional C-terminal bipartite NLS. Besides, N-terminal of apoptin was reported 
containing a leucine rich hydrophobic region that corresponds for the multimerisation of the 
protein (Leliveldc et al., 2003). Thus, removal of N-terminal of apoptin in truncated apoptin 
gene cassettes also aimed to increase the solubility of recombinant apoptin. These designs 
would like to reduce the potential formation of huge multimers that always lead to instability 
and insolubility of protein.   
In this study, soluble protein level of recombinant apoptin (gene cassettes: PR-VP3-HK, PR-
GFP-VP3-HK and PR-EGF-CatAd-VP3-HK) was also tried to be enhanced by co-expression 
with bZIP proteins (17, 28 and 60), which belong to a group of transcriptional factors 
involving in elevated level of chaperone proteins. Overexpression of recombinant proteins 
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always results in a huge amount of unfolded proteins, consequently, inducing the unwanted 
ER stress/unfolded protein response (UPR) (Ruberti et al., 2015). bZIP proteins are released 
during 
UPR and play roles as transcriptional factors to enhance transcription of chaperone proteins 
involving in protein folding activity (Vitale, 2013). Hence, the present study was performed 
to understand the effect of co-expressions of bZIP17, bZIP28 and bZIP60 with apoptin gene 
cassettes and the elevated amount of soluble recombinant apoptin was expected and could be 
harvested via this approach. 
In conclusion, all apoptin gene variants were ingeniously designed and cloned into vectors, 
namely pGR-D4, pGR-DN and pGR-D. Codon optimised apoptin gene sequences were 
synthesised incorporating with signal peptide PR1a as well as ER retention signal.  Apoptin 
gene cassettes that targeted protein to apoplast and cytoplasm were also generated. Besides, 
apoptin gene cassettes harbouring apoptin gene in fusion to GFP, lichenase and tumor 
specific ligands (H22 and EGF) were also designed and cloned into targeted vectors in hope 
to enhance yield, solubility and stability of recombinant apoptin proteins.  
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4.1 Introduction 
Transient expression is conventionally used for rapid assessment of gene functions at 
the first place. However, this technique has been recently adopted for production of 
recombinant proteins in plants attributed by its several creditable advantages. High 
expression yield, short incubation time and absence of adverse effects that are 
induced by permanent integration of DNA, have made transient expression a robust 
approach for production of high demanding recombinant proteins (Sainsbury and 
Lomonossoff, 2014). Among several gene delivery techniques, agroinfiltration is one 
of the most commonly used techniques by employing Agrobacterium as a delivery 
vector to transfer foreign genes into plants (Chen et al., 2013). Infiltrated plants are 
incubated for 2-8 days for transient expression of foreign genes without requiring any 
selection activity. Although agroinfiltration is a non-expensive, scalable, rapid and 
simple gene delivery approach, a requirement for infection of Agrobacterium towards 
specific host range has limited this application.   
Conventional Agrobacterium transformation protocol allows Agrobacterium come 
into contact with surface or wounding sites of plant samples by incubating plant 
specimens in Agrobacterium suspension. However, agroinfiltration allows bacteria 
penetrating into deeper and inner layers of infected tissues via infiltration technique, 
which could be achieved with simple and non-expensive syringes or specialised 
vacuum system. Using syringe infiltration, diluted bacterial cultures are injected into 
leaf abaxial side and pressure of injection allows bacteria penetrating into 
intercellular space of leaf mesophyll rather than leaf surface. Requirements for only 
small volume of cultures, inexpensive needleless syringes and tolerance with multiple 
injections using different recombinant vectors on the same leaf have made this 
approach becoming favourable for researchers working in lab or bench-scale study. 
However, syringe infiltration approach is no longer feasible for infiltration for large 
volume of plants in a pilot scale; hence, vacuum infiltration system is essential for 
efficient infiltration work (Chen et al., 2013). Using vacuum infiltration system, 
plants are firstly submerged into bacterial cultures and subsequently, application of 
vacuum removes air from plants and cultures. Pressure change causes agrobacterial 
culture penetrating into intercellular space of leaf mesophyll when vacuum system 
releases air into the chamber. Currently, this system is used by several 
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biopharmaceutical companies for production of recombinant proteins that are highly 
valuable for medical purposes, including Medicago Inc (USA), Fraunhofer Center for 
Molecular Biotechnology (FhCMB, USA), Kentucky Bioprocessing (USA) and Icon 
Genetics (Germany).   
There are always several hurdles encountered in the expression of recombinant 
proteins in plants in order to recover a satisfied amount of recombinant proteins. First, 
silencing of transgenes, one of the crucial challenges in this field, occurs at both 
transcriptional and post-transcriptional levels which is often induced by the presence 
of multiple copies of transgenes, integration of transgene in highly methylated 
chromosomal regions and accumulation of high level of aberrant RNA (Stam et al., 
1997). Second, incompetent transcription and translation of foreign genes also lead to 
the low recovery of recombinant proteins. Low availability of transcripts restricts 
subsequent translation process and this is always attributed to the instability of 
transcripts and inefficient promoters (Streatfield, 2007). In addition, the bias of codon 
usage and inefficient translation initiation cause low level of expression, while the 
turnover rate of proteins in plant cells also directly affects the total amount of 
recombinant proteins yielded. Other than the induction of gene silencing, 
overexpression and toxicity of recombinant proteins sometimes also induce stress and 
unwanted early necrosis symptom to the host plants. Hence, an optimised transgene 
expression cassette is always required in order to achieve a high level of protein 
expression for subsequent downstream processing.  
In current study, recombinant apoptin vector variants were designed as described in 
Chapter 3 in order to explore the optimised recombinant apoptin vectors leading to a 
high level of protein expression. To enhance transcription and translation efficiency, 
apoptin gene sequences were codon-optimised based on codon usage of Nicotiana 
benthamiana and cloned in high expression vectors, i.e. pGR-D4 (TMV-based viral 
vector) and pGR-DN (binary vector). Signal peptides such as tobacco pathogenesis 
related protein 1a (PR1a) and endoplasmic reticulum (ER) retention signal (KDEL) 
were incorporated into recombinant apoptin vector variants in order to target the 
apoptin to apoplast and ER for accumulation of protein at higher quantity in plant 
system. In addition, recombinant vector variants harbouring apoptin gene in fusion to 
C-terminal of fusion proteins including green fluorescent protein (GFP) and lichenase 
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were also designed and constructed in order to increase protein solubility. Whereas, 
recombinant vector variants harbouring apoptin gene in fusion to C-terminal of H22 
single chain antibody, epidermal growth factor (EGF) and molecular adaptor (CatAd) 
were also constructed for targeting and internalisation of purified recombinant 
apoptin into specific cancer cells that overexpressed CD64 and EGF receptors. 
Apoptin gene cassettes were also cloned into pGR-DN vectors that harboured bZIP17, 
bZIP28 and bZIP60 gene sequences. Co-expression of bZIP proteins and apoptin was 
aimed to enhance solubility and yield of recombinant apoptin.  
In this chapter, recombinant apoptin vector variants were transformed into 
Agrobacterium tumefaciens and delivered into N. benthamiana using vacuum 
infiltration approach. Meanwhile, delivery of Agrobacterium harbouring recombinant 
vectors with pGR-D and pGR-DN backbones were co-infiltrated with gene silencing 
suppressors. All infiltrated plant leaf samples were harvested from 3 to 8 days post 
infiltration (dpi) for time course study of accumulation of recombinant proteins. Total 
protein and total soluble protein extracts from leaf samples were analysed and the 
results were used as references for subsequent protein purification procedures. 
Besides, localisation of recombinant apoptin in fusion to green fluorescent protein 
(GFP) in plant cells was also visualised using confocal microscope.  
Therefore, the specific objectives for this chapter were (i) to deliver recombinant 
apoptin vector variants into N. benthamiana via vacuum infiltration, (ii) to compare 
the yield of total soluble and total protein among recombinant apoptin vector variants 
expressed in N. benthamiana, (iii) to determine the kinetic expression profiles of 
infiltrated N. benthamiana for the peak accumulation of recombinant apoptin and (iv) 
to examine subcellular localisation of recombinant apoptin in infiltrated N. 
benthamiana leaves. 
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4.2 Materials and Methods 
4.2.1 General materials 
4.2.1.1 Plant materials 
Four to five weeks old Nicotiana benthamiana, serving as a host plant was used for 
agroinfiltration. N. benthamiana was grown in hydroponic system with temperature 
set at 25±3°C and humidity at ~70% RH receiving 12 hours of light and 12 hours of 
darkness. Infiltrated plants were also incubated at the similar condition.  
4.2.1.2 Bacterial strains and recombinant vectors 
Two strains of Agrobacterium tumefaciens, GV3101 and AGLI, were used in this 
study to deliver recombinant vectors into the host plant. Studies reported that delivery 
of viral vector with pGR-D4 backbone using GV3101 gave higher protein expression; 
however, delivery of non-viral vector with pGR-D or pGR-DN backbone using AGLI 
produce higher protein yield. Hence, recombinant vectors, namely pGR-D4:: PR-
VP3-HK, pGR-D4:: PR-VP3-H, pGR-D4:: VP3-H, pGR-D4:: PR-GFP-VP3-HK, 
pGR-D4:: PR-GFP-VP3-H, pGR-D4:: GFP-VP3-H, pGR-D4:: PR-Lic-VP3-HK, 
pGR-D4:: PR-Lic-VP3-H, pGR-D4:: Lic-VP3-H, pGR-D4:: PR-H22-CatAd-VP3-HK, 
pGR-D4:: PR-H22-CatAd-VP3-40-121-HK, pGR-D4:: PR-H22-CatAd-VP3-60-121-
HK, pGR-D4:: PR-H22-CatAd-VP3-80-121-HK, pGR-D4:: PR-EGF-CatAd-VP3-HK, 
pGR-D4:: PR-EGF-CatAd-VP3-40-121-HK, pGR-D4:: PR-EGF-CatAd-VP3-60-121-
HK and pGR-D4:: PR-EGF-CatAd-VP3-80-121-HK were transformed into 
agrobacterial strain GV3101. However, pGR-D:: PR-GFP-VP3-HK__mCherryNuc, 
pGR-D:: PR-GFP-VP3-H__mCherryNuc, pGR-D:: GFP-VP3-H__mCherryNuc, 
pGR-DN:: PR-VP3-HK__bZIP17, pGR-DN:: PR-VP3-HK__bZIP28, pGR-DN:: PR-
VP3-HK__bZIP60, pGR-DN:: PR-GFP-VP3-HK__bZIP17, pGR-DN:: PR-GFP-
VP3-HK__bZIP28, pGR-DN:: PR-GFP-VP3-HK__bZIP60, pGR-DN:: PR-EGF-
CatAd-VP3-HK__bZIP17, pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP28 and pGR-
DN:: PR-EGF-CatAd-VP3-HK__bZIP60 were transformed into agrobacterial strain 
AGLI. Meanwhile, pCB:: P19 and pCB:: P1/HC-Pro were transformed into 
agrobacterial strain GV3101. 
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4.2.1.3 Reagents 
MagicMark™ XP Western Protein Standard, SeeBlue Plus2 Pre-stained Protein 
Standard, BenchMark™ His-tagged Protein Standard and BenchMark™ Protein 
Ladder (ThermoFisher Scientific, USA) were protein markers used in protein gel 
electrophoresis. Besides, HAI standard (FhCMB, USA) and bovine serum albumin 
(BSA) standard (ThermoFisher Scientific, USA) were also used in protein gel 
electrophoresis. I-Block™ Protein-Based Blocking Reagent (ThermoFisher Scientific, 
USA) was used to block membranes prior incubation with antibodies. Tetra·His 
mouse monoclonal antibody (1: 2 000) (Qiagen, USA), anti-VP3 mouse monoclonal 
antibody (1: 20 000) (JCU/CAV/1C1) (TropBio Pty Ltd, Australia) and goat anti-
mouse antibody (1: 5 000) (Jackson ImmunoResearch Inc, USA) were used to detect 
the presence of apoptin via Western blotting technique. In addition, SuperSignal West 
Pico Chemiluminescent Substrate (ThermoFisher Scientific, USA) was used for 
horseradish peroxidase (HRP) reaction in the Western detection procedure. 
Coomassie Protein Assay Reagent (ThermoFisher Scientific, USA) was used in this 
study to stain protein gels.  
4.2.1.4 Specialised equipment and accessories  
Transformation of Agrobacterium via electroporation was performed by using 
MicroPulser™ Electroporator system (Biorad, USA). Sterile Gene Pulser 
Electroporation Cuvettes (0.1 cm) (Biorad, USA) were used for each electroporation 
reaction. Vacuum infiltration system used for infiltration of plant was customised by 
FhCMB (USA). Protein gel electrophoresis was performed using Mini-PROTEAN 
Tetra Cell system (Biorad, USA) and protein transfer from gel to (PVDF) membrane 
was performed using Trans-Blot® Turbo™ (Biorad, USA). In addition, GENE 
GNOME Chemiluminescence imaging system (Syngene, USA) was used to capture 
signals and save images of Western blots; HP Scanjet G3110 scanner was used to 
capture images of protein gels stained by Coomassie blue dye. Besides, Nikon Eclipse 
Ti Inverted Microscope (Nikon Instruments Inc, USA) and Zeiss 5 Live DUO 
Highspeed Confocal Microscope (Zeiss, USA) were also used in this study to observe 
the localisation of apoptin within the plant cells.      
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4.2.1.5 Analysis tools 
Images of Western blots were analysed using GeneSnap and GeneTools (Syngene, 
USA). Photos taken by Nikon Eclipse Ti Inverted Microscope were analysed using 
Nikon NIS Elements (Nikon Instruments Inc, USA); on the other hand, photos taken 
by Zeiss 5 Live DUO Highspeed Confocal Microscope were analysed using Zeiss 
LSM 5 (Zeiss, USA). 
4.2.2 Transformation of Agrobacterium tumefaciens   
Hundred nanograms of recombinant vectors were incubated with bacterial cells on ice 
for 5 minutes. Bacterial cell mixtures were subsequently electroporated based on a 
protocol recommended by manufacturer with voltage at 2.4 kV was applied for 5 
milliseconds. Hundred-fifty microlitre of Luria Broth (LB) broth was added to 
electroporated cells and cell mixtures were subsequently incubated at 28°C as well as 
shaken horizontally at 220 rpm for at least an hour. Bacterial cells were then plated on 
LB agar containing 50 mg/L kanamycin and incubated at 28°C for 48 hours. 
4.2.3 Agoinfiltration 
Overnight bacterial cultures were harvested and diluted to OD600 ranging at 0.2 - 1.0 
with buffers as described in Table 4.1.  
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Table 4.1: Dilution of A. tumefaciens harbouring recombinant vectors.  
No Recombinant vectors Agrobacterial strains OD600 Buffers 
1 pGR-D4:: PR-VP3-HK GV3101 0.5 Distilled water 
2 pGR-D4:: PR-VP3-H GV3101 0.5 Distilled water 
3 pGR-D4:: VP3-H GV3101 0.5 Distilled water 
4 pGR-D4:: PR-GFP-VP3-HK GV3101 0.5 Distilled water 
5 pGR-D4:: PR-GFP-VP3-H GV3101 0.5 Distilled water 
6 pGR-D4:: GFP-VP3-H GV3101 0.5 Distilled water 
7 pGR-D4:: PR-Lic-VP3-HK GV3101 0.5 Distilled water 
8 pGR-D4:: PR-Lic-VP3-H GV3101 0.5 Distilled water 
9 pGR-D4:: Lic-VP3-H GV3101 0.5 Distilled water 
10 pGR-D4:: PR-H22-CatAd-VP3-HK GV3101 0.5 Distilled water 
11 pGR-D4:: PR-H22-CatAd-VP3-40-121-HK GV3101 0.5 Distilled water 
12 pGR-D4:: PR-H22-CatAd-VP3-60-121-HK GV3101 0.5 Distilled water 
13 pGR-D4:: PR-H22-CatAd-VP3-80-121-HK GV3101 0.5 Distilled water 
14 pGR-D4:: PR-EGF-CatAd-VP3-HK GV3101 0.5 Distilled water 
15 pGR-D4:: PR-EGF-CatAd-VP3-40-121-HK GV3101 0.5 Distilled water 
16 pGR-D4:: PR-EGF-CatAd-VP3-60-121-HK GV3101 0.5 Distilled water 
17 pGR-D4:: PR-EGF-CatAd-VP3-80-121-HK GV3101 0.5 Distilled water 
18 pGR-D:: PR-GFP-VP3-HK-mCherry__Nuc AGLI 1.0 MMA 
19 pGR-D:: PR-GFP-VP3-H__mCherryNuc AGLI 1.0 MMA 
20 pGR-D:: GFP-VP3-H__mCherryNuc AGLI 1.0 MMA 
21 pGR-DN:: PR-VP3-HK__bZIP17 AGLI 1.0 CMA 
22 pGR-DN:: PR-VP3-HK__bZIP28 AGLI 1.0 CMA 
23 pGR-DN:: PR-VP3-HK__bZIP60 AGLI 1.0 CMA 
24 pGR-DN:: PR-GFP-VP3-HK __bZIP17 AGLI 1.0 CMA 
25 pGR-DN:: PR-GFP-VP3-HK __bZIP28 AGLI 1.0 CMA 
26 pGR-DN:: PR-GFP-VP3-HK __bZIP60 AGLI 1.0 CMA 
27 pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP17 AGLI 1.0 CMA 
28 pGR-DN:: PR-EGF-CatAd-VP3-HK__ bZIP28 AGLI 1.0 CMA 
29 pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP60 AGLI 1.0 CMA 
30 pCB:: P1/HC-Pro GV3101  0.2 MMA 
31 pCB:: P19 GV3101 0.2 CMA 
Note: MMA= Inifltration buffer composed of 10mM MES, 10 mM MgCl2, 0.15 mM 
Acetosyringone; CMA= Inifltration buffer composed of 10mM citrate (pH 5.8), 10 
mM MgCl2, 0.15 mM Acetosyringone. 
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Diluted agrobacterial strain AGLI harbouring recombinant vectors, namely pGR-D:: 
PR-GFP-VP3-HK__mCherryNuc, pGR-D:: PR-GFP-VP3-H__mCherryNuc and 
pGR-D:: GFP-VP3-H__mCherryNuc were mixed with agrobacterial strain GV3101  
harbouring pCB:: P1/HC-Pro. Diluted agrobacterial strain AGLI  harbouring 
recombinant vectors, namely pGR-DN:: PR-VP3-HK__bZIP17, pGR-DN:: PR-VP3-
HK__bZIP28, pGR-DN:: PR-VP3-HK__bZIP60, pGR-DN:: PR-GFP-VP3-HK 
__bZIP17, pGR-DN:: PR-GFP-VP3-HK __bZIP28, pGR-DN:: PR-GFP-VP3-HK 
__bZIP60, pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP17, pGR-DN:: PR-EGF-
CatAd-VP3-HK__bZIP28 and pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP60 were 
also mixed with agrobacterial strain GV3101  harbouring pCB:: P19. All bacterial 
mixtures were incubated at room temperature for at least 2 hours. On the other hand, 
agrobacterial strain GV3101 harbouring recombinant vectors, namely pGR-D4:: PR-
VP3-HK, pGR-D4:: PR-VP3-H, pGR-D4:: VP3-H, pGR-D4:: PR-GFP-VP3-HK, 
pGR-D4:: PR-GFP-VP3-H, pGR-D4:: GFP-VP3-H, pGR-D4:: PR-Lic-VP3-HK, 
pGR-D4:: PR-Lic-VP3-H, pGR-D4:: Lic-VP3-H, pGR-D4:: PR-H22-CatAd-VP3-HK, 
pGR-D4:: PR-H22-CatAd-VP3-40-121-HK, pGR-D4:: PR-H22-CatAd-VP3-60-121-
HK, pGR-D4:: PR-H22-CatAd-VP3-80-121-HK, pGR-D4:: PR-EGF-CatAd-VP3-HK, 
pGR-D4:: PR-EGF-CatAd-VP3-40-121-HK, pGR-D4:: PR-EGF-CatAd-VP3-60-121-
HK and pGR-D4:: PR-EGF-CatAd-VP3-80-121-HK were used immediately after 
dilution with distilled water for infiltration. 
Four to five weeks old N. benthamiana leaves were infiltrated with bacterial 
suspension at 28 inHg for 1 minute and subsequently brief-rinsed with distilled water. 
4.2.4 Protein extraction 
Plant leaf samples were collected between 3-8 days post infiltration (dpi). Leaf tissues 
were homogenised with 3 volumes of phosphate-buffered saline (PBS) with 1 mM 
Dieca. Triton X-100 (0.5% v/v) was added into the lysate to generate soluble protein 
extract (TSP-T) and 1x sodium dodecyl sulfate (SDS) reducing loading buffer [50mM 
Tris-Cl (pH 6.8), 2% SDS, 0.1M DTT] was used to generate total protein extract (TP). 
All cell lysates were pelleted at 16, 000 xg before the supernatant was analysed in 12% 
polyacrylamide gel electrophoresis.   
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4.2.5 Western blotting 
Electrophoresed gels were transferred onto 0.2 µm PVDF membrane using Trans-
Blot TurboTM blotting system with a preprogrammed protocol at 25 V for 7 minutes. 
Blotted membranes were brief-rinsed in PBS before blocking in I-Block buffer for at 
least half an hour. Membranes were subsequently incubated in either Tetra-His or 
VP3 monoclonal primary antibody for 1-2 hours. Three-time washing steps with 
PBS-Tween (PBS-T) buffer at 4-minute intervals were performed before membranes 
were incubated with secondary antibody for another hour. Membranes were washed 
again for three times with PBS-T buffer at 4-minute intervals. Then, membranes were 
incubated in SuperSignal West Pico Chemiluminescent Substrate for 4 minutes before 
images of membranes were captured and recorded. 
Protein bands detected in western blotting was measured using GeneTools and 
expression of recombinant proteins was quantified in relative to HAI standard (60 ng, 
30 ng and 15 ng) loaded on the same gel. Fold change of protein expression was 
calculated as an approach to compare protein expression between recombinant 
vectors.  
4.2.6 Microscopy 
A slice of leaf sample from plants infiltrated with recombinant vectors, pGR-D:: PR-
GFP-VP3-HK__mCherryNuc, pGR-D:: PR-GFP-VP3-H__mCherryNuc and pGR-D:: 
GFP-VP3-H__mCherryNuc on 5 dpi were prepared for observations under Nikon 
Eclipse Ti Inverted Microscope and Zeiss 5 Live DUO Highspeed Confocal 
Microscope. 
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4.3 Results 
4.3.1 Protein expression profiles of recombinant apoptin 
4.3.1.1 Expression and accumulation of recombinant 
apoptin alone in subcellular compartments 
Time course study for expression of recombinant apoptin was detected between 3 
days post infiltration (dpi) and 8 dpi. Expression profile of Nicotiana benthamiana 
infiltrated with recombinant vector without gene insert (mock) confirmed that mock 
samples were free of recombinant proteins (Appendix 4.1). Expression of 
recombinant apoptin alone in total soluble protein extract with 0.5% triton (TSP-T) 
gave low protein yield, which was less than 15% of total protein (TP), in all three 
recombinant vectors including pGR-D4:: PR-VP3-HK, pGR-D4:: PR-VP3-H and 
pGR-D4:: VP3-H (Figure 4.1). Hence, most of recombinant apoptin could only be 
recovered from insoluble plant extract. Plant infiltrated with recombinant vectors, 
pGR-D4:: PR-VP3-HK (Figure 4.2-a) and pGR-D4:: PR-VP3-H (Figure 4.2-b), by 
which recombinant proteins were expected accumulating in endoplasmic reticulum 
(ER) and apoplast, showed necrosis symptom as early as 3-4 dpi. Severe necrosis was 
subsequently observed on 5 dpi. Interestingly, necrosis was not found on plants 
infiltrated with recombinant pGR-D4:: VP3-H (Figure 4.2-c). 
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 Lane Sample Expression vector 
Estimated 
size 
 
 P 
MagicMark™ XP Western Protein 
Standard 
   
 Q 
BenchMark™ His-tagged Protein 
Standard 
   
 1-3 
60 ng, 30 ng and 15 ng of HAI 
standard  
 ~ 70 kDa  
 4-5 
TSP-T extract from leaf samples 
harvested on 4 and 5 dpi 
pGR-D4:: PR-VP3-HK ~ 18 kDa  
 6-7 
TP extract from leaf samples 
harvested on 4 and 5 dpi 
pGR-D4:: PR-VP3-HK ~ 18 kDa  
 8-10 
TSP-T extract from leaf samples 
harvested on 3, 4 and 5 dpi 
pGR-D4:: PR-VP3-H ~ 18 kDa  
 11-13 
TP extract from leaf samples 
harvested on 3, 4 and 5 dpi 
pGR-D4:: PR-VP3-H ~ 18 kDa  
 14-18 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: VP3-H ~ 18 kDa  
 19-23 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: VP3-H ~ 18 kDa  
      
Figure 4.1: Protein expression profiles of recombinant apoptin alone in subcellular 
compartment of Nicotiana benthamiana leaves. Detection was carried out via 
Western blotting technique which showed recombinant apoptin expressed from 
recombinant vectors, (a) pGR-D4:: PR-VP3-HK, (b) pGR-D4:: PR-VP3-H and (c) 
pGR-D4:: VP3-H using Tetra-His mouse monoclonal antibody.  
a b 
c 
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Figure 4.2: Physical appearances of N. benthamiana infiltrated with recombinant 
vectors, pGR-D4:: PR-VP3-HK, pGR-D4:: PR-VP3-H and pGR-D4:: VP3-H on 5 dpi. 
Plants showed necrosis symptom when infiltrated with recombinant vectors, (a) pGR-
D4:: PR-VP3-HK and (b) pGR-D4:: PR-VP3-H as early as 3 dpi. Plants infiltrated 
with recombinant vector, (c) pGR-D4:: VP3-H did not show necrosis symptom but 
survived even incubation was extended until 8 dpi. 
4.3.1.2 Expression of recombinant apoptin in fusion to C-
terminal of green fluorescent protein (GFP) 
Recombinant apoptin in fusion to C-terminal of GFP (recombinant vectors: pGR-D4:: 
PR-GFP-VP3-HK and pGR-D4:: GFP-VP3-H) (Figure 4.3-a and -c) except for 
recombinant GFP-apoptin (recombinant vector: pGR-D4:: PR-GFP-VP3-H) (Figure 
4.3-b) showed an increased TP level to approximately 2-3 folds. Among these three 
recombinant vectors, recombinant GFP-apoptin (recombinant vector: pGR-D4:: GFP-
VP3-H) exhibited the highest expression on both protein (Figure 4.3-c) and 
fluorescence (Figure 4.4-c) signals but TSP-T extract of this protein was only 
accounted ~10% of TP level (Figure 4.3-c).   
On the other hand, TSP-T extracts of recombinant GFP-apoptin targeted to ER and 
apoplast (recombinant vectors: pGR-D4:: PR-GFP-VP3-HK and pGR-D4:: PR-GFP-
VP3-H) were estimated 10 folds higher than recombinant apoptin expressed alone 
(recombinant vectors: pGR-D4:: PR-VP3-HK and pGR-D4:: PR-VP3-H) (4.1-a and -
b). TSP-T extract of recombinant GFP-apoptin accumulated in ER was ~50% of TP 
level (4.3-a). However, TSP-T extract of recombinant GFP-apoptin accumulated in 
apoplast was ~90% of TP level (Figure 4.3-b). TSP-T extract of recombinant GFP-
apoptin accumulated in ER was slightly higher than protein accumulated in apoplast 
a b c 
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but it was ~2.5 folds higher than protein that was not targeted into secretory pathway 
(recombinant vector: pGR-D4:: GFP-VP3-H).  
      
 
  
 
 
 
  
      
 Lane Sample Expression vector 
Estimated 
size 
 
 P 
MagicMark™ XP Western Protein 
Standard 
   
 1-3 
60 ng, 30 ng and 15 ng of HAI 
standard  
 ~ 70 kDa  
 4-8 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-GFP-VP3-HK ~ 42 kDa  
 9-13 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-GFP-VP3-HK ~ 42 kDa  
 14-18 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-GFP-VP3-H ~ 42 kDa  
 19-23 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-GFP-VP3-H ~ 42 kDa  
 24-28 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: GFP-VP3-H ~ 42 kDa  
 29-33 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: GFP-VP3-H ~ 42 kDa  
      
Figure 4.3：Protein expression profiles of recombinant apoptin in fusion to C-
terminal of GFP. Detection was carried out via Western blotting technique which 
showed recombinant GFP-apoptin expressed from recombinant vectors, (a) pGR-D4:: 
PR-GFP-VP3-HK, (b) pGR-D4:: PR-GFP-VP3-H and (c) pGR-D4:: GFP-VP3-H 
using Tetra-His mouse monoclonal antibody. 
a b
c 
c 
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Figure 4.4: GFP fluorescent signals detected using UV lamp of plants infiltrated with 
recombinant vectors, (a) pGR-D4:: PR-GFP-VP3-HK, (b) pGR-D4:: PR-GFP-VP3-H 
and (c) pGR-D4:: GFP-VP3-H. Recombinant pGR-D4:: GFP-VP3-H exhibited the 
highest GFP signal. 
Under microscopic observation, recombinant GFP-apoptin (recombinant vector: 
pGR-D:: GFP-VP3-H__mCherryNuc) (Green) expressed in cytoplasm, was 
relocalised and accumulated in plant cell nucleus. This argument is in concordance 
with the expectation of the same localisation pattern as mCherry (Red) protein pre-
incorporated with a nuclear localisation signal, was redirected into the nucleus 
(Figure 4.5-c). However, relocalisation of protein into nucleus was not observed when 
recombinant GFP-apoptin targeted to ER and apoplast (recombinant vectors: pGR-D:: 
PR-GFP-VP3-HK__mCherryNuc and pGR-D:: PR-GFP-VP3-H__mCherryNuc) 
(Figure 2-a and -b). 
 
 
 
 
 
 
 
a b c 
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Figure 4.5: Microscopic observation of co-expression of recombinant GFP-VP3 
(Green) and mCherryNuc (Red) in N. benthamiana cells. mCherry protein containing 
nuclear localisation signal on C-terminal end is expected to be relocated into plant 
cell nucleus as evidenced in previous study. Images above show the redistribution of 
protein in cells instead of directing into cell nucleus for (a) and (b) occurred with the 
addition of signal peptides to VP3 protein. Expression of (c) GFP-VP3 showed the 
protein accumulation within the nucleus of plant cells since mCherry and GFP signals 
were co-localised at the same position.   
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4.3.1.3 Expression of recombinant apoptin in fusion to C-
terminal of lichenase  
Expression of recombinant lichenase-apoptin showed similar expression profiles as 
recombinant apoptin alone (Figure 4.6). Necrosis symptom was observed when 
recombinant lichenase-apoptin targeted to ER (recombinant vector: pGR-D4:: PR-
Lic-VP3-HK) (Figure  4.7-a) and apoplast (recombinant vector: pGR-D4:: PR-Lic-
VP3-H) (Figure 4.7-b) but not for recombinant vector pGR-D4:: Lic-VP3-H (Figure  
4.7-c). Low TSP-T level was detected for all three recombinant proteins. However, 2-
3 folds higher level of insoluble protein (TP) was able to be collected from 
recombinant lichenase-apoptin (recombinant vector: pGR-D4:: Lic-VP3-H) (Figure 
4.6-c) than recombinant apoptin alone (recombinant vector: pGR-D4:: VP3-H) 
(Figure 4.1-c) and recombinant GFP-apoptin (recombinant vector: pGR-D4:: GFP-
VP3-H) (Figure 4.3-c).    
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 Lane Sample Expression vector 
Estimated 
size 
 
 P 
MagicMark™ XP Western Protein 
Standard 
   
 1-3 
60 ng, 30 ng and 15 ng of HAI 
standard  
 ~ 70 kDa  
 4-6 
TSP-T extract from leaf samples 
harvested on 3, 4 and 5 dpi 
pGR-D4:: PR-Lic-VP3-HK ~ 40 kDa  
 7-9 
TP extract from leaf samples 
harvested on 3, 4 and 5 dpi 
pGR-D4:: PR-Lic-VP3-HK ~ 40 kDa  
 10-12 
TSP-T extract from leaf samples 
harvested on 3, 4 and 5 dpi 
pGR-D4:: PR- Lic-VP3-H ~ 40 kDa  
 13-15 
TP extract from leaf samples 
harvested on 3, 4 and 5 dpi 
pGR-D4:: PR- Lic-VP3-H ~ 40 kDa  
 16-20 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: Lic-VP3-H ~ 40 kDa  
 21-25 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: Lic-VP3-H ~ 40 kDa  
      
Figure 4.6: Protein expression profiles of recombinant apoptin in fusion to C-terminal 
of lichenase. Detection was carried out via Western blotting technique which showed 
recombinant lichenase-apoptin expressed from recombinant vector, (a) pGR-D4:: PR-
Lic-VP3-HK, (b) pGR-D4:: PR-Lic-VP3-H and (c) pGR-D4:: Lic-VP3-H using 
Tetra-His mouse monoclonal antibody. 
 
a b 
c 
 4-20 
 
 
 
 
 
 
Figure 4.7: Physical appearances of N. benthamiana infiltrated with recombinant 
vectors, pGR-D4:: PR-Lic-VP3-HK, pGR-D4:: PR-Lic-VP3-H and pGR-D4:: Lic-
VP3-H on 5 dpi. Plants showed necrosis symptom when infiltrated with recombinant 
vectors, (a) pGR-D4:: PR-Lic-VP3-HK and (b) pGR-D4:: PR-Lic-VP3-H as early as 
3 dpi. Plants infiltrated with recombinant vector, (c) pGR-D4:: Lic-VP3-H did not 
show necrosis symptom but were viable even incubation was extended until 8 dpi. 
4.3.1.4 Expression of full length and truncated recombinant 
apoptin in fusion to C-terminal of H22 single chain 
antibody and CatAd molecular adaptor 
All four recombinant H22-CatAd-apoptin showed low expression level (Figure 4.8). 
Instead of full size protein, degradation was observed in all four recombinant protein 
expression profiles. Presence of 2-3 lower molecular weight protein bands was 
observed instead of the expected full size proteins. For example, full size protein for 
recombinant H22-CatAd-apoptin (recombinant vector: pGR-D4:: PR-H22-CatAd-
VP3-HK) was expected to be 43 kDa but smaller molecular weight protein band was 
detected at sizes between 30 and 40 kDa (Figure 4.8-a). Similar observation could be 
detected in expression profiles of recombinant vectors, pGR-D4:: PR-H22-CatAd-40-
121-VP3-HK (Figure 4.8-b), pGR-D4:: PR-H22-CatAd-60-121-VP3-HK (Figure 4.8-
c) and pGR-D4:: PR-H22-CatAd-80-121-VP3-HK (Figure 4.8-d). 
 
 
b a c 
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 Lane Sample Expression vector 
Estimated 
size 
 
 P 
MagicMark™ XP Western Protein 
Standard 
   
 1-3 
60 ng, 30 ng and 15 ng of HAI 
standard  
 ~ 70 kDa  
 4-8 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-H22-CatAd-VP3-
HK 
~ 43 kDa  
 9-13 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-H22-CatAd-VP3-
HK 
~ 43 kDa  
 14-18 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-H22-CatAd-40-
121-VP3-HK 
~ 40 kDa  
 19-23 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-H22-CatAd-40-
121-VP3-HK 
~ 40 kDa  
 24-28 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-H22-CatAd-60-
121-VP3-HK 
~ 37 kDa  
 29-33 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-H22-CatAd-60-
121-VP3-HK 
~ 37 kDa  
 34-38 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-H22-CatAd-80-
121-VP3-HK 
~ 35 kDa  
 39-43 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-H22-CatAd-80-
121-VP3-HK 
~ 35 kDa  
      
Figure 4.8: Protein expression profiles of recombinant apoptin in fusion to C-terminal 
of H22 single chain antibody and CatAd molecular adaptor. Detection was performed 
via Western blotting technique using Tetra-His mouse monoclonal antibody which 
showed recombinant H22-CatAd-apoptin expressed from recombinant vectors, (a) 
pGR-D4:: PR-H22-CatAd-VP3-HK, (b) pGR-D4:: PR-H22-CatAd-40-121-VP3-HK, 
(c) pGR-D4:: PR-H22-CatAd-60-121-VP3-HK and (d) pGR-D4:: PR-H22-CatAd-80-
121-VP3-HK.  
a b 
c d 
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4.3.1.5 Expression of full length and truncated recombinant 
apoptin in fusion to C-terminal of epidermal growth 
factor (EGF) and CatAd molecular adaptor 
Detectable levels of TP and TSP-T for recombinant EGF-CatAd-apoptin were 
observed in expression profiles of recombinant vector,  pGR-D4:: PR-EGF-
CatAd-VP3-HK (Figure 4.9-a). In addition, approximately 2-3 folds higher level was 
observed in expression profiles of recombinant vectors, pGR-D4:: PR-EGF-CatAd-
VP3-40-121-HK (Figure 4.9-b) and pGR-D4:: PR-EGF-CatAd-VP3-80-121-HK 
(Figure 4.9-d) but severe early necrosis symptom appeared on recombinant pGR-D4:: 
PR-EGF-CatAd-VP3-80-121-HK (Figure 4.10-d) only. Low expression of 
recombinant vector, pGR-D4:: PR-EGF-CatAd-VP3-60-121-HK (Figure 4.9-c) was 
detected in both TP and TSP-T extracts as compared to three other recombinant 
vectors. No significant degradation band was observed in expression of recombinant 
EGF-CatAd-apoptin. 
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 Lane Sample Expression vector 
Estimated 
size 
 
 P 
MagicMark™ XP Western Protein 
Standard 
   
 1-3 
60 ng, 30 ng and 15 ng of HAI 
standard  
 ~ 70 kDa  
 4-8 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-EGF-CatAd-VP3-
HK 
~ 30 kDa  
 9-13 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR- EGF-CatAd-
VP3-HK 
~ 30 kDa  
 14-18 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR- EGF-CatAd-40-
121-VP3-HK 
~ 25 kDa  
 19-23 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR- EGF-CatAd-40-
121-VP3-HK 
~ 25 kDa  
 24-28 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR- EGF-CatAd-60-
121-VP3-HK 
~ 22 kDa  
 29-33 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR- EGF-CatAd-60-
121-VP3-HK 
~ 22 kDa  
 34-36 
TSP-T extract from leaf samples 
harvested on 3, 4 and 5 dpi 
pGR-D4:: PR- EGF-CatAd-80-
121-VP3-HK 
~ 20 kDa  
 37-39 
TP extract from leaf samples 
harvested on 3, 4 and 5 dpi 
pGR-D4:: PR- EGF-CatAd-80-
121-VP3-HK 
~ 20 kDa  
      
Figure 4.9: Protein expression profiles of recombinant apoptin in fusion to C-terminal 
of EGF and CatAd molecular adaptor. Detection was performed via Western blotting 
technique using Tetra-His mouse monoclonal antibody which showed recombinant 
EGF-CatAd-apoptin expressed from recombinant vectors, (a) pGR-D4:: PR-EGF-
CatAd-VP3-HK, (b) pGR-D4:: PR-EGF-CatAd-40-121-VP3-HK, (c) pGR-D4:: PR-
EGF-CatAd-60-121-VP3-HK and (d) pGR-D4:: PR-EGF-CatAd-80-121-VP3-HK.  
a b 
c 
d 
 4-24 
 
 
 
 
 
Figure 4.10: Physical appearances of N. benthamiana infiltrated with recombinant 
vectors, pGR-D4:: PR-EGF-CatAd-VP3-HK, pGR-D4:: PR-EGF-CatAd-40-121-
VP3-HK, pGR-D4:: PR-EGF-CatAd-60-121-VP3-HK and pGR-D4:: PR-EGF-
CatAd-80-121-VP3-HK on 5 dpi. Plants showed early necrosis symptom when 
infiltrated with recombinant vectors, (d) pGR-D4:: PR-EGF-CatAd-80-121-VP3-HK 
as early as 3 dpi. Mild necrosis symptom was also observed on plants infiltrated with 
recombinant vector, (a) pGR-D4:: PR-EGF-CatAd-VP3-HK on 7 dpi. However, 
recombinant vectors, (b) pGR-D4:: PR-EGF-CatAd-40-121-VP3-HK and (c) pGR-
D4:: PR-EGF-CatAd-60-121-VP3-HK did not show any necrosis symptom where 
plants were viable even until 8 dpi. 
4.3.1.6 Co-expression of recombinant apoptin alone, 
recombinant GFP-apoptin and recombinant EGF-
CatAd-VP3 with ER stress proteins, bZIP17, 
bZIP28 and bZIP60 
Expression of recombinant apoptin alone was low in recombinant vector, pGR-D4:: 
PR-VP3-HK (Figure 4.1-a); however, expression of recombinant apoptin alone was 
increased when co-expressed with ER stress proteins (Figure 4.11). In comparison to 
pGR-D4:: PR-VP3-HK, expression of recombinant apoptin alone was ~6 folds higher 
in TP and TSP-T extracts when co-expressed with bZIP17 (recombinant vector: pGR-
DN:: PR-VP3-HK__bZIP17) (Figure 4.11-a). Meanwhile, it was ~10 folds higher in 
TP and TSP-T extracts when protein was co-expressed with bZIP60 (recombinant 
vector: pGR-DN:: PR-VP3-HK__bZIP60) (Figure 4.11-c). For recombinant apoptin 
co-expressed with bZIP28 (Figure 4.11-b), ~5 folds higher level of TP was able to be 
harvested but not significantly increased as observed in TSP-T extract compared with 
that of expression of recombinant vector, pGR-D4:: PR-VP3-HK. Plants infiltrated 
with recombinant vectors, pGR-DN:: PR-VP3-HK__bZIP17 (Figure 4.12-a) and 
pGR-DN:: PR-VP3-HK__bZIP28 (Figure 4.12-b) showed early necrosis symptom 
a b c d 
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similar to plants infiltrated with recombinant vector, pGR-D4:: PR-VP3-HK (Figure 
4.2-a). However, mild necrosis symptom was also observed in plants infiltrated with 
recombinant vector, pGR-DN:: PR-VP3-HK__bZIP60 (Figure 4.12-c).  
      
 
  
 
 
 
  
      
 Lane Sample Expression vector 
Estimated 
size 
 
 P 
MagicMark™ XP Western Protein 
Standard 
   
 1-3 
60 ng, 30 ng and 15 ng of HAI 
standard  
 ~ 70 kDa  
 4-8 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-VP3-
HK__bZIP17 
~ 18 kDa  
 9-13 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-VP3-
HK__bZIP17 
~ 18 kDa  
 14-18 
TSP-T extract from leaf samples 
harvested on 3, 4, 5, 6 and 7 dpi 
pGR-DN:: PR-VP3-
HK__bZIP28 
~ 18 kDa  
 19-23 
TP extract from leaf samples 
harvested on 3, 4, 5, 6 and 7 dpi 
pGR-DN:: PR-VP3-
HK__bZIP28 
~ 18 kDa  
 24-28 
TSP-T extract from leaf samples 
harvested on 3, 4, 5, 6 and 7 dpi 
pGR-DN:: PR-VP3-
HK__bZIP60 
~ 18 kDa  
 29-33 
TP extract from leaf samples 
harvested on 3, 4, 5, 6 and 7 dpi 
pGR-DN:: PR-VP3-
HK__bZIP60 
~ 18 kDa  
      
Figure 4.11: Protein expression profiles of recombinant apoptin alone co-expressed 
with ER stress proteins in N. benthamiana leaves. Detection was conducted via 
Western blotting technique which showed expressions of (a) recombinant apoptin 
alone that co-expressed with bZIP17 (recombinant vector: pGR-DN:: PR-VP3-
HK__bZIP17),  (b) recombinant apoptin alone that co-expressed with bZIP28 
(recombinant vector: pGR-DN:: PR-VP3-HK__bZIP28) and (c) recombinant apoptin 
alone that co-expressed with bZIP60 (recombinant vector: pGR-DN:: PR-VP3-
HK__bZIP60) reacted with Tetra-His mouse monoclonal antibody. 
a b 
c 
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Figure 4.12: Physical appearances of N. benthamiana infiltrated with recombinant 
vectors, pGR-DN:: PR-VP3-HK__bZIP17, pGR-DN:: PR-VP3-HK__bZIP28 and 
pGR-DN:: PR-VP3-HK__bZIP60 on 5 dpi. Plants showed early necrosis symptom 
when infiltrated with recombinant vectors, (a) pGR-DN:: PR-VP3-HK__bZIP17 and 
(b) pGR-DN:: PR-VP3-HK__bZIP28 as early as 3-4 dpi. Plants infiltrated with 
recombinant vector, (c) pGR-DN:: PR-VP3-HK__bZIP60 showed milder necrosis 
symptom on 5 dpi. 
Approximately 2-fold increment on TSP-T expression levels for recombinant vectors, 
pGR-DN:: PR-GFP-VP3-HK__bZIP17 (Figure 4.13-a) and pGR-DN:: PR-GFP-VP3-
HK__bZIP60 (Figure 4.13-c) were observed when compared to expression of 
recombinant vector, pGR-D4:: PR-GFP-VP3-HK (Figure 4.3-a). However, 
expression of TSP-T level for recombinant GFP-apoptin that co-expressed with 
bZIP28 (pGR-DN:: PR-GFP-VP3-HK__bZIP28) (Figure 4.13-b) did not show 
significant difference from expression of recombinant vector, pGR-D4:: PR-GFP-
VP3-HK. Nevertheless, ~2-4 folds of increment in TP levels of recombinant GFP-
apoptin that co-expressed with all three ER stress proteins (bZIP17, bZIP28 and 
bZIP60) were noticed. 
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b
c
b 
 4-27 
 
 
 
 
 
  
 
 
 
  
      
 Lane Sample Expression vector 
Estimated 
size 
 
 P 
MagicMark™ XP Western Protein 
Standard 
   
 1-3 
60 ng, 30 ng and 15 ng of HAI 
standard  
 ~ 70 kDa  
 4-8 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-GFP-VP3-
HK__bZIP17 
~ 42 kDa  
 9-13 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-GFP-VP3-
HK__bZIP17 
~ 42 kDa  
 14-18 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-GFP-VP3-
HK__bZIP28 
~ 42 kDa  
 19-23 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-GFP-VP3-
HK__bZIP28 
~ 42 kDa  
 24-28 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-GFP-VP3-
HK__bZIP60 
~ 42 kDa  
 29-33 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-GFP-VP3-
HK__bZIP60 
~ 42 kDa  
      
Figure 4.13: Protein expression profiles of recombinant GFP-apoptin co-expressed 
with ER stress proteins. Detection was carried out via Western blotting analysis using 
Tetra-His mouse monoclonal antibody which showed expressions of (a) recombinant 
GFP-apoptin that co-expressed with bZIP17 (recombinant vector: pGR-DN:: PR-
GFP-VP3-HK__bZIP17),  (b) recombinant GFP-apoptin that co-expressed with 
bZIP28 (recombinant vector: pGR-DN:: PR-GFP-VP3-HK__bZIP28) and (c) 
recombinant GFP-apoptin that co-expressed with bZIP60 (recombinant vector: pGR-
DN:: PR-GFP-VP3-HK__bZIP60). 
a b 
c 
 4-28 
 
 
 
 
In comparison to recombinant vector pGR-D4:: PR-EGF-CatAd-VP3-HK (Figure 
4.9-a), expression of recombinant EGF-CatAd-apoptin increased in 2-4 folds when 
co-expressed with ER stress proteins. Especially, recombinant vector, pGR-DN:: PR-
EGF-CatAd-VP3-HK__bZIP28 (Figure 4.14-d) gave the highest yield of TSP-T 
among three recombinant vectors, which was ~4 folds of protein higher than that 
expressed by recombinant vector, pGR-D4:: PR-EGF-CatAd-VP3-HK. Mild necrosis 
symptom was observed on plants infiltrated with recombinant vector, pGR-DN:: PR-
EGF-CatAd-VP3-HK__bZIP28 (Figure 4.15-b). 
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 Lane Sample Expression vector 
Estimated 
size 
 
 P 
MagicMark™ XP Western Protein 
Standard 
   
 1-3 
60 ng, 30 ng and 15 ng of HAI 
standard  
 ~ 70 kDa  
 4-8 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-EGF-CatAd-
VP3-HK__bZIP17 
~ 30 kDa  
 9-13 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-EGF-CatAd-
VP3-HK__bZIP17 
~ 30 kDa  
 14-18 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-EGF-CatAd-
VP3-HK__bZIP28 
~ 30 kDa  
 19-23 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-EGF-CatAd-
VP3-HK__bZIP28 
~ 30 kDa  
 24-28 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-EGF-CatAd-
VP3-HK__bZIP60 
~ 30 kDa  
 29-33 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-DN:: PR-EGF-CatAd-
VP3-HK__bZIP60 
~ 30 kDa  
      
Figure 4.14: Protein expression profiles of recombinant EGF-CatAd-apoptin co-
expressed with ER stress proteins. Detection was performed by Western blotting 
analysis which showed expressions of (a) recombinant EGF-CatAd-apoptin that co-
expressed with bZIP17 (pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP17), (b) 
recombinant EGF-CatAd-apoptin that co-expressed with bZIP28 (pGR-DN:: PR-
EGF-CatAd-VP3-HK__bZIP28)  and (c) recombinant EGF-CatAd-apoptin that co-
expressed with bZIP60 (pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP60) reacted with 
Tetra-His mouse monoclonal antibody. 
a b 
c 
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Figure 4.15: Physical appearances of N. benthamiana infiltrated with recombinant 
vectors, pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP17, pGR-DN:: PR-EGF-CatAd-
VP3-HK__bZIP28 and pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP60 on 5 dpi. 
Plants infiltrated with recombinant vectors, (a) pGR-DN:: PR-EGF-CatAd-VP3-
HK__bZIP17 and (b) pGR-DN:: PR-EGF-CatAd-VP3-HK__bZIP28 were healthy 
throughout until the last harvest date on 8 dpi. Plants showed mild necrosis symptom 
when infiltrated with recombinant vector, (c) pGR-DN:: PR-EGF-CatAd-VP3-
HK__bZIP60 on 5 dpi. 
 
 
 
 
 
 
 
 
 
 
 
 
a b c 
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4.4 Discussion 
This chapter illustrates the delivery of recombinant apoptin vector variants into 
Nicotiana benthamiana via agroinfiltration and expression profiling on the production 
of recombinant apoptin proteins in order to seek for the most ideal recombinant 
cassettes that could offer high yield and stable proteins for subsequent downstream 
purification study. This study fully hired vacuum infiltration as a delivery approach 
for Agrobacterium to get into N. benthamiana. A standard infiltration protocol was 
applied for all infiltration works, hence, the delivery efficiency of Agrobacterium to 
plants is expected to be the same for all recombinant vectors. As described above, 
vacuum infiltration is an efficient way to infiltrate large batches of plants in a short 
period of time. Thus, time spent for infiltration works was reduced in this study 
especially when large quantities of leaf materials were required for downstream 
purification work (Chen et al., 2013). Besides, adverse injuries of infiltrated plants 
that always occur during syringe infiltration could also be eliminated when vacuum 
infiltration system was applied. Therefore, the necrosis symptoms observed in this 
study was believed to be solely induced by the expression of recombinant apoptin.  
Other than the importance of optimised design for expression cassettes, the uses of 
agrobacterial concentration for infiltration and gene silencing suppressors are also the 
two factors that affect expression yield of recombinant proteins. An optimised 
concentration of Agrobacterium required for infiltration is always studied when a 
specific and optimised expression cassette is obtained. It was reported that high 
concentration of bacteria always induces hypersensitive response of plants and 
undoubtedly, an insufficient amount of bacteria also cause a lower level of protein 
expression (Leuzinger et al., 2013). Concentration of Agrobacterium cultures for 
agroinfiltration was adjusted to OD600 = 0.5-1.0 in current study, fitting well into the 
recommended range for agroinfiltration by previous studies (Lindbo, 2007; 
Wroblewski et al., 2005).  
Gene silencing suppressors, P19 and P1/HC-Pro (Proteinase1/Helper component-
proteinase), were used together with the recombinant vectors, pGR-D and pGR-DN 
(binary vectors) in this study in order to enhance protein expression level. Occurrence 
of gene silencing in plants suppresses expression of genes and hence resulting low 
protein expression levels. Especially, post transcriptional gene silencing (PTGS) in 
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plants is induced by the presence of double stranded RNA (dsRNA), which is 
possibly caused by the transcription of antisense genes, overexpression of mRNA and 
virus infection (Escobar and Dandekar, 2000-2013). To confront the silencing effect 
of infected plants, viral gene silencing suppressors are always found during viral 
infection. For example, P19 and P1/ HC-Pro are the commonly found gene silencing 
suppressors in virus, which are believed playing a role in interrupting the assembly of 
RNA-induced silencing complex (RISC) and preventing translation inhibition caused 
by RISC (Burgyan and Havelda, 2011). Therefore, gene silencing suppressors were 
employed to co-infiltrate with transgenes to prevent inhibitory effect of host plants on 
foreign protein expression (Feller et al., 2013; Garabagi et al., 2012; Shah et al., 
2013). Instead of using external gene silencing suppressors, it was reported that 126k 
protein of tobacco mosaic virus (TMV) was believed involving in gene silencing 
suppression activities leading to the accumulation of sufficient short RNA (sRNA) 
(Vogler et al., 2007). Hence, there was no gene silencing suppressor used when 
infiltration was performed using a TMV-based vector, pGR-D4 since an internal gene 
silencing suppressor had already been included.   
In this study, accumulation of recombinant apoptin was compared when protein was 
targeted to cytoplasm, ER and apoplast. Recombinant apoptin was targeted to ER 
using tobacco pathogenesis related protein 1a (PR1a) signal peptide and ER retention 
signal (KDEL) (gene cassettes: PR-VP3-HK, PR-GFP-VP3-HK and PR-Lic-VP3-
HK). Meanwhile, recombinant apoptin was targeted into secretory pathway by 
incorporating PR1a signal peptide only which resulted protein accumulation in 
apoplast of plant cells (gene cassettes: PR-VP3-H, PR-GFP-VP3-H and PR-Lic-VP3-
H). Recombinant apoptin without signal peptide and ER retention signal (gene 
cassettes: VP3-H, GFP-VP3-H and Lic-VP3-H) was expected to accumulate in cell 
cytoplasm; however, recombinant GFP-apoptin (gene cassette: GFP-VP3-H) was 
observed relocalising into cell nucleus rather than staying in cytoplasm (Figure 4.5) 
as observed under the microscope. Similar observation was reported by Lacorte and 
his colleagues (2007) when they expressed Chicken Anemia Virus (CAV) Viral 
Protein 1 (VP1), VP2 and VP3 in N. benthamiana. Localisation of apoptin in cell 
nucleus was initially identified in chicken lymphoblastoid T-cell line, MDCC-MSBI 
and subsequently in mammalian cancerous cell lines (Noteborn et al., 1994; Noteborn 
et al., 1998). It was believed that the localisation activity of apoptin was directed by 
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the bipartite nuclear localisation signal (NLS) residing on C-terminal of protein 
(amino acids 82-88 and 111-121) (Danen-Van Oorschot et al., 2003; Poon et al., 
2005). Nevertheless, the authentic activities of apoptin in plant cells are remained to 
be determined.   
Focusing on the accumulation of recombinant apoptin in three cellular compartments, 
it is interesting to find out that recombinant apoptin always showed the highest 
protein expression (at least 2-3 folds higher) when it is accumulated in nucleus in 
comparison to protein accumulated in ER and apoplast in this study. However, most 
of the expressed proteins were in the insoluble fraction. These proteins could only be 
harvested by using strong denaturants, such as sodium dodecyl sulfate (SDS) which 
was present in SDS reducing loading buffer (in section 4.2.4) or guanidium 
hypochlorite (GuHCl) (to be described in Chapter 5). Insoluble fraction of 
recombinant apoptin might be caused by the formation of large multimers that are 
hardly solubilised in the buffer without strong denaturants due to the huge size of 
protein. Formation of protein aggregates by apoptin was first observed in CAV-VP3 
transfected lymphoblastoid T-cell line, MDCC-MSBI (Noteborn et al., 1994). 
Furthermore, formation of large multimers were also discovered when recombinant 
apoptin in fusion with maltose binding protein (MBP) was expressed in Escherichia 
coli as well as in mammalian cell Saos-2 (Lelivelda et al., 2003). Ectopically 
expressed MBP-apoptin in Saos-2 cells formed dense protein aggregates, which could 
be pelleted at 10, 000 – 30, 000 xg centrifugation speed. Besides, Lelivelda and his 
colleagues (2003) also reported that the multimerised recombinant MBP-apoptin 
harvested from E. coli remained active when protein was microinjected into 
mammalian cells.  
On the other hand, detectable level of soluble recombinant apoptin was observed but 
extremely low when protein was targeted to apoplast and ER (gene cassettes: PR-
GFP-VP3-HK, PR-GFP-VP3-H, PR-Lic-VP3-HK and PR-Lic-VP3-H) as compared 
to accumulation that occurred in nucleus. Targeting recombinant protein into 
secretory pathway always results a higher yield of soluble protein and this most likely 
due to the presence of higher quantity of chaperones that involve in the protein 
folding process. In the study of Streatfield and his colleagues (2003), they showed 
that more than 100 folds of recombinant receptor binding (B) subunit of the heat-
labile toxin (Lt-B) protein of enterotoxigenic E. coli was recovered when protein was 
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accumulated in vacuole, cell surface and ER rather than cytoplasm of transgenic corn. 
Besides, spider silk-elastin was also successfully produced at 80 mg per kg of 
transgenic tobacco leaf materials when protein was targeted into ER (Scheller et al., 
2004). 
Early necrosis symptom (observed from 3 dpi) was detected on plants infiltrated with 
recombinant apoptin vector variants especially those gene cassettes that targeted 
protein accumulation in ER and apoplast (gene cassettes: PR-VP3-HK, PR-VP3-H, 
PR-Lic-VP3-HK and PR-Lic-VP3-H). It is believed that the plant death might be co-
related to the ER stress response/unfolded protein response (UPR) induced by the 
overexpression of recombinant protein. When protein translation exceeds the capacity 
of protein processing in ER lumen, efficiency of protein folding is questionable and 
this always leads to accumulation of unfolded or misfolded proteins (Kopito, 2000). 
As the amount of unfolded proteins accumulated over a threshold, UPR would be 
triggered to resolve the ER stress condition. This includes restraining protein 
biosynthesis, preventing protein loading into ER lumens, up-regulation of UPR genes 
especially those encode chaperone proteins and ER associated degradation of 
unfolded protein via ubiquitin-proteosome pathway in cytoplasm (Duwi Fanata et al., 
2013). ER stress-induced apoptosis would also be triggered that causes an irreversibly 
lethal effect if the stress condition is not resolved. Risk of unfolded protein is not only 
present in plants, similar issues are also observed in other system. For example, 
‘inclusion body’ is always formed as a result of aggregation of unfolded protein 
induced by overexpression of recombinant proteins in E. coli expression system 
(Kopito, 2000). In human, misfolded proteins also form protein aggregates leading to 
several lethal diseases, such as type II diabetes, Alzheimer, Parkinson and Huntington 
diseases (Ashraf et al., 2014).     
In plant expression system, there are several fusion proteins used to increase 
solubility and stability of recombinant proteins, for examples, Zera, Elastin like 
protein (ELP),  ubiquitin, b-glucuronidase, cholera toxin B (CTB), viral coat protein 
(CP) and human immunoglobulin A (IgA). In this study, solubility of recombinant 
protein was increased especially when apoptin was in fusion to green fluorescent 
protein (GFP) and epidermal growth factor (EGF). Soluble protein expression of 
recombinant GFP-apoptin (gene cassette: PR-GFP-VP3-HK) and recombinant EGF-
apoptin (gene cassette: PR-EGF-CAtAd-VP3-HK) was approximately 5 folds over 
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that of recombinant apoptin alone (gene cassette: PR-VP3-HK). In the study of 
Lelivelda and his co-workers (2003), as much as 100 mg per liter of recombinant 
apoptin was also obtained from E. coli when large fusion tag, maltose binding protein 
(MBP) was incorporated in the cassette; however, only 40 mg per liter of recombinant 
apoptin was able to be harvested from bacterial inclusion bodies. Although 
mechanisms of fusion protein partners increasing solubility of recombinant proteins 
are still unclear, there are several suggested explanations such as formation of fusion 
proteins in micelle-like structure, high propensity of fusion partners on attraction of 
chaperone proteins, presence of intrinsic chaperone-like activity and preventing 
formation of protein aggregates by electrostatic repulsion (Costa et al., 2014). In 
addition to enhance expression of recombinant proteins, fusion proteins are also used 
for purification purpose which include short peptides, such as polyhistidine-tag (His-
tag), FLAG-tag and c-myc, as well as large polypeptides, including MBP and 
Glutathione S-transferase (Terpe, 2003). In current study, hexa-histidine tag was 
fused to C-terminal of all recombinant apoptin. Fusion of tag is important for 
subsequent protein purification step since immobilized affinity chromatography 
(IMAC) was chosen as the approach used in the capturing step (to be described in 
Chapter 5). Yet, instead of increasing yield and solubility of recombinant protein, 
fusion proteins sometimes also cause unexpected side effects on recombinant proteins, 
including changes of protein conformation, loss of bioactivity of recombinant 
proteins and induction of unwanted immunogenic reaction (Chelur et al., 2008).  
Severe protein degradation was noticed in this study when recombinant apoptin was 
in fusion to H22 single chain antibody (gene cassettes: PR-H22-CatAd-VP3-HK, PR-
H22-CatAd-40-121-VP3-HK, PR-H22-CatAd-60-121-VP3-HK and pGR-D4:: PR-
H22-CatAd-80-121-VP3-HK). Hence, careful selection of a suitable fusion protein 
candidate for the targeted proteins and methods for removal of fusion proteins during 
purification must be considered.  
Other than fusion protein, truncated version of recombinant apoptin was also studied 
to enhance solubility of protein. Amino acid 29-69 of recombinant MBP-apoptin was 
reported as multimerisation domain by Leliveldb and his colleagues (2003); in 
addition, amino acids 80-121 and 1-69 on C-terminal of recombinant apoptin in 
fusion to GFP retained ~50% and 17% of apoptotic activity as induced by the full 
length GFP-VP3 (Danen-Van Oorschot et al., 2003). Hence, truncated apoptin was 
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generated in this study by removal of short peptide from N-terminal of apoptin. For 
recombinant EGF-apoptin, it was noted that higher soluble protein was detected when 
amino acids 1-40 and 1-80 of apoptin were removed but not the removal of amino 
acid 1-60. Although the inhibition of amino acids 60-80 on the expression of 
truncated recombinant EGF-apoptin is unclear, presence of unexpected secondary 
structure might be one of the possible considerations that prevent expression of 
proteins.  
Plant death symptom observed in infiltrated plants was suspected to be related to ER 
stress. Hence, recombinant apoptin was co-expressed with transcriptional factors, 
namely bZIP17, bZIP28, and bZIP60, which are always incorporated in stimulating 
expression of UPR related genes. Up regulation of UPR related genes always leads to 
increased availability of chaperone proteins (Duwi et al., 2013; Vitale, 2013); 
therefore, more folded and soluble recombinant proteins are expected to be harvested. 
In current study, co-expression of bZIP60 with apoptin alone (PR-VP3-HK) resulted 
several folds of higher protein expression and early plant death symptom also did not 
appear on infiltrated plants. Nevertheless, this did not apply to co-expression of 
recombinant apoptin with transcriptional factors, bZIP17 and bZIP28. Effect of bZIP 
proteins towards the expression of recombinant GFP-VP3 and EGF-VP3 proteins also 
did not contribute any huge changes. Therefore, a combination use of bZIP proteins 
could be tried in future instead of using a single kind of bZIP protein, which scarcely 
paved a significant impact to the expression of recombinant apoptin.  
Expression profiles of recombinant apoptin variants had shown several suitable 
candidates used for downstream purification study. For recombinant apoptin 
expressed alone, recombinant vector, pGR-D4:: VP3-H gave high insoluble protein 
expression on 7 dpi while recombinant pGR-DN:: PR-VP3-HK yielded high soluble 
protein from 3-7 dpi (infiltrated plants on 4 dpi were harvested for purification). In 
addition, recombinant vectors, pGR-D4:: PR-GFP-VP3-HK (7 dpi) and pGR-D4:: 
GFP-VP3-H (7 dpi) yielded the highest soluble and insoluble recombinant GFP-
apoptin, respectively. On the other hand, recombinant vector, pGR-D4:: Lic-VP3-H 
(7 dpi) yielded the highest insoluble recombinant lichenase-apoptin and recombinant 
vector, pGR-D4:: PR-EGF-VP3-HK also gave the highest soluble recombinant EGF-
apoptin on 5 dpi. All these recombinant vectors generating high expression yield were 
chosen for subsequent purification study. Expression profiling study in this chapter 
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was carried out for only once for each expression vector; hence, a relative 
quantification was indicated to compare expression profiles between vectors. 
Expression yield for selected recombinant apoptin variants was evaluated in protein 
purification analysis (with 2-3 replicates) and illustrated in Chapter 5. 
In conclusion, recombinant apoptin variants have been successfully expressed in N. 
benthamiana via vacuum infiltration of transformed Agrobacterium that harboured 
recombinant vectors into plant cells. Expression profiles and incubation time for 
accumulation of recombinant apoptin were assessed and several recombinant vectors 
(Chapter 5) were chosen rationally based on the screening results as discussed above 
for downstream purification works. Besides, it is noteworthy to mention that apoptin 
expressed in N. benthamiana also retains the intrinsic nuclear localisation activity of 
protein in plants which might generate an interest for further study in future focusing 
on the plant death or apoptotic effects of apoptin in plant system.  
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5.1 Introduction 
Protein purification is essential for the recovery of recombinant proteins through a series of 
fractionation procedures by segregating targeted proteins from host cell proteins (HCP). 
Purification work could not be omitted, unless recombinant proteins were produced in edible 
hosts or as by-products of expression hosts. For instance, productions of edible vaccine in 
potato tubers against dengue virus 2 (Kim et al., 2016), oral vaccine in probiotic strain 
Lactobacillus against Streptococcus pyogenes M6 antigen (Mansour and Abdelaziz, 2016) 
and recombinant cytokine (hG-CSF) in milk of goat (Batista et al., 2014), are free from 
purification works and direct consumption is feasible. It is not surprised that protein 
purification can account for more than 80% of total production cost (Barh, 2013). Hence, a 
cost-effective purification approach is always required. In fact, it is sometimes more 
preferably for manufacturers to invest in optimising the upstream process of production in 
order to enhance protein expression yield when a satisfactory protein purification efficiency 
has not been achieved. To date, common steps in protein purification include extraction, 
clarification and fractionation.  
The secreted proteins produced in plant expression system could proceed directly to 
centrifugation and fractionation steps without a pre-requisite extraction work. This approach 
is highly attractive when high amount of recombinant proteins are secreted with good 
stability in culture medium of stably transformed plant cell lines or hydroponic plant 
(Borisjuk et al., 1999; James et al., 2000; Lee et al., 2002). However, extraction or 
homogenisation is always the first step for the recovery of non-secreted recombinant proteins 
from host plants. Leaf is the most widely chosen tissue for expression of recombinant 
proteins, especially the tobacco plant leaf which gives a large volume of biomass. The most 
common leaf protein extraction method involves mechanical disruption of cells. This could 
be achieved using pestle and mortar at a laboratory scale or homogeniser at a pilot scale. 
Alternatively, solid-liquid separation (Wilken and Nikolov, 2012), vacuum infiltration 
(Kingsbury and McDonald, 2014) and enzyme digestion (Fischer et al., 1999) approaches are 
also applied to isolate recombinant proteins. During the extraction process, huge amounts of 
unspecific plant products are released including the plant proteins (such as proteases), 
secondary metabolites, nucleotides, plant viruses and Agrobacterium. Hence, a proper 
formulation of extraction buffer containing appropriate pH, salt concentration, detergents and 
additives is important to obtain a high recovery of recombinant proteins from plant tissues 
during the extraction process (Buyel et al., 2015).  
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In order to separate large particulates and precipitates from crude protein extracts, 
clarification is always performed using high-speed centrifugation and ultrafiltration 
technique before the protein extracts are subjected for subsequent chromatography based 
purification procedures (Scopes, 1994). Generally, protein fractionation includes capturing, 
intermediate and polishing. Various kinds of chromatography or non-chromatography based 
methods could be combined and applied in these three steps in order to achieve a final 
product with higher purity. Using chromatography based protein fractionation method; 
targeted protein could be separated from total protein based on specific protein properties 
including affinity, charge, hydrophobicity and size of protein (Berg et al., 2002). In affinity 
chromatography, antibody and fusion tag proteins such as FLAG-tag, maltose binding 
protein (MBP), glutathione S-transferase (GST), polyHis tag, are the most widely used 
affinity purification tools (GE Healthcare1, 2016). Affinity chromatography isolates specific 
protein from total protein pool based on specific interaction between regions on protein and 
affinity media. This approach is suitable to be used in capturing step of protein purification 
process and the selective purification allows purity of eluted protein to increase from hundred 
to thousand folds in majority of cases just within a single step (Urh et al., 2009). Owing to 
the presence of specific net surface charge of a protein in a specific pH range, ion exchange 
chromatography (IEX) performs a group separation of protein sample by encouraging a 
reversible binding of charged protein to opposite-charged media. In addition to pH, 
interaction of protein to media is affected by the ionic strength of buffers since the presence 
of high concentration of ions is a competitor of bound proteins (GE Healthcare2, 2016). 
However, protein binding is enhanced when high concentration of salt is present in the buffer 
of hydrophobic interaction chromatography (HIC). Protein binding to HIC media is attributed 
by the suitable hydrophobic interaction; the reverse phase chromatography (RPC) also 
applies similar principle in the purification process. However, protein is eluted in non-polar 
organic solvent and usually in denaturing condition since protein is strongly bound to higher 
concentration of hydrophobic ligands in RPC (GE Healthcare3, 2016). Application of IEX, 
HIC and RPC is suitable for group separation of proteins; hence, they are mostly used in 
capturing step when affinity chromatography is not applicable or used in intermediate step to 
remove the unwanted contaminants. Size exclusion chromatography (SEC) is always the 
recommended tool for polishing step in protein purification. Purified protein samples could 
be easily separated from a small amount of unspecific host protein contaminants based on 
size difference. On the other hand, non-chromatography based method has been developed 
rapidly since the costly chromatography based purification is always a huge challenge in the 
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production process of recombinant proteins. Particularly, cross flow filtration, two aqueous 
phase separation and sucrose gradient purification have successfully developed to recover a 
large variety of recombinant proteins (Azevedo et al., 2009; Biemelt et al., 2003; Forman et 
al., 1990).   
Expressions of recombinant apoptin alone, green fluorescent protein (GFP)-apoptin, 
lichenase (Lic)-apoptin and epidermal growth factor (EGF)-apoptin have been analysed and 
illustrated in details in Chapter 3. In this chapter, protein purification works were carried out 
on plant leaves infiltrated with recombinant vectors, pGR-D4:: VP3-H, pGR-D4:: PR-GFP-
VP3-HK, pGR-D4:: GFP-VP3-H, pGR-D4:: Lic-VP3-H and pGR-D4:: PR-EGF-CatAd-
VP3-HK that yielded relatively higher amount of recombinant protein (> 20 mg/kg of total 
protein). Hexa-histidine sequence was present in all C-terminal of recombinant apoptin; 
hence, immobilised metal affinity chromatography (IMAC) was chosen as the major 
capturing tool for the purification works to isolate the recombinant apoptin from total plant 
proteins. Besides, IEX and HIC were used to remove plant protein contaminants and SEC 
was performed to elucidate the molecular weight of the purified recombinant apoptin in this 
study. Hence, the specific objectives for this chapter were (i) to illustrates the purification of 
recombinant apoptin, GFP-apoptin and EGF-apoptin using IMAC in native and denaturing 
conditions, (ii) to remove host cell protein from recombinant GFP-apoptin and EGF-apoptin 
using IEX (HiTap SP) and HIC (Phenyl Sepharose 6TM FF (high sub), HiTrap Butyl 
Sepharose HP and HiTrap Octyl Sepharose FF) and (iii) to characterise size  of recombinant 
GFP-apoptin using size exclusion chromatography (SEC).  
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5.2 Materials and Methods 
5.2.1 General materials 
5.2.1.1 Plant materials  
All plant materials used for purification were prepared as described in Chapter 3. Plants 
infiltrated with recombinant vectors, namely pGR-D4:: VP3-H, pGR-D4:: PR-GFP-VP3-HK, 
pGR-D4:: GFP-VP3-H and pGR-D4:: Lic-VP3-H were harvested on 7 days post infiltration 
(dpi), when the infiltrated plants gave the highest protein expression; however, plants 
infiltrated with recombinant vector, pGR-D4:: PR-EGF-CatAd-VP3-HK were harvested on 5 
dpi when the infiltrated plants produced the highest protein yield as discussed in Chapter 4. 
Approximately 10-100 g of leaf material was used for each purification experiment.  
5.2.1.2 Columns and kits 
HisTrap HP 1ml and 5 ml columns were used for immobilised metal affinity chromatography 
(IMAC) (GE Healthcare, USA). HiTrap SP HP 1ml column was used for ion exchange 
chromatopgraphy (IEX) (GE Healthcare, USA). HiTrap Butyl Sepharose HP 1ml, HiTrap 
Octyl Sepharose FF 1 ml and Phenyl Sepharose 6TM FF (high sub) columns were used for 
hydrophobic interaction chromatography (HIC) (GE Healthcare, USA). Analytical Superdex 
200 10/300GL column (GE Healthcare, USA) and Sepax SRT SEC 1000 (Sepax 
Technologies, Inc) column were used for size exclusion chromatography (SEC). QuickfoldTM 
Protein Refolding Kit (Athena Environmental Sciences, Inc) was used to refold recombinant 
protein. Slide-A-Lyzer™ Dialysis Cassettes (ThermoScientific, USA) were used for buffer 
exchange and protein refolding activities. Besides, PD-10 desalting columns (GE Healthcare, 
USA) were also used for buffer exchange of protein sample prior loading into HIC or IEX 
column. Amicon Ultra-4 and 15 Centrifugal Filter Units were used for concentrating purified 
protein. 
5.2.1.3 Buffers 
All buffers components used for protein purification are listed as in Table 5.1. 
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Table 5.1: Components of buffers. 
No Buffers Components 
1 IMAC Extraction Buffer A 
50 mM sodium phosphate, 500 mM sodium chloride, 20 mM imidazole, 
1 mM Dieca, pH 8.0, 4°C 
2 IMAC Extraction Buffer B 
50 mM sodium phosphate, 500 mM sodium chloride, 20 mM imidazole, 
0.5% Triton, 1 mM Dieca, pH 8.0, 4°C 
3 IMAC Extraction Buffer C 
6 M Guanidine hypochlorite, 50 mM sodium phosphate, 500 mM 
sodium chloride, 20 mM imidazole, pH 8.0, 4°C 
4 IMAC Extraction Buffer D 
6 M Guanidine hypochlorite, 50 mM sodium phosphate, 500 mM 
sodium chloride, 20 mM imidazole, 0.5% Triton, pH 8.0, 4°C 
5 IMAC Extraction Buffer E 
6 M Guanidine hypochlorite, 50 mM sodium phosphate, 500 mM 
sodium chloride, 2.5 mM imidazole, 20 mM Glycine, 2 mM GSH, pH 
7.4, 4°C 
6 IMAC Wash Buffer A 
50 mM sodium phosphate, 500 mM sodium chloride, 20 mM imidazole, 
pH 7.5, 4°C 
7 IMAC Wash Buffer B 
6 M Guanidine hypochlorite, 50 mM sodium phosphate, 500 mM 
sodium chloride, 20 mM imidazole, pH 7.5, 4°C 
8 IMAC Wash Buffer C 
50 mM sodium phosphate, 500 mM sodium chloride, 20 mM imidazole, 
0.5% Triton, pH 7.5, 4°C 
9 IMAC Wash Buffer D 
6 M Guanidine hypochlorite, 50 mM sodium phosphate, 500 mM 
sodium chloride, 20 mM imidazole, 2 mM GSH, pH 7.4, 4°C 
10 IMAC Wash Buffer E 
50 mM sodium phosphate, 400 mM sodium chloride, 5 mM imidazole, 2 
mM GSH, 2 mM MgCl2, pH 6.5, 4°C 
11 IMAC Elution Buffer A 
50 mM sodium phosphate, 500 mM sodium chloride, 500 mM 
imidazole, pH 7.5, 4°C 
12 IMAC Elution Buffer B 
6 M Guanidine hypochlorite, 50 mM sodium phosphate, 500 mM 
sodium chloride, 500 mM imidazole, pH 7.5, 4°C 
13 IMAC Elution Buffer C 
50 mM sodium phosphate, 400 mM sodium chloride, 500 mM 
imidazole, 2 mM GSH, 2 mM MgCl2, pH 6.5, 4°C 
14 Storage Buffer A 50mM sodium phosphate, 100mM NaCl, pH 7.5, 4°C 
15 Customised Buffer 11 
50 mM Tris-Cl, 9.6 mM NaCl, 0.4 mM KCl, 1 mM EDTA, 1 mM DTT, 
0.5 % Triton, pH 8.5 
16 Customised Buffer 13 
50 mM Tris-Cl, 240 mM NaCl, 10 mM KCl, 1 mM EDTA, 1 mM DTT, 
500 mM Arginine, 750 mM GuHCl, 0.5 % Triton, pH 8.5 
17 HIC Starting Buffer A 50mM sodium phosphate, 0.7 M NaCl, pH 7.5, 4°C 
18 HIC Starting Buffer B 50mM sodium phosphate, 1.0 M NaCl, pH 7.5, 4°C 
19 HIC Elution Buffer  50mM sodium phosphate, pH 7.5, 4°C 
20 IEX Starting Buffer A 50mM sodium phosphate, pH 6.7, 4°C 
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21 IEX Starting Buffer B 50mM Bicine, pH 9.0, 4°C 
22 IEX Starting Buffer C 50mM Bicine, pH 8.5, 4°C 
23 IEX Starting Buffer D 50mM sodium phosphate, pH 7.7, 4°C 
24 IEX Starting Buffer E 50mM sodium phosphate, pH 8.0, 4°C 
25 IEX Starting Buffer F 50mM sodium phosphate, 0.2 M NaCl, pH 8.0, 4°C 
26 IEX Elution Buffer A 50mM sodium phosphate, 1M NaCl, pH 6.7, 4°C 
27 IEX Elution Buffer B 50mM Bicine, 1M NaCl, pH 9.0, 4°C 
28 IEX Elution Buffer C 50mM Bicine, 1M NaCl, pH8.5, 4°C 
29 IEX Elution Buffer D 50mM sodium phosphate, 1 M NaCl, pH 7.7, 4°C 
30 IEX Elution Buffer E 50mM sodium phosphate, 1 M NaCl, pH 8.0, 4°C 
 
5.2.1.4 Specialised equipment 
Akta Purifier (GE Healthcare, USA) was used to perform all protein purification activities.  
Besides, peristaltic pump (EP-1 Econo Pump) (Biorad, USA) was also used for small scale 
work. Size exclusion chromatography (SEC) of protein samples were analysed using Agilent 
1260 system (Agilent Technologies, USA) and multi-angle light scattering (MALS) was 
performed using Wyatt HELEOS (Wyatt Technology, USA).  
5.2.1.5 Analysis software 
Purification performed using Akta Purifier was analysed using UnicornTM 5.11 (GE 
Healthcare, USA).  
5.2.2 Overview of protein purification study for recombinant apoptin variants 
Recombinant GFP-apoptin, namely GFP-VP3-HK (expressed from recombinant vector, 
pGR-D4:: PR-GFP-VP3-HK), and recombinant EGF-apoptin, namely EGF-VP3-HK 
(expressed from recombinant vector, pGR-D4:: PR-EGF-CatAd-VP3-HK), yielded ~ 50% of 
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soluble protein. Hence, capturing of recombinant GFP-VP3-HK and EGF-VP3-HK from 
total plant protein extract was carried out using IMAC (HisTrap HP column) in native 
condition with or without presence of detergent (such as triton). Size of purified recombinant 
GFP-VP3-HK was subsequently analysed using Analytical Superdex 200 10/300GL column 
and SRT SEC-1000 column. However, partial purified recombinant EGF-VP3-HK was 
further purified using HiTrap SP, HiTrap Butyl Sepharose HP 1ml, HiTrap Octyl Sepharose 
FF 1 ml and Phenyl Sepharose 6TM FF (high sub) columns.  
High amount of recombinant apoptin VP3-H (expressed from vector pGR-D4:: VP3-H), 
recombinant GFP-apoptin GFP-VP3-H (expressed from vector pGR-D4:: GFP-VP3-H) and 
recombinant Licchenase-apoptin Lic-VP3-H (expressed from vector pGR-D4:: Lic-VP3-H) 
were detected in insoluble fraction of plant extracts (Chapter 3). Hence, recombinant VP3-H, 
GFP-VP3-H and Lic-VP3-H were captured and recovered from total insoluble protein of 
plant extract using IMAC in denaturing condition. Purified recombinant GFP-VP3-H and 
Lic-VP3-H were subsequently refolded with phosphate buffer. Protein purification of 
recombinant apoptin variants was summarized as shown in Table 5.2.  
Table 5.2: Protein purification of recombinant apoptin variants. 
No Recombinant vector 
Recombinant 
protein 
Protein purification 
strategy 
Purification 
condition 
Purification 
procedure 
1 pGR-D4:: VP3-H VP3-H IMAC Denaturing 5.2.3.2 
2 
pGR-D4:: PR-GFP-
VP3-HK 
GFP-VP3-HK IMAC; SEC Native 5.2.3.1 and 5.2.8 
3 pGR-D4:: GFP-VP3-H GFP-VP3-H IMAC Denaturing 5.2.3.3  
4 pGR-D4:: Lic-VP3-H Lic-VP3-H IMAC Denaturing  5.2.3.2 
5 
pGR-D4:: PR-EGF-
CatAd-VP3-HK 
EGF-VP3-HK IMAC; HIC; IEX Native 
5.2.3.1, 5.2.6 and 
5.2.7 
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5.2.3 General immobilised metal affinity chromatography (IMAC) procedures 
5.2.3.1 Native condition 
Three volumes of Extraction Buffer A (v/w) were added into frozen leaf tissues (~50-100 g) 
and homogenised. The homogenised leaf extract was mixed by stirring and incubated for 20 
minutes at 4°C; subsequently, the extract was pelleted at 16, 000 xg for 30 minutes at 4°C. 
Supernatant was filtered using miracloth and 0.2 µm polyethersulfone (PES) filter before 
loaded into column. HisTrap HP column was equilibrated using 5 column volume (CV) of 
Wash Buffer A, 5 CV of Elution Buffer A and followed by 5 CV of Wash Buffer A. Extract 
was loaded into column at 5 ml/min for 5 ml column and 1 ml/min for 1 ml column. 
Subsequently, column was washed with 5 CV of Wash Buffer A and protein was eluted from 
column in stepwise gradient using 4% (40 mM imidazole), 9% (60 mM imidazole), 60% 
(300 mM imidazole) and 100% (500 mM imidazole) of Elution Buffer A. Protein samples 
from each fraction were collected for Western blotting analysis (which was similarly 
described in Chapter 4, section 4.2.5).  
5.2.3.2 Denaturing condition (Protocol 1) 
Three volumes of Extraction Buffer B (v/w) were used to homogenise the frozen leaf tissues 
(~50-100 g). The homogenised leaf extract was stirred and incubated for 20 minutes at 4°C; 
subsequently, the extract was pelleted at 16, 000 xg for 30 minutes at 4°C. Extraction with 
Extraction Buffer A was repeated for additional 3 times before pellet was resuspended with 
1.5 V of Extraction Buffer C. Protein extract was incubated at 4°C for 20 minutes, 
subsequently, extract was sonicated (amplitude: 70%) for 4 minutes (20 seconds on and 20 
seconds off) before extract was pelleted at 16, 000 xg for 30 minutes at 4°C. Supernatant was 
filtered using miracloth and 0.2 µm PES filter before loaded into column. HisTrap HP 
column was equilibrated using 5 CV of Wash Buffer B, 5 CV of Elution Buffer B and 
followed by 5 CV of Wash Buffer B. Extract was loaded into columns at 5 ml/min and 1 
ml/min for 5 ml and 1 ml columns, respectively. Then, column was washed with 5 CV of 
Wash Buffer B and protein was eluted from column in stepwise gradient using 4% (40 mM 
imidazole), 9% (60 mM imidazole), 60% (300 mM imidazole) and 100% (500 mM imidazole) 
of Elution Buffer B. Protein samples collected from each fraction were subjected to Western 
blotting analysis.  
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5.2.3.3 Denaturing condition (Protocol 2) 
Similar preparation steps of leaf samples were conducted as described in section 5.2.2.2 
(Protocol 1) until the soluble protein extract was pelleted. Extraction with Extraction Buffer 
B was repeated for additional 3 times before extract pellet was resuspended with 1.5 V of 
Extraction Buffer D. Protein extract was incubated at 4°C for 20 minutes, subsequently, 
extract was sonicated (amplitude: 70%) for 4 minutes (20 seconds on and 20 seconds off) 
before extract was pelleted again at 16, 000 xg for 30 minutes at 4°C. Supernatant was 
filtered using miracloth and 0.2 µm PES filter before the filtrate was diluted at 20X in 
Extraction Buffer B. Diluent was mixed at 4°C for 20 minutes and followed by filtration 
using 0.2 µm PES filter. HisTrap HP column was equilibrated using 5 CV of Wash Buffer C, 
5 CV of Elution Buffer A and followed by 5 CV of Wash Buffer C. Extract was loaded into 5 
ml HisTrap HP overnight. Subsequently, the column was washed with 5-10 CV of Wash 
Buffer C and 5-10 CV of Wash Buffer A. Protein was eluted from column in stepwise 
gradient using 4% (40 mM imidazole), 9% (60 mM imidazole), 60% (300 mM imidazole) 
and 100% (500 mM imidazole) of Elution Buffer A. Protein samples were ready for Western 
blotting analysis.  
5.2.4 Buffer exchange 
Purified protein was transferred into Slide-A-Lyzer™ Dialysis Cassettes before incubated in 
~100 volumes of storage buffer A or phosphate buffer saline (PBS) (v/v) for at least 4 hours. 
Incubation was repeated with fresh buffer before protein samples were analysed.  
Protein refolding using QuickfoldTM Protein Refolding Kit was performed as recommended 
by manufacturer. Approximately 50 µg of protein was added into 950 µl of buffers (buffers 
1-15). Mixtures were vortexed and mixed before incubated at 4°C overnight. Mixtures were 
centrifuged at 16, 000 xg for 15 minutes and supernatant was analysed using Western 
blotting.  
Buffer of recombinant protein eluted from IMAC was exchanged to starting buffer of 
hydrophobic interaction chromatography (HIC) or ion exchange chromatography (IEX) 
before sample was loaded into the HIC or IEX column. Buffer exchange was carried out 
using PD10 column and gravity flow protocol. PD10 column was initially equilibrated using 
25 ml of starting buffer before 2.5 ml of protein sample was added to the column. Flow 
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through from PD10 column was discarded and protein was subsequently eluted using 3.5 ml 
of starting buffer.  
5.2.5 Concentrating protein  
Protein was concentrated using Amicon Ultra-4 and 15 Centrifugal Filter Units. Protein 
sample was centrifuged at 3 000 – 6 000 rpm until a desired volume was remained in the 
filter unit.  
5.2.6 Hydrophobic interaction chromatography (HIC) 
HiTrapTM Butyl Sepharose HP 1ml, HiTrapTM Octyl Sepharose FF 1 ml and Phenyl 
Sepharose 6TM FF (high sub) columns were equilibrated using 5 CV of starting buffer, 5 CV 
of elution buffer following by 5 CV of starting buffer. Protein sample was loaded into 
column at 1 ml/min. Subsequently, column was washed and eluted using ~ 3 CV of elution 
buffer and deionised buffer. 
5.2.7 Ion exchange chromatography (IEX) 
HiTrapTM SP HP 1ml column was equilibrated using 5 CV of starting buffer, 5 CV of elution 
buffer followed by 5 CV of starting buffer. Protein sample was loaded into column at 1 
ml/min. Subsequently, column was washed and eluted in stepwise gradient using 20%-100% 
(containing 200 mM NaCl – 1M NaCl) of elution buffer. 
5.2.8 Size exclusion chromatography (SEC) and multi-angle light scattering     
(MALS) 
SEC analysis of recombinant GFP-apoptin (GFP-VP3-H) was performed and analysed by Dr 
Mark Jone and Ms April Horsey (Fraunhofer CMB, USA). Purified protein samples were 
analysed using SEC SRT-1000 column at flow speed ~1 ml/minute and separated proteins 
were subsequently analysed using MALS Wyatt HELEOS. SEC-MALS analysis was 
performed using Storage Buffer A.  
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5.3 Results 
 Protein purification of recombinant apoptin using immobilised metal 
chromatography (IMAC) 
5.3.1.1 Purification of recombinant apoptin alone VP3-H 
Recombinant apoptin VP3-H expressed alone (without fusion) in plants infiltrated with pGR-
D4:: VP3-H (Chapter 4) gave very low amount of soluble protein but with high level of 
insoluble protein detected. Hence, this recombinant VP3-H was attempted to be purified from 
insoluble protein extract (IMAC purification in denaturing condition, protocol 1). Total 
protein (TP) harvested from leaf material yielded ~ 31 mg/kg (Figure 5.1-a: Lane 4); 
however, amount of total soluble protein with 0.5% triton (TSP-T) (Figure 5.1-a: Lane 5) 
was lower than the detectable range. Extraction of recombinant protein using Extraction 
buffer C containing high concentration of denaturant (GuHCl) was able to harvest ~ 4 mg/kg 
(Figure 5.1-a: Lane 6) of protein and only ~ 1.2 mg/kg (30% of recovery) of recombinant 
apoptin (~ 18 kDa) was able to be recovered from IMAC eluent containing 300 mM 
imidazole (Figure 5.1-a: Lane 11). Since purified protein was in low amount, no detectable 
protein was observed on gel stained with coomassie blue (Figure 5.1-b: Lane 16).   
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 Lane Sample Estimated size    
 P MagicMark™ XP Western Protein Standard   
 Q BenchmarkTM Protein Ladder   
 1-3 60 ng, 30 ng and 15 ng of HAI standard  ~ 70 kDa  
 4 TP extract from leaf sample 
~ 18 kDa for recombinant  
VP3-H 
 
 5 TSP-T extract from leaf sample 
~ 18 kDa for recombinant  
VP3-H  
 
 6 Insoluble protein extract from leaf sample 
~ 18 kDa for recombinant  
VP3-H  
 
 7 Flow through fraction from IMAC 
~ 18 kDa for recombinant  
VP3-H  
 
 8-12 
IMAC eluent containing 20, 40, 60, 300 and 500 
mM imidazole 
~ 18 kDa for recombinant  
VP3-H  
 
 13-15 0.9, 0.6 and 0.3 mg  of BSA protein standard ~ 67 kDa  
 16 IMAC eluent containing 300 mM imidazole 
~ 18 kDa for recombinant  
VP3-H 
 
      
Figure 5.1: IMAC protein purification profiles of recombinant apoptin alone VP3-H. (a) 
Western profiles showed the detection of recombinant apoptin at a molecular size of ~ 18 
kDa reacted with Tetra-His mouse monoclonal antibody in each step of IMAC. All sample 
volume was adjusted to the volume of starting material and subsequently loaded into gel at 
the same volume for all fractions. (b) SDS-PAGE profiles of coomassie blue-stained protein 
samples recovered from IMAC eluent containing 300 mM imidazole. No expected protein 
band (~ 18 kDa) was identified from the gel.  
a b 
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5.3.1.2 Purification of recombinant green fluorescent protein 
(GFP)-apoptin  
Plants infiltrated with recombinant vector, pGR-D4:: PR-GFP-VP3-HK yielded higher 
soluble protein level in relative to those of recombinant vectors, pGR-D4:: PR-GFP-VP3-H 
and pGR-D4:: GFP-VP3-H (Chapter 4). Therefore, IMAC was carried out using soluble 
protein extract from leaves infiltrated with pGR-D4:: PR-GFP-VP3-HK. The TP extract from 
this GFP-VP3-HK protein was ~ 20 mg/kg (Figure 5.2-a: Lane 4), while total soluble protein 
(TSP) yielded ~ 9 mg/kg (~ 50% of total protein) (Figure 5.2-a: Lane 5). Approximately 7 
mg/kg (~ 80% recovery) of recombinant GFP-VP3-HK was recovered from IMAC eluent 
containing 300 mM imidazole (Figure 5.2-a: Lane 10 and Figure 5.2-c: Lane 19). 
Nevertheless, ~ 50 kDa plant protein contaminant was also present in purified recombinant 
GFP-VP3-HK eluted from IMAC eluent containing 300 mM imidazole (Figure 5.2-c: Lane 
19). Hence, an additional step was required to remove the plant protein contaminant.  
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 Lane Sample Estimated size  
 P MagicMark™ XP Western Protein Standard   
 Q BenchmarkTM Protein Ladder   
 1-3 60 ng, 30 ng and 15 ng of HAI standard  ~ 70 kDa  
 4 and 13 TP extract from leaf sample 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 5 and 14 TSP extract from leaf sample 
~ 45 kDa for recombinant 
GFP-VP3-HK  
 
 6 and 15 Flow through fraction from IMAC 
~ 45 kDa for recombinant 
GFP-VP3-HK  
 
 
7-11 and  
16-20 
IMAC eluent containing 20, 40, 60, 300 and         
500 mM imidazole 
~ 45 kDa for recombinant 
GFP-VP3-HK  
 
 12 IMAC eluent containing 300 mM imidazole 
~ 45 kDa for recombinant 
GFP-VP3-HK  
 
      
Figure 5.2: IMAC protein purification profiles of recombinant GFP-apoptin (GFP-VP3-HK) 
in native condition. (a) Western profiles showed the detection of recombinant GFP-apoptin at 
a molecular size of ~ 45 kDa reacted with Tetra-His mouse monoclonal antibody in each step 
of IMAC. All sample volume was adjusted to the volume of starting material and 
subsequently loaded into gel at the same volume for all fractions. (b) Western profiles 
showed the detection of recombinant GFP-VP3-HK eluted from IMAC eluent containing 300 
a b 
c 
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mM imidazole at a molecular size of ~ 45 kDa reacted with anti-VP3 mouse monoclonal 
antibody. (c) SDS-PAGE profiles of coomassie blue-stained protein extracts and samples 
recovered from IMAC fractions. A 50 kDa plant protein was eluted with recombinant GFP-
VP3-HK from IMAC eluent containing 300 mM imidazole. 
 
In addition, IMAC of recombinant GFP-VP3-HK was also performed using TSP-T plant 
extract (9 mg/kg). Low amount of this recombinant protein (~ 13% recovery) was eluted 
from column if triton was removed during the purification process (Figure 5.3-a). However, 
higher amount of protein was eluted from column when column was washed and eluted with 
0.031% (~ 95% recovery) (Figure 5.3-b) and 0.015% (~ 74% recovery) (Figure 5.3-c) of 
triton containing elution buffer. However, a high amount of plant protein contaminants was 
still found in the eluent of recombinant GFP-VP3-HK especially the ~ 50 kDa proteins 
(Figure 5.3-d). 
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 Lane Sample Estimated size  
 P MagicMark™ XP Western Protein Standard   
 Q BenchmarkTM Protein Ladder   
 1-3 60 ng, 30 ng and 15 ng of HAI standard  ~ 70 kDa  
 4, 12 and 20 TP extract from leaf sample 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 5, 13 and 21  TSP-T extract from leaf sample 
~ 45 kDa for recombinant 
GFP-VP3-HK  
 
 6, 14 and 22 Flow through fraction from IMAC 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 7-11 
IMAC eluent containing 20, 40, 60, 300 and         
500 mM imidazole without triton 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 15-19  
IMAC eluent containing 20, 40, 60, 300 and        
500 mM imidazole with 0.031% of triton 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 23-27 
IMAC eluent containing 20, 40, 60, 300 and        
500 mM imidazole with 0.015% of triton 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 28 and 29 
IMAC eluent containing 300 mM imidazole with 
0.031% and 0.015% of triton 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
      
a b 
c d 
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Figure 5.3: IMAC protein purification profiles of recombinant GFP-apoptin (GFP-VP3-HK) 
in TSP-T extract. All sample volume was adjusted to the volume of starting material and 
subsequently loaded into gel at the same volume for all fractions tested by using Western 
blotting. Western profiles showed the detection of recombinant GFP-VP3-HK at a molecular 
size of ~ 45 kDa reacted with Tetra-His mouse monoclonal antibody in each step of IMAC. 
(a) Triton was removed from washing and elution buffer. (b) Protein bound in IMAC column 
was washed and eluted using buffer containing 0.031% of triton. (c) Protein bound in IMAC 
column was washed and eluted using buffer containing 0.015% of triton. (d) SDS-PAGE 
profiles of coomassie blue-stained protein samples recovered from IMAC eluent containing 
300 mM imidazole with 0.031% and 0.015% of triton. A 50 kDa plant protein was eluted 
with recombinant GFP-VP3-HK from IMAC eluent. 
Instead of purifying recombinant GFP-apoptin in native condition, recombinant GFP-apoptin 
(GFP-VP3-H) showing high protein expression in insoluble protein fraction was also purified 
in denaturing condition (protocol 2) using leaf materials infiltrated with recombinant vector, 
pGR-D4:: GFP-VP3-H (Chapter 4). Insoluble protein extract of GFP-VP3-H was estimated 
at more than 25 mg/kg (Figure 5.4-a: Lane 2) and ~ 21 mg/kg (> 70% recovery) of 
recombinant GFP-apoptin was able to be eluted from IMAC eluent containing 500mM 
imidazole (Figure 5.4-a: Lane 10). Purified recombinant GFP-VP3-H was relatively clean 
since no major plant protein contaminant band was detected in IMAC eluent (Figure 5.4-c: 
Lane 18). Purified recombinant GFP-VP3-H was buffer exchanged and concentrated (Figure 
5.4-c: Lane 19) and subsequently used for microinjection procedure as described in Chapter 6. 
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 Lane Sample Estimated size  
 P MagicMark™ XP Western Protein Standard   
 Q BenchmarkTM Protein Ladder   
 1 TP extract from leaf sample 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 2 
Insoluble protein extract from leaf sample using 
IMAC Extraction Buffer D 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 3 
Pellet of leaf sample after insoluble protein 
extraction 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 4 
20X dilution of insoluble protein with IMAC 
Extraction Buffer B 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 5 Flow through fraction from IMAC 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 6 IMAC column washed using IMAC Wash Buffer C  
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 7-10 
IMAC eluent containing 20, 40, 60 and 500 mM 
imidazole using IMAC Elution Buffer A 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 11-13 60 ng, 30 ng and 15 ng of HAI standard ~ 70 kDa  
 14 and 18 IMAC eluent containing 500 mM imidazole  
~ 45 kDa for recombinant 
GFP-VP3-H 
 
a b 
c 
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 15-17 0.9, 0.6 and 0.3 mg of BSA protein standard ~ 67 kDa  
 19 
Buffer exchanged recombinant GFP-apoptin in 
storage buffer A 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
      
Figure 5.4: IMAC protein purification profiles of recombinant GFP-apoptin (GFP-VP3-H) in 
denaturing condition. (a) Western profiles showed the detection of recombinant GFP-VP3-H 
at a molecular size of ~ 45 kDa reacted with Tetra-His mouse monoclonal antibody in each 
step of IMAC. All sample volume was adjusted to the volume of starting material and 
subsequently loaded into gel at the same volume for all fractions. (b) Western profiles 
showed the recombinant GFP-VP3-H eluted in IMAC eluent containing 300 mM imidazole 
was detected at a molecular size of ~ 45 kDa by using anti-VP3 mouse monoclonal antibody. 
(c) SDS-PAGE profiles of coomassie blue-stained protein samples recovered from IMAC 
eluent containing 300 mM imidazole and buffer exchanged. No major plant protein 
contaminant band was detected in IMAC eluent. 
5.3.1.3 Purification of recombinant lichenase (Lic)-apoptin 
IMAC was performed in denaturing condition (protocol 1) using leaves infiltrated with 
recombinant vector, pGR-D4:: Lic-VP3-H since high expression level of insoluble protein (~ 
40 mg/kg) (Figure 5.5-a and b: Lane 6 and 17) was detected (Chapter 4). Approximately 20 
mg/kg of recombinant Lic-apoptin (Lic-VP3-H) (Figure 5.5-a and b: Lane 11 and 22) was 
recovered from IMAC column with 50% of protein did not bind to column which resembled 
~50% recovery (Figure 5.5-a and b: Lane 7 and 18). A clear band of recombinant Lic-VP3-H 
was identified in gel stained using coomasssie blue and no major plant protein contaminant 
band was detected in IMAC eluent (Figure 5.5-b: Lane 22). Protein was precipitated when 
IMAC eluent was buffer exchanged with PBS buffer (Figure 5.5-a and b: Lane 13, 14, 24 and 
25). Using refolding kit, recombinant Lic-VP3-H did not precipitate in buffer 11 and 13 
(Figure 5.5-c: Lane 27 and 28); however, removal of triton from buffer 11 and 13 caused a 
protein precipitation (Figure 5.5-c: Lane 31 and 32). 
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 Lane Sample Estimated size  
 P MagicMark™ XP Western Protein Standard   
 Q BenchmarkTM Protein Ladder   
 1-3 60 ng, 30 ng and 15 ng of HAI standard  ~ 70 kDa  
 4 and 15 TP extract from leaf sample 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 5 and 16 TSP-T extract from leaf sample 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 6 and 17 Insoluble protein extract from leaf sample 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 7 and 18 Flow through fraction from IMAC 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 
8-12 and  
19-23 
IMAC eluent containing 20, 40, 60, 300 and 500 
mM imidazole 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 13 and 24 Dialysis against PBS (Supernatant) 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 14 and 25 Dialysis against PBS (Pellet) ~ 40 kDa for recombinant Lic-  
a b 
c 
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VP3-H 
 26 IMAC Eluent containing 300 mM imidazole 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 27 Refolded protein using Quickfold Buffer 11 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 28 Refolded protein using Quickfold Buffer 13 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 29 Refolded protein using customised Buffer 11 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 30 Refolded protein using customised Buffer 13 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 31 
Refolded protein using customised Buffer 11 
without triton 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 32 
Refolded protein using customised Buffer 13 
without triton 
~ 40 kDa for recombinant Lic-
VP3-H 
 
      
Figure 5.5: IMAC protein purification profiles of recombinant Lic-apoptin (Lic-VP3-H) in 
denaturing condition. (a) Western profiles showed the detection of recombinant Lic-VP3-H 
at a molecular size of ~ 40 kDa reacted with Tetra-His mouse monoclonal antibody in each 
step of IMAC. All sample volume was adjusted to the volume of starting material and 
subsequently loaded into gel at the same volume for all fractions. (b) SDS-PAGE profiles of 
coomassie blue-stained protein samples recovered from each step of IMAC. No major plant 
protein contaminant band was detected in IMAC eluent. (c) Western profiles of recombinant 
Lic-VP3-H refolding from IMAC eluent containing 300 mM imidazole using Quickfold 
refolding kit and customised buffers. Bands of ~ 40 kDa Lic-VP3-H reacted with Tetra-His 
mouse monoclonal antibody were detected.  
Other than performing buffer exchange after IMAC, high concentration of denaturant was 
also removed when protein was binding in IMAC column using IMAC Wash Buffer D and 
IMAC Wash Buffer E. In comparison to the purification in complete denaturing condition, 
only 16% of Lic-VP3-H (Figure 5.6-a: Lane 10 and 11) was able to be recovered in IMAC 
using this method.  
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 Lane Sample Estimated size  
 P MagicMark™ XP Western Protein Standard   
 Q BenchmarkTM Protein Ladder   
 1-3 60 ng, 30 ng and 15 ng of HAI standard  ~ 70 kDa  
 4 and 13 TP extract from leaf sample 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 5 and 14 TSP-T extract from leaf sample 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 6 and 15 
Insoluble protein extract from leaf sample using 
IMAC Extraction Buffer E 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 7 and 16 Flow through fraction from IMAC using  
~ 40 kDa for recombinant Lic-
VP3-H 
 
 8 and 17 IMAC column washed using IMAC Wash Buffer D 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 9 and 18 IMAC column washed using IMAC Wash Buffer E 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 
10-11 and  
19-20 
IMAC eluent containing 500 mM imidazole 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 12 and 21 Dialysis supernatant 
~ 40 kDa for recombinant Lic-
VP3-H 
 
 22 Dialysis (pellet) 
~ 40 kDa for recombinant Lic-
VP3-H 
 
     
 
a b 
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Figure 5.6: IMAC protein purification profiles of recombinant Lic-VP3-H in denaturing 
condition. (a) Western profiles showed the detection of recombinant Lic-VP3-H at a 
molecular size of ~ 40 kDa reacted with Tetra-His mouse monoclonal antibody in each step 
of IMAC. All sample volume was adjusted to the volume of starting material and 
subsequently loaded into gel at the same volume for all fractions. (b) SDS-PAGE profiles of 
coomassie blue-stained protein samples recovered from each step of IMAC. No major plant 
protein contaminant band was detected in IMAC eluent. 
5.3.1.4 Purification of recombinant epidermal growth factor 
(EGF)-apoptin 
TP extract of recombinant EGF-apoptin (EGF-VP3-HK) from leaves infiltrated with pGR-
D4:: PR-EGF-CatAd-VP3-HK was ~ 29 mg.kg (Figure 5.7-a: Lane 4) and ~ 8-11 mg/kg of 
TSP was detected (Figure 5.7-a: Lane 5). However, only ~ 3-4 mg/kg of recombinant EGF-
VP3-HK was detected in IMAC eluent (Figure 5.7-a: Lane 10 and 12) and huge amount of 
plant protein contaminant (especially 50 kDa plant protein) was detected in the IMAC eluent 
(Figure 5.7-b: Lane 16).   
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 Lane Sample Estimated size  
 P MagicMark™ XP Western Protein Standard   
 Q BenchmarkTM Protein Ladder   
 1-3 60 ng, 30 ng and 15 ng of HAI standard  ~ 70 kDa  
 4 TP extract from leaf sample 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 5 TSP extract from leaf sample 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 6 Flow through fraction from IMAC column 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 7-11 
IMAC eluent containing 20, 40, 60, 300 and         
500 mM imidazole  
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 12 and 16 IMAC eluent containing 300 mM imidazole 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 13-15 0.9, 0.6 and 0.3 mg of BSA protein standard ~ 67 kDa  
      
Figure 5.7: IMAC protein purification profiles of recombinant EGF-apoptin (EGF-VP3-HK) 
in native condition. (a) Western profiles showed the detection of recombinant EGF-VP3-HK 
at a molecular size of ~ 30 kDa reacted with Tetra-His (Lane 1-11) and anti-VP3 (Lane 12) 
mouse monoclonal antibodies in each step of IMAC. All sample volume was adjusted to the 
volume of starting material and subsequently loaded into gel at the same volume for all 
fractions. (b) SDS-PAGE profiles of coomassie blue-stained protein samples recovered from 
IMAC eluent containing 300 mM imidazole. A 50 kDa plant protein was eluted with 
recombinant EGF-VP3-HK from IMAC eluent. 
a b 
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Purified recombinant EGF-VP3-HK in IMAC eluent containing 300 mM imidazole was 
eluted with huge amount of ~ 50 kDa plant protein contaminant. Hence, IMAC was 
performed again on IMAC eluent in order to remove the impurities. It was noticed that 
additional IMAC purification step did not improve the purity of recombinant EGF-apoptin 
and only 37% of protein was able to be recovered from samples loaded into the IMAC 
column (Figure 5.8-a and -b: Lane 9 and 18).   
      
 
  
 
 Lane Sample Estimated size  
 P MagicMark™ XP Western Protein Standard   
 Q BenchmarkTM Protein Ladder   
 1 and 10 TSP extract from leaf sample 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 2 and 11 IMAC eluent containing 300 mM imidazole 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 3 and 12 
Supernatant of IMAC eluent after centrifuged at 40, 
000 xg 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 4 and 13 
Buffer exchange of IMAC eluent buffer containing 
300 mM imidazole to IMAC Extraction Buffer A 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 5 and 14 Flow through fraction from IMAC 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 
6-9 and  
15-18 
IMAC eluent containing 20, 40, 60 and 500 mM 
imidazole 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
      
Figure 5.8: IMAC protein purification profiles of recombinant EGF-apoptin (EGF-VP3-HK) 
in native condition. (a) Western profiles showed the detection of recombinant EGF-VP3-HK 
at a molecular size of ~ 30 kDa reacted with anti-VP3 mouse monoclonal antibody in each 
step of IMAC. All sample volume was adjusted to the volume of starting material and 
subsequently loaded into gel at the same volume for all fractions. (b) SDS-PAGE profiles of 
coomassie blue-stained protein samples recovered from each step of IMAC.  A plant protein 
a 
b 
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(50 kDa) was the major plant protein contaminant eluted with recombinant EGF-VP3-HK 
from IMAC eluent. 
 Improvement for protein purity 
5.3.2.1 Hydrophobic interaction chromatography (HIC) 
In addition to IMAC, partial purified recombinant EGF-apoptin (EGF-VP3-HK) was further 
separated from plant protein impurities using HIC and IEX.  Using HIC, EGF-VP3-HK  
bound tightly to HIC mediums, including Phenyl Sepharose 6TM FF (high sub), HiTrapTM 
Butyl Sepharose HP and HiTrapTM Octyl Sepharose FF, and protein was not able to be 
recovered from mediums (Figure 5.9-a, -b and -c: Lane 6, 11 and 17).  
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 Lane Sample Estimated size  
 P MagicMark™ XP Western Protein Standard   
 Q BenchmarkTM Protein Ladder   
 1, 7 and 13 IMAC eluent containing 300 mM imidazole 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 2 
Supernatant of IMAC eluent after centrifuged at 40, 
000 xg 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 3 
Buffer exchange IMAC eluent to HIC Starting 
Buffer A 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 4 
Flow through fraction from Phenyl Sepharose 6TM 
FF (high sub) 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 5 
Phenyl Sepharose 6TM FF (high sub) medium 
washed using HIC Starting Buffer A 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 6 
Phenyl Sepharose 6TM FF (high sub) medium eluted 
using HIC Elution Buffer 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
a b 
c 
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 8 and 14 
Buffer exchange IMAC eluent to HIC Starting 
Buffer B 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 9 
Flow through fraction from HiTrap Butyl Sepharose 
HP column 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 10 
HiTrap Butyl Sepharose HP column washed using 
HIC Starting Buffer B 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 11 
HiTrap Butyl Sepharose HP column eluted using 
HIC Elution Buffer 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 12  
HiTrap Butyl Sepharose HP column eluted using 
deionised water 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 15 
Flow through fraction from HiTrap Octyl Sepharose 
FF column 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 16 
HiTrap Octyl Sepharose FF column washed using 
HIC Starting Buffer B 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 17 
HiTrap Octyl Sepharose FF column eluted using 
HIC Elution Buffer 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 18 
HiTrap Octyl Sepharose FF column eluted using 
deionised water 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
      
Figure 5.9: HIC protein purification profiles of recombinant EGF-apoptin (EGF-VP3-HK) in 
native condition. All sample volume was adjusted to the volume of starting material and 
subsequently loaded into gel at the same volume for all fractions. Western profiles showed 
the detection of recombinant EGF-apoptin at a molecular size of ~ 30 kDa reacted with anti-
VP3 mouse monoclonal antibody in each step of HIC using (a) Phenyl Sepharose 6TM FF 
(high sub) column, (b) HiTrap Butyl Sepharose HP column and (c) HiTrap Octyl Sepharose 
FF column. No protein was successfully eluted from these columns using respective elution 
buffers. 
5.3.2.2 Ion exchange chromatography (IEX) 
Isoelectric point of recombinant EGF-apoptin (EGF-VP3-HK) was estimated as ~ pH 7.7. 
Using cationic exchanger HiTrap SP column, positively charged recombinant EGF-VP3-HK 
bound column tightly and protein was not able to be eluted from column (Figure 5.10-a: Lane 
5-9) when chromatography was performed at pH 6.7. In contrast, when IEX was performed 
at pH 9.0, most of the protein was able to be eluted from column (Figure 5.10-b: Lane 18) 
and small amount of protein was detected in the flow through fraction (Figure 5.10-b: Lane 
16). When IEX was performed at pH 8.5, approximately 35% of loaded recombinant EGF-
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VP3-HK was eluted in fraction using buffer containing 0.4 M of sodium chloride (Figure 
5.10-c: Lane 25). However, this approach did not successfully remove plant protein 
contaminants from the partial purified products (Figure 5.10-c: Lane 28). 
      
 
  
 
 
 
  
      
 Lane Sample Estimated size  
 P MagicMark™ XP Western Protein Standard   
 1, 13 and 19 IMAC eluent containing 300 mM imidazole 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 2, 14 and 20 
Supernatant of IMAC eluent after centrifuged at 40, 
000 xg 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 3 
Buffer exchange of IMAC eluent containing 300 
mM imidazole to IEX Starting Buffer A 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 4 Flow through fraction from HiTrap SP column 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 5-9 
Eluent containing 0.2, 0.4, 0.6, 0.8 and 1 M NaCl 
from HiTrap SP column using IEX Elution Buffer A 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 10-12 60 ng, 30 ng and 15 ng of HAI standard ~ 70 kDa  
 15 
Buffer exchange of IMAC eluent containing 300 
mM imidazole sample to IEX Starting Buffer B 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
a b 
c 
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 16 Flow through fraction from HiTrap SP column 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 17 
HiTrap SP column washed using IEX Starting 
Buffer B 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 18 
HiTrap SP column eluted using IEX Starting Buffer 
B 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 21 
Buffer exchange of IMAC Eluent containing 300 
mM imidazole sample to IEX Starting Buffer C 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 22 Flow through fraction from HiTrap SP column 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 23 
HiTrap SP column washed using IEX Starting 
Buffer C 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 24-27 
Eluent containing 0.2, 0.4, 0.6 and 0.8 M NaCl from 
HiTrap SP column using IEX Elution Buffer C 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
 28 Eluent containing 0.4 M NaCl 
~ 30 kDa for recombinant 
EGF-VP3-H 
 
      
Figure 5.10: IEX protein purification profiles of recombinant EGF-apoptin (EGF-VP3-HK) 
in native condition using 1 ml HiTrapTM SP column. All sample volume was adjusted to the 
volume of starting material and subsequently loaded in the same volume for all fractions. (a) 
Western profiles showed the detection of recombinant EGF-apoptin at a molecular size of ~ 
30 kDa reacted with anti-VP3 mouse monoclonal antibody (Lane 1-9) in each step of IEX 
performed at pH 6.7. Western profiles showed the detection of recombinant EGF-VP3-HK at 
a molecular size of ~ 30 kDa reacted with Tetra-His mouse monoclonal antibody in each step 
of IEX performed at (b) pH 9.0 and (c) pH 8.5. 
5.3.3 Characterisation of recombinant GFP-apoptin 
In gel filtration analysis, recombinant GFP-apoptin (GFP-VP3-H), always separated as ~ 45 
kDa protein molecule in reduced SDS page (Figure 5.4), did not migrate as monomer when 
analysed using SRT SEC1000 column in Storage Buffer A. In SEC analysis, GFP-VP3-H (~ 
0.75 mg/ml) migrated as a single peak at 10 ml with a small shoulder ~ 10.7 ml (Figure 5.11-
a). Majority of these protein molecules showed a similar molecular mass, which was ~ 944.3 
kDa (size estimation based on normalisation of BSA from Zenix C 300 column) (Figure 
5.11-b).   
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Figure 5.11: SEC-MALS analysis of recombinant GFP-apoptin. (a) SEC of recombinant 
GFP-VP3-H using SRT SEC1000 column in Storage Buffer A yielded a single peak at 10 ml 
and a shoulder at 10.7 ml. (b) MALS analysis of recombinant GFP-VP3-H immediately after 
SEC. Majority of the proteins showed a similar molecular mass of ~ 944. 3 kDa (size 
estimation based on normalisation of BSA from Zenix C 300 column).    
 
 
 
 
a 
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5.4 Discussion 
In this chapter, a detailed description was provided on the study of downstream processing of 
recombinant apoptin alone (without fusion, VP3-H), GFP-apoptin (GFP-VP3-HK and GFP-
VP3-H), Lichenase-apoptin (Lic-VP3-H) as well as EGF-apoptin (EGF-VP3-HK). The 
purified recombinant proteins obtained from this study would be used for subsequent cell-
based assays. At the beginning, hexa-histidine sequence was added to C-terminal end of all 
recombinant apoptin which aimed to employ immobilised affinity chromatography (IMAC) 
as the major purification approach. Owing to the selective binding of IMAC resin to histidine 
tags which are present on the protein surface, IMAC is widely used in capturing step of 
purification process to recover the targeted proteins as well as eliminate majority of 
unspecific host proteins. IMAC was performed in both denaturing and native conditions in 
this study based on the solubility of the recombinant proteins.  
Expression of recombinant apoptin alone (VP3-H) procured the highest protein yield as 
compared to those leaves infiltrated with recombinant vectors, i.e. pGR-D4:: PR-VP3-HK 
and pGR-D4:: PR-VP3-H. Protein purification was however performed in denaturing 
condition using high concentration of denaturants, guanidine hypochloride (GuHCl) because 
majority of protein was found in insoluble state. In fact, insoluble recombinant apoptin alone 
was not extracted efficiently from leaf materials even with the use of high concentration of 
denaturants. Therefore, alternative buffering systems or additional additives might be 
necessary to enhance the recovery of protein during extraction process, such as sugars, salt, 
reducing agents, detergents and chaotropic agents (Leibly et al., 2012). According to the 
IMAC, only 30% recombinant apoptin was able to be recovered and this resulted low amount 
of purified protein (~ 1.2 mg/kg) harvested (section 5.3.1). Based on protein expression 
profiles in Chapter 4, soluble recombinant apoptin was detected in higher quantity (~ 4 
mg/kg) when leaf was infiltrated with pGR-DN:: PR-VP3-HK__bZIP60 compared to pGR-
DN:: PR-VP3-HK__bZIP17, pGR-DN:: PR-VP3-HK__bZIP28, pGR-D4:: PR-VP3-HK, 
pGR-D4:: PR-VP3-H and pGR-D4:: VP3-H. However, IMAC purification performed using 
50 g leaf materials infiltrated with recombinant vector, pGR-DN:: PR-VP3-HK__bZIP60 
yielded low amount of purified protein (< 1 mg/kg) (Appendix 5.1).  Purification of 
recombinant apoptin alone has been reported by Lelivelda and his colleague (2003) from 
Escherichia coli expression system. High amount (~ 40 mg/L of culture) of recombinant 
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apoptin in fusion to hexa-histidine tag was recovered using two-step chromatographic 
process, i.e. cation exchange chromatography following by Ni2+-NTA-agarose in denaturing 
condition. It was reported that only 50% of protein refolded efficiently and protein migrated 
as single species at 400 ± 50 kDa on Superose 6 HR 10/30. Although small amount (2 mg/L 
of culture) of soluble recombinant apoptin alone was obtained in the previous study of 
Nogueira-Dantas et al. (2007), majority of the recombinant apoptin was remained in the 
bacterial inclusion body which could only be recovered using high-concentration denaturant 
containing buffer or in bacterial pellet. In relative to E. coli system, expression yield of 
recombinant apoptin was low in plant system obtained in this study. Nevertheless, 
recombinant apoptin alone was found accumulating in insoluble protein fraction either in E. 
coli or Nicotiana benthamiana expression system.  
In contrast to recombinant apoptin alone, expression of soluble recombinant apoptin was 
detected upon fusion to green fluorescent protein (GFP), especially GFP-VP3-HK which 
yielded 50% soluble protein (~ 9-10 mg/kg). IMAC recovered 80% of GFP-apoptin from 
total soluble protein extract (Figure 5.2). However, a  50 kDa plant protein, which might be 
Rubisco was detected in purified recombinant GFP-apoptin eluent. Removal of host cell 
proteins from tobacco extract (especially Rubisco protein) has always been a major issue 
encountered in downstream processing of recombinant proteins (Buyel et al., 2015).  In order 
to remove host cell protein, chromatography (Kittur et al., 2015) and acidic precipitation 
methods (adjusting protein extract to ~ pH 5) are the commonly used method. Application of 
polishing step using ion exchange chromatography (IEX) HiTrap SP column was not 
efficient to remove the unspecific plant proteins (Appendix 5.2).  It is noted that most plant 
host cell proteins always have low pI value (Azzoni et al., 2002). Therefore, as long as the 
targeted recombinant proteins are stable in acidic condition, a lower pH nearing pI of host 
cell proteins could be adjusted in order to precipitate these unspecific contaminating proteins. 
However, the recombinant GFP-apoptin was found precipitated at acidic condition 
(Appendix 5.4) as well. Therefore, using either cationic exchange chromatography HiTrap 
SP column or low pH precipitation method was not ideal to remove these unwanted host cell 
proteins. When triton was added to extraction buffer, yield of soluble protein of recombinant 
GFP-apoptin was not increased. Triton (MW= 625 Da) is a kind of non-ionic surfactant used 
for disruption of cell membrane during extraction process. However, huge micelle size 
(MW= 90 kDa) of triton disabled the surfactant to be removed via dialysis approach from the 
final purified product. Hence, it is always encouraged to remove triton during the purification 
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process. However, it was also observed that removal of triton during purification caused 
protein precipitation in the column and a minimum of ~ 0.015% triton was required to avoid 
the precipitation occurrence (Figure 5.3). Instead of solely purifying recombinant GFP-
apoptin from soluble protein fraction, the insoluble fraction of GFP-VP3-H protein harvested 
was also purified using IMAC. Insoluble recombinant GFP-apoptin was isolated using 
extraction buffer containing strong denaturant (GuHCl) and triton. The denatured 
recombinant protein could be refolded and diluted for 20 times in buffer without denaturants 
but in the presence of triton prior loading into IMAC column (section 5.2.3.3 – Denaturing 
protocol 2) (Figure 5.4). Recombinant GFP-VP3-H purified using this strategy showed a 
higher recovery yield and lower amount of unspecific plant protein contaminants. In addition, 
refolding efficiency of protein via this method was believed to be higher than that of protein 
purified under denaturing condition with subsequent refolding process (section 5.2.3.2 – 
Denaturing protocol 1) (Appendix 5.3). This could be explained as protein was concentrated 
after purification process and low refolding efficiency always obtained at high protein 
concentration. Aggregation usually arose due to hydrogen bond formation between protein 
chains of partially folded intermediate that close to each other in high protein concentration 
(Gupta et al., 1998). So far, no membrane penetrating domain was detected on either apoptin 
or GFP. Therefore, external delivery tools would be required to transfer the protein into 
intracellular space of mammalian cells in order to examine for the bioactivity of purified 
protein. In this circumstance, the presence of surfactants (such as triton) or chemicals (such 
as GuHCl) used for protein purification would threaten the viability of mammalian cells. 
Hence, all these chemicals were removed from the final product before the protein sample 
was used for cell-based assay as illustrated in Chapter 6.  
Refolded GFP-apoptin (GFP-VP3H) analysed using SEC-MALS showed the protein owed a 
multimeric structure (~ 944.3 kDa) instead of presence as a monomer (~ 45 kDa). Majority of 
GFP-VP3-H proteins were from a single population composed of approximately 20 units of 
monomer. Multimerisation of recombinant apoptin was also shown in the study of Lelivelda 
et al. (2003) for purified recombinant MBP-apoptin and refolded apoptin from E. coli 
expression system. Results showed that ~ 30-40 monomers of recombinant MBP-apoptin 
(monomer: 56 kDa) assembled into multimeric form as 2.5 ± 0.3 MDa in size (Leliveldb et 
al., 2003); while ~ 27 monomers of refolded apoptin (monomer: 14.5 kDa) assembled into 
400 ± 50 kDa mutimers. In addition, MBP-apoptin was presented as globular particles with a 
radius of ± 40 nm under scanning electron microscope in a uniform population. Recombinant 
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MBP-apoptin and apoptin protein molecules could be broken down into monomer with SDS 
(similar as recombinant GFP-apoptin); therefore, interaction of apoptin molecules is believed 
to be non-covalently linked.  
Purification of recombinant Lic-apoptin (Lic-VP3-H) was performed under denaturing 
condition and refolding of protein required the presence of triton (Figure 5.5). Besides, 
refolding of recombinant protein in IMAC column showed poor protein yield in IMAC 
eluent (Figure 5.6). Although IMAC purified recombinant Lic-apoptin showed high purity in 
this study, refolding process of protein did not work as expected. On the other hand, IMAC 
purification of recombinant EGF-apoptin (EGF-VP3-HK) in native condition showed poor 
yield (~3-4 mg/kg) and low purity. Besides, polishing chromatography using IMAC, HIC, 
IEX and acidic precipitation method (Appendix 5.4) also did not improve the situation. 
Recombinant EGF-apoptin yielded ~ 50 % of soluble protein, so, by starting purification 
from insoluble protein fraction would loss half of the protein amount. Hence, IMAC 
purification from denaturing condition had been performed from total protein of recombinant 
EGF-apoptin extract (Appendix 5.5). Unfortunately, the contaminating host cell proteins 
(especially ~ 50 kDa) were detected in IMAC eluent (Appendix 5.5).   
Based on the current observations, recombinant apoptin purified in native condition 
(recombinant GFP-VP3-HK and EGF-VP3-HK) was always encountered with challenges of 
having host protein contaminants in the final purified products. The low ratio of recombinant 
apoptin to total protein pool with the initial attribution of low expression level is suspected to 
be one of the reasons that affect the selectivity of IMAC resin. Currently, IMAC was 
performed using nickel ion and other immobilized metal ions, such as copper, zinc and cobalt, 
could also be used to recover recombinant apoptin in future study. IMAC performed in 
denaturing condition (recombinant GFP-VP3-H and Lic-VP3-H) always required several 
washing steps with soluble protein extraction buffer (such as IMAC Extraction Buffer A) in 
the presence of triton before the recombinant apoptin was extracted from pellet using 
insoluble protein extraction buffer containing high concentration of strong denaturants. These 
washing steps are imperative to remove huge amount of soluble host cell proteins in addition 
to increase the ratio of recombinant apoptin to protein pool in the protein extract. Thus, a 
higher purity of recombinant apoptin could be detected in IMAC eluent. Instead of using 
IMAC, other affinity chromatography methods could be considered in the future.  
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It is known from previous studies that fusion of recombinant apoptin to other large protein 
would increase its solubility, stability as well as expression yield. Hence, large fusion tag 
proteins, such as maltose binding proten (MBP) and glutathione S-transferase (GST), are the 
favorable choices. In the study of Lee et al. (2012), recombinant GST-TAT-apoptin was 10-
fold higher in expression quantity in relation to recombinant Histidine-TAT-apoptin. Besides, 
Lee et al. (2003) also showed soluble recombinant MBP-apoptin was 2.5-fold higher 
expression level in relation to the recombinant apoptin-histidine that was present in inclusion 
body. Fusion of either MBP or GST to recombinant EGF-apoptin would be one of the 
solutions in order to recover this protein more efficiently. Numerous approaches are available 
for downstream processing and yet, a suitable purification protocol can be found only after 
attempting various combinations of purification strategies.     
In conclusion, a few protein purification protocols of recombinant apoptin extracted from 
tobacco leaf materials were attempted and further study might be required to enhance 
purification efficiency in future. Based on current findings, recombinant apoptin alone (VP3-
H), GFP-apoptin (GFP-VP3-HK) and Lichenase apoptin (Lic-VP3-H) did not yield good 
purity or promising amount of purified proteins. On the other way, good purity of refolded 
GFP-apoptin (GFP-VP3-H) was collected at ~ 2 mg/ml. Although purification of 
recombinant EGF-apoptin (EGF-VP3-HK) did not yield high purity in the final product, this 
purified protein was still tested in subsequent cell-based study. Recombinant EGF-apoptin 
was expected to be selectively internalised into EGF overexpressed cell via endocytosis after 
the binding of recombinant protein to EGF receptors and passed through plasma membrane 
via the CatAd molecular adaptor. Hence, refolded GFP-apoptin and IMAC purified EGF-
apoptin were used for cell-based study to determine the bioactivity of both plant expressed 
apoptin in mammalian cells. 
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6.1 Introduction 
Viral protein 3 (VP3) from Chicken Anemia Virus (CAV) is responsible for the destruction of 
lymphocytes during viral infection by induction of apoptosis; hence, the protein was named 
“apoptin” (Los et al., 2009). Apoptin is a 14 kDa non-structural protein. There is a leucine rich 
region, resides between amino acids 33-46, and a bipartite nuclear localization signal (NLS), 
resides between amino acids 82-88 and 111-121. Apoptin showed selective killing activity 
towards ~ 70 cancer or transformed cell lines including breast cancer, osteosarcoma, lung 
carcinoma, hepatoma, SV-40 transformed fibroblast and adenovirus-5-transformed embryonal 
retinoblasts (Noteborn et al., 2008). However, apoptosis was usually not induced by apoptin in 
normal and non-transformed cells such as human umbilical cord vascular endothelial cells 
(HUVEC), smooth muscle (HSM), primary T cells and rat embryo fibroblasts (REF) (Danen-van 
Oorschot et al., 1997; Noteborn et al., 2008). Apoptin-induced apoptosis is independent of p53 
(Zhuang et al., 1995) and involves mitochondria-mediated apoptotic pathway by loss of 
mitochondrial membrane potential (MMP), releasing of cytochrome c and activation of caspase 3 
(Danen-van Oorschot et al., 2000). Currently, cell killing ability of apoptin was tested in various 
cancer cell lines as well as in mice using various kinds of delivery method including viral vectors, 
bacteria (Salmonella typhimurium), intratumoral injection, electroporation and cell penetrating 
peptides (such as trans-activator protein (TAT) from human immunodeficiency virus (HIV) or 
protein transduction domain 4 (PTD4)) (Rollano Peñaloza et al., 2014).       
Apoptosis, also named as programmed cell death, is one of the cell death mechanisms that plays 
role in various kinds of cellular activities such as cell number controlling (Hall et al., 1994), 
elimination of self-reactive lymphocytes (Parijs et al., 1998) and cellular stresses (induced by 
irradiation or drugs) leading to cellular DNA damage (Enoch and Norbury, 1995) as well as 
senescence. Regulated apoptosis is crucial since excess activity of apoptosis caused atrophy and 
defective in apoptosis results the progression of cancer. Round in shape, shrink, smaller in size 
and losing contact with neighbouring cells, chromatin condensation, DNA fragmentation and 
formation of apoptotic bodies are the several features observed during apoptosis (Walker et al., 
1994). Apoptosis is induced through extrinsic (cell death receptor) or intrinsic (mitochondria) 
pathway. Apoptosis induced by extrinsic pathway involves activation of receptors located on 
plasma membrane such as TNF-R (tumour necrosis factor receptor) and Fas receptor (Ashkenazi, 
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2008). On the other hand, intrinsic pathway is induced by the loss of mitochondrial membrane 
potential, releasing of cytochrome c and formation of apoptosome (Elmore, 2007). Triggering of 
apoptotic pathway eventually leads to the activation of caspases that are important for the 
degradation of cellular proteins in apoptotic cells, activation of other cellular proteins involved in 
apoptosis and DNA fragmentation (McIlwain et al., 2013).  
The lipophilic feature of plasma membrane restrains the direct transport of biomolecules, hence, 
macromolecules (such as DNA, RNA and proteins) and micromolecules (such as ions and 
organic molecules) could not freely pass through the membrane without involving a specific 
transport mechanism. In order to determine bioactivity of pharmacological drugs, delivery of 
these compounds into intracellular space or specific cellular compartment is always a challenge 
with low risk of damage or toxic effect towards the tested cell lines or animals. Currently, there 
are two major categories of delivery methods including invasive approach (such as 
microinjection and electroporation) and non-invasive approach (such as liposomes, nanoparticles 
and cell penetrating peptides). Microinjection is a precise delivery method for single cell 
transduction with high transduction efficiency. Microinjection has lower cytotoxicity in relative 
to chemical transfection and it is feasible for the transduction of cells with difficulty in 
transfection (Zhang and Yu, 2008). However, microinjection requires specialised equipment as 
well as involves sophisticated and laborious techniques to deliver exogenous biomolecules into 
the cells. Currently, this technique is always used for developmental biology, neurobiology, cell 
biology, and signal transduction (Carroll, 2009).  Cell penetrating peptides (CPPs) or peptide 
transfer domains (PTD) are short peptides that facilitate entry of macromolecules or drugs (such 
as DNA, RNA or proteins) through the plasma membrane into intracellular space. Mechanisms 
of internalisation for these CPPs include endocytosis, direct translocation, inverted micelle 
formation and pore formation (Bechara and Sagan, 2013). Most of these CPPs are low toxicity 
and less immunogenic and these peptides have been used for intestinal delivery of insulin, cell 
immunity, cancer therapy and enzyme replacement (Dinca et al., 2016). A molecular adaptor, 
catAd, was a cell penetrating peptide composes of membrane transfer sequence (MTS), cytosolic 
cleavable unit (CCU) and endosomal cleavable unit (ECU). Cell specific ligands or antibodies 
were linked to adaptor to increase the selectiveness of the drugs binding to targeted cells. Drug 
molecules (toxins or proteins) bound to the adaptor were endocytosed into cells and subsequently 
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transferred through plasma membrane via the MTS sequence from the adaptor. Drug molecules 
were then released into cell cytosol by the cleavage of CCU. This adaptor was used for the 
delivery of immunotoxins, such as diphtheria toxin (Keller et al., 2001), saporin (Fuchs et al., 
2007; Heisler et al., 2003) and human angiogenin (Hetzel et al., 2008).  
In this chapter, bioactivity of purified recombinant GFP-apoptin (GFP-VP3-H) and recombinant 
EGF-apoptin (EGF-VP3-HK) was tested in human lung carcinoma A549. In the absence of cell 
penetrating peptides on recombinant GFP-VP3-H, the purified protein was delivered into A549 
cells using microinjection approach. Viability of cells injected with recombinant GFP-VP3-H 
was determined by checking the morphology of cell nucleus. However, recombinant EGF-VP3-
HK was directly added into culture medium since this protein contained molecular adaptor 
harbouring a membrane transfer peptide. Translational fusion of apoptin with EGF (EGF-VP3-
HK) was expected to target the recombinant protein towards EGF receptors (EGFR) that are 
overexpressed at lung cancer cell surface. Therefore, the binding activity of recombinant EGF-
VP3-HK to EGFR was determined using enzyme-linked immunosorbent assay (ELISA). 
Viability of cells treated with recombinant EGF-VP3-HK was quantified by checking the 
cleavage of tetrazolium salt WST-1 to formazan by mitochondrial dehydrogenases which are 
present in viable cells. Besides, loss of mitochondrial membrane potential and activation of 
caspase 3/7 which are among the hallmarks of apoptosis were determined in cells receiving 
individual treatments of recombinant apoptin (GFP-VP3-H and EGF-VP3-HK).  
Therefore, the specific objectives of this chapter were: (i) to examine the interactions between 
the respective recombinant apoptin (GFP-VP3-H and EGF-VP3-HK) and A549 cells as well as 
EGF receptors; (ii) to deliver recombinant GFP and GFP-VP3-H into A549 cells via 
microinjection; (iii) to investigate the cellular activities including cell killing, nuclear localisation 
and apoptosis potential of recombinant GFP-VP3-H in A549 cells; (iv) to examine the 
internalisation of recombinant EGF-VP3-HK into A549 cells; and (v) to evaluate cell killing 
efficiency and apoptosis potential of recombinant EGF-VP3-HK in A549 cells.  
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6.2 Materials and Methods 
6.2.1 General materials 
6.2.1.1 Cells and cell culture reagents 
Human lung adenocarcinoma epithelial cell A549 (ATCC® CCL-185™) (American Type Cell 
Collection –ATCC) was used for the assessment of bioactivity of recombinant apoptin purified 
using method as described in Chapter 5. A549 cell line was maintained in F-12 Ham medium 
without phenol red (Sigma Aldrich, USA), supplemented with 10% fetal bovine serum (FBS), 
0.29 mg/ml L-glutamine, 1.5 mg/L sodium bicarbonate and antibiotic solutions (100 IU 
penicillin and 100 µg/ml streptomycin) (Corning, USA).  
6.2.1.2 Protein samples 
Recombinant GFP-apoptin (GFP-VP3-H) was prepared as described in Chapter 5 (section 5.3.1.2) 
and recombinant EGF-apoptin (EGF-VP3-HK) was prepared as described in Chapter 5 (section 
5.3.1.4). Recombinant GFP-apoptin was buffer exchanged to Storage buffer A (50 mM sodium 
phosphate, 100 mM NaCl, pH 7.5, 4°C) and concentrated to 2.4 mg/ml. Small aliquots of protein 
was prepared and stored at -80°C. Recombinant GFP (19 mg/ml) was prepared using 
immobilised affinity chromatography (IMAC) by Dr Konstantin Musiychuk (Fraunhofer CMB, 
USA). Recombinant GFP was diluted to 2.5 mg/ml using Storage buffer A and small aliquots 
were stored at -80°C.  
6.2.1.3 Reagents and injection consumables 
For microinjection, femtotips II (Eppendorf, USA), microloader tips (Eppendorf, USA), 35 mm 
collagen coated glass bottom dish  (No. 1.5 Coverslip, 14 mm Glass Diameter) (Matek 
Corporation, USA), dextran conjugated fluorescein (70 000 MW) Anionic (Thermo scientific, 
USA) and lysine fixable dextran conjugated texas red (10 000 MW) (Thermo Scientific, USA) 
were used in this study.  Propidium iodide (PI) with RNase (ThermoScientific, USA), SYB 
Green I for nuclei acid stain and ready to used 200 µg/ml hoechst 33342 (Immunochemistry 
Technologies LLC, USA) were used for staining of cell nucleus. Mouse monoclonal VP3 
antibody (JCU/CAV/1C1) (1: 200) (TropBio Pty Ltd, Australia), rabbit polyclonal anti-GFP 
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antibody (1: 250) (Invitrogen), rhodamine (TRITC) affiniPure goat anti-mouse IgG (H+L) (1:100) 
(Jackson Immunoresearch Laboratories Inc, USA) and anti-rabbit conjugated FITC (1:100) were 
used for immunofluorescence (IF) assay. Human EGFR/HER1/ErbB1 protein (His tag) (100001-
H08H, Sino Biological Inc, China), rabbit monoclonal antibody to human EGFR/ErbB/HER1 
(10001-R021, Sino Biological Inc, China), Epidermal growth factor (EGF) recombinant protein 
(RP-10914, ThermoScientific, USA), human EGF Monoclonal antibody (M806, 
ThermoScientific, USA), Peroxidase AffiniPure Goat Anti-Mouse IgG (H+L) (Jackson 
Immunoresearch Laboratories Inc, USA), peroxidase affiniPure Goat Anti-Rabbit IgG (H+L) 
(Jackson Immunoresearch Laboratories Inc, USA) and sigma Fast OPD (Sigma-Aldrich, USA) 
were used for enzyme-linked immunosorbent assay (ELISA). slowFade® diamond antifade 
mountant (ThermoScientific, USA) was used to mount cell samples used for microscopic 
examination. Cell proliferation reagent WST-1 (Roche Applied Science, USA) was used to 
measure viability of cultures. MitoPT TMRM assay kit (Immunochemistry Technologies, USA) 
and magic red caspase 3 & 7 assay kit were used to analyse depolarization of mitochondrial 
membrane potential and caspase activity of apoptin-treated cell samples.  
6.2.1.4 Specialised equipment 
Nikon Instruments Eclipse Ti-E inverted microscope and Zeiss Observer Z1 microscope and 
Zeiss LSM 510 META highspeed confocal microscope were used for microscopic imaging of 
cell samples. FemtoJet pressure unit (Eppendorf, USA), three-axis coarse positioning 
micromanipulator MMN-1 (Narishige, USA) and three-axis joystick type oil hydraulic fine 
micromanipulator MMO-202ND (Narishige, USA) were the microinjection system used to 
deliver recombinant GFP and GFP-apoptin into mammalian A549 cells. Inverted microscope 
Axiovert 40°C (Zeiss) was used for visualising cells during microinjection. Molecular Devices 
MPR-100 SpectraMax M2 was used to collect absorbance for ELISA and cell viability assay.  
6.2.1.5 Bioinformatics and statistical analysis 
Photos taken by Nikon Eclipse Ti Inverted Microscope were analysed using Nikon NIS Elements 
(Nikon Instruments Inc, USA); while, photos taken by Zeiss 5 Live DUO Highspeed Confocal 
Microscope were analysed using Zeiss LSM 5 (Zeiss, USA). Data collected from cell viability 
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assay and enzyme-linked immunosorbent assay (ELISA) were plotted using four parameter 
fitting model from Microsoft Excel. 
6.2.2 Enzyme-linked immunosorbent assay (ELISA) 
A549 cells were seeded at 0.8 X 104 cells/ well on 96-wells plate and incubated at 37°C 
overnight. ELISA plates were also coated with 2.5 mg/ml of human EGFR/HER1/ErbB1 protein 
at 4ºC for 24 hours. A549 cells were fixed with 1% formaldehyde for 10 minutes, methanol for 5 
minutes and 80% acetone for 2 minutes (Zhang et al., 2003). Fixed cells as well as coated ELISA 
plates were blocked using 0.5% I-block buffer (dissolved in PBST-T) for at least an hour. 
Recombinant EGF-apoptin (EGF-VP3-HK), GFP-apoptin (GFP-VP3-H) and recombinant GFP 
were incubated with fixed A549 cells or pre-coated ELISA plates at room temperature for at 
least an hour. Samples were then washed for 6 times with 1 X PBS buffer. Primary antibodies 
(Table 6.1) were added to samples and incubated for another hour. Samples were washed for 6 
times with 1 X PBS buffer and followed by incubation with secondary antibodies (Figure 6.1) for 
an hour. Again, samples were washed similarly as abovementioned. Subsequently, 90 µl of 
Sigma Fast OPD was added to each well of samples and incubated at room temperature in dark 
for 20-30 minutes. Reactions were then stopped by adding 10 µl 5 M of sulphuric acid (H2SO4) 
and absorbance was taken at 492 nm. Absorbance for each sample was normalised with negative 
control to eliminate unspecific binding caused by rabbit polyclonal anti-GFP antibody or mouse 
monoclonal VP3 antibody.  
Table 6.1: List of antibodies used in ELISA.  
No Protein samples 
Incubation with primary antibodies 
and amount used in ELISA 
Incubation with secondary antibodies 
and amount used in ELISA 
1 Recombinant GFP 
Rabbit polyclonal anti-GFP 
antibody (1 µg/ml) 
Peroxidase AffiniPure Goat Anti-
Rabbit IgG (H+L) (1: 25 000) 
2 Recombinant GFP-VP3-H 
Rabbit polyclonal anti-GFP 
antibody (1 µg/ml) 
Peroxidase AffiniPure Goat Anti-
Rabbit IgG (H+L) (1: 25 000) 
3 Recombinant GFP-VP3-H 
Mouse monoclonal VP3 antibody 
(1: 10 000) 
Peroxidase AffiniPure Goat Anti-
Mouse IgG (H+L) (1: 7 500) 
4 Recombinant EGF-VP3-HK 
Mouse monoclonal VP3 antibody 
(1: 10 000) 
Peroxidase AffiniPure Goat Anti-
Mouse IgG (H+L) (1: 7 500) 
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6.2.3 Microinjection procedures 
A549 cells were seeded on coverslip at 40-50% confluency a day (preferable incubation for at 
least 24 hours) before microinjection. Protein samples (2.5 mg/ml recombinant GFP or ~ 0.8-1.0 
mg/ml GFP-VP3-H) were prepared as described in section 6.2.1.2. Ideally, protein concentration 
~ 3 mg/ml was recommended for microinjection work; however, concentration of recombinant 
GFP-VP3-H (~ 0.8-1.0 mg/ml) is the maximum protein concentration could be obtained in 
current study. For the identification of injected cells, protein samples were prepared with 2 
mg/ml of dextran conjugated fluorescein (70 000 MW) Anionic or lysine fixable dextran 
conjugated texas red (10 000 MW). Injection mixtures were centrifuged at 15 000 xg for 20 
minutes immediately before microinjection to eliminate precipitates that might clog the opening 
of microinjection capillary. Approximately 3.5 µl of mixtures were transferred to microloader 
tips in order to load samples into femtotips II. Femtotips II loaded with protein mixture was then 
incubated vertically at room temperature for 1-2 minutes for capillary reaction to fill the tip with 
protein sample. Air bubbles trapped in the liquid sample within the capillary should be removed 
with a gentle tap before pushing sample out from the capillary into a fresh PBS buffer using a 
pre-set <clean> function of microinjector at maximum pressure. Culture was replaced with fresh 
medium prior microinjection. Microinjection parameters were optimised by observing the 
condition of the cells which were microinjected with recombinant GFP. Thereafter, both 
recombinant GFP and GFP-VP3-H were delivered into cells by using microinjection pressure at 
100 hPa and injection time for 1s. Approximately 50-100 cells were injected for each sample. 
Culture was replaced with fresh medium again immediately after the microinjection procedure.   
 
6.2.4 Indirect immunofluorescence (IF) assay  
The A549 cells receiving microinjection (GFP-VP3-H) and recombinant EGF-VP3-HK were 
washed for 3 times with 1X PBS buffer before cells were fixed with 1% formaldehyde for 10 
minutes, methanol for 5 minutes and 80% acetone for 2 minutes (Zhang et al., 2003). Fixed cell 
samples were blocked using 0.5% I-block buffer (dissolved in PBST-T) for at least an hour 
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before samples were incubated with primary antibody (Table 6.2) for another hour. Subsequently, 
cells were washed for 3 times with 1X PBS-T buffer (5 minutes interval). Cells were then 
incubated with secondary antibody (Table 6.2) for an hour following by the same 3-time washing 
step with 1X PBS-T buffer. Eventually, cell nucleus was stained using nuclear staining dye 
(Hoechst, PI or SYB Green). Nuclei of detected cells were stained using PI (for cells 
microinjected with recombinant GFP) and SYB Green (for cells microinjected with recombinant 
GFP-VP3-H). The mounted samples were viewed and images were captured. For cells 
microinjected with recombinant GFP and GFP-VP3-H, all detected cells were counted to 
quantify for the detection and survival rate of cells.  
Table 6.2: List of antibodies used in IF. 
No Cell samples 
Incubation with primary antibodies 
and amount used in IF 
Incubation with secondary 
antibodies and amount used in IF 
1 
Cells microinjected with 
recombinant GFP-VP3-H 
Mouse monoclonal VP3 antibody  
(1: 250) 
Rhodamine (TRITC) affiniPure 
Goat Anti-Mouse IgG (H+L) 
(1:100) 
2 
Cells incubated with 
recombinant EGF-VP3-HK 
Mouse monoclonal VP3 antibody 
 (1: 250) 
Rhodamine (TRITC) affiniPure 
Goat Anti-Mouse IgG (H+L) 
(1:100) 
3 
Cells incubated with 
recombinant EGF-VP3-HK 
Rabbit monoclonal antibody to human 
EGFR/ErbB/HER1 (10 µg/ml) 
Anti-rabbit conjugated FITC 
(1:100) 
 
6.2.5 Cell Proliferation Reagent WST-1 assay 
A549 cells were seeded at 0.8 x 104 cells/ well (96-well plates) in 100 µl of culture medium a 
day before the experiment. Recombinant EGF-VP3-HK (330-3000 nM) and recombinant EGF 
(0.15-15 000 nM) were incubated separately with A549 cells (3 replicates for each samples) for 
72 hours before 10 µl of cell proliferation reagent WST-1 was added into each well of cell 
samples. Cell and reagent mixtures were incubated for ~ 1.5-2 hours. Samples were gently 
shaken before absorbance was measured at 420 nm. Cell viability of cells incubated with 
recombinant EGF-VP3-HK and recombinant EGF was calculated in relative to untreated cells 
(reflected as 100% of viable cells). Cell viability of recombinant EGF-VP3-HK and recombinant 
EGF was then plotted using four parameter fitting model from Microsoft Excel. 
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6.2.6 Mitochondrial membrane potential assay (MMP) 
Mitochondrial membrane is polarised when it is intact. Polarised mitochondrial membrane is 
negative charged within mitochondria and positive charged at the outer region. Loss of 
mitochondrial membrane potential is always caused by the depolarisation of charges or damage 
of mitochondrial membrane, which can occur in cells that are undergoing stress or apoptosis. 
Cell permeant, positively charged and lipophilic TMRM dye accumulates in mitochondria of 
normal cells and hence red fluorescence will be observed. However, red fluorescence is 
diminished as the membrane of mitochondria becomes permeable or depolarised in apoptotic or 
stressed cells. The charged reagent does not accumulate in mitochondria but disperses in the 
cytoplasm. The redistribution of this reagents causes the significant drop of signal; thus, red 
fluorescent signal will no longer be observed.    
In order to assess the MMP, microinjection was performed on every cells located within a grid. 
On the other hand, MMP test was performed on recombinant EGF-VP3-HK treated A549 cells 
using 3030 nM of recombinant protein. Cells microinjected with recombinant GFP and GFP-
VP3-H as well as cells incubated with recombinant EGF and recombinant EGF-VP3-HK were 
washed for 3 times with PBS buffer before samples were incubated with 200 nM of MitoPT 
assay TMRM reagent for 15-20 minutes at 37°C in dark. Cell samples were washed for 3 times 
with PBS buffer before image of samples were captured using Nikon Eclipse Ti inverted 
microscope.   
6.2.7 Caspase 3/7 assay  
Activation of caspase is also a hallmark for apoptosis. Evaluation for activity of caspase could be 
assessed by examining cleaving activity of caspases (such as caspase 3) towards targeted amino 
acid aspartate-glutamate-valine-aspartate, (z-DEVD)2 peptide. Cell permeant magicred caspase-
3/7 reagent is DEVD-based caspase substrate coupled with cresyl violet fluorophore. Upon the 
cleavage of DEVD targeted sequence by caspase, the active fluorophores will be released and 
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more intense fluorescent signal is observed after the cleavage. Hence, elevated amount of 
caspases in cells could be assessed by the elevation of the fluorescent signal.    
In order to assess the caspases activity, microinjection was performed on every cells located 
within a grid. On the other hand, caspases activity was performed on recombinant EGF-VP3-HK 
treated A549 cells using 3030 nM of recombinant protein. Cells microinjected with recombinant 
GFP and GFP-VP3-H as well as cells incubated with recombinant EGF and recombinant EGF-
VP3-HK were washed for 3 times with PBS buffer before samples were incubated with magicred 
caspase-3/7 reagent (1:150) for 60 minutes at 37°C. Then, cell samples were rinsed twice with 
PBS buffer (1 minute per rinse) before images were captured using Nikon Eclipse Ti inverted 
microscope.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6-13 
 
 
 
 
6.3 Results 
6.3.1 Evaluation for the interaction of recombinant apoptin (GFP-VP3-H and 
EGF-VP3-HK), A549 cells and EGF receptors 
Epidermal growth factor receptors (EGFR) were overexpressed on cell surface of A549 cells; 
hence, A549 cells and recombinant EGF receptors were used to determine the specific binding 
efficiency of recombinant apoptin (GFP-VP3-H and EGF-VP3-HK). Serving as a control, 
recombinant GFP did not bind to EGF receptors (dark green line) but it bound to A549 cells 
(light green line) at very low efficiency (Figure 6.1). Recombinant GFP-VP3-H bound to Human 
EGF receptors (red lines) as well as A549 cells (purple lines) (Figure 6.1). Binding of 
recombinant GFP-VP3-H to A549 cells was steadily higher than that of Human EGF receptors as 
reacted with both antibodies. Besides, detection levels of recombinant GFP-VP3-H using rabbit 
polyclonal anti-GFP antibody (dark purple and dark red) were shown higher than those of mouse 
monoclonal VP3 antibody (blue and pink). 
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Figure 6.1: Binding activities of recombinant GFP (green lines) and GFP-VP3-H (red and purple 
lines) towards A549 cells and Human EGF receptors as tested by ELISA. Absorbance for each 
sample was normalised with negative control to eliminate unspecific binding caused by rabbit 
polyclonal anti-GFP and mouse monoclonal VP3 antibodies. Collected data was plotted using 
four parameter fitting model from Microsoft Excel. In contrast to recombinant GFP control 
(green lines), recombinant GFP-VP3-H (purple and red lines) bound strongly to A549 cells and 
Human EGF receptors but with a higher level towards A549 cells.  
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Recombinant EGF-VP3-HK bound to A549 cells as well as human EGF receptors (Figure 6.2). 
Binding of recombinant EGF-VP3-HK to human EGF receptors (dark blue) was slightly stronger 
than that of A549 cells (light blue). 
 
Figure 6.2: Binding activities of recombinant EGF-VP3-HK towards A549 cells (light blue) and 
Human EGF receptors (dark blue) as tested by ELISA. Absorbance for each sample was 
normalised with negative control to eliminate unspecific binding caused by rabbit polyclonal 
anti-GFP and mouse monoclonal VP3 antibodies. Collected data was plotted using four 
parameter fitting model from Microsoft Excel. Recombinant EGF-VP3-HK bound to A549 cells 
as well as EGF receptors with the latter shown a higher level.  
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6.3.2 Bioactivity of recombinant GFP-apoptin (GFP-VP3-H) in A549 cells 
delivered via microinjection 
 Standardisation of microinjection procedure 
Microinjection was performed for ~ 100-150 cells per sample. Intrinsic signal of recombinant 
GFP protein was detected in microinjected cells from 2 to 24 hours (Figure 6.3). It was estimated 
that ~ 60% of cells microinjected with recombinant GFP protein was detected and remained 
healthy until 24 hours post microinjection. However, signal of the GFP protein was gradually 
faded over time with the lowest level was observed from microinjected samples incubated for 24 
hours (Figure 6.3 -e).  
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Figure 6.3: Fluorescence microscopic observation of A549 cells microinjected with recombinant 
GFP protein. Images of microinjected A549 cells were captured at (a) 2 hours, (b) 4 hours, (c) 6 
hours, (d) 12 hours and (e) 24 hours post microinjection. Recombinant GFP was microinjected at 
2.4 mg/ml and intrinsic signal of recombinant GFP was detected in microinjected cells using 
Nikon Instruments Eclipse Ti-E inverted microscope. Intrinsic GFP signal of recombinant GFP 
faded when cells were incubated for a longer period, especially at 24 hours post microinjection.  
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 Immunofluorescence detection of A549 cells microinjected with 
recombinant GFP-VP3-H 
Since concentration of recombinant GFP-VP3-H was low (~ 0.8 – 1.0 mg/ml), intrinsic signal of 
GFP was difficult to be detected in microinjected cells. Therefore, detection of cells 
microinjected with recombinant GFP-VP3-H was performed using indirect immunofluorescence 
assay (IF) using mouse monoclonal VP3 antibody and Rhodamine (TRITC) AffiniPure Goat 
Anti-Mouse IgG (H+L). Cells were successfully microinjected with recombinant GFP-VP3-H 
would fluorescent in red (Figure 6.4) after IF was performed. Nuclei of detected cells were 
stained using PI (for cells microinjected with recombinant GFP) and SYB Green (for cells 
microinjected with recombinant GFP-VP3-H). Viability of cells (50-100 cells) was scored based 
on the morphology of cell nucleus (Figure 6.5). Figure 6.5 shows only viability of cells generated 
from a single experiment. Cell viability for microinjection of recombinant GFP remained above 
50% when samples were incubated from 2 to 12 hours; however, cell viability was dropped to ~ 
35% when samples incubated for 24 hours (Figure 6.5). For microinjection of recombinant GFP-
VP3-H, chromatin condensation was observed (Figure 6.6) and viable cells were found as low as 
20-35 % at 2-4 hours post microinjection. This conformed to the number of cells microinjected 
with recombinant GFP-VP3-H with red fluorescent signal decreased over time and almost 
diminished at 24 hours post microinjection (Figure 6.4 -e). Hence, limited viable cells was 
considered since very low red fluorescent signal was detected.  
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Figure 6.4: Fluorescence microscopic observation of A549 cells microinjected with recombinant 
GFP-VP3-H protein under IF using mouse monoclonal VP3 antibody and Rhodamine (TRITC) 
AffiniPure Goat Anti-Mouse IgG (H+L). Images of microinjected A549 cells were captured at (a) 
2 hours, (b) 4 hours, (c) 6 hours, (d) 12 hours and (e) 24 hours post microinjection. Recombinant 
GFP-VP3-H was microinjected at ~0.8-1.0 mg/ml. Detected signal of recombinant GFP-VP3-H 
(red fluorescence) faded when cells were incubated for a longer period. 
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Figure 6.5: Viability of cells microinjected with recombinant GFP and GFP-VP3-H calculated 
based on total cell numbers receiving microinjection. Cells microinjected with recombinant GFP 
was determined based on intrinsic signal of the protein; however, cells microinjected with 
recombinant GFP-VP3-H was identified based on IF using mouse monoclonal VP3 antibody and 
Rhodamine (TRITC) AffiniPure Goat Anti-Mouse IgG (H+L). Nuclei of detected cells were 
stained using PI (for cells microinjected with recombinant GFP) and SYB Green (for cells 
microinjected with recombinant GFP-VP3-H). Viability of cells (50-100 cells) was scored based 
on the morphology of cell nucleus. The data were represented only viability of cells obtained 
from a single experiment. Complete scoring data for detected cells as well as viability of cells are 
shown in Appendix 6.3. For microinjection of recombinant GFP-VP3-H, viability of cells was 
lower than that of cells microinjected with recombinant GFP. In general, decrements of detected 
as well as viable cell numbers were observed in cells microinjected with recombinant GFP-VP3-
H.   
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Figure 6.6: Immunofluorescence microscopic observation of cells microinjected with 
recombinant GFP-VP3-H its stained nuclei. Photos in this section were representative data for 
microinjected cells showing morphological changes at 6 and 24 hours. Nevertheless, similar 
morphological changes could also been observed on other time points. (a) A549 cells 
microinjected with recombinant GFP-VP3-H at pressure 100 hPa at 6 hours post microinjection 
under IF using mouse monoclonal VP3 antibody and Rhodamine (TRITC) AffiniPure Goat Anti-
Mouse IgG (H+L). Red colours indicated the location of recombinant GFP-VP3-H in A549 cells. 
(b) Nuclear staining of A549 cells microinjected with recombinant GFP-VP3-H at pressure 100 
hPa at 6 hours post microinjection using SYB Green. Chromatin condensation (white arrowheads) 
was observed in some A549 cells microinjected with recombinant GFP-VP3-H in contrast to 
normal and healthy nuclei (yellow arrowheads). (c) A549 cells microinjected with 
recombinant GFP-VP3-H at pressure 50 hPa at 24 hours post microinjection under IF using 
mouse monoclonal VP3 antibody and Rhodamine (TRITC) AffiniPure Goat Anti-Mouse IgG 
(H+L). Red colours indicated the location of recombinant GFP-VP3-H in A549 cells. (blue 
arrowheads). (d) Nuclear staining of A549 cells microinjected with recombinant GFP-VP3-H at 
a b 
c d 
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pressure 50 hPa using SYB Green. Chromatin fragmentation (blue arrowheads) was observed in 
some A549 cells microinjected with recombinant GFP-VP3-H in contrast to normal and healthy 
nuclei.   
 Nuclear localisation characteristics of recombinant GFP-VP3-
H microinjected into A549 cells  
Recombinant GFP and GFP-VP3-H were microinjected into cytoplasm of A549 cells. 
Microinjected recombinant GFP distributed equally in A549 cells (Figure 6.7 -a(i)); however, 
majority of recombinant GFP-VP3-H was localised to cell nucleus (Figure 6.7  -b and c(ii)). 
Nuclear localisation activity of recombinant GFP-VP3-H was confirmed by the staining of cell 
nucleus using Hoechst dye. IF signal detected for recombinant GFP-VP3-H (red) was co-
localised with Hoechst dye (blue). Nuclear localisation activity of recombinant GFP-VP3-H was 
detected as early as 2 hours post microinjection. 
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Figure 6.7: Immunofluorescence microscopic observation of A549 cells microinjected with 
recombinant GFP and GFP-VP3-H proteins at 2 hours post microinjection. Photos in this section 
were representative data for microinjected cells showing morphological changes at 6 and 24 
hours. Nevertheless, similar morphologhical changes could also been observed on other time 
points. (a) Microinjected A549 cells with recombinant GFP. Microinjected recombinant GFP 
was distributed evenly in A549 cells. (a-i) Image captured at 465-495 nm was intrinsic signal of 
recombinant GFP in microinjected A549 cells. (a-ii) Image captured at 528-553 nm was nuclei 
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of cells microinjected with recombinant GFP stained with PI. (b and c) Representative images of 
microinjected A549 cells with recombinant GFP-VP3-H. (b-i and c-i) Images captured at 465-
495 nm were fluorescent signal detected from cells microinjected with recombinant GFP-VP3-H 
and Dextran conjugated Fluorescein (70 000 MW). (b-ii and c-ii) Images captured at 528-553 nm 
were IF assay of microinjected cell samples using mouse monoclonal VP3 antibody 
(JCU/CAV/1C1). (b-iii and c-iii) Nuclei of microinjected cells were stained by Hoechst dye. (b-
iv and c-iv) Overlaid images of stained nuclei and fluorescent signal detected upon IF for 
recombinant GFP-VP3-H protein in A549 cells.  
 Evaluation of depolarization of mitochondrial membrane 
potential (MMP) for cells microinjected with recombinant 
GFP-VP3-H 
MMP was evaluated for cells microinjected with recombinant GFP-VP3-H. Since loss of MMP 
is an early event of apoptosis, MMP assay was performed for 2 hours and 6 hours post 
microinjection. Red fluorescent signal due to the accumulation of MitoPT TMRM reagent in 
mitochondria was observed in normal and untreated A549 cells (Figure 6.8 -a and c). Loss of 
fluorescent signal should be observed if the MMP has been disturbed (refer to Appendix 6.4 
using a positive control). However, no apparent difference of fluorescent signal was observed 
between untreated cells and cells microinjected with recombinant GFP-VP3-H (Figure 6.8 -b and 
d). 
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Figure 6.8: Immunofluorescence microscopic observation of A549 cells microinjected with 
recombinant GFP-VP3-H under MMP assay. MMP assay was performed on untreated control at 
(a) 2 hours and (c) 6 hours post microinjection as well as on cells microinjected with 
recombinant GFP-VP3-H at (b) 2 hours and (d) 6 hours post microinjection. No difference was 
observed between fluorescent signal from untreated samples and cells microinjected with 
recombinant GFP-VP3-H. Most mitochondrial membranes of cells microinjected with 
recombinant GFP-VP3-H were still intact.  
 Assessment of Caspase 3/7 activity for cells microinjected with 
recombinant GFP-VP3-H 
Activation of caspases is an event happens at a later stage of apoptosis; hence, caspase 3/7 assay 
was performed started at 6 hours to 48 hours. The presence of activated capase 3 and 7 in 
apoptotic cells causes the accumulation of red fluorescent signal in cells, which could be 
observed from the result using a positive control as shown in Appendix 6.5. However, no 
fluorescent signal was observed in untreated A549 cells (Figure 6.9 -a, c and e) and cells 
microinjected with recombinant GFP-VP3-H (Figure 6.9 -b, d and f).  
a b 
c d 
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Figure 6.9: Immunofluorescence microscopic observation for caspase 3/7 assay performed for 
microinjected recombinant GFP-VP3-H. Caspase 3/7 assay performed on untreated control at (a) 
6 hours (c) 24 hours and (e) 48 hours post microinjection. Besides, caspase 3/7 assay performed 
on cells microinjected with recombinant GFP-VP3-H at (b) 6 hours, (d) 24 hours and (f) 48 
hours post microinjection. No fluorescent signal was observed from untreated samples as well as 
cells microinjected with recombinant GFP-VP3 proteins. Hence, caspase 3 and 7 might not be 
activated. 
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6.3.3 Bioactivity of recombinant EGF-apoptin (EGF-VP3-HK) in A549 cells 
6.3.3.1 Immunofluorescence detection of recombinant EGF-VP3-HK 
in A549 cells incubated with recombinant EGF-VP3-HK 
Recombinant EGF-apoptin (EGF-VP3-HK) is expected to bind to EGF receptors located on the 
cell surface of A549 cells and internalised into cells via catAd molecular adaptor; hence, no 
physical or chemical delivery tool was required to transfer the protein into intracellular space. At 
18 hours post treatment, IF results showed that recombinant EGF-VP3-HK was randomly 
distributed on cells at either cell surface or cytoplasm (Figure 6.10) without any apparent nuclear 
localisation signal as contrasted to which was found in ectopically expressed apoptin in A549 
cells (Appendix 6.1) and cells microinjected with recombinant GFP-VP3-H.     
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Figure 6.10: Immunofluorescence microscopic observation of recombinant EGF-VP3-HK treated 
A549 cells on ~ 18 hours post incubation using mouse monoclonal VP3 antibody. Images were 
captured using Zeiss LSM 510 META highspeed confocal microscope. (a) Detection of 
recombinant EGF-VP3-HK on treated A549 cell samples under IF using mouse monoclonal VP3 
antibody and Rhodamine (TRITC) AffiniPure Goat Anti-Mouse IgG (H+L). (b) Cell nuclei of 
treated cell samples were stained using Hoechst dye. (c) Images of differential interference 
contrast (DIC) of treated cell samples. (d) Overlaid image of (a), (b) and (c). Recombinant EGF-
VP3-HK was still able to be detected 1 day post incubation of recombinant protein in A549 cells; 
however, distribution of protein was randomly located on either cell surface or cytoplasm.  
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c d 
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In order to identify the internalisation of recombinant EGF-VP3-HK protein into intracellular 
space of cells, EGF receptors on A549 cells were detected using monoclonal antibody raised 
against Human EGFR/ErbB/HER1to determine the location of plasma membrane of cells (Figure 
6.11 and Figure 6.12). In untreated A549 cells, EGF receptors were distributed evenly on plasma 
membrane of the cells, which could be observed in Figure 6.11 (b-ii) and Figure 6.12  (a). 
Inclusion of a negative control confirmed the signal (Figure 6.11 -c) detected was due to specific 
binding of Rabbit Monoclonal antibody to Human EGFR/ErbB/HER1 to EGF receptor located 
on A549 cells and not the unspecific binding of anti-rabbit conjugated FITC to A549 cells. From 
Figure 6.12 (a), Z-stack images of untreated A549 cells clearly showed that EGF receptors 
formed a layer of Green, which was expected to be the plasma membrane of A549 cells, locating 
out of nucleus region (blue fluorescent signal as a result of staining by Hoechst dye). However, 
signal of EGF receptors (Green) obtained from recombinant EGF-VP3-HK treated A549 cells 
(Figure 6.11-a-ii) did not show the normal distribution of EGF receptors (Figure 6.11-b-ii) but 
the signal was found sharing similar distribution as that of recombinant EGF-VP3-HK (red) 
(Figure 6.11-a-iii). Since plasma membrane of recombinant EGF-VP3-HK treated A549 cells 
could not be indicated by the presence of EGF receptors, which supposed to be arranged on the 
cell surface, hence, the localisation of recombinant EGF-VP3-HK in either intracellular or 
extracellular could not be confirmed.  
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Figure 6.11: Immunofluorescence microscopic observation of recombinant EGF-VP3-HK treated 
and untreated A549 cells on ~ 18 hours post incubation using Rabbit Monoclonal antibody to 
Human EGFR/ErbB/HER1 and mouse monoclonal VP3 antibody. Images were captured using 
Zeiss LSM 510 META highspeed confocal microscope. (a) Detection of recombinant EGF-VP3-
HK in treated A549 cells. Signal of recombinant EGF-VP3-HK showed similar location as signal 
detected from EGF receptors. (b) Detection of EGF receptors in untreated A549 cells. EGF 
receptors were distributed evenly on plasma membrane of A549 cells. (c) Detection of untreated 
A549 cells serving as a negative control for IF assay. Images of nuclei were shown for (a-i) 
A549 cells incubated with recombinant EGF-VP3-HK, (b-i) and (c-i) untreated A549 cells 
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stained with Hoechst dye. Besides, detection of EGF receptors was conducted by using Rabbit 
Monoclonal antibody to Human EGFR/ErbB/HER1 and anti-rabbit conjugated FITC for (a-ii) 
A549 cells incubated with recombinant EGF-VP3-HK and (b-i) untreated A549 cells. (c-ii) 
Image of untreated A549 cells incubated with anti-rabbit conjugated FITC without Rabbit 
Monoclonal antibody to Human EGFR/ErbB/HER1. In addition, images for detection of 
recombinant EGF-VP3-HK using mouse monoclonal VP3 antibody and Rhodamine (TRITC) 
AffiniPure Goat Anti-Mouse IgG (H+L) were also shown for recombinant EGF-VP3-HK treated 
A549 cells (a-iii) as well as untreated A549 cells (b-iii and c-iii). (a-iv), (b-iv) and (c-iv) 
Overlaid signal from stained nuclei, EGF receptors and detected recombinant EGF-VP3-HK.  
      
 
  
 
    
Figure 6.12: Immunofluorescence microscopic examination at higher resolution of recombinant 
EGF-apoptin (EGF-VP3-HK) treated and untreated A549 cells on ~ 18 hours post incubation. 
The Z-stack images were captured using Zeiss LSM 510 META highspeed confocal microscope. 
(a) Z-stack images of untreated A549 cells detected using mouse monoclonal VP3 antibody, 
Rhodamine (TRITC) AffiniPure Goat Anti-Mouse IgG (H+L), Rabbit Monoclonal antibody to 
Human EGFR/ErbB/HER1 and anti-rabbit conjugated FITC. EGF receptors which represented 
as a green layer, was expected to be the plasma membrane, located outside of cell nucleus. (b) Z-
stack images of recombinant EGF-VP3-HK treated A549 cells detected using mouse monoclonal 
VP3 antibody and Rhodamine (TRITC) AffiniPure Goat Anti-Mouse IgG (H+L). Recombinant 
EGF-VP3-HK could not be confirmed to localise inside the cell nucleus.  
a b 
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6.3.3.2 Cell viability assessment for A549 cells incubated with 
recombinant EGF-VP3-HK 
Viability of recombinant EGF-VP3-HK treated A549 cells were assessed using Cell Proliferation 
Reagent WST-1 at 72 hours post incubation (Figure 6.13). Measurement for viability of 
treatment was represented by the ratio between recombinant EGF as well as recombinant EGF-
VP3-HK treated A549 cell samples to untreated A549 smaples. Recombinant EGF did not show 
any cell toxicity but promoted cell proliferation even at high concentration (~ 1500 nM). 
Recombinant EGF-VP3-HK also showed similar cell growth induction activty but a dose-
dependent growth inhibitory was observed when cell was treated at high concentration of 
recombinant protein (~ 3000 nM).   
 
Figure 6.13: Cell viability of A549 cells treated with recombinant EGF-VP3-HK as tested by 
using Cell Proliferation Reagent WST-1 at 72 hours post incubation. Recombinant EGF 
promoted cell growth even at high centration at ~1500 nM. A similar effect was seeen in 
recombinant EGF-VP3-HK treated A549 cells. Cell growth was noticed to have dose-dependent 
inihibitory effect at high concentration (~ 3000 nM). Measurement for viability of treatment was 
represented by the ratio between recombinant EGF as well as recombinant EGF-VP3-HK treated 
A549 cell samples to untreated A549 smaples. Data was plotted using four parameter fitting 
model from Microsoft Excel to fit all data on the best line.     
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6.3.3.3 Evaluation of depolarization of mitochondrial membrane 
potential (MMP) for A549 cells treated with recombinant 
EGF-VP3-HK  
MitoPT TMRM assay kit was also used to check depolarization of mitochondrial membrane of 
recombinant EGF-VP3-HK treated A549 cells. Results showed that the accumulation of MitoPT 
TMRM reagent in untreated and recombinant EGF treated A549 cells (Figure 6.14 -a and b) 
since strong red fluorescent signal was observed. However, red fluorescent signal in recombinant 
EGF-VP3-HK treated cells (Figure 6.14-c) were lost. Loss of the fluorescent signal indicated that 
mitochondrial membrane of cells might become permeable or membrane potential had been lost.  
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Figure 6.14: Fluorescence microscopic observation of recombinant EGF-VP3-HK treated A549 
cells for the evaluation of MMP. Accumulation of MitoPT TMRM reagents (red) was observed 
in (a) untreated and (b) recombinant EGF treated A549 cells. Accumulation of MitoPT TMRM 
reagents indicated that mitochondrial membrane of the cells was intact without losing membrane 
potential. Red fluorescent signal diminished as A549 cells were incubated with (c) 3030 nM of 
recombinant EGF-VP3-HK for 72 hours. This showed that treatment of recombinant EGF-VP3-
HK caused the loss of mitochondrial membrane potential or the increase of permeability of A549 
cells.  
6.3.3.4 Assessment of caspase 3/7 activity in A549 cells treated with 
recombinant EGF-VP3-HK  
Results showed that limited red signal was detected on both untreated (Figure 6.15 -a) as well as 
recombinant EGF (Figure 6.15-b) treated A549 cells. The faint signal might be caused by the 
background signal from MagicRed Caspase-3/7 substrate. No red fluorescent signal was 
observed in A549 cell samples treated with recombinant EGF-VP3-HK; therefore, caspase 3 or 7 
might not be activated in A549 cells treated with recombinant EGF-VP3-HK.  
c 
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Figure 6.15: Fluorescence microscopic observation of A549 cells treated with recombinant EGF 
and EGF-VP3-HK for the assessment of Caspase 3/7 activity. Limited fluorescent signal was 
observed from (a) untreated and (b) recombinant EGF treated A549 cells. The faint signal might 
be caused by the background signal from MagicRed Caspase-3/7 substrate. However, no 
fluorescent signal was observed from (c) recombinant EGF-VP3-HK treated A549 cells. Hence, 
caspase 3/7 might not be activated in A549 cells treated with 3030 nM recombinant EGF-VP3-
HK for 72 hours.  
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6.4 Discussion 
This chapter discusses the cell-based study of recombinant apoptin. More than 20 years, apoptin 
had shown effective cell killing ability in more than 70 cancer cell lines including breast cancer 
(MCF-7), osteosarcoma (Saos-2 and U2OS), lung carcinoma (SLCC-1 and SLCC-2), hepatoma 
(HepG2 and Hep3B), SV-40 transformed fibroblast (Pre) and adenovirus-5-transformed 
embryonal retinoblasts (911) (Noteborn et al., 2008). Apoptin-induced apoptosis was reported 
that it triggers apoptosis via intrinsic (mitochondria-mediated) apoptosis pathway (Los et al., 
2009) and most of the studies reported that apoptosis induced by apoptin is independent of 
extrinsic pathway. Mitochondria-mediated apoptosis pathway was determined by several 
apoptotic events including loss of mitochondrial membrane potential, releasing of cytochrome c, 
formation of apoptosome and subsequently activation of caspases (especially caspases 3 and 9). 
In the study of Danen-van Oorschot et al. (2000), apoptin-induced apoptosis involved loss of 
mitochondrial membrane potential, releasing of cytochrome c and activation of caspase 3 in 
human osteosarcoma cell line Saos-2. In addition, apoptin-induced apoptosis is also independent 
on the presence of p53 and regulated by anti-apoptotic Bcl-2 in several tumour cell lines (Los et 
al., 2009).  
In this study, lung carcinoma (A549) was chosen to investigate for the recombinant apoptin due 
to the overexpression of epidermal growth factor receptors (EGFR) on the cell surface (Qian et 
al., 2014) (Figure 6.11-b) which is important to determine the activity of the plant-made 
recombinant EGF-apoptin (EGF-VP3-HK). Based on previous study, A549 cells were 
susceptible to apoptin when recombinant Newcastle disease virus was employed as delivery tool 
(Olijslagers et al., 2006). Activity of ectopically expressed apoptin had also been evidenced in 
A549 cells (Appendix 6.1). Significant cell death was observed from cells expressing apoptin 
alone, GFP-apoptin and EGF-apoptin on 4, 5 and 6 days post transfection. Besides, cell 
shrinkage, chromatin condensation and fragmentation of cell nucleus, which are the hallmarks of 
apoptosis, were observed from cells that expressing apoptin (Appendix 6.1- Figure A6.4). A549 
cells was confirmed to be susceptible to apoptin-induced apoptosis and hence this cell line was 
used to evaluate for the bioactivity of both recombinant GFP-apoptin (GFP-VP3-H) and EGF-
apoptin (EGF-VP3-HK).          
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Since A549 cell line was chosen for evaluating the bioactivity of the recombinant apoptin, 
interaction between apoptin and A549 cells was also studied by using enzyme-linked 
immunosorbent assay (ELISA). Apoptin was found interacting with A549 cells as well as EGFR 
in this ELISA binding assay. Instead of the expected binding activity from recombinant EGF-
VP3-HK, recombinant GFP-VP3-H was also noticed interacting with EGFR (Figure 6.1). For the 
detection, rabbit polyclonal anti-GFP antibody and mouse monoclonal VP3 antibody were both 
employed for the detection of recombinant GFP-VP3-H and EGF-VP3-HK. Higher detection 
was observed by using rabbit polyclonal anti-GFP antibody and this most likely due to the 
presence of small amount of degraded protein (Figure 5.4) as well as differences in binding 
efficiency for both kinds of antibodies. Up to date, there is no study of interaction between 
apoptin and EGFR. Besides, there is also no homology sequence found between apoptin and 
ligands of EGFR, including EGF, amphiregulin, Heparin-binding EGF-like growth factor and 
Betacellulin. A leucine rich regions (LRS) of apoptin, located on amino acids 33-46, was a 
region responsible for the multimerisation activity of protein (Leliveldb et al., 2004). Apoptin 
monomers interact via hydrophobic interaction into huge multimers via this LRS region. Leucine 
rich regions were also found in EGFRs separately on L1 and L2 extracellular domains (Ward and 
Garrett, 2001). Besides, small leucine-rich proteoglycan decorins was also found interacting with 
EGFRs via leucine rich region on both decorins and EGFRs (Santra et al., 2002). Hence, it is 
speculated that apoptin might interact with EGFRs via this LRS region located on both apoptin 
and EGFRs. Anyway, specific region results the interaction between apoptin and EGFRs should 
be studied and point mutation would be one of suitable option for study the region responsible 
for protein interaction in future.  
In this study, recombinant GFP-apoptin did not have cell penetrating peptides; therefore, delivery 
tool was required to assist the penetration of protein into intracellular space of A549 cells. 
PULSin® protein delivery reagent had been employed to deliver the protein into A549 cells; 
however, huge protein aggregates and clumps were found on A549 cells when IF was performed 
on transfected cells using mouse monoclonal VP3 antibody (Appendix 6.2). One of the possible 
reasons to form protein aggregates on transfected cells was the changes of environmental buffer 
and temperature, which were non-favorable for the stability of recombinant GFP-apoptin 
(Ciechanover, 2005).  Besides, apoptin was found that it might interact with A549 cells or EGF 
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receptors, which were also overexpressed on surface of A549 cells. Aggregation of EGF 
receptors occurs upon the binding of ligands.  Hence, protein aggregates on A549 cells after 
protein transfection procedure may be also caused by the aggregation of apoptin-EGF receptor 
complexes. Recombinant apoptin may clump into huge aggregates via the interaction of apoptin 
protein via the LRS region. The huge size of protein aggregates was the key research challenge 
for internalisation of the protein into A549 cells. For this instance, protein transfection as 
delivery tool was not successful. 
Hence, microinjection, an alternative delivery tool, was used for the delivery of recombinant 
GFP-apoptin (GFP-VP3-H) into cytoplasm of A549 cells. Microinjection, a direct and precise 
delivery approach, is usually performed at 50-120 hPa to deliver high concentration of protein (~ 
3mg/ml) into mammalian cells (Li et al., 1997; Lim et al., 2011). In this study, GFP was 
microinjected into A549 cells as negative control since GFP is of low toxicity to mammalian 
cells (Appendix 6.3) and it was a fusion protein for the recombinant apoptin (GFP-VP3-H). 
Based on a thorough observation for several attempts, cells microinjected with recombinant GFP 
was always detected at ~ 50-60% after the procedure and the remaining microinjected cells were 
suspected killed by the mechanical injury during injection process. Although microinjection can 
deliver protein precisely to cells and even to specific cellular compartment, minimising the 
mechanical injury induced during microinjection process is a huge challenge for this approach. 
Especially, microinjection in this study was performed manually, which may directly increase 
the risk of mechanical damage to microinjected cells. Besides, concentration of recombinant 
GFP-VP3-H was low (~ 0.8 mg/ml); hence, injection pressure was set at 100 hPa with injection 
time of ~ 1s. With this parameter set for microinjection, cells microinjected with recombinant 
GFP was still detected at ~ 50-60% and survived cells also maintained above 50%.  
In order to safeguard the bioactivity of recombinant apoptin using microinjection, assessment of 
the protein was performed within 24 hours (Lim et al., 2011; Zhang et al., 2003). In the study of 
Zhang et al. (2003), apoptin-induced apoptosis in osteosarcoma cells (Saos-2) was observed 
starting from 2 hours post microinjection and almost 80% of microinjected cells was dead at 24 
hours post microinjection. In this study, cells microinjected with recombinant GFP-VP3-H could 
not be identified based on the intrinsic signal of GFP from the protein since the green fluorescent 
signal was not detectable. Failure for the detection of intrinsic GFP signal from the recombinant 
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GFP-VP3-H after microinjection might be due the low amount of microinjected protein since the 
initial concentration of the protein was low. Besides, it might also due to the denaturation of 
protein after microinjected into the cells with a non-favorable environment for protein stability. 
In order to detect cells microinjected with recombinant GFP-VP3-H, indirect immunofluorescent 
(IF) assay was carried out using mouse monoclonal VP3 antibody. Based on the IF results, it was 
noticed that number of detected cells microinjected with recombinant GFP-VP3-H decreased 
rapidly when cell samples were incubated at 2-24 hours post microinjection (Figure 6.4). The 
most possible reason contributing to the reduced cell numbers from 2-24 hours post 
microinjection might due to the presence of intracellular proteolysis. Degradation of 
microinjected protein is probable as the decrease of intrinsic GFP signal of recombinant GFP in 
microinjected cells occurred when cells were incubated for a longer period (12-24 hours) (Figure 
6.3 and Table A6.1). The major challenge using proteins as therapeutic drugs is the stability of 
proteins after delivering into mammalian cells or animals. Intracellular stability of foreign 
proteins is always challenged by physiological pH, temperatures, salts and endogenous proteases 
(Torchilin, 2008). Denaturation or changes of folding state of proteins in the non-favourable 
cellular environment always lead to the loss of function and eventually to be degraded by 
proteolytic system such as ubiquitin-based proteolysis (Ciechanover, 2005). In this study, IF 
signal from cells injected with recombinant GFP-VP3-H was also 3-5 times lower than that of 
ectopically expressed cells undergoing apoptosis (Appendix 6.1). This might be due to the low 
concentration of protein stock used in microinjection. With the low amount of recombinant 
protein, the presence of intracellular proteolysis would further reduce the availability of protein 
in the cell, which might directly affect the activity of apoptin-induced apoptosis.       
The decrease of cell number may also be caused by the putative cell killing effect of recombinant 
GFP-VP3-H. Detected number of cells injected with recombinant GFP-VP3-H decreased faster 
than the number of cells injected with recombinant GFP (Appendix 6.3); hence, the decrease of 
detected cell number might not be attributed by the mechanical injury induced by the 
microinjection. To investigate the cell killing effect of recombinant GFP-VP3-H, protein 
localisation, nucleus morphology, depolarization of mitochondrial membrane potential (MMP) 
and activation of caspase 3/7 of microinjected cells were examined. Nuclear localisation of 
recombinant GFP-apoptin was observed in majority of injected cells (~ 70% of cells) and the 
localization activity of the protein was detected as early as 2 hours post microinjection (Figure 
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6.7). Nuclear localisation of apoptin was observed in various types of cancer cells (Noteborn et 
al., 1998) as well as in our study when apoptin was expressed ectopically in A549 cells 
(Appendix 6.1). Besides, apoptin was also found that it interacted with DNA and colocalised 
with heterochromatin (Danen-Van Oorschot2 et al., 2003; Leliveldc et al., 2004). Hence, the 
DNA binding ability of apoptin was believed playing a role in regulating expression of gene 
involving in apoptosis. On the other hand, chromatin condensation was observed in nuclei of 
some cells microinjected with recombinant GFP-VP3-H (Figure 6.6). However, it was found that 
cells injected with recombinant GFP-VP3-H did not show detectable positive result in the tests of 
depolarization of mitochondrial membrane potential (MMP) and activation of caspases 3/7. 
Increasing permeability of mitochondrial membrane or loss of mitochondrial membrane potential 
was an early event occurred in mitochondria-mediated apoptosis pathway. The release of 
cytochrome c always due to the permeable mitochondrial membrane leads to the formation of 
apoptosome, which is crucial to activate caspase 9. Active caspase 9 cleaves caspases 3, 6 and 7 
that involve in cellular protein degradation. Previous study of Maddika et al. (2005) confirmed 
that apoptin-induced apoptosis involves the loss of mitochondrial membrane potential and 
release of cytochrome c in Jurkat cells. Activation of caspase 3 was also confirmed in apoptin-
induced apoptosis in Jurkat as well as MCF-7 cells (Maddika et al., 2005; Burek et al., 2006). 
Nevertheless, increment in permeability of MMP and activation of caspase 3/7 were not 
convincingly detectable in cells microinjected with recombinant GFP-VP3-H. One of the reasons 
might be due to the low concentration of recombinant protein microinjected into cells, which is 
unable to trigger an apparent apoptosis in these two assays. Nevertheless, the probable induction 
of apoptosis cannot be absolutely ruled out as nuclear localization activity and some features of 
apoptosis (chromatin condensation and fragmentation as shown in Figure 6.6) were evidenced in 
the microinjected cells. Yet, more investigations on apoptotic activity induced by apoptin in 
current study are necessitated for a concrete confirmation.  
Based on the results of ELISA, binding of recombinant EGF-VP3-HK to EGF receptors was 
confirmed which might be due to the interaction between EGF and/or apoptin to EGF receptors. 
Upon the binding, recombinant EGF-VP3-HK is expected to be internalised into A549 cells 
without requiring any delivery tool. In this study, EGF linked molecular adaptor, containing 
membrane transfer sequence (MTS) and cytosolic cleavable unit (CCU), was employed to 
deliver the apoptin into A549 cells that overexpressed with the EGF receptors. In theory, EGF 
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from recombinant EGF-apoptin would bind to EGF receptors of A549 cells that subsequently 
internalised the apoptin into the cells via clathrin-mediated endocytosis. MTS could assist the 
penetration of apoptin through endosomal membrane and cleavage at cytosolic cleavable unit 
(CCU) could release apoptin into cytosol. Currently, the data as shown in section 6.3.3 could not 
confirm the exact location that the recombinant EGF-VP3-HK bound which could be either 
inside or outside the cells. This is owing to the location of EGF receptors, which supposed to be 
an indicator for the location of plasma membrane of recombinant EGF-VP3-HK treated A549 
cells was unlikely redistributed. Signal of EGF receptors was found at area exactly where signal 
of recombinant EGF-VP3-HK was detected in IF assay (Figure 6.11-a). Besides, EGF receptors 
were found aggregated into patches in contrast to the even distribution on plasma membrane, 
which is the case for the untreated A549 cells (Figure 6.11-b).  Aggregation of EGF receptors 
into patches was reported by Schlessinger et al (1978) upon the binding of EGF ligands before 
the ligand-receptors complexes were internalized via endocytosis. Hence, it is believed that the 
EGF receptor patches observed from the recombinant EGF-VP3-HK treated cultures might be 
induced by the binding of recombinant EGF from the protein. Besides, microscopic images 
showed that recombinant EGF-VP3-HK precipitated into huge size and distributed randomly in 
recombinant EGF-VP3-HK treated A549 culture (Figure 6.10). This protein did not localise to 
cell nucleus, which was contrarily observed in ectopically expressed apoptin (Appendix 6.1). To 
date, the reason for the precipitation of protein is still unknown. Hence, it is crucial to investigate 
whether aggregation of protein is induced before or after internalisation since the aggregation of 
protein might hamper the internalisation of protein into cytoplasm as well as localisation into 
nucleus. For future study, application of fluorescence scanning electron microscope (FL-SEM) 
and fluorescence integrated transmission electron microscope will be necessary to examine for 
the internalisation of protein by using fluorescence based protocols.  
From the current findings, the growth of A549 cells was not inhibited at ~ 500 -1500 nM of 
recombinant EGF-VP3-HK. However, treated A549 cells with recombinant EGF-VP3-HK 
induced proliferation of cells, which could also be observed from the cells treated with 
recombinant EGF (Figure 6.13). This result could be explained since binding of EGF to EGFR 
could lead to numerous kinds of cellular activities, including an enhancement of cell proliferation, 
differentiation and cancer development (Hyder et al., 2012). However, a dose-dependent growth 
inhibitory effect was observed when cells were incubated with recombinant EGF-VP3-HK at a 
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higher concentration (~ 3000 nM) though with an only ~20% reduced viability. Unlikely, due to 
limited protein, further concentrations could not be continued in the assay. Activation of caspase 
3/7 was not observed in this study but result showed that cells had a loss of MMP after 
incubation with recombinant EGF-VP3-HK at 3000 nM which concentration was coincided with 
the evidence of reduced cell viability. Considering the fact that the loss of MMP requiring a 
constant threshold stimulus of pro-apoptotic proteins, such as Bax; owing to the limited 
concentrations of EGF-VP3-HK tested, it may be speculated that the insufficient stimulus of Bax 
may halt the subsequent release of cytochrome c and thereby diminishing the probable formation 
of executioner caspase cascades including the caspase 3/7 activation which could not be detected 
currently in the study. In contrarily, one of the possible reasons leading to the growth inhibitory 
effect and undetectable caspase 3/7 activation at this high concentration of recombinant EGF-
VP3-HK may be due to the overloaded cultures with considerable amount of impure proteins. 
Purification of recombinant EGF-VP3-HK did not yield a good purity of protein as observed in 
Chapter 5 and huge amount of plant protein contaminants were detected in final eluted protein 
sample. Increasing MMP is an early event of apoptosis but it can also occur when cells 
undergoing a stress condition. Therefore, the recombinant EGF-VP3-HK treated A549 cells may 
be in stress condition rather than in the process of apoptosis. Further tests on the cellular Bax 
level and cytochrome c release as well as plant protein contaminant effect on cells should be 
conducted in order to verify for the actual reason and address the shortfall in the interpretations 
of apoptotic activity induced by the recombinant apoptin. 
In shorts, ectopically expressed apoptin using DNA transfection approach confirmed that A549 
cell line was susceptible to apoptin. Via ELISA binding assay, recombinant GFP-VP3-H and 
EGF-VP3-HK interacted with A549 cells as well as EGF receptors. However, the reasons for the 
interaction between recombinant apoptin and EGF receptors are yet to be made known. In this 
study, recombinant GFP-VP3-H was confirmed to be delivered into A549 cells using 
microinjection. Cells microinjected with recombinant GFP-VP3-H decreased rapidly when the 
cultures were incubated for a longer period. Although apoptotic features were observed in some 
cells, the decrease of microinjected cells still could not be concluded to be caused by the 
apoptosis induced by apoptin. Nevertheless, confirmation of nuclear localisation activity of 
recombinant GFP-VP3-H confirms the nuclear localisation domains of apoptin is active. In 
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current stage of study, recombinant EGF-VP3-HK was found binding to EGF receptors located 
on A549 cells due to the detected clumps of EGF receptors upon treatment. However, 
internalisation of recombinant EGF-VP3-HK is yet to be confirmed. Recombinant EGF-VP3-HK 
stimulated cell proliferation but a dose-dependent growth inhibitory effect was observed when 
cells were incubated with recombinant protein at a higher concentration. In addition, apoptin-
induced apoptosis still could not be verified by current study for A549 cells treated with 
recombinant EGF-VP3-HK. In order to make apoptin becoming a great anticancer candidate in 
the future, an efficient delivery of the protein must be developed and understanding on the 
mechanisms of apoptin-induced apoptosis is also critical in order to correctly target apoptin to 
cancer cells.  
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Chapter 7 
General Discussion  
Apoptin, the smallest 14 kDa non-structural Viral Protein (VP3) of Chicken Anemia 
Virus (CAV), is responsible for the destruction of lymphocytes via induction of 
apoptosis (Noteborn et al., 1994). Due to the apoptosis-inducing feature of the protein, 
VP3 was called as “apoptin” by Noteborn and Koch (1995). Other than inducing 
apoptosis in chicken lymphoblastoid T and myeloid cells that are susceptible to CAV 
infection, apoptin-induced apoptosis was also found in tumourigenic and transformed 
mammalian cells (Zhuang et al., 1995). More than 70 cancer cells were reported 
sensitive to apoptin and underwent apoptosis eventually (Los et al., 2009.). Up to date, 
normal or non-transformed cells, including chicken fibroblast that lacks susceptibility 
to CAV infection are not sensitive to apoptin. Apoptin contains 121 amino acids 
coding for a leucine rich region (LRR), locating at amino acids 33-16, and a bipartite 
nuclear localisation signal NLS1 and NLS2, locating at amino acids 82-88 and 111-
121. Although exact mechanisms of apoptin-induced apoptosis are yet to be 
elucidated, the intrinsic pathway involvement had been evidenced and a huge variety 
of apoptosis-related proteins were found interacting with apoptin (Los et al., 2009.). 
Study of apoptin was achieved in mice as well as mammalian cell lines via liposome-
based DNA transfection, nanoparticles, viral vectors, recombinant proteins and 
intratumoural injection (Rollano Penaloza et al., 2014). Up to date, recombinant 
apoptin had been successfully expressed in bacteria (E. coli), plants (Nicotiana 
benthamiana) and mammalian cells (HUVEC) (Zhang et al., 2003; Lacorte et al., 
2007; Ma et al., 2012). The apoptotic induction activity in tumor cells was obtained 
from recombinant apoptin recovered from bacterial and mammalian cells. However, 
bioactivity of plant-made apoptin has not been assessed in mammalian cell lines. 
Besides, several issues have been encountered during the research of apoptin, 
including uneven delivery of apoptin gene into cancer cells using DNA transfection 
method, risk of potential infection when mammalian viral vectors are used, cytotoxic 
effect from transfection reagents as well as huge amount of recombinant apoptin 
harvested from insoluble protein fraction (Anson, 2004; Backendorf et al., 2008). 
Hence, this study would like to evaluate the feasibility of plant expression system for 
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the production of recombinant apoptin. Besides, some preliminary studies were also 
performed to explore the apoptosis-inducing potential of plant-made apoptin.  
Flexibility for up-scaling, high expression level as well as lack of potential infectious 
or pathogenic microbes are the attractive benefits of using plant-based system. In this 
study, tobacco, N. benthamiana, was used for the expression of recombinant apoptin 
since N. benthamiana is a non-crop, model plant as well as a huge amount of biomass 
could be harvested from its leaf tissue (Tremblay et al., 2010.). Agroinfiltration, a 
scalable, non-expensive, rapid and simple gene delivery tool, was employed in this 
study to deliver recombinant DNA vectors into leaves of N. benthamiana. Instead of 
using syringe, vacuum infiltration, a more efficient and productive way, was used to 
infiltrate large batches of plants in order to generate a huge amount of plant materials 
in a short period of times for downstream bioprocessing procedures. With the similar 
delivery efficiency for each batch of plants, data generated for protein expression-
associated morphological changes as well as comparative expression profiles of 
recombinant vectors were more reliable.  
In order to obtain an optimal protein expression and ease for purification, several 
gene cassettes were designed. Recombinant apoptin was inserted into vectors as 
apoptin gene alone (gene cassettes: PR-VP3-HK, PR-VP3-H and VP3-H), apoptin 
gene in fusion to C-terminal of green fluorescent protein (GFP) (gene cassettes: PR-
GFP-VP3-HK, PR-GFP-VP3-H and GFP-VP3-H) and apoptin gene in fusion to C-
terminal of lichenase (gene cassettes: PR-Lic-VP3-HK, PR-Lic-VP3-H and Lic-VP3-
H). Signal peptide (PR1a), hexa-histidine tag as well as endoplasmic reticulum 
(ER)(KDEL) retention signal were separately fused to apoptin gene cassettes in order 
to target recombinant proteins to ER, apoplast or cytoplasm. Besides, apoptin gene 
was also designed in fusion to H22 single chain antibody (gene cassettes: PR-H22-
CatAd-VP3-HK, PR-H22-CatAd-VP3-40-121-HK, PR-H22-CatAd-VP3-60-121-HK 
and PR-H22-CatAd-VP3-80-121-HK) and epidermal growth factor (EGF) (gene 
cassettes: PR-EGF-CatAd-VP3-HK, PR-EGF-CatAd-VP3-40-121-HK, PR-EGF-
CatAd-VP3-60-121-HK and PR-EGF-CatAd-VP3-80-121-HK). The design of fusion 
to H22 single chain antibody and EGF was to target the protein to specific cancer 
cells that overexpressed immunoglobulin G (IgG)(CD64) and EGF receptors. 
Truncated apoptin versions in fusion to H22 single chain antibody as well as EGF 
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were also attempted. Protein expression profiles of all gene cassettes were compared 
and the most ideal recombinant vectors with promising protein yield were selected for 
the use in the downstream purification steps.    
In order to obtain high protein yield for recombinant apoptin from plant-based 
expression system, several improvement strategies were applied at transcriptional and 
translational levels which could be achieved by using recombinant vectors enabling 
high expression of protein, co-expression with gene silencing suppressors as well as 
codon optimisation for gene of interest. In this study, tobacco mosaic viral (TMV) 
based vector pGR-D4 as well as binary vector pGR-DN were used for the expression 
of recombinant apoptin. Expression of recombinant proteins using viral vectors 
always yields several folds higher of proteins. High expression of proteins is normally 
induced by the strong promoters and untranslated regions located on viral genome 
(Kanoria and Burma, 2012). Recombinant apoptin was also expressed using binary 
vector, pGR-DN, that harbours a strong promoter (CaMV double 35S promoter) and 
tobacco etch virus (TEV) enhancer. Infiltration of transformants bearing the 
recombinant vector, pGR-DN requires the co-infiltration with gene silencing 
suppressors (P19 and P1/HC-Pro). Employment of gene silencing suppressors is 
crucial for inhibiting gene silencing events from host plants that suppress 
transcription as well as translation programme of foreign proteins (Feller et al., 2013). 
Gene silencing suppressor is not used with TMV-based vector since 126k protein of 
TMV is believed involving in gene silencing suppression activities. Codon 
optimisation is also commonly performed to increase preferable codons used by the 
host plants in order to increase transcription and translation efficiency (Quax et al., 
2015). In this study, codon optimisation was performed on sequences of recombinant 
apoptin and fusion proteins, including green fluorescent protein (GFP), lichenase, 
H22 single chain antibody and epidermal growth factor (EGF), to increase the 
percentage of N. benthamiana preferable codon and remove mRNA secondary 
structure that might hamper the translation process. Codon adaptation index (CAI), a 
measurement for codon adaptiveness of a gene sequence towards the favorable codon 
usage of highly expressed gene in a host species, of optimised gene sequences 
increased from 0.6-0.7 to 0.8 (Chapter3). In addition, effective number of codon 
(ENC) value of optimised gene sequences was also reduced showing a bias of codon 
towards the preference codons used by N. benthamiana.    
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Besides, several approaches were applied to increase the yield of recombinant apoptin 
at post translational level. Recombinant apoptin was in fusion to large protein, 
targeted to specific cellular compartment, co-expressed with endoplasmic reticulum 
(ER) stress proteins as well as expressed in truncated peptides in order to stabilise the 
protein and escape from proteolytic degradation. Fusion of recombinant apoptin to 
large proteins, especially GFP (recombinant pGR-D4:: PR-GFP-VP3-HK) and 
lichenase (recombinant pGR-D4:: PR-Lic-VP3-HK), was observed with several folds 
of protein yield increase as compared to apoptin expressed alone (recombinant pGR-
D4:: PR-VP3-HK) (Chapter 4). The fusion to large proteins might promote stability 
and consequently increase solubility of the targeted protein via formation of fusion 
proteins in micelle-like structure, high propensity of fusion partners in the attraction 
of chaperone proteins, presence of intrinsic chaperone-like activity and preventing the 
formation of protein aggregates by electrostatic repulsion (Costa et al., 2014). 
However, not all fusion proteins might result a positive impact for the expression of 
recombinant apoptin. In this study, fusion of apoptin to H22 single chain antibody 
yielded a huge amount of degraded bands instead of full length recombinant H22-
apoptin. Besides, recombinant apoptin was also stored at specific plant cellular 
compartments in order to rescue proteins from degradation by a high amount of 
cytosolic active proteases as well as receive a proper folding (Streatfield, 2007.). It 
was noticed that apoptin gene cassettes without signal peptide and ER retention signal 
were expected to be accumulated in cytoplasm. However, the protein was in fact 
accumulated in nucleus (gene cassette: GFP-VP3-H) and this might be due to the 
nuclear localisation activity caused by the bipartite nuclear localisation signal (NLS) 
located at the C-terminal end of apoptin. Accumulation of soluble fraction of 
recombinant apoptin showed a higher amount in ER than in nucleus and apoplast. In 
particular, recombinant GFP-apoptin (recombinant pGR-D4:: PR-GFP-VP3-HK) 
yielded ~ 2 folds of soluble protein when was accumulated in ER rather than in 
apoplast (recombinant pGR-D4:: PR-GFP-VP3-H) and nucleus (recombinant pGR-
D4:: GFP-VP3-H). However, it was noticed that recombinant apoptin, including 
apoptin alone, GFP-apoptin and lichenase-apoptin, targeted to nucleus produced the 
highest amount of proteins in relative to ER and apoplast. Hence, a higher solubility 
of protein could be obtained when the protein was targeted and retained in ER 
compartment. This is most probably due to the presence of a huge variety of 
chaperones that always facilitates protein folding (Streatfield, 2007). Overexpression 
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of recombinant gene always leads to ER stress response as a result of loss of balance 
for protein processing in ER lumen (Kopito, 2000). ER stress response causes the 
accumulation of insoluble protein as well as early plant death in infiltrated plants. 
Early plant death was observed in plants infiltrated with recombinant pGR-D4:: PR-
VP3-HK, pGR-D4:: PR-VP3-H, pGR-D4:: PR-Lic-VP3-HK and pGR-D4:: PR-Lic-
VP3-H. ER stress proteins, such as bZIP17, bZIP28 and bZIP60, are transcriptional 
factors inducing expression of unfolded protein response (UPR) related genes. Up-
regulation of UPR genes would lead to an elevated level of chaperones (Duwi Fanata 
et al., 2013). In this study, co-expression of bZIP60 with apoptin alone (recombinant 
pGR-DN:: PR-VP3-HK_bZIP60) had resolved early plant death symptom as 
observed when apoptin was expressed alone. On the other hand, co-expression of 
recombinant apoptin alone with ER stress proteins bZIP60 also caused increasing 
protein expression in soluble fraction as well as total protein. However, co-expression 
of recombinant bZIP 28 and bZIP17 did not cause any significant changes for the 
plants as well as protein expression. Besides, co-expression of ER stress proteins also 
did not improve expression of recombinant GFP-apoptin (gene cassette: PR-GFP-
VP3-HK) and EGF-apoptin (gene cassette: PR-EGF-VP3-HK). In the other hand, 
expression of truncated domains of recombinant apoptin was also studied. Since the 
N-terminal region of apoptin was responsible for the aggregation activity (Leliveldc et 
al., 2003), truncated versions of apoptin (VP3-40-121, VP3-60-121 and VP3-80-121) 
in fusion to EGF and H22 single chain antibody were generated by removing the N-
terminal region of the protein. Higher amount of recombinant apoptin was obtained in 
soluble fraction from recombinant EGF-apoptin reserving amino acid 40-121 and 80-
121. However, lower amount of recombinant EGF-apoptin was recovered when 
amino acids 1-60 were removed. Fusion of truncated apoptin to H22 single chain 
antibody produced degraded protein fragments showing a similar result as full length 
apoptin in fusion to H22 single chain antibody. Indeed, not all approaches were 
suitable applied for the expression of recombinant apoptin in N. benthamiana. 
Combination of approaches might be required to further investigate a better method 
for enhancing the protein expression yield of recombinant apoptin in N. benthamiana. 
Nevertheless, recombinant vectors were selected from each group of recombinant 
apoptin, including apoptin alone, GFP-apoptin, lichenase-apoptin and EGF-apoptin, 
for downstream protein purification works. These included the recombinant vectors, 
pGR-D4:: VP3-H, pGR-DN:: PR-VP3-HK_bZIP60, pGR-D4:: PR-GFP-VP3-HK, 
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pGR-D4:: GFP-VP3-H, pGR-D4:: Lic-VP3-H and pGR-D4:: EGF-CatAd-VP3-H by 
which the infiltrated plants were harvested, extracted and purified in various defined 
processes.  
Hexa-histidine tag was fused to the C-terminal of all proteins; hence, immobilised 
metal affinity chromatography (IMAC) was employed in the capturing step to purify 
the recombinant apoptin. Recombinant proteins were isolated from total protein pool 
based on a specific interaction between hexa-histidine regions and divalent metal 
nickel (Ni2+). In this study, IMAC was performed in both non-denaturing and 
denaturing conditions as the recombinant apoptin was present in both soluble and 
insoluble fractions. For IMAC purification performed in non-denaturing condition, 
recombinant apoptin alone (recombinant vector pGR-DN:: PR-VP3-HK) was 
recovered at a low amount of purified protein (< 1 mg/kg). However, ~7 mg/kg of 
recombinant GFP-apoptin (recombinant vector pGR-D4:: PR-GFP-VP3-HK) was 
recovered and ~3-4 mg/kg of EGF-apoptin (pGR-D4:: PR-EGF-CatAd-VP3-HK) was 
also recovered from IMAC in non-denaturing condition. A large amount of host cell 
proteins (HCPs) was always detected in the final eluted recombinant apoptin, 
including apoptin alone, GFP-apoptin as well as EGF-apoptin, in non-denaturing 
condition of IMAC. In fact, removal of HCPs contamination with acidic precipitation 
as well as second chromatography, using hydrophobic interaction (HIC) columns 
(including Phenyl Sepharose 6TM FF (high sub), HiTrap Butyl Sepharose HP and 
HiTrap Octyl Sepharose FF) and cation exchange chromatography (IEX) column 
(HiTrap SP), did not give a positive feedback for the trials. Instead of purifying 
protein from soluble protein fraction, recombinant apoptin expressed in insoluble 
protein fraction was also performed using IMAC in denaturing condition. 
Recombinant apoptin alone (from recombinant vector pGR-D4:: VP3-H) did not 
solubilise completely in extraction buffer by using high concentration of guanidium 
hypochlorite (GuHCl); hence, a low amount of protein (~ 1 mg/kg) was recovered 
from IMAC. On the other hand, recombinant GFP-apoptin (from recombinant vector 
pGR-D4:: GFP-VP3-H) and lichenase-apoptin (from recombinant vector pGR-D4:: 
Lic-VP3-H) yielded a high amount of protein with good purity from IMAC in 
denaturing condition. Recombinant GFP-apoptin (GFP-VP3-H) was recovered at 21 
mg/kg and purified protein was refolded without the requirement of other additives; ~ 
20 mg/kg of recombinant lichenase-apoptin (Lic-VP3-H) was harvested from IMAC 
  
 
7-7 
 
 
in denaturing condition but refolding of recombinant Lic-VP3-H required the addition 
of triton in order to stabilise the protein in the buffer. Characterisation of protein 
multimerisation was also performed for refolded recombinant GFP-VP3-H using size 
exclusion chromatography coupled with multi-angle light scattering (SEC-MALS). 
Recombinant GFP-VP3-H was migrated as a single peak at 10 ml with a small 
shoulder at ~ 10.7 ml in SRT SEC1000 column and MALS analysis showed that 
majority of these protein molecules shared a similar molecular mass, which was ~ 
944.3 kDa. This data showed that refolded GFP-VP3-H was existed in a multimerised 
state with ~ 20 monomers per protein molecules. A similar result was also reported 
by Lelivelda et al. (2003). Since refolded GFP-VP3-H was recovered at a high 
amount with good purity and partial purified recombinant EGF-VP3-HK was able to 
be internalised directly into targeted cancer cells; hence, both proteins were subjected 
to subsequent cell-based experiments in order to collect some preliminary 
understanding regarding bioactivity of plant-made apoptin in mammalian cells.  
Human lung adenocarcinoma epithelial cell A549 cell line was chosen for evaluating 
the bioactivity of recombinant GFP-VP3-H and EGF-VP3-HK. The key reason of 
using A549 cells is due the overexpression of EGF receptors was present on the cell 
surface as this is crucial for evaluation of bioactivity of recombinant EGF-VP3-HK. 
In addition, ectopically expression of apoptin via DNA transfection also confirmed 
that A549 cell line was susceptible to apoptin. Interaction between recombinant 
apoptin and A549 cells was also studied using enzyme-linked immunosorbent assay 
(ELISA) binding assay. Based on the ELISA result, recombinant apoptin (GFP-VP3-
H and EGF-VP3-HK) interacted with EGF receptors as well as A549 cells, which 
overexpressed with EGF receptors. Up to date, there is no report about the 
interactions between apoptin and EGF receptors as well as apoptin and cell surface of 
cancers. The interaction between apoptin and EGF receptors might be due to the 
presence of leucine rich region (LRR), a region that is responsible for the 
multimerization of apoptin, on both apoptin and EGF receptors. Nevertheless, the 
underlying mechanism for the interaction between apoptin and EGF receptors 
requires more investigations.  
Although recombinant GFP-apoptin (GFP-VP3-H) could bind to EGF receptors and 
A549 cells, this protein did not have cell penetrating peptides and a delivery tool was 
required to transfer protein into the intracellular space of A549 cells. Presence of 
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protein aggregates on A549 cells was observed when recombinant GFP-apoptin 
(GFP-VP3-HK) was delivered into A549 cells using PULSin® protein delivery 
reagent. The changes of buffer condition and temperature may cause the incidence of 
protein aggregates. Besides, clumping of recombinant apoptin-EGF receptor 
complexes may also be the reason causing the protein aggregates. Since the size of 
protein precipitates was huge, the internalisation of protein was a challenge. Instead 
of using transfection reagent, microinjection, a precise delivery method, was used to 
deliver recombinant GFP-apoptin (GFP-VP3-H) into A549 cells. By using 
microinjection, recombinant GFP-VP3-H was directly introduced into cytoplasm of 
cells and huge protein aggregates were no longer observed. In microinjection, number 
of cells microinjected with recombinant GFP-VP3-H reduced rapidly in relative to 
those cells microinjected with recombinant GFP when the cell samples were 
incubated from 2-24 hours post microinjection. The most possible reason contributing 
to the decrease of cell numbers might be due to the intracellular degradation activity 
since reducing signal of recombinant GFP in microinjected cells was also observed. It 
is not surprised to find that intracellular bioavailability of recombinant proteins is 
always challenged by the changes of physiological pH, temperature, salt as well as 
the presence of proteases (Torchilin, 2008). Besides, cell killing activity of 
recombinant apoptin might also contribute for the decrease of cells since changes of 
nuclear morphology was observed in small amount of microinjected cells. Besides, 
microinjected recombinant GFP-VP3-H was also localised into cell nucleus of A549 
cells which is crucial for apoptosis induction. However, it could not be concluded at 
this stage that the decreased cell number was absolutely due to apoptotic activity 
induced by the recombinant apoptin since no convincingly positive result was 
collected from the tests for depolarization of mitochondrial membrane potential 
(MMP) and activation of caspase 3/7, which are both significant hallmarks for an 
apoptosis event.  
On the other hand, recombinant EGF-VP3-HK is expected to bind specifically to 
EGF receptors located on cell surface of A549 cells and the protein will then be 
internalised into cell via endocytosis. Subsequently, apoptin would be transferred and 
released into cytoplasm via the activity of membrane transfer unit (MTU) as well as 
cytosolic cleavable unit (CCU) from CatAd adaptor linked between EGF and apoptin. 
Based on current indirect immunofluorescent (IF) assay, internalisation of 
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recombinant EGF-VP3-HK could not be confirmed after it was applied on the culture. 
This is because the identification of plasma membrane by detecting the EGF receptors 
was interrupted by the redistribution of EGF receptors. The redistribution of EGF 
receptors was believed due to the binding of recombinant EGF. Hence, a future study 
on the protein internalisation is required by using other plasma membrane staining 
markers. The recombinant EGF-VP3-HK induced cell proliferation of A549 cells at a 
lower concentration, which was also observed in the cells incubated with recombinant 
EGF. However, a dose-dependent growth inhibitory effect was observed when cells 
were incubated at a higher concentration of recombinant proteins. In current study, no 
activation for caspase 3/7 activity was observed in cells incubated with recombinant 
EGF-VP3-HK; however, loss of mitochondrial membrane potential (MMP) was 
observed. Since a loss of mitochondrial membrane potential occurs in both cells 
undergoing apoptosis as well as stress, activation of apoptin-induced apoptosis is 
probable, however, the loss of MMP caused by the cells under a stress condition 
could not be ruled out too. Apoptin protein concentration is a limiting factor in the 
study. Therefore, the protein may provide inadequate stimulus for cellular pro-
apoptotic proteins involving in the upstream event of apoptosis, such as Bax and Bak. 
Increasing level of these cellular proteins may lead to the loss of MMP; however, 
inadequate stimulus may render the activation of caspase 3, which is the executor 
caspase actived at later stage in apoptosis pathway. Evaluation for activation of pro-
apoptotic proteins, which is upstream event for apoptosis before loss of mitochondria, 
could be performed to investigate this assumption. Besides, activation for cellular 
proteins (such as caspase 9, cytochrome c and apaf-1) involving in apoptosis, which 
activated after loss of MMP and before activation for caspase 3,  could also be 
measured to examine this hypothesis.   
Limitations of the Current Study and Future Recommendations 
Some limitations of the current study are found and prospective research of apoptin is 
highlighted herein. The main objective of this study was to evaluate the potential of 
using a plant-based system, i.e. agroinfiltration approach for the production of 
recombinant apoptin. By using plant as a biofactory, it was found that only a low 
amount of recombinant apoptin in soluble protein fraction was able to be recovered 
and fusion of apoptin to a large protein had increased the yield of soluble protein. In 
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the current study, GFP, lichenase as well as EGF were adopted in fusion to apoptin 
and yields of soluble protein varied among these fusion proteins (~ 10-20 mg/kg). In 
comparison to E. coli expression, plant-derived apoptin alone and apoptin in fusion 
with the abovementioned proteins have not resulted a more satisfactorily soluble 
protein yield. In fact, other large proteins could be considered to be fused to apoptin 
in future in order to enhance the solubility and stability of recombinant apoptin. For 
examples, maltose binding protein (MBP), glutathione S-transferase (GST) and 
elastin like protein (ELP) are the commonly used large proteins for fusion purpose. In 
the study of Lelivelda et al. (2003), MBP-apoptin fusion had been proven to 
significantly increase the soluble recombinant protein production with a level up to ~ 
40 mg/L in E. coli system. Besides, the employment of MBP or GST as a fusion 
protein to recombinant apoptin could also be an alternative protein purification option 
over IMAC, which might improve the overall purity of recombinant apoptin, better 
than that of generated by IMAC in this study. Removal of fusion protein after 
purification is also a concern for the production of recombinant protein since fusion 
protein might induce an unwanted response in the animal experiment. In the current 
study, an enterokinase site was incorporated between apoptin and fusion proteins 
making the apoptin can be purified as a single pure protein. However, cleavage of 
fusion protein and evaluation for the stability of apoptin after cleavage have yet to be 
carried out for current study.  
Besides, protein targeting was also one of the strategies used in the current study to 
increase stability of recombinant protein. Among three cellular compartments, 
recombinant apoptin showed a high soluble protein level when protein was 
accumulated in ER. However, protein was accumulated in nucleus at the highest 
amount but in an insoluble state. Accumulation of recombinant apoptin in ER at 
lower quantity might be due to the activation of proteolysis machinery for unfolded or 
improper folded proteins produced rapidly in a short period of time. Instead of using a 
strong promoter, a weak promoter like nopaline synthase can be attempted in future to 
reduce the rate of protein synthesis, which might in turn lead to a higher amount of 
soluble protein to be harvested. Besides, recombinant protein could also be targeted to 
chloroplast, which is an alternative protein accumulation site within plant cells. In 
addition to protein fusion, several parameters, including agrobacterium strain, 
infiltration bacterial OD, vectors, gene silencing suppressors and storage of protein in 
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specific cellular compartments, could also be optimised in order to enhance protein 
expression.  
In the protein purification process, IMAC dependent on the interaction between hexa-
histidine and metal ion, was the major tool used for capturing recombinant protein 
from total protein pool in this study. Other purification approaches, such as ion 
exchange chromatography (IEX), glutathione-S-transferase GST-based affinity 
chromatography and MBP-based chromatography, could be examined for purification 
of recombinant apoptin in the future. Besides, multimerisation of apoptin is 
interesting but the mechanism has yet been understood. The multimerisation 
characteristics of recombinant protein had been analysed in this study using SEC and 
MALS to evaluate the molecular weight of the recombinant protein. For future 
investigations, hydrodynamic radius of recombinant apoptin could be measured by 
using dynamic light scattering (DLS) and size of protein could be further validated 
using electron microscopy (EM). A lack of elucidation of the protein structure of 
recombinant apoptin is one of the major missing parts in this study. Protein structure 
could be analysed using circular dichroism to characterise for the secondary structure 
of protein. Up to date, no crystallography of apoptin has been reported. The protein 
structure captured after crystallisation might have a great impact in the current 
apoptin research in order to understand the three-dimensional structure of apoptin 
macromolecules at an atomic resolution. Understanding on the proper protein folding 
and structure could give a guidance for the design of gene cassettes and probably help 
to explain the mechanism of apoptin-induced apoptosis.  
Protein stability is also required for future study. Instability of recombinant apoptin 
was noticed during protein purification process; however, recruitment of suitable 
stabilising agents, such as sucrose and glycerol, has yet to be conducted. Difficulty 
for studying protein function in subsequent cell-based or animal experiments has been 
encountered in current study since the protein precipitation occurred upon storage. 
Hence, investigation for improving the stability of recombinant protein is important in 
future to overcome this research bottleneck.  
Lung adenocarcinoma was chosen as the cell lines tested for activity of recombinant 
apoptin in the current study. However, apoptin is actively against various kinds of 
cancer cells. Hence, it is also suggested to test recombinant apoptin in other cancer 
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cell lines. Besides, low protein concentration is also a critical limiting factor in this 
study. Significant apoptosis activity might be able to be detected when apoptin is 
tested in other cells since efficient cell killing dosage of therapeutic proteins might 
not be the same for different cell lines. In the other hand, an unexpected interaction 
between apoptin and EGF receptors was noticed in this study. However, there is no 
study reported regarding this sort of interaction between apoptin and EGF receptors 
or cancer cells. Truncated or point mutation study on recombinant GFP-apoptin 
sequences could be performed in future for elucidating the region which is 
responsible for the interaction. More studies on protein interaction and domain 
binding between apoptin and EGFR are important for determining the suitability of 
EGFR as a site for recombinant protein binding and successful internalisation.  
Besides, recombinant GFP- apoptin could not pass through plasma membrane directly 
and employment of microinjection technique was required for the delivery of 
recombinant protein into the cells. Microinjection is not a favourable delivery tool for 
long term study of recombinant protein since the technique is of high cost, laborious 
and not feasible when protein is tested in vivo. Therefore, the use of cell-penetrating 
peptides (CPPs) may resolve these research problems as identified. Up to date, 
researches have employed Tat protein from HIV and PTD4 to deliver apoptin into 
animal cells and significant cell death was observed in treated tumour cells (Sun et al., 
2009: Lee et al., 2012). In this study, cell specific ligands, such as EGF and H22 
single chain antibody, were used in addition to CPPs. However, H22-apoptin did not 
yield a good amount of proteins and recombinant EGF-apoptin requires more studies 
in order to elucidate the protein internalisation activity. EM would be a direct method 
to check for the localisation of protein inside A549 cells. Besides, internalisation of 
protein could also be quantified using MALDI-TOF MS in addition to fluorescence-
based protocol (Benchara, 2012). Hence, in addition to the study of internalisation of 
recombinant EGF-apoptin, other cell specific ligands could also be exploited, such as 
RGD tri-peptide, Bombesin (BBN) peptide, somatostatin and follicle-stimulating 
hormone analogs, which could increase the targeting efficiency for cancer cells (Raha 
et al., 2011). In addition, evaluation on the cleavage of apoptin from EGF fusion 
protein after internalisation will also be one of the important parameters to study the 
delivery strategy. Cytosolic cleavage site located between apoptin and EGF harbours 
cellular enzyme cleavage sites, such as Caspase-1 and Caspase-3 cleavage sites. 
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Hence, cleavage efficiency of apoptin from EGF fusion protein could be determined 
by incubating the protein with cellular cytoplasmic extract that containing high 
amount of enzymes. Cleavage of apoptin from EGF fusion protein is important to 
release apoptin from vesicle and allow apoptin to be relocalised to nucleus, where the 
protein expected to trigger apoptosis pathway.   
Upon several attempts, the results in the current study were not conclusive enough to 
validate the apoptosis activity. One of the major factors that contributes to this 
research outcome is the low concentration of recombinant protein, especially for the 
recombinant GFP-apoptin used in microinjection procedure. Hence, stability of 
recombinant apoptin is the main challenge for next investigations in order to evaluate 
for the functionality of recombinant protein in mammalian cell lines and animal 
model. Instead of checking the activity of caspase 3/7 and MMP, other cellular 
proteins activated during apoptosis could also be determined, such as Bax, Bak, 
cytochrome c, Nur77, caspase 9 and Apoptotic protease activating factor 1 (Apaf-1).  
Conclusions 
It is of no doubt that the recombinant apoptin alone, GFP-apoptin, Lic-apoptin, EGF-
apoptin as well as H22-apoptin had been successfully expressed in N. benthamiana. 
In current study, recombinant apoptin, GFP-apoptin as well as EGF-apoptin could not 
be purified from soluble protein fraction efficiently since eluted proteins were always 
contaminated with a huge amount of HCPs. Alternatively, purification using 
denaturing condition yielded the protein at higher purity, especially recombinant 
GFP-apoptin (GFP-VP3-H) and lichenase-apoptin (Lic-VP3-H). In preliminary cell-
based experiments, apoptin-induced apoptosis was not able to be confirmed in cells 
microinjected with recombinant GFP-VP3-H; however, majority of injected protein 
was found localising to cell nucleus. On the other hand, a dose-dependent growth 
inhibitory was observed when recombinant EGF-VP3-HK at high concentration was 
incubated with A549 cells. Internalisation of recombinant EGF-VP3-HK could not be 
confirmed in this study and more studies might be necessary to clarify for the 
internalisation activity of the protein. Although current cell-based experiment could 
not provide convincing data for the bioctivity of plant-made apoptin, there was some 
important findings that suggested future research orientation.
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Chapter 9 
Appendices 
Appendices for Chapter 3 
3.1 Nucleotide and amino acid sequences of synthetic apoptin gene cassette, PR-VP3-
HK  
Nucleotide sequence 
TGTACATTAATTAAATGGGTTTCGTGCTGTTCAGCCAGCTGCCTTCTTTCCTTCTTGT
GTCTACCCTTCTGCTGTTCCTGGTGATCTCTCATTCTTGCAGGGCTATGGATGCTCTG
CAAGAGGATACTCCTCCTGGTCCTTCTACTGTTTTCAGGCCTCCTACTTCTAGCAGGC
CTCTTGAAACTCCTCACTGCAGAGAGATCAGGATCGGTATCGCTGGTATTACCATCA
CCCTTTCTTTGTGCGGTTGCGCTAATGCTAGGGCTCCTACTCTTAGATCTGCTACCGC
TGATAACAGCGAGAGCACCGGTTTCAAGAACGTGCCAGATCTTAGGACCGATCAGC
CTAAGCCTCCAAGCAAGAAGAGAAGCTGCGATCCTTCTGAGTACAGGGTGAGCAAG
CTGAAAGAGAGCCTTATCACTACCACCCCTTCTAGGCCAAGGACTGCTAAGAGAAG
GATTAAGCTTCATCACCATCACCACCACAAGGATGAGCTGTAGCTCGAGGGCGCGC
CGCTAGC 
Amino acid sequence 
MGFVLFSQLPSFLLVSTLLLFLVISHSCRAMDALQEDTPPGPSTVFRPPTSSRPLETPHCRE
IRIGIAGITITLSLCGCANARAPTLRSATADNSESTGFKNVPDLRTDQPKPPSKKRSCDPSE
YRVSKLKESLITTTPSRPRTAKRRIKLHHHHHHKDEL* 
Features 
Signal peptide PR1a  : (nucleotide) 15…104 (amino acid) 1…30 
VP3-A    : (nucleotide) 105…467 (amino acid) 31…151 
Hexahistidine   : (nucleotide) 468…485 (amino acid) 152…157 
ER retention signal  : (nucleotide) 486…497 (amino acid) 158…161 
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3.2 Nucleotide and amino acid sequences of synthetic apoptin gene cassette, PR-GFP-
VP3-HK  
Nucleotide sequence 
TGTACATTAATTAAATGGGTTTCGTGCTGTTCAGCCAGCTGCCTTCTTTCCTTCTTGT
GTCTACCCTTCTGCTGTTCCTGGTGATCTCTCATTCTTGCAGGGCTGCTTCTAAGGGT
GAGGAACTTTTCACTGGTGTGGTGCCTATTCTGGTTGAGCTGGATGGTGATGTGAAC
GGTCACAAGTTCTCTGTGTCTGGTGAAGGTGAGGGTGATGCTACCTACGGTAAGCTG
ACCCTTAAGTTCATCTGTACCACCGGAAAGTTGCCTGTGCCTTGGCCTACTCTTGTGA
CCACTTTCTCATACGGTGTGCAGTGCTTCAGCAGGTATCCTGATCATATGAAGAGGC
ACGATTTCTTCAAGAGCGCTATGCCTGAGGGTTACGTGCAAGAGAGGACCATCTTCT
TCAAGGATGATGGTAACTACAAGACCAGGGCTGAGGTGAAGTTCGAAGGTGATACC
CTTGTGAACAGGATCGAGCTGAAGGGTATCGATTTCAAAGAGGATGGAAACATCCT
GGGTCACAAGCTTGAGTACAACTACAACAGCCACAACGTTTACATCACCGCTGATA
AGCAGAAGAACGGTATCAAGGCTAACTTCAAGATCAGGCACAACATCGAGGATGGT
AGCGTGCAGCTTGCTGATCATTACCAGCAGAACACCCCTATCGGTGATGGTCCTGTT
CTGCTTCCTGATAACCACTACCTGTCTACCCAGTCCGCTCTGTCTAAGGATCCTAACG
AGAAGAGGGATCACATGGTGCTGCTTGAGTTCGTTACCGCTGCTGGTATTACCCACG
GTATGGATGAGCTGTATAAGGACGATGATGATAAGATGGATGCTCTGCAAGAGGAT
ACCCCTCCTGGTCCTTCTACTGTTTTTAGGCCTCCTACCTCTAGCAGGCCTCTTGAAA
CTCCACACTGCAGAGAGATCAGGATCGGTATCGCTGGAATTACCATCACCCTGTCTT
TGTGCGGTTGCGCTAATGCTAGGGCTCCTACTCTTAGATCTGCTACCGCAGATAACA
GCGAGAGCACCGGTTTCAAGAACGTGCCAGATCTTAGGACCGATCAGCCTAAGCCT
CCAAGCAAGAAGAGAAGCTGCGATCCTTCTGAGTACAGGGTGAGCAAGCTGAAAGA
GAGCCTTATTACCACCACCCCTTCAAGGCCTAGGACTGCTAAGAGAAGGATTAAGCT
TCATCACCACCACCATCACAAGGATGAGCTTTAGCTCGAGGGCGCGCCGCTAGC 
Amino acid sequence 
MGFVLFSQLPSFLLVSTLLLFLVISHSCRAASKGEELFTGVVPILVELDGDVNGHKFSVSG
EGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPE
GYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHN
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VYITADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSK
DPNEKRDHMVLLEFVTAAGITHGMDELYKDDDDKMDALQEDTPPGPSTVFRPPTSSRP
LETPHCREIRIGIAGITITLSLCGCANARAPTLRSATADNSESTGFKNVPDLRTDQPKPPSK
KRSCDPSEYRVSKLKESLITTTPSRPRTAKRRIKLHHHHHHKDEL* 
Features 
Signal peptide PR1a  : (nucleotide) 15…104 (amino acid) 1…30 
GFP    : (nucleotide) 105…818 (amino acid) 31…268 
VP3-A    : (nucleotide) 834…1196 (amino acid) 274…394 
Enterokinase site  : (nucleotide) 819…833 (amino acid) 269…273 
Hexahistidine   : (nucleotide) 1197…1214 (amino acid) 395…400 
ER retention signal  : (nucleotide) 1215…1226 (amino acid) 401…404 
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3.3 Nucleotide and amino acid sequences of synthetic apoptin gene cassette, PR-Lic-
VP3-HK  
Nucleotide sequence 
TGTACATTAATTAAATGGGTTTCGTGCTGTTCAGCCAGCTGCCTTCTTTCCTTCTTGT
GTCTACCCTTCTGCTGTTCCTGGTGATCTCTCATTCTTGCAGGGCTCAGAACGGTGGT
TCCTACCCTTATAAGTCTGGTGAGTACAGGACCAAGAGCTTCTTCGGTTACGGTTAC
TACGAGGTGAGGATGAAGGCTGCTAAGAACGTGGGTATCGTGTCCAGCTTCTTTACC
TACACCGGTCCAAGCGATAACAACCCTTGGGATGAGATTGATATCGAGTTCCTGGGT
AAGGATACCACCAAGGTGCAGTTCAACTGGTACAAGAATGGTGTGGGTGGTAACGA
GTACCTGCACAACCTTGGTTTCGATGCTTCCCAGGATTTCCACACCTACGGTTTTGAG
TGGAGGCCTGATTACATCGATTTCTATGTGGATGGTAAGAAGGTTTACAGGGGTACT
AGGAACATCCCTGTGACCCCTGGTAAGATCATGATGAACCTTTGGCCTGGTATCGGT
GTGGATGAGTGGCTTGGTAGATACGATGGTAGGACTCCTCTGCAGGCTGAGTACGA
GTACGTTAAGTACTACCCTAACGGTAGGTCCGAGTTCAAGCTTGTGGTGAATACTCC
TTTCGTGGCTGTGTTCAGCAACTTCGATTCTAGCCAGTGGGAGAAGGCTGATTGGGC
TCAGGGTTCTGTTTTCAACGGTGTGTGGAAGCCTTCTCAGGTGACCTTCTCTAACGGT
AAGATGATCCTGACCCTGGATAGGGAATACGACGATGATGATAAGATGGATGCTCT
GCAAGAGGATACCCCTCCTGGTCCTTCTACTGTTTTTAGGCCTCCTACCTCTAGCAGG
CCTCTTGAAACTCCACACTGCAGAGAGATCAGGATCGGTATCGCTGGTATTACCATC
ACCCTTTCTTTGTGCGGTTGCGCTAATGCTAGGGCTCCTACTCTTAGATCTGCTACCG
CTGATAACAGCGAGAGCACCGGTTTCAAGAACGTGCCAGATCTTAGGACCGATCAG
CCTAAGCCTCCAAGCAAGAAGAGAAGCTGCGATCCTTCTGAGTACAGAGTGAGCAA
GCTGAAAGAGTCCCTTATCACCACTACCCCTTCTAGGCCAAGGACAGCTAAGAGAA
GGATTAAGCTTCATCACCATCACCACCACAAGGATGAGCTGTAGCTCGAGGGCGCG
CCGCTAGC 
Amino acid sequence 
MGFVLFSQLPSFLLVSTLLLFLVISHSCRAQNGGSYPYKSGEYRTKSFFGYGYYEVRMK
AAKNVGIVSSFFTYTGPSDNNPWDEIDIEFLGKDTTKVQFNWYKNGVGGNEYLHNLGF
DASQDFHTYGFEWRPDYIDFYVDGKKVYRGTRNIPVTPGKIMMNLWPGIGVDEWLGRY
 9-5 
  
DGRTPLQAEYEYVKYYPNGRSEFKLVVNTPFVAVFSNFDSSQWEKADWAQGSVFNGV
WKPSQVTFSNGKMILTLDREYDDDDKMDALQEDTPPGPSTVFRPPTSSRPLETPHCREIR
IGIAGITITLSLCGCANARAPTLRSATADNSESTGFKNVPDLRTDQPKPPSKKRSCDPSEY
RVSKLKESLITTTPSRPRTAKRRIKLHHHHHHKDEL* 
Features 
Signal peptide PR1a  : (nucleotide) 15…104 (amino acid) 1…30 
Lichenase   : (nucleotide) 105...773 (amino acid) 31…253 
VP3-A    : (nucleotide) 789...1151 (amino acid) 259…379 
Enterokinase site  : (nucleotide) 774…788 (amino acid) 254…258 
Hexahistidine   : (nucleotide) 1152…1169 (amino acid) 380…385 
ER retention signal  : (nucleotide) 1170…1181 (amino acid) 386…389 
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3.4 Nucleotide and amino acid sequences of synthetic gene, mCherryNuc 
Nucleotide sequence 
ATGGTGAGCAAGGGTGAAGAGGATAACATGGCTATCATCAAAGAGTTCATGAGGTT
CAAGGTGCACATGGAAGGTAGCGTGAACGGTCACGAGTTTGAGATTGAAGGTGAGG
GTGAGGGTAGGCCTTATGAGGGTACTCAAACCGCTAAGCTGAAGGTTACAAAGGGT
GGTCCTCTTCCTTTCGCTTGGGATATTCTGAGCCCTCAGTTCATGTACGGTAGCAAGG
CTTACGTTAAGCACCCTGCTGATATCCCTGATTACCTGAAGCTGTCTTTCCCAGAGG
GTTTCAAGTGGGAGAGGGTGATGAATTTCGAGGATGGTGGTGTGGTGACTGTGACC
CAGGATTCTTCACTTCAGGATGGTGAGTTCATCTACAAGGTGAAGCTGAGGGGTACT
AACTTCCCTTCTGATGGTCCTGTGATGCAGAAAAAGACTATGGGTTGGGAGGCTTCA
AGCGAGAGAATGTATCCTGAAGATGGTGCTCTGAAGGGTGAGATCAAGCAGAGGCT
GAAGCTGAAAGATGGTGGTCACTACGATGCTGAGGTTAAGACCACCTACAAGGCTA
AGAAGCCTGTTCAGCTTCCTGGTGCTTACAACGTGAACATCAAGCTGGATATCACCA
GCCACAACGAGGATTACACCATCGTTGAGCAGTATGAGAGGGCTGAGGGAAGGCAT
TCTACTGGTGGTATGGATGAGCTTTACAAAGATCCTAAGAAGAAGAGGAAAGTTGA
TCCAAAGAAAAAAAGAAAAGTTGATCCTAAAAAGAAGAGAAAGGTTTAG 
Amino acid sequence 
MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGP
LPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDS
SLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKD
GGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMD
ELYKDPKKKRKVDPKKKRKVDPKKKRKV 
Features 
mCherry   : (nucleotide) 1…708  (amino acid) 1…236 
Nuclear localisation signal : (nucleotide) 709...783 (amino acid) 237…260 
(Nuc) 
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3.5 Nucleotide and amino acid sequences of synthetic gene, H22 single chain antibody 
Nucleotide sequence 
CAGGTTCAGCTGGTTGAGTCTGGTGGTGGTGTTGTTCAACCTGGAAGATCTCTGAGG
CTGAGCTGCTCATCTAGCGGTTTCATCTTCAGCGATAACTACATGTACTGGGTGAGG
CAGGCTCCTGGTAAGGGTCTTGAATGGGTGGCAACCATTTCCGATGGTGGTAGCTAC
ACCTACTACCCTGATTCTGTGAAGGGAAGGTTCACCATCAGCAGGGATAACAGCAA
GAACACCCTGTTCCTTCAGATGGATAGCCTGAGGCCTGAAGATACCGGTGTTTACTT
TTGCGCTAGAGGATATTACAGGTACGAGGGTGCTATGGATTACTGGGGTCAAGGTA
CTCCTGTGACCGTTTCTAGCGGAGGTGGTGGATCAGGTGGTGGTGGAAGTGGTGGTG
GTGGTTCTGATATTCAGCTTACCCAGAGCCCTAGCAGCCTTTCTGCTTCTGTTGGTGA
TAGGGTGACCATTACCTGCAAGTCCTCTCAGTCTGTGCTGTACTCCAGCAACCAGAA
GAACTACCTGGCTTGGTATCAGCAGAAGCCTGGAAAGGCTCCTAAGCTGCTTATCTA
CTGGGCTTCCACTAGGGAATCTGGTGTGCCTTCTAGGTTCTCCGGTTCTGGTTCTGGT
ACTGATTTCACCTTCACCATCTCCAGCCTTCAGCCTGAGGATATCGCTACTTACTACT
GCCACCAGTACCTGTCCTCTTGGACTTTTGGTCAGGGTACTAAGCTTGAGATCAAA 
Amino acid sequence 
QVQLVESGGGVVQPGRSLRLSCSSSGFIFSDNYMYWVRQAPGKGLEWVATISDGGSYT
YYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGYYRYEGAMDYWGQGTP
VTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVTITCKSSQSVLYSSNQKNYLA
WYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSS
WTFGQGTKLEIK 
Feature 
H22 single chain antibody : (nucleotide) 1…741  (amino acid) 1…247 
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3.6 Nucleotide and amino acid sequences of synthetic gene, epidermal growth factor 
(EGF) 
Nucleotide sequence 
AACAGCGATAGCGAGTGCCCTCTGTCTCATGATGGTTACTGCTTGCATGATGGTGTG
TGCATGTATATCGAGGCTCTGGATAAGTACGCTTGCAACTGCGTGGTGGGTTACATT
GGTGAGAGATGCCAGTACAGGGATCTGAAGTGGTGGGAACTTAGA 
Amino acid sequence 
NSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELR 
Feature 
Epidermal growth factor  : (nucleotide) 1…159  (amino acid) 1…53 
(EGF) 
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3.7 Nucleotide and amino acid sequences of synthetic gene, bZIP17 
Nucleotide sequence 
ATGCTGTACAATGGCTGAACCAATCACCAAGGAGCAGCCTCCTCCACCTGCTCCGGA
CCCTAATTCCACCTACCCTCCTCCGTCCGATTTTGATTCCATCTCGATCCCTCCGTTA
GATGATCATTTCTCCGATCAGACTCCGATTGGTGAACTAATGTCCGATCTGGGGTTT
CCCGATGGTGAATTCGAGCTCACTTTCGACGGTATGGACGATCTTTACTTCCCTGCTG
AGAATGAGTCGTTTCTCATCCCTATCAATACGTCCAATCAAGAACAGTTTGGTGATT
TCACTCCGGAGTCTGAAAGTTCTGGAATTTCCGGTGATTGTATTGTTCCCAAAGATG
CAGATAAGACTATTACAACTTCCGGTTGCATTAACCGGGAATCTCCTAGAGATTCCG
ATGATCGTTGCTCCGGTGCTGACCATAATTTAGATCTACCGACTCCATTGTCCTCTCA
GGGTTCGGGTAATTGCGGTTCTGATGTTTCGGAAGCTACAAATGAATCGTCGCCTAA
ATCGAGAAACGTTGCGGTCGACCAGAAGGTTAAAGTGGAAGAAGCTGCTACGACGA
CGACGTCTATTACCAAGAGGAAGAAAGAGATCGATGAGGATTTGACTGACGAGTCT
AGGAACAGTAAGTACAGGAGATCGGGAGAGGATGCTGACGCTAGTGCTGTTACCGG
TGAAGAAGATGAGAAAAAGAGAGCTAGACTCATGAGAAACCGTGAAAGTGCTCAG
CTTTCTAGGCAGAGGAAGAAGCATTACGTCGAGGAGCTTGAAGAAAAGGTTAGGAA
TATGCATTCTACGATTACGGATTTGAACGGTAAGATATCGTATTTCATGGCTGAGAA
TGCTACTCTAAGGCAGCAATTGGGTGGCAATGGAATGTGCCCGCCGCATCTTCCACC
ACCTCCGATGGGAATGTATCCACCTATGGCTCCAATGCCTTATCCATGGATGCCTTG
TCCTCCTTATATGGTGAAGCAACAAGGATCTCAAGTGCCTTTGATTCCTATTCCTAGG
TTGAAACCACAGAACACCCTTGGAACATCCAAGGCTAAGAAGTCCGAGAGTAAGAA
GAGTGAAGCTAA 
Amino acid sequence 
MAEPITKEQPPPPAPDPNSTYPPPSDFDSISIPPLDDHFSDQTPIGELMSDLGFPDGEFELTF
DGMDDLYFPAENESFLIPINTSNQEQFGDFTPESESSGISGDCIVPKDADKTITTSGCINRE
SPRDSDDRCSGADHNLDLPTPLSSQGSGNCGSDVSEATNESSPKSRNVAVDQKVKVEEA
ATTTTSITKRKKEIDEDLTDESRNSKYRRSGEDADASAVTGEEDEKKRARLMRNRESAQ
LSRQRKKHYVEELEEKVRNMHSTITDLNGKISYFMAENATLRQQLGGNGMCPPHLPPPP 
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MGMYPPMAPMPYPWMPCPPYMVKQQGSQVPLIPIPRLKPQNTLGTSKAKKSESKKSEA
KT* 
Feature 
bZIP17    : (nucleotide) 1…1092  (amino acid) 1…363 
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3.8 Nucleotide and amino acid sequences of synthetic gene, bZIP28 
Nucleotide sequence 
ATGACGGAATCAACATCCGTGGTTGCTCCTCCGCCGGAGATACCTAATCTGAACCCT
AGCATGTTTTCTGAGTCCGATTTGTTTTCTATTCCGCCGCTAGATCCTCTTTTCCTATC
TGATTCTGATCCGATTTCAATGGATGCGCCAATCTCCGATCTCGACTTCTTACTCGAC
GATGAGAACGGAGATTTCGCTGATTTTGATTTCTCGTTTGATAATTCTGATGATTTCT
TCGATTTCGATTTATCGGAGCCCGCGGTGGTGATCCCTGAGGAGATCGGTAACAATC
GTTCGAATTTGGACTCATCGGaAAACAGAAGCGGCGATGGAGGTTTAGAAGGAAGA
TCTGAGTCTGTTCATTCACAGGTTTCATCTCAAGGCTCCAAGACTTTTGTGTCCGACA
CCGTTGACGCATCATCCTCCCCTGAATCAAGCAATCACCAGAAATCTTCTGTTAGCA
AGAGGAAGAAGGAAAATGGAGACTCCAGTGGCGAATTAAGGAGCTGCAAGTACCA
AAAGTCCGATGATAAATCAGTCGCTACGAACAACGAAGGTGATGATGACGACGACA
AGAGGAAGTTGATAAGGCAGATTAGGAACCGTGAAAGTGCTCAGCTTTCGAGGTTG
AGGAAGAAGCAACAAACTGAGGAGCTTGAAAGAAAAGTGAAGAGTATGAATGCTA
CCATTGCTGAATTGAATGGTAAGATTGCTTATGTTATGGCTGAGAATGTCGCTTTAA
GGCAACAAATGGCTGTTGCTTCTGGTGCTCCTCCTATGAATCcTTATATGGCTGCCCC
GCCTTTACCGTATCAATGGATGCCGTATCCGCCGTATCCTGTTAGGGGATATGGATC
ACAGACACCTTTGGTTCCCATTCCTAAGTTAAATCCTAAGCCTGTATCGAGTTGTAG
ACCGAAGAAGGCAGAGAGTAAGAAGAATGAGGGTAAAAGTAAGCTCTGA 
Amino acid sequence 
MTESTSVVAPPPEIPNLNPSMFSESDLFSIPPLDPLFLSDSDPISMDAPISDLDFLLDDENGD
FADFDFSFDNSDDFFDFDLSEPAVVIPEEIGNNRSNLDSSENRSGDGGLEGRSESVHSQVS
SQGSKTFVSDTVDASSSPESSNHQKSSVSKRKKENGDSSGELRSCKYQKSDDKSVATNN
EGDDDDDKRKLIRQIRNRESAQLSRLRKKQQTEELERKVKSMNATIAELNGKIAYVMAE
NVALRQQMAVASGAPPMNPYMAAPPLPYQWMPYPPYPVRGYGSQTPLVPIPKLNPKPV
SSCRPKKAESKKNEGKSKL* 
Feature 
bZIP28    : (nucleotide) 1…960  (amino acid) 1…320 
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3.9 Nucleotide and amino acid sequences of synthetic gene, bZIP60 
Nucleotide sequence 
ATGGTGGATGACATCGATGATATCGTTGGACACATCAATTGGGACGATGTAGATGA
CCTCTTCCACAACATTCTAGAGGATCCCGCCGACAATCTCTTCTCTGCTCATGATCCG
TCCGCGCCGTCTATCCAGGAGATCGAGCAGCTTCTCATGAACGATGATGAAATCGTC
GGTCACGTGGCTGTCGGAGAGCCTGATTTTCAACTTGCTGACGACTTTCTCTCCGAC
GTGCTAGCCGATTCTCCTGTTCAGTCCGATCTTTCTCACTCTGATAAAGTCATTGGAT
TCCCCGATTCCAAGGTTTCAAGTTGCTCAGAGGTTGATGATGACGACAAAGACAAG
GAGAAGGTTTCCCAGTCGCGGATTGACTCTAAGGACGGCTCTGACGAACTAAACTGT
GATGATCCCGTCGATAAAAAGCGTAAGAGGCAATTGAGAAACAGAGATGCAGCTGT
CAGGTCACGAGAGCGGAAGAAGTTGTATGTTAGGGATCTTGAGTTGAAGAGTAGAT
ACTTTGAATCAGAGTGCAAGAGGTTGGGGTTAGTTCTCCAGTGCTGTCTTGCAGAAA
ATCAAGCTTTGCGCTTCTCTTTGCAGAATGGCAATGCTAATGGTGCTTGTATGACCA
AGCAGGAGTCTGCTGTGCTCTTGTTGGAATCCCTGCTGTTGGGTTCCCTGCTTTGGTT
CCTGGGCATCATATGCCTGCTCATTCTTCCCAGCCAACCCTGGTTAATTCCAGAAGA
AAATCAACGAAGCAGAAACCACGGTCTTCTGGTTCCGATAAAGGGAGGAAATAAGG
CTGGTCGGATTTTTGAGTTCCTGTCCTTCATGATGGGCAAGAGATGCAAAGCTTCAA
GATCGAGGATGAAGTTCAATCCCCATTCTTTGGGAATTGTTATGTGA 
Amino acid sequence 
MVDDIDDIVGHINWDDVDDLFHNILEDPADNLFSAHDPSAPSIQEIEQLLMNDDEIVGHV
AVGEPDFQLADDFLSDVLADSPVQSDLSHSDKVIGFPDSKVSSCSEVDDDDKDKEKVSQ
SRIDSKDGSDELNCDDPVDKKRKRQLRNRDAAVRSRERKKLYVRDLELKSRYFESECK
RLGLVLQCCLAENQALRFSLQNGNANGACMTKQESAVLLLESLLLGSLLWFLGIICLLIL
PSQPWLIPEENQRSRNHGLLVPIKGGNKAGRIFEFLSFMMGKRCKASRSRMKFNPHSLGI
VM*  
Feature 
bZIP60    : (nucleotide) 1…900  (amino acid) 1…300 
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3.10 List of primers 
Primers Sequences 
pVP3-F TGTACATTAATTAAATGGGTTTCGTGCTGTT 
VP3H-R 
GCTAGCGGCGCGCCCTCGAGCTAGTGGTGGTGATGGT
GATGAAGCTT 
VP3-F TGTACATTAATTAAATGGATGCTCTGCAAGAGGATAC 
gVP3H-R 
GCTAGCGGCGCGCCCTCGAGCTAGTGATGGTGGTGGT
GATGAAGCTT 
gVP3-F TGTACATTAATTAAATGGCTTCTAAGGGTGAGGAACT 
LicVP3-F TGTACATTAATTAAATGCAGAACGGTGGTTCCTACCC 
PRH22-F 
TGTACATTAATTAAATGGGTTTCGTGCTGTTCAGCCAG
CTGCCTTCTTTCCTTCTTGTGTCTACCCTTCTGCTGTTC
CTGGTGATCTCTCATTCTTGCAGGGCTCAGGTTCAGCT
GGTTGAGTCTGGTG 
HCatVP3-R GGTATCCTCTTGCAGAGCATCCATAGGACCCCTATC 
HCatVP3-40-121-R GGTGATGGTAATAGGACCCCTATCAACTTCATCGTG 
HCatVP3-60-121-R ATCTGCGGTAGCAGGACCCCTATCAACTTCATCGTG 
HCatVP3-80-121-R AGGCTTAGGCTGAGGACCCCTATCAACTTCATCGTG 
HCatVP3-F CACGATGAAGTTGATAGGGGTCCTATGGATGCTCTG 
VP3-HK_R GCTAGCGGCGCGCCCTCGAGCTAAAGCTCA 
HCatVP3-40-121-F GATAGGGGTCCTATTACCATCACCCTGTCTTTGTGC 
 9-14 
  
HCatVP3-60-121-F GATAGGGGTCCTGCTACCGCAGATAACAGCGAGAGC 
HCatVP3-80-121-F GATAGGGGTCCTCAGCCTAAGCCTCCAAGCAAGAAG 
PREGF-F 
TGTACATTAATTAAATGGGTTTCGTGCTGTTCAGCCAG
CTGCCTTCTTTCCTTCTTGTGTCTACCCTTCTGCTGTTC
CTGGTGATCTCTCATTCTTGCAGGGCTAACAGCGATA
GCGAGTGCCCTCTGT 
ECatVP3-R CAGAGCATCCATAGGACCTCTATCAACTTCATCGTG 
ECatVP3-F GATAGAGGTCCTATGGATGCTCTGCAAGAGGATACC 
YFE-1-T-F 
TGTACATTAATTAAATGGGTTTCGTGCTGTTCAGCCAG
CT 
ECatVP3-40-121-R GGTGATGGTAATAGGACCTCTATCAACTTCATCGTG 
ECatVP3-60-121-R ATCTGCGGTAGCAGGACCTCTATCAACTTCATCGTG 
ECatVP3-80-121-R AGGCTTAGGCTGAGGACCTCTATCAACTTCATCGTG 
ECatVP3-40-121-F GATAGAGGTCCTATTACCATCACCCTGTCTTTGTGC 
ECatVP3-60-121-F GATAGAGGTCCTGCTACCGCAGATAACAGCGAGAGC 
ECatVP3-80-121-F GATAGAGGTCCTCAGCCTAAGCCTCCAAGCAAGAAG 
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3.11 Codon usage table of Nicotiana benthamiana (N. benthamiana) 
This data was adopted from URL: http://www.kazusa.or.jp/codon/cgi-
bin/showcodon.cgi?species=4100 
Features: [codon] [frequency: per thousand] ([number]) 
UUU 23.7 (  1036) UCU 22.3 (   974) UAU 15.8 (   690) UGU  9.2  (   404) 
UUC 17.6 (    771)  UCC 10.4 (   453) UAC 12.8 (   562) UGC  7.2  (   315) 
UUA 12.8 (   559)  UCA 17.2 (   752) UAA  0.7  (     32) UGA  0.9  (     39)  
UUG 24.3 (  1062) UCG  5.6  (   247) UAG  0.7  (     29) UGG 12.4 (   542) 
 
CUU 24.9 (  1091)  CCU 18.9 (   826) CAU 12.9  (   566) CGU  7.7  (   335) 
CUC 12.5 (    545)  CCC  6.4  (   278) CAC  8.2   (   360) CGC  4.2  (   183) 
CUA  9.2  (    404)  CCA 16.8 (   734) CAA 18.1  (   790) CGA  5.8  (   253) 
CUG 11.9 (    522)  CCG  6.5  (   284) CAG 17.0  (   745) CGG  5.3  (   233) 
 
AUU 26.7 (  1170) ACU 17.4 (   762) AAU 29.1  (  1272) AGU 14.7 (   642) 
AUC 13.9 (    610)  ACC 10.1 (   443) AAC 16.9  (    741) AGC 10.7 (   469) 
AUA 12.1 (    530) ACA 15.2 (   665) AAA 29.0  (  1269) AGA 15.8 (   690) 
AUG 23.9 (  1044) ACG  5.4  (   236) AAG 38.0  (  1662) AGG 13.0 (   569) 
 
GUU 26.1 (  1142) GCU 33.2 ( 1452) GAU 38.5  (  1686) GGU 24.3 ( 1065) 
GUC 10.6 (    465)  GCC 12.6 (   550) GAC 16.4  (    719) GGC 11.4 (   500) 
GUA  9.9  (    435) GCA 23.5 ( 1029) GAA 35.2  (  1541) GGA 22.5 (   986) 
GUG 15.6 (    684) GCG  6.5  (   283) GAG 30.9  (  1351) GGG 11.1 (   485) 
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Appendices for Chapter 4 
4.1   Expression profile for mock infected plant sample 
Protein expression profile of plants infected with recombinant vector without gene insert (as a 
negative control/ pGR-D4) was analysed using western blotting. No band was detected from total 
protein (TP) and total soluble protein (with triton) (TSP-T) fraction from protein samples 
extracted from plants infected with recombinant vector without gene insert.   
      
 
  
 
      
 Lane Sample Expression vector 
Estimated 
size 
 
 P 
MagicMark™ XP Western Protein 
Standard 
   
 1-3 
60 ng, 30 ng and 15 ng of HAI 
standard  
 ~ 70 kDa  
 4-8 
TP extracts from leaf samples 
harvested from 4, 5, 6, 7 and 8 dpi 
pGR-D4   
 9-13 
TP extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: GFP-VP3-H ~ 42 kDa  
 14-18 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4   
 19-23 
TSP-T extract from leaf samples 
harvested on 4, 5, 6, 7 and 8 dpi 
pGR-D4:: PR-GFP-VP3-H ~ 42 kDa  
      
Figure A4.1: Protein expression profile of mock infected plants. (a) Western profiles showed the 
detection of TP from mock infected (pGR-D4) plants and plants infiltrated with recombinant 
pGR-D4:: PR-GFP-VP3-H using Tetra-His mouse monoclonal antibody. (b) Western profiles 
showed the detection of TP from mock infected (pGR-D4) plants and plants infiltrated with 
recombinant pGR-D4:: PR-GFP-VP3-H using Tetra-His mouse monoclonal antibody. 
a b
c 
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Appendices for Chapter 5 
5.1 IMAC purification of recombinant apoptin from leaves infiltrated with recombinant 
vector pGR-DN:: PR-VP3-HK__bZIP60 
Total protein (TP) harvested from leaf materials infiltrated with recombinant vector, pGR-DN:: 
PR-VP3-HK__bZIP60 yielded ~ 20 mg/kg (Figure A5.1-a: Lane 4); however, amount of total 
soluble protein (TSP) (Figure A5.1-a: Lane 5) was ~ 4 mg/kg. Recovery of soluble recombinant 
apoptin in eluent containing 300 mM imidazole was ~ 10% of TSP. Protein eluent contained 
high amount of unspecific protein (Figure A5.1-a: Lane 15). 
      
 
  
 
      
 Lane Sample Estimated size  
 P 
MagicMark™ XP Western Protein 
Standard 
  
 Q BenchmarkTM Protein Ladder   
 1-3 60 ng, 30 ng and 15 ng of HAI standard  ~ 70 kDa  
 4 TP extract from leaf sample 
~ 18 kDa for recombinant 
VP3-HK 
 
 5 TSP extract from leaf sample 
~ 18 kDa for recombinant 
VP3-HK 
 
a b 
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 6 Flow through fraction from IMAC 
~ 18 kDa for recombinant 
VP3-HK 
 
 7-11 
IMAC eluent containing 20, 40, 60, 300 
and 500 mM imidazole 
~ 18 kDa for recombinant 
VP3-HK 
 
 12-14 900 ng, 600 ng and 300 ng of BSA standard ~ 66.5 kDa  
 15 
IMAC eluent containing 300 mM 
imidazole 
~ 18 kDa for recombinant 
VP3-HK 
 
      
Figure A5.1: IMAC protein purification profiles of recombinant apoptin alone from leaves 
infiltrated with recombinant pGR-DN:: PR-VP3-HK__bZIP60. (a) Western profiles showed the 
detection of recombinant apoptin at a molecular size of ~ 18 kDa reacted with Tetra-His mouse 
monoclonal antibody in each step of IMAC. All sample volume was adjusted to the volume of 
starting material and subsequently loaded into gel at the same volume for all fractions. (b) 
Protein sample from IMAC eluent containing 300 mM imidazole was electrophoresed in SDS-
PAGE and stained with coomassie blue. 
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5.2 Ion exchange chromatography (IEX) of IMAC purified recombinant GFP-apoptin 
using HiTrap SP column  
IMAC purified recombinant GFP-apoptin (GFP-VP3-HK) was further purified with HiTrap SP 
column at pH 7.7 (Figure A5.2-b), pH 8.5 (Figure A5.2-a) and pH 8.0 (Figure A5.2-c and -d). 
Among these three conditions, purification using HiTrap SP column gave the highest purification 
yield (~ 40% recovery) at pH 8.0 using eluent buffer containing 0.6 M NaCl. However, 
unspecific plant protein at  50 kDa still remained as a major contaminant in this purified 
product.   
      
 
  
 
 
  
 
 
 
  
a b 
c 
d 
e 
 9-20 
  
      
 Lane Sample Estimated size  
 P 
MagicMark™ XP Western Protein 
Standard 
  
 1-3 60 ng, 30 ng and 15 ng of HAI standard  ~ 70 kDa  
 
4, 13, 21 
and 29 
Supernatant of IMAC Eluent after 
centrifuged at 40, 000 xg 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 5 
Buffer exchange IMAC eluent to IEX 
Starting Buffer C 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 6 
Flow through fraction from HiTrap SP 
column at pH 8.5 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 7 
HiTrap SP column washed using IEX 
Starting Buffer C 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 8-11 
Eluent with 0.2, 0.4, 0.6 and 0.8 M NaCl 
containing buffer using IEX Elution Buffer 
C 
~ 45 kDa for recombinant 
GFP-VP3-HK  
 
12, 20, 28 
and 37 
IMAC eluent containing 300 mM 
imidazole buffer 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 14 
Buffer exchange IMAC eluent to IEX 
Starting Buffer D 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 15 
Flow through fraction from HiTrap SP 
column at pH 7.7 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 16 
HiTrap SP column washed using IEX 
Starting Buffer D 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 17-19 
Eluent with 0.2, 0.4 and 0.6 M NaCl 
containing buffer using IEX Elution Buffer 
D 
~ 45 kDa for recombinant 
GFP-VP3-HK  
 22 
Buffer exchange IMAC eluent to IEX 
Starting Buffer E 
~ 45 kDa for recombinant 
GFP-VP3-HK 
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 23 
Flow through fraction from HiTrap SP 
column at pH 8.0 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 24 
HiTrap SP column washed using IEX 
Starting Buffer E 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 25-27 
Eluent with 0.2, 0.4 and 0.6 M NaCl 
containing buffer using IEX Elution Buffer 
E 
~ 45 kDa for recombinant 
GFP-VP3-HK  
 30 
Buffer exchange IMAC eluent to IEX 
Starting Buffer F 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 31 
Flow through fraction from HiTrap SP 
column at pH 8.0 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 32 
HiTrap SP column washed using IEX 
Starting Buffer F 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 33-36 
Eluent with 0.4, 0.6, 0.8 and 1.0 M NaCl 
containing buffer using IEX Elution Buffer 
E 
~ 45 kDa for recombinant 
GFP-VP3-HK  
 38 
Eluent with 0.6 M NaCl containing buffer 
(pH 8.0) 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
      
Figure A5.2: Protein purification profiles of IMAC purified recombinant GFP-apoptin (GFP-
VP3-H). All sample volume was adjusted to the volume of starting material and subsequently 
loaded in the same volume for all fractions. Western profiles showed the detection of 
recombinant GFP-apoptin at a molecular size of ~ 45 kDa reacted with with Tetra-His mouse 
monoclonal antibody in each step of purification performed at (a) pH 8.5. (b) pH 7.7 (c) pH 8.0 
and (d) pH 8.0 with 0.2 M of NaCl in starting buffer. (e) Protein samples from IMAC eluent 
containing 300 mM imidazole and IEX eluent containing 0.6 M NaCl were electrophoresed in 
SDS-PAGE and stained with coomassie blue. 
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5.3 IMAC purification of recombinant GFP-apoptin from insoluble extract 
Recombinant GFP-apoptin (GFP-VP3-H) purified using IMAC under denaturing condition 
showed a recovery of ~ 50% (Figure A5.3). IMAC eluent containing GFP-apoptin required 
subsequent buffer exchange step to remove and refold protein. It was noticed that refolded 
recombinant protein showed a weak GFP signal compared to protein purified using method 
described in Chapter 5 (section 5.3.1.2) (Figure A5.4). 
      
 
  
 
      
 Lane Sample Estimated size  
 P 
MagicMark™ XP Western Protein 
Standard 
  
 Q BenchmarkTM Protein Ladder   
 1-3 60 ng, 30 ng and 15 ng of HAI standard  ~ 70 kDa  
 4 TP extract from leaf sample 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 5 TSP-T extract from leaf sample 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 6 
Insoluble protein extract from leaf sample 
with triton 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 7 
Insoluble protein extract filtered with 0.2 
µm filter 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
a b 
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 8 Flow through fraction from IMAC 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 9-13 
IMAC eluent containing 20 (+0.5% triton), 
20, 40, 60 and 300 mM imidazole 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
 14-16 900 ng, 600 ng and 300 ng of BSA standard ~ 66.5 kDa  
 17 
IMAC eluent containing 300 mM 
imidazole 
~ 45 kDa for recombinant 
GFP-VP3-H 
 
      
Figure A5.3: IMAC protein purification profiles of recombinant GFP-apoptin (GFP-VP3-H). (a) 
Western profiles showed the detection of recombinant GFP-apoptin at a molecular size of ~ 45 
kDa reacted with Tetra-His mouse monoclonal antibody in each step of IMAC. All sample 
volume was adjusted to the volume of starting material and subsequently loaded into gel at the 
same volume for all fractions. (b) Protein sample from IMAC eluent containing 300 mM 
imidazole was electrophoresed in SDS-PAGE and stained with coomassie blue.  
 
 
Figure A5.4: Fluorescence signal of recombinant GFP-apoptin (GFP-VP3-H) under UV lamp. (a) 
Refolded recombinant GFP-apoptin purified under denaturing condition as described in this 
section showing unapparent green fluorescence. Protein concentration was estimated as 0.1 
mg/ml. (b) Refolded recombinant GFP-apoptin purified under native condition as described in 
Chapter 5 (section 5.3.1.2) showing green fluorescence. Protein concentration was estimated as 
0.07 mg/ml. 
 
a b 
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5.4 Extraction of recombinant GFP-apoptin and EGF-apoptin  
Recombinant GFP-apoptin was extracted from leaf materials infiltrated with recombinant vector, 
pGR-D4:: PR-GFP-VP3-HK using buffer at pH 5.5-9.0 (Figure A5.5: Lane 4-8). Similarly, 
recombinant EGF-apoptin was extracted from leaf materials infiltrated with recombinant vector, 
pGR-D4:: PR-EGF-CatAD-VP3-HK using similar condition (Figure A5.5: Lane 9-13). It was 
noticed that both proteins had high solubility at pH 8.0 and most of the proteins were precipitated 
at acidic condition.  
      
 
 
  
      
 Lane Sample Estimated size  
 P 
MagicMark™ XP Western Protein 
Standard 
  
 1-3 60 ng, 30 ng and 15 ng of HAI standard  ~ 70 kDa  
 4-8 
Protein extract of recombinant GFP-apoptin 
at      pH 5.5, 6.0, 7.0, 8.0 and 9.0 
~ 45 kDa for recombinant 
GFP-VP3-HK 
 
 9-13 
Protein extract of recombinant EGF-
apoptin at      pH 5.5, 6.0, 7.0, 8.0 and 9.0 
~ 30 kDa for recombinant 
EGF-VP3-HK 
 
      
Figure A5.5: Protein extraction profiles of recombinant GFP-apoptin (GFP-VP3-HK) and EGF-
apoptin (EGF-VP3-HK) using buffer at pH 5.5-9.0. Western profiles showed the detection of 
recombinant GFP-VP3-HK (a molecular weight of ~ 45 kDa) and EGF-VP3-HK (a molecular 
weight of ~ 30 kDa) reacted with Tetra-His mouse monoclonal antibody. 
a 
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5.5 IMAC purification of recombinant EGF-apoptin in denaturing condition 
Total protein (TP) harvested from leaf material infiltrated with recombinant vector, pGR-D4:: 
PR-EGF-CatAd-VP3-HK yielded ~ 30 mg/kg (Figure A5.6-a: Lane 4). Recovery of recombinant 
EGF-apoptin in eluent containing 300 mM imidazole was ~ 50% of total protein extract in 
denaturing condition (Figure A5.1-a: Lane 9). Unspecific host protein ~ 50 kDa was detected in 
IMAC eluent (Figure A5.1-a: Lane 16). 
 
      
 
  
 
      
 Lane Sample Estimated size  
 P 
MagicMark™ XP Western Protein 
Standard 
  
 Q Benchmark protein standard   
 1-3 60 ng, 30 ng and 15 ng of HAI standard  ~ 70 kDa  
 4 and 11 Insoluble protein extract from leaf sample  
~ 30 kDa for recombinant 
EGF-VP3-HK 
 
 5 and 12 Flow through fraction from IMAC 
~ 30 kDa for recombinant 
EGF-VP3-HK 
 
 
6-10 and 
13-17 
IMAC eluent containing 20, 40, 60, 300 
and 500 mM imidazole  
~ 30 kDa for recombinant 
EGF-VP3-HK 
 
a b 
 9-26 
  
 
 18-20 900ng, 600 ng and 300 ng BSA standard ~ 66.5 kDa  
      
Figure A5.6: IMAC protein purification profiles of recombinant EGF-apoptin (EGF-VP3-HK) in 
denaturing condition. (a) Western profiles showed the detection of recombinant EGF-apoptin at a 
molecular size of ~30 kDa reacted with anti- Tetra-His mouse monoclonal antibody in each step 
of IMAC. All sample volume was adjusted to the volume of starting material and subsequently 
loaded into gel at the same volume for all fractions. (b) Protein samples from each step of IMAC 
were electrophoresed in SDS-PAGE and stained with coomassie blue. 
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Appendices for Chapter 6 
 
6.1 Activity of ectopically expressed apoptin in A549 cells 
Activity of ectopically expressed apoptin was assessed in A549 cells in order to identify for the 
susceptibility of A549 cells towards apoptin. Gene sequence of GFP, GFP-VP3, VP3-A and 
EGF-VP3 were synthesized by GeneArtTM Gene Synthesis, Thermo Scientific (USA). Besides, 
GFP and EGF gene sequences were optimised based on codon usage of Homo sapiens.  Gene 
sequence of apoptin (VP3) was synthesised based on sequence of Mohd-Azmi et al. (1997) 
(Malaysia isolate) (GenBank accession number: AAB86420.1). Synthesised genes were cloned 
into mammalian expression vector pCDNA3.0(+) and generated recombinant vectors, 
pCDNA3.0(+):: GPF, pCDNA3.0(+):: GFP-VP3-A, pCDNA3.0(+):: VP3-A and pCDNA3.0(+):: 
EGF-VP3-A. All recombinant vectors were delivered into A549 cells using Lipofectamine 3000 
(Thermo Scientific, USA) by following the instruction provided by the manufacturer. Expression 
of proteins in A549 cells were evaluated using IF (described in section 6.2.4) on 2, 4, 5 and 6 
days post transfection. For evaluation of activity of apoptin in A549 cells, ~50 cells were 
examined for cells expressed each recombinant protein. Survival of apoptin or GFP expressed 
cells were quantified by checking the morphology of cell nucleus stained by SYB Green or PI. 
Data collected were analysed by statistical analysis ANOVA by using GraphPad Prism. 
Significance of cell death was evaluated by comparing cells expressing GFP to cells expressing 
GFP-VP3, VP3-A and EGF-VP3.   
Significant cell death was not observed on apoptin expressed cells on 2 days post transfection; 
but instead, it was observed on 4, 5 and 6 days post transfection (Figure A6.3). DNA 
condensation and nucleus fragmentation occurred in cells expressing apoptin (Figure A6.4). 
Instead of quantifying the viability of cells expressing apoptin, localisation of protein was also 
studied. GFP protein expressed in A549 cells was distributed evenly within the cells; however, 
ectopically expressed apoptin was relocalised into cell nucleus (Figure A6.5).  Relocalisation of 
apoptin into cell nucleus was reported in various kinds of cancer cells and this activity of protein 
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was mainly due to the bipartite nuclear localisation signal residing in C-terminal of apoptin (Los, 
2009). 
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Figure A6.1: Evaluation of survival rate of ectopically expressed apoptin in A549 cells. Cells 
expressing recombinant GFP, GFP-apoptin (GFP-VP3), apoptin alone (VP3-A) and EGF-apoptin 
(EGF-VP3) were firstly confirmed by using indirect immunofluorescent assay (IF). Viability of 
cells expressing recombinant proteins was quantified by evaluating morphology of cells using 
a 
b 
c 
d 
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propidium iodide (PI) or SYBGreen. Cells expressing recombinant GFP and apoptin showed 
similar rate of survival (p=0.67) on 2 days post transfection; however, cells expressing apoptin 
showed significant cell death in relative to cells expressing GFP protein on 4 (p= 0.0008), 5 (p= 
0.0003) and 6 (p< 0.0001) days post transfection.  
 
      
 
 
 
 
 
 
 
 
 
 
 
 
  
      
Figure A6.2: Fluorescence microscopic observation of ectopically expressed apoptin in A549 
cells captured using Nikon Instruments Eclipse Ti-E inverted microscopes. (a) Cells expressing 
apoptin showed normal and healthy conditions. Cell nuclei remained round and intact. (b) Cells 
expressing apoptin showed chromatin condensation with evidence of bright green fluorescence 
a b 
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stained DNA. (c) Cells expressing apoptin showed nuclear fragmentation morphology. Nucleus 
of cells was no longer intact and had been broken into pieces.    
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Figure A6.3: Fluorescence microscopic observation of ectopically expressed apoptin in A549 
cells captured using Zeiss Observer Z1 microscope and Zeiss LSM 510 META highspeed 
confocal microscope. (a) Cells expressing apoptin (red) (detected using mouse monoclonal VP3 
antibody) showed protein aggregation in cell nucleus (stained by Hoechst dye). (b) Cells 
expressing GFP protein showed even distribution of protein in A549 cells.     
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6.2 Delivery of recombinant GFP-VP3-HK into A549 cells using Pulsin protein 
transfection reagent 
Since recombinant GFP-VP3-HK did not harbor cell penetrating peptide, refolded GFP-VP3-HK 
was transfected into A549 cells using PULSin® protein delivery reagent (Polyplus transfection, 
France) based on the protocols provided by the manufacturer. PULSin® protein delivery reagent 
is a kind of cationic amphiphile molecule that forms non-covalent complexes with proteins. 
Complexes are internalized via anionic cell-adhesion receptors and are released into the 
cytoplasm where they are disassembled. In this study, cells were incubated with recombinant 
GFP-VP3-HK and PULSin® protein delivery reagent for 4 hours. Subsequently, fresh culture 
medium was used to replace medium containing recombinant GFP-VP3-HK and transfection 
reagent. IF (described in section 6.4) was performed to identify for the location of recombinant 
GFP-VP3-HK. Fluorescence microscopic images showed that positive control R-Phycoerythrin 
(~ 240 kDa), as provided by manufacturer, was successfully delivered into A549 cells as shown 
in Figure A6.6. However, delivery of recombinant GFP was not as efficient as R-Phycoerythrin 
since limited green fluorescent signal was observed from transfected cells. For recombinant 
GFP-VP3-HK, huge aggregates were observed on A549 cells and these aggregates were proven 
to be recombinant GFP-VP3-HK by IF using mouse monoclonal VP3 antibody.  
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Figure A6.4: Fluorescence microscopic observation of A549 cells transfected with R-
Phycoerythrin, GFP and recombinant GFP-VP3-HK. (a and b) Images of A549 cells transfected 
with R-Phycoerythrin. R-Phycoerythrin (fluorescent in red) was successfully delivered into A549 
cells as shown in image (b) (white arrows). (c and d) Images of A549 cells transfected with 
recombinant GFP protein. Limited numbers of cells (d) were successfully transfected with 
recombinant GFP protein. (e and f) Images of A549 cells transfected with recombinant GFP-
VP3-HK protein. Huge amount of aggregates was noticed locating on A549 cells (e) and these 
aggregates were proven to be recombinant GFP-VP3-HK as shown in image (f), by which IF was 
performed using Mouse monoclonal VP3 antibody.  
a b 
c d 
e f 
 9-33 
  
6.3 Scoring for microinjection efficiency and viability of A549 cells microinjected with 
recombinant GFP and GFP-VP3-H 
Microinjection was chosen as delivery tool to transfer recombinant GFP-VP3-H into A549 cells 
since the protein did not have cell penetrating peptide. Efficiency as well as viability of cells 
microinjected with recombinant GFP and GFP-VP3-H was scored and presented as in Table 
A6.1. Efficiency of microinjection for recombinant GFP was scored based on the detected 
intrinsic signal of GFP present in the microinjected cells; however, microinjected cells turned up 
with signal from indirect immunofluorescence (IF) staining of recombinant GFP-VP3-H using 
mouse monoclonal VP3 antibody and Rhodamine (TRITC) AffiniPure Goat Anti-Mouse IgG 
(H+L) which was calculated as the efficiency of microinjection. The nuclei of cells microinjected 
with recombinant GFP were stained with propidium iodide (PI) while nuclei of cells 
microinjected with recombinant GFP-VP3-H were stained with SYB Green. Staining of cell 
nuclei allowed for the identification of the nuclear morphology of cells and determination of the 
survival of injected cells (Figure 6.6). Only those with intact and round nucleus were considered 
as survived cells, which did not include cells with condensed chromatin or fragmented nuclei.  
Table A6.1: Survival of cells microinjected with recombinant GFP and GFP-VP3-H. 
Recombinant 
Proteins 
Efficiency and viability 
of microinjected cells 
Time (hours) 
2 4 6 12 24 
G
F
P
 
Detected cells 60 % 58 % 66 % 68 % 41 % 
Survived cells  55 % 52 % 61 % 58 % 37 % 
G
F
P
-
V
P
3
-H
 Detected cells  40 % 57 % 17 % 7 % 1 % 
Survived cells  18 % 34 % 11 % 4 % 0 % 
Note: Detected cells - Cells detected after 2-24 hours post microinjection based on intrinsic 
signal of recombinant GFP or fluorescent signal shown in IF of cells microinjected with 
recombinant GFP-VP3-H were classified as detected cells. The calculation was 
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 performed by [ (detected cell numbers/ total injection number) 
x 100]. 
 Survived cells - Microinjected cells with intact and normal nuclear features 
were considered as survived cells. The calculation was 
performed by [ (survived cell numbers/ total injection number) 
x 100]. 
 
Data shown in Table A6.1 were calculated from a single experiment. Cells microinjected with 
recombinant GFP showed survival rate of more than 50% during the period of 2-12 hours post 
microinjection. Survival of cell microinjected with recombinant GFP decreased starting at 24 
hours post microinjection and this most likely due to the decrease of detected cells that caused by 
the overturn of recombinant protein in live cells. Decrease of cells microinjected with 
recombinant GFP-VP3-H was also observed. The lower cell numbers might be caused by the 
overturn of apoptin protein as well as cell killing effect from recombinant GFP-VP3-H.  
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6.4 Mitochondrial membrane permeability (MMP) evaluation of A549 cells using 
carbonyl cyanide 3-chlorophenylhydrazone (CCCP) 
MMP evaluation for A549 cells using a reversible proton gradient uncoupling agent, carbonyl 
cyanide 3-chlorophenylhydrazone (CCCP), was performed as a positive control for MMP assay, 
which would be performed for microinjected A549 cells with recombinant GFP as well as 
recombinant EGF-VP3-HK treated A549 cells. In untreated and normal cells, positively charged 
MitoPT TMRM dye was accumulated in mitochondria and red fluorescent signal was detected 
(Figure A6.1 -b). By using CCCP as low as 50 µM, mitochondrial membrane potential of A549 
cells was disturbed and red fluorescent signal was depleted (Figure A6.1 -f).  
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Figure A6.5: Mitochondrial membrane permeability activity of A549 cells treated with carbonyl 
cyanide 3-chlorophenylhydrazone (CCCP) for an hour. (a and b) Untreated A549 cells. (c and d) 
A549 cells treated with 5 µM of CCCP. (e and f) A549 cells treated with 50 µM of CCCP. (g and 
h) A549 cells treated with 500 µM of CCCP. Loss of mitochondrial membrane potential 
(represented by the loss of red fluorescent signal) was observed as dose-dependent of CCCP 
effect.  
6.5 Caspase 3/7 activity of A549 cells treated with Camptothecin 
Commercially available Camptothecin is a cytotoxic drug that induces apoptosis in mammalian 
cells via activation of caspases activity. In this study, Camptothecin was employed to be a 
positive control used to examine for the activation of caspase 3/7 using MagicRed Caspase 3/7 
kit in A549 cells. No fluorescent signal was detected for untreated A549 cells indicating no 
activation of caspase 3/7. While activation of caspase 3/7 causes the cleavage of MagicRed 
Caspase 3/7 substrate and releasing of cresyl violet fluorophore, which will cause the cells 
fluoresced in red. A549 cells showed red fluorescent signal (Figure A6.2 -d) as the cells were 
treated with 0.625 µg/ml of Camptothecin.   
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Figure A6.6: Caspase 3/7 activity of A549 cells treated with 0.625 µg/ml of Camptothecin for 2 
days post incubation. (a and b) Untreated A549 cells. (c and d) A549 cells treated with 0.625 
µg/ml of Camptothecin. Activation of caspase 3/7 was detected on A549 cells (red fluorescence) 
treated with Camptothecin.    
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